<SEC-DOCUMENT>0001816590-22-000115.txt : 20221103
<SEC-HEADER>0001816590-22-000115.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103070539
ACCESSION NUMBER:		0001816590-22-000115
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPASS Pathways plc
		CENTRAL INDEX KEY:			0001816590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39522
		FILM NUMBER:		221356153

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		1-646-905-3974

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Compass Rx Ltd.
		DATE OF NAME CHANGE:	20200701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cmps-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da,d:2c038f1b3ae34b9980fe150878abee2f--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:cmps="http://compasspathways.com/20220930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cmps-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF8yLTItMS0xLTEwNDEzNg_da10d4d1-1035-418c-955e-e858f42d2409">0001816590</ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF8zLTItMS0xLTEwNDEzNg_d227ce8a-23fc-4e69-8562-265cfaac683f">2022</ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF80LTItMS0xLTEwNDEzNg_56875547-fd6c-4cab-8891-f70e47e07d9e">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF81LTItMS0xLTEwNDEzNg_fc2b2f17-c872-4d68-8205-614f53dcecba">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF82LTItMS0xLTEwNDEzNg_c5af4957-1d1e-48b2-893c-99e2f3ad2399">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i4d2c2cd2dd514780800da78d3597eca4_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTAyNA_35a1f89c-3484-499d-8cd2-515ba09fe46d">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i7bd0dc2a39da4366b43fee2182928463_D20220801-20220801" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MzEvZnJhZzpmNmRjZGE4ZTQwNTQ0NzA5OTFmNzU3ZWNhMGUwNGM2My90ZXh0cmVnaW9uOmY2ZGNkYThlNDA1NDQ3MDk5MWY3NTdlY2EwZTA0YzYzXzEwOTk1MTE2Mjc3ODA_10f99276-69e6-4cdb-a1e4-e476841d8d4d">0.25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="idba4a10786e24fbcba7e73fb1aa9d665_D20220801-20220801" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MzEvZnJhZzpmNmRjZGE4ZTQwNTQ0NzA5OTFmNzU3ZWNhMGUwNGM2My90ZXh0cmVnaW9uOmY2ZGNkYThlNDA1NDQ3MDk5MWY3NTdlY2EwZTA0YzYzXzEwOTk1MTE2Mjc3ODQ_f34e585c-93b7-45fd-b8c9-cf97135e8cfb">0.75</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cmps-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i596c4fa459a842c792706b9aaaa22360_I20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2d514775b1f24e1599e2725db606daf3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if05f01a2352340f19929b84e2fdb783c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0474e1eeb0af47839fe1968b78c85d88_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d9f4c025464876950314f425750639_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i95405ef6eec44bbaac9fdee032a0137a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c91b535c5d4deab01c85d4d735656c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic85a709a97804361a3e0501cf690f852_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e99a1e2762468ba33ad456ee6384e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946e6c79976c439793df16cc9ad150f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7d6429579e4d5489d901de0c7b760d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e7c838434a4743bb3511c468433615_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc87b096855342a28b7610a6c449b3cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1066678671241ee8df1293eba5ee43f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89069162ebf84150934609fed74281ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb7a414f30d846af97155958e7d21aa6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ad4c5e2814404694ba16c54c9efd7a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9e32ee38ba4810ab4493f286127787_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c8df0b02b474d6d9d1369e7470155ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5c404dbf07411487c062c65fb44ea2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic794b704bc624a2c8e82ca8a90a87e57_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d35501a7b994b798bb3b150095bde6a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56a347d696345219a31e7675ac71b27_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6755946d0ae7463594da91d4a5e9a57a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5925242606241eda223f30a9b342280_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48210596e684e8b87d26aeeb8c60c98_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib515d46f69b343fc9a56d22004bb2629_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13bdb58279f54f18a78e5e0b660a5a40_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98da39a461bd466bb89f458b884735f4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185ef63d08ed431a91fd1bb8a28346cc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c092cad9544d7182cc6b0f1ebbbbbd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060c433da7a748b5839bed1921540abe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2f615c6fb3418d80683fcbc8681e63_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12fd33674544d41aa2a56f391291315_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c40baf5bb840f4a2732edb5af34c95_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i845c82217dbc4bbcaf62c5bea30b2432_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c008660987437795f6004bdf3aa8f2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae288fd8ae146d4bc365c5abf5bc0d8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9479266e364845e5bcca2f38d03e9949_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a02125e33964e9fa1af31b586645796_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d27dd8120d4b11b43f64710a22d3ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792cfb0299e04fd8a2fdee2f25255774_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125f25c0dca643febb4347815b8ad76f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84383e2bd7e84205988fc419ca82f7c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c315e44b8bc431fa86ce4c0715a7db0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72b982b97b964b6793d8992648332702_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebfc5653c5b8429d8f749dc4fedac7c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091b6e0de623464a98074345e2575290_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7dd95d805cd40f39509fb6515797148_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb224cca99b54f1db1729d2b867bfada_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8bc5bae85b48c9924bda0d62dcbc4d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb3a6d558d7437b86d516564947533b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666fe11914564071afc01b589931e866_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96551c10145d4467af80d00b2f8ec49e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib906b2d3cb24439f813b95288f8ba9ec_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040af099c030461699b8808e3daabecc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0eac4c061d4c7fb0a29e209902295d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie748da8f76a746f280de5263b489baed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a070c3e49fc4a47b4a3837aa83925d6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic982ac60ad0243d6a23af0d1772047e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4807ff1430444da1b1c019311c325e45_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27028a6c13f4e2185c22066785a346c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37af0655d52644088f3ca93ae36fddc8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0006602ef04e3ea9db6289df6795e2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieecac8bd3165451b8d042df19c203fc2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3137c453e903495eaaf7d9ad3254c18d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4120f8256c42b8b85596ceb05ffa7b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e65128b96b64b4d953bc090ea8f9461_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e8120c9d53e4a378e74d67421c6687c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728c5692d6704623aa8c0fcc42770d12_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7191433cf01d4df1bb228323c1facbe9_I20211008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib94f580649ab49a0896b34592f4b080d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7276d186a62437988e54f6972e90adc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ad1f7848464166b04ff803b503d684_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca94ba54c5c4d338293cf60580918bb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="region"><xbrli:measure>cmps:region</xbrli:measure></xbrli:unit><xbrli:context id="i3abee071f8fa481083b1445474906b6a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1704314f1ea450d9933186d70a008df_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i8952b53cbd2045e785cda206c0dbefa7_D20200306-20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cmps:DelixTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-06</xbrli:startDate><xbrli:endDate>2020-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291d3af8cf514f328ce6b2496870c764_I20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cmps:DelixTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76776d937084bb6b068aef14a3affac_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71781fc181fd4d39bb070c8c01a27ba1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief874743632e4333a3f835ba18d45264_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086cfe97e6384515ace3b2cd9e1a8caf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b536a3e71446ef897b88f79dc31c3d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d60c51518a44be9b0594797b5f26453_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb55899e87ce45a0a6e5f48a7d035dfb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15077b2d3fd4730b187893fbb83cd38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a1067ba8c745c39aa70a7c93efb438_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b33a16f531f4d5e8eb681ad202ab246_D20210813-20210813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-13</xbrli:startDate><xbrli:endDate>2021-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7b97b682754dbe8249580f1dc607a3_D20210504-20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985155b2f2d949c18fb2718219f25234_D20210519-20210519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-19</xbrli:startDate><xbrli:endDate>2021-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb10d785bf534ccd8a1515186b019eee_D20210504-20210519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cd6c80c90e48c2b80e5fc3ba599bcd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>cmps:vote</xbrli:measure></xbrli:unit><xbrli:context id="i116fea83328e4122a910788f7882e8d5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2c2cd2dd514780800da78d3597eca4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie927c44e5cb04850896477090264ffbc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fc213c5d7f4036bd82a5d59fa39b09_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8252967fea954920a4963de621717ddc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214715ae51834a1089d9817b0bf23379_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335fc987c66a4b2aba594c6855452579_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>cmps:day</xbrli:measure></xbrli:unit><xbrli:context id="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a328d9f64c4104a3a8029417180e0a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec562706b0534cfeb692067a09d83c1b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610168e4d50d4341abec1f5d08582cad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943a4addcd6943e98158e8fe064d19ae_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1626078e6ffb423ca90396bef3017393_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d03b7f170b4a6d82400d749c8536c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41471be5a1e8469eb1c6407abc7d16dd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168b4e16d7474cce8e24f284c7f15369_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if753486ce3c14daba4fcbe1f311b43da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8531ca535d9d45e38737a9c50ff3c640_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3977e8c2424d11b3e78355783d2144_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732830fb1c7142c5a6f37a0707285a52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdbbcb43854149dfbf0bcce7cd02755f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7964b739ce6343c381ccfca5dfb1ea6a_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36db55c852ef4eaa89b999164b7a2a99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34b90f4692c4d4f9bc74dd8fc80e8c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6d7c3a8be24750a3f82abce012253e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70760bf78092452f9552082498923167_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d9f56a071347a7afea2e8409054eaa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016ce66a6c4e4fc9aca63c6f704fddfc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd618f6b010d4a5f99e94d9218acf147_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ed6fe991c1471db93324917ceeb126_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92840f8d4bd4abeb1cb6f957e873ca3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487b8d6412304b83aef12793165358c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd0dc2a39da4366b43fee2182928463_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba4a10786e24fbcba7e73fb1aa9d665_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87aefa457f98460d9ba72963b7697019_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7c123bcb2043639356b3682899ec41_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b8dd5142c74e14af90b4df630e08e7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icefa4748348444fa952bab3678989dc2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18cd041e9674a2fa8a04ceae64ee78a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03df66d076904953a72557ea780c6f6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9696938fd04b1da48bd8c16ddcb336_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187723a49dae400c970198d5678bbf0d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d9eda1626844e1a4d7a56935aef2e0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0192aff8fc8a44639feb49e5ff26383e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf53ccfc8a04ca7aca822f4ae66c4bd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3fc341a339e466c85a21126366804be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6445d031d3af49a6a06ea1db2dc1ffdd_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:NewYorkNYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ibb6279cd6f4344d69acccb3e96e46e53_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:NewYorkNYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c93062327a04098856532f8d1e3bcff_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d32385fb8994518b1f04d199668f0e8_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:EastbourneTerraceLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da6eb55524b416f9a934077e9e0964b_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:EastbourneTerraceLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5dcf53d81a142d5b2daa60f4b084c52_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia57eb47573b842caa7eb13f5560d4cce_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SanFranciscoCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SanFranciscoCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6417d20a4747be9ada6c3270634e36_I20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397deef1a4764e6097cd7f14b27e8ec0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2c038f1b3ae34b9980fe150878abee2f_1"></div><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.377%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjMz_960c7156-acf0-49fd-8b0a-751c5309ffa1">10-Q</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM4_af3c226f-8d20-4a96-8172-fb0db626e690">&#8864;</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjY_2fc40a15-a34a-49a1-89c7-0480005a1601">September&#160;30, 2022</ix:nonNumeric><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI1_7187b4e5-0d9a-4e9a-bd4a-be3a1c043ee2">&#9744;</ix:nonNumeric>   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM0_25eb558f-5cf6-4fee-968b-994145f0dacc">001-39522</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQw_866202cf-a69e-4d3f-9cd2-ac27fe3825e2">COMPASS Pathways plc</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.035%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6NzUzMGJlYzY0OWRmNDY0N2I5ZjY5ZjE1ZjJiMmU3N2UvdGFibGVyYW5nZTo3NTMwYmVjNjQ5ZGY0NjQ3YjlmNjlmMTVmMmIyZTc3ZV8wLTAtMS0xLTEwNDEzNg_14afd546-3f7f-4f92-8f4f-573f8800de88">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM1_57ad67f8-8c09-453b-90cf-13bd40ed7603">33 Broadwick Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI3_dc2a609d-a7f4-4c4d-be0f-29ca5beb8835">London</ix:nonNumeric> <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQx_5594f9e4-d492-4946-a780-778f4be9eb82">W1F 0DQ</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjIz_2abaa8ba-fca8-4caa-8706-eff555b6004e">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> +1 (<ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQy_41a3c113-c9c4-4fb9-b7c3-66246365a2cc">716</ix:nonNumeric>) 676<ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI4_2dc36193-d819-484e-a71f-c6f68ac3c3c0">-6461</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.265%"><tr><td style="width:1.0%"></td><td style="width:32.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTAtMS0xLTEwNDEzNg_af6ae789-aee9-4218-b3b2-6f5166750d5d">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTItMS0xLTEwNDEzNg_866bd6c8-0281-48e9-b2a1-2dd2faf957cd">CMPS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTQtMS0xLTEwNDEzNg_9bc54161-f74f-47c1-9800-e60cffbb2c59">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI5_9c4a335c-c8cf-4382-9a9d-79b6222afb96">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjMw_6f1ba793-cda7-4f51-acda-bfa9acad1ef5">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8wLTAtMS0xLTEwNDEzNg_a51c86d6-ae2b-4761-aa2b-96dd8e40895e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8xLTMtMS0xLTEwNDEzNg_c63e5d57-632e-44b4-8cd6-131d47e599a0">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8yLTMtMS0xLTEwNDEzNg_ea79f1d3-3e3d-4346-8352-26df8306d8b0">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQz_59a3e247-705c-41bb-bead-49ca4c81628d">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="i596c4fa459a842c792706b9aaaa22360_I20221102" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV84MjQ2MzM3MjEwNjI4_65174503-9237-4a7d-8aff-8a04a5608d17">42,576,544</ix:nonFraction> shares of common stock outstanding as of November 2, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_7"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_16">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets As of September 30, 2022 and December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss for The Three Months and Nine Months Ended September 30, 2022 and 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity for The Three and Nine Months Ended September 30, 2022 and 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows for The Nine Months Ended September 30, 2022 and 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_37">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_97">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_121">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_124">40</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_127">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_130">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_130">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_130">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_133">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_133">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_133">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_136">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_136">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_136">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_139">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_139">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_139">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_142">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_142">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_142">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_145">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_145">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_145">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_148">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_148">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c038f1b3ae34b9980fe150878abee2f_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_10"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &#8220;Securities Act,&#8221; and Section 21E of the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these words or other similar terms or expressions. The forward-looking statements and opinions contained in this 10-Q are based upon information available to our management as of the date of this 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of our investigational COMP360 psilocybin therapy, including statements regarding the timing of initiation and completion of trials or studies and related preparatory work,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the timing of the launch and completion of our Phase 3 clinical program for treatment-resistant depression, or TRD, the period during which the results of the trials will become available and our research and development programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on the success of our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the size of the eligible patient populations for COMP360 psilocybin therapy, if approved for commercial use;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify third-party clinical sites to conduct our trials and our ability to identify and train appropriately qualified therapists to administer COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement our business model and our strategic plans for our business and our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify new indications for COMP360 beyond our current primary focuses on TRD, anorexia nervosa, and post-traumatic stress disorder, or PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, develop or acquire digital technologies to enhance our administration of our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to leverage our technology and drug development candidates to advance new psychedelic compounds in other areas of unmet mental health need;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully establish and maintain Centers of Excellence and our ability to achieve our goals with respect to the Center for Mental Health Research and Innovation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing, coverage and reimbursement of our investigational COMP360 psilocybin therapy, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scalability and commercial viability of our manufacturing methods and processes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our investigational COMP360 psilocybin therapy, in particular, and psilocybin-based therapies, in general;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish or maintain collaborations or strategic relationships or obtain additional funding; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</span></div><div style="text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding potential benefits of our investigational COMP360 psilocybin therapy and our therapeutic approach generally;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations around regulatory development paths and with respect to Controlled Substances Act designation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we and any current or future licensors or collaboration partners are able to establish and maintain for intellectual property rights covering COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States, under the laws and regulations of England and Wales, and other jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our internal control over financial reporting;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, capital requirements and needs for and ability to raise additional financing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our anticipated growth;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of global financial, economic and geopolitical events, including fluctuations in the stock market, rising interest rates and inflation, and foreign exchange fluctuations, particularly the Pound Sterling to U.S. Dollar, on our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of the COVID-19 pandemic, including the emergence of any variants or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future mitigation efforts and current or future economic effects, on any of the foregoing or other aspects of our business or operations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are classified as a controlled foreign corporation, or CFC, or a passive foreign investment company, or PFIC, under the Internal Revenue Code of 1986, as amended, for current and future periods; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future trading price of the ADSs and impact of securities analysts&#8217; reports on these prices.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Form 10-Q.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events, which speak only as of the date made. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A, of this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as otherwise required by the securities laws of the United States, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</span></div><div style="text-align:justify"><span><br/></span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_13"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage mental health care company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin therapy. Our ability to raise additional funds may be adversely impacted by macroeconomic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide.  Failure to obtain additional funding when needed or on favorable terms may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to holders of our ordinary shares and ADSs, restrict our operations or require us to relinquish rights to COMP360 or any future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the successful development of our investigational COMP360 psilocybin therapy. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COMP360 is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, or changes in these laws and regulations may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition. In addition, during the review process of COMP360, and prior to any approval, the U.S. Food and Drug Administration, or FDA, and/or other regulatory bodies may require additional data, including with respect to whether COMP360 has abuse or misuse potential, which may delay approval and any potential rescheduling process;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COMP360 contains controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding COMP360, in particular, and psilocybin-based therapies, in general, or our current or future investigational therapies using psilocybin may negatively influence the success of these therapies;  </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of COMP360 psilocybin therapy or any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates on a timely basis or at all, which will adversely affect our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COMP360 psilocybin therapy and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of COMP360 psilocybin therapy or any future therapeutic candidates or following approval, if any, we may need to abandon our development of such therapeutic candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The future commercial success of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</span></div><div style="text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business and commercialization strategy depends on our ability to identify, qualify, prepare, certify and support third-party therapy sites offering any approved therapy. If we are unable to do so, our commercialization prospects would be limited and our business, financial condition and results of operations would be harmed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on qualified therapists working at third-party clinical trial sites to administer our investigational COMP360 psilocybin therapy in our clinical trials and we expect this to continue upon approval, if any, of COMP360 or any future therapeutic candidates. If third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intellectual property rights of third parties could adversely affect our ability to develop or commercialize our investigational therapies, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational therapies. Such litigation or licenses could be costly or not available on commercially reasonable terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and could have a material adverse effect on our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to supply and manufacture the psilocybin and psilocin incorporated in COMP360 and expect to continue to rely on third parties to supply and manufacture any future therapeutic candidates, and we will rely on third parties to manufacture these substances for commercial supply, if approved. If any third-party provider fails to meet its obligations to manufacture COMP360 or our future therapeutic candidates, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substances and the commercialization of any therapies, if approved, could be stopped, delayed or made commercially unviable, less profitable or may result in enforcement actions against us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There are a number of third parties who conduct investigator-initiated studies, or IISs, using COMP360 provided by us. Any failure by a third party to meet its obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may delay or impair our ability to obtain regulatory approval for COMP360. IISs of COMP360 or any future therapeutic candidates may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360 and any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.  Economic uncertainty and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">worsening or deteriorating global economic conditions and financial market conditions may materially and adversely affect our business, including our ability to raise capital and our financial results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pandemic, epidemic, or outbreak of an infectious disease, or new variant of COVID-19, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition and our competitors may discover, develop or commercialize therapies before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to economic, political, regulatory and other risks associated with international operations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We previously identified and subsequently remediated material weaknesses in our internal control over financial reporting. We may identify future material weaknesses in our internal controls over financial reporting. If we fail to  maintain effective internal controls, we may be unable to produce accurate and timely financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our ADS price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</span></div><div style="text-align:justify"><span><br/></span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_16"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_19"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_22"></div><div><span><br/></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNC0xLTEtMS0xMDQxMzY_7e2af6aa-7152-47ae-90c0-b2ebfaa75eff">173,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNC0zLTEtMS0xMDQxMzY_1bcea230-d477-48d3-8acf-ed77d0dc31c6">273,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNS0xLTEtMS0xMDQxMzY_d1efcab8-6a1d-4249-b9fc-70c0213d5f9f">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNS0zLTEtMS0xMDQxMzY_bd1f85ad-3407-4c0d-a4f5-9ccb6bbde1e1">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNi0xLTEtMS0xMDQxMzY_617bc170-9a8c-4cb0-8ea3-4a7a435b1f32">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNi0zLTEtMS0xMDQxMzY_9bab8beb-e047-4a22-aa14-ccf9faa8ffb9">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNy0xLTEtMS0xMDQxMzY_260ab389-4092-4a81-8365-0836fcc95877">44,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNy0zLTEtMS0xMDQxMzY_0e490286-b785-4407-8e7f-f51d0a1d7045">21,621</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfOC0xLTEtMS0xMDQxMzY_0dcd46b2-64e7-49b9-9702-e7dd166def8a">218,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfOC0zLTEtMS0xMDQxMzY_25c4958a-3613-4b33-bf91-e7b5fcf9eb9c">295,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT ASSETS:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTAtMS0xLTEtMTA0MTM2_649015c5-09df-42ed-9311-1b2f3fba312b">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTAtMy0xLTEtMTA0MTM2_09520d92-b25c-44c3-9fb3-2cc650930da2">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTEtMS0xLTEtMTA0MTM2_108dd3d0-df3e-4ded-bfc4-9a3a7d554792">555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTEtMy0xLTEtMTA0MTM2_f77ac4d0-6675-4f1b-8476-1957fd3cfab6">398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTItMS0xLTEtMTA0MTM2_fdaaa799-c2f1-4ec4-9184-dbdb31f6061b">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTItMy0xLTEtMTA0MTM2_ae651fbd-4faa-452b-94b1-418e0ae186be">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTMtMS0xLTEtMTA0MTM2_27c2fa38-4c17-4c8c-94b7-43268a4900f4">2,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTMtMy0xLTEtMTA0MTM2_bb1d593d-8164-4d18-9fa5-f90b07e1786a">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTQtMS0xLTEtMTA0MTM2_25b8a68a-e920-4584-9cb0-c85bf59b240e">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTQtMy0xLTEtMTA0MTM2_8e964ccc-4288-4631-bd17-cae0b667dc2e">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTUtMS0xLTEtMTA0MTM2_5500e237-b712-4bd4-8b08-5b0f039e15f4">224,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTUtMy0xLTEtMTA0MTM2_33b80224-5755-469e-ab57-d0a127ed9b07">300,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTgtMS0xLTEtMTA0MTM2_5c065c2c-1a45-4e3d-88f1-3ce197d62c15">19,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTgtMy0xLTEtMTA0MTM2_aa80e48e-b09d-4455-8fe0-55dc064753bf">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTktMS0xLTEtMTA0MTM2_46e56ddf-a021-4671-bf16-340dfec93621">7,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTktMy0xLTEtMTA0MTM2_35b91e2f-6ccc-4388-9037-247f7fdda653">10,308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjAtMS0xLTEtMTA0MTM2_ef2833f4-b667-4566-bb22-86b3fab7012b">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjAtMy0xLTEtMTA0MTM2_1e7a00da-c55a-47ac-9485-7736e1c5822b">2,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjEtMS0xLTEtMTA0MTM2_2adeacb9-c99d-45dd-85b2-901ddfe252d9">29,533</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjEtMy0xLTEtMTA0MTM2_39158612-7e1e-4b10-bf06-3468613c3da3">15,107</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjMtMS0xLTEtMTA0MTM2_cc198d43-3467-4dfa-9993-49a6a59636d3">425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjMtMy0xLTEtMTA0MTM2_27489017-50b2-419c-8d9a-50b9741dd7f9">1,379</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjQtMS0xLTEtMTA0MTM2_3e40407b-ccb7-432e-ba6b-43469dea1df2">29,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjQtMy0xLTEtMTA0MTM2_56162f9d-24a2-46c6-b0a6-a958d7b07626">16,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjYtMS0xLTEtMTA0MTM2_9bf950fc-5ca4-41ff-9377-8c3fe72e0896"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjYtMy0xLTEtMTA0MTM2_f986a9f9-f7c6-455d-8b78-92d697af3652"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDUw_5614bd2c-79d7-4b10-861e-96acf62d6f5f"><ix:nonFraction unitRef="gbpPerShare" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDUw_84d60964-9626-4a3a-84b4-f2a4e1d6866d">0.008</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_3ad59db3-3281-4dc7-a61f-d500e6214889"><ix:nonFraction unitRef="shares" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_92024132-5f2d-4b17-b021-7a098dabb7fa"><ix:nonFraction unitRef="shares" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_9ebb4c1a-ce62-4f04-a4d2-9c68d6c7ec51">42,554,384</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_3070fbe9-7aee-4ca3-b600-d739dd38b046"><ix:nonFraction unitRef="shares" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_87e306fb-c781-43b5-8f0c-2b4fb886dd48"><ix:nonFraction unitRef="shares" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_d903db7a-36ed-461e-9015-eac286f1a7a1">42,019,874</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMS0xLTEtMTA0MTM2_5e454983-6e37-4d3e-84d0-c38750c45a32">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMy0xLTEtMTA0MTM2_86f4882c-17a2-4d47-a4da-9b13684e4456">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDIw_2ca43e7e-4ac0-4018-828c-4665c19683d4"><ix:nonFraction unitRef="gbpPerShare" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDIw_f91c4667-0502-4178-8137-27f0d458386e">21,921.504</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_7584eeef-99b0-4297-9a1e-cf425eaacc98"><ix:nonFraction unitRef="shares" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_7c1f8640-ffac-4d64-b2b3-99fb4af5a74b"><ix:nonFraction unitRef="shares" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_89f30b60-28e4-4012-b7c5-60f52375a5e5"><ix:nonFraction unitRef="shares" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_ca1d484b-9880-4260-b7cb-6592326eb636"><ix:nonFraction unitRef="shares" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_cfd85e04-0082-46ff-9797-e0ed6ef04925"><ix:nonFraction unitRef="shares" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_ece06e4d-9651-476c-ad47-9e4c1dd70607">one</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> share authorized, issued and outstanding at September 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMS0xLTEtMTA0MTM2_eb2c81a8-1b9f-435a-a322-85997ff510d0">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMy0xLTEtMTA0MTM2_4bd3eb5a-a336-4f18-9c48-9ac607a98467">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzAtMS0xLTEtMTA0MTM2_690bd229-c4aa-4632-a377-6e2fa66291e6">454,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzAtMy0xLTEtMTA0MTM2_c2d9d336-77e7-4325-aecd-6744681f1659">444,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss)/income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzEtMS0xLTEtMTA0MTM2_0116814d-07ee-44ad-94c8-74208b80bbd0">30,643</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzEtMy0xLTEtMTA0MTM2_ce08f612-f857-4dc8-bd83-0beeec7b3167">8,840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzItMS0xLTEtMTA0MTM2_15010639-d825-4165-bb89-cf974e4a523a">230,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzItMy0xLTEtMTA0MTM2_18cfd6ac-4683-4aea-917c-c8e77e92fdfa">169,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzMtMS0xLTEtMTA0MTM2_3abb39d5-983a-465e-a0d9-3cb97c61d8cb">194,562</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzMtMy0xLTEtMTA0MTM2_d545ae9f-289b-44f5-8b10-5bc3fffb50c9">284,412</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzQtMS0xLTEtMTA0MTM2_0e940dbe-e0ca-44af-8322-416a7adaa204">224,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzQtMy0xLTEtMTA0MTM2_a40077b8-181b-44c9-a518-b7abd69aef01">300,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</span></div><div style="text-align:justify"><span><br/></span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_28"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy0xLTEtMS0xMDQxMzY_bac6a4f2-9b0f-4180-90ee-ada63d1544a3">13,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy0zLTEtMS0xMDQxMzY_c9817bab-fab1-4a2a-932d-ce9e61eec6d5">12,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy01LTEtMS0xMDQxMzY_bca15a8e-293c-4987-b057-a392af17bf66">45,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy03LTEtMS0xMDQxMzY_fe5241f0-4b4c-4281-b9fd-419f9d21e478">30,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC0xLTEtMS0xMDQxMzY_e19e4024-01b1-447c-baf9-f39975f04dbf">11,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC0zLTEtMS0xMDQxMzY_2c1de744-56b2-486a-b85d-65911fd286a3">9,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC01LTEtMS0xMDQxMzY_99bdc94b-b801-491c-adda-39a250579e8c">32,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC03LTEtMS0xMDQxMzY_577d0156-9830-41d6-8a33-a2035fb5c946">24,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS0xLTEtMS0xMDQxMzY_2efa4470-a4e8-49f4-a229-8c7ae0bb7f19">25,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS0zLTEtMS0xMDQxMzY_04422109-2475-4b60-b503-ee6fdf49c406">21,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS01LTEtMS0xMDQxMzY_2651d6f2-8620-4747-9385-267a9bf904a4">78,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS03LTEtMS0xMDQxMzY_0f62386b-ba5f-42be-b978-4d5666adcd9d">54,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi0xLTEtMS0xMDQxMzY_0a074d83-9c46-4948-b737-132821f6eff0">25,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi0zLTEtMS0xMDQxMzY_87f3dff6-97ae-4b95-8f74-aaf739ee96ad">21,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi01LTEtMS0xMDQxMzY_35e18a2d-ca3f-4e9c-ab4f-f81821d5dc50">78,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi03LTEtMS0xMDQxMzY_c6ed773e-bb5b-4110-825b-e3bff787e6b3">54,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC0xLTEtMS0xMDQxMzY_2b384d67-70fc-4929-8f16-6cc2419be2e9">3,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC0zLTEtMS0xMDQxMzY_0348fdf0-2d78-44d7-8dce-f9c022e7f5b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC01LTEtMS0xMDQxMzY_125a76bc-982f-46c8-ac4b-bbd3c111c5a5">3,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC03LTEtMS0xMDQxMzY_9bfea561-4efb-4393-ba80-78fe838fee0e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS0xLTEtMS0xMDQxMzY_4c88c8dd-18c6-41d2-91bc-8a7d82e852d3">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS0zLTEtMS0xMDQxMzY_d410452a-efe6-47f4-a2af-502de776b28d">3,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS01LTEtMS0xMDQxMzY_959219ef-334b-4b99-81fd-6e1789968162">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS03LTEtMS0xMDQxMzY_c749720a-18cd-4bf5-9545-45688036e269">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtMS0xLTEtMTA0MTM2_4ab72ad6-d937-49e2-8cd6-ed3e701bcebd">2,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtMy0xLTEtMTA0MTM2_6e707df4-c020-4aa7-88e3-0c4c10283719">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtNS0xLTEtMTA0MTM2_0e303e6f-69f0-45a4-a818-3a994f293b2a">9,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtNy0xLTEtMTA0MTM2_dcdb6952-d626-47b7-8176-f02ea72eb1c8">6,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtMS0xLTEtMTA0MTM2_b601fe1f-8069-4c5c-a47e-0ce004b43637">7,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtMy0xLTEtMTA0MTM2_f1beba89-0cc7-4d0e-a758-b0094023f835">5,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtNS0xLTEtMTA0MTM2_ee49984e-710c-435d-b40b-dfa564e19fd7">17,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtNy0xLTEtMTA0MTM2_29ff1a86-24c3-4cb6-8177-85e586ccefe9">8,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItMS0xLTEtMTA0MTM2_9fab2541-46d9-47d4-8cfc-eca1dda0b180">18,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItMy0xLTEtMTA0MTM2_b4135b87-65cc-43ee-b748-85413bbb81d4">15,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItNS0xLTEtMTA0MTM2_2bd4e8fa-d881-4e2f-accf-e984f5a24e49">60,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItNy0xLTEtMTA0MTM2_079475d7-7449-4af2-bed1-51defc554fb8">45,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtMS0xLTEtMTA0MTM2_c4e5a32b-2263-4f89-ba13-3fc88f3dd8e5">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtMy0xLTEtMTA0MTM2_a5e19509-9d87-479e-b827-2b3c23626951">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtNS0xLTEtMTA0MTM2_85288f40-c566-47ec-8d8e-40f589b38bc7">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtNy0xLTEtMTA0MTM2_e292ae97-15eb-4afe-b345-cee27063264c">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtMS0xLTEtMTA0MTM2_fd43d91a-2a58-4f58-bde5-473aa5897cb1">18,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtMy0xLTEtMTA0MTM2_8b7e1d46-7cff-4d5e-82fc-eb6e25b9b55c">15,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtNS0xLTEtMTA0MTM2_936e523f-b89d-4e06-b090-12b0e77269e5">60,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtNy0xLTEtMTA0MTM2_257a5202-7d03-4e58-ab0d-897e507dd52a">46,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtMS0xLTEtMTA0MTM2_db22f148-7568-4deb-b26f-d7a51d5d1dca">15,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtMy0xLTEtMTA0MTM2_34ce8fbc-d6bb-4f04-8591-af0c941465de">8,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtNS0xLTEtMTA0MTM2_c819421d-f26f-41fc-824a-21eade625d20">39,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtNy0xLTEtMTA0MTM2_2b6a6fa5-2002-4ffa-b373-c3bc2bca4dac">6,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctMS0xLTEtMTA0MTM2_cda23808-6be7-4e0e-8bfc-c80ef4c47713">33,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctMy0xLTEtMTA0MTM2_4175607b-a686-4b25-9077-f483b34e1002">24,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctNS0xLTEtMTA0MTM2_1a655ebf-4010-4bda-b1c5-2b9fd161ffc5">100,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctNy0xLTEtMTA0MTM2_0ea63f0d-b8c6-4993-9116-34b566deabbe">52,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders&#8212;basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMS0xLTEtMTA0MTM2_9b0a06c5-3500-4d80-ab2c-5645f8c22303"><ix:nonFraction unitRef="usdPerShare" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMS0xLTEtMTA0MTM2_b2f95888-8166-42c1-a3cf-541f2bf200b5">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMy0xLTEtMTA0MTM2_47477322-f876-45b4-bbe7-d37f46637dab"><ix:nonFraction unitRef="usdPerShare" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMy0xLTEtMTA0MTM2_a20c1ad0-c162-4041-a78e-cf2062b010a9">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNS0xLTEtMTA0MTM2_59c778bd-0ec7-4408-8869-32918940b9ba"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNS0xLTEtMTA0MTM2_b2dcd02b-1b35-4899-be99-d43edc9cb2ff">1.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNy0xLTEtMTA0MTM2_6289e683-f587-4cd3-8623-82d6420bb078"><ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNy0xLTEtMTA0MTM2_f3ea93e2-4df0-40bb-8f3e-e606cd6cf2c6">1.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ordinary shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMS0xLTEtMTA0MTM2_af1c51eb-ef91-4a1c-aeff-bd98dd83a166"><ix:nonFraction unitRef="shares" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMS0xLTEtMTA0MTM2_d6ac0a4a-61b2-4ff4-9e17-bbad927b6863">42,525,855</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMy0xLTEtMTA0MTM2_54d6696b-44a7-4e39-9edd-6f1089cc7d34"><ix:nonFraction unitRef="shares" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMy0xLTEtMTA0MTM2_aa3e67ad-4bdd-4aa0-b965-20087b895c6b">41,708,220</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNS0xLTEtMTA0MTM2_472d6d6f-0ff5-4f72-bd4f-e27360f08382"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNS0xLTEtMTA0MTM2_4c5deaa4-fee3-4b02-b0a0-a64fe4ba5a52">42,377,895</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNy0xLTEtMTA0MTM2_3b524fa0-14cb-4d35-b1fc-a1b520860dad"><ix:nonFraction unitRef="shares" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNy0xLTEtMTA0MTM2_888c188d-4882-4bae-8f57-65c2e004f067">39,378,824</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</span></div><div style="text-align:justify"><span><br/></span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.210%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ORDINARY SHARES &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMC0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjoyYWM5OTk3NTVhZmM0MGFjODVjMGJlZjc4YmU1YzdlOV8xNjQ5MjY3NDQxNjg4_5614bd2c-79d7-4b10-861e-96acf62d6f5f"><ix:nonFraction unitRef="gbpPerShare" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMC0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjoyYWM5OTk3NTVhZmM0MGFjODVjMGJlZjc4YmU1YzdlOV8xNjQ5MjY3NDQxNjg4_84d60964-9626-4a3a-84b4-f2a4e1d6866d">0.008</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DEFERRED SHARES </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PAR VALUE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMS01LTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjowNjc0N2QyNzBmYjQ0ZmFiYmVlMmZjMDNmOTBlMzFmZV81NDk3NTU4MTM5MDY_2ca43e7e-4ac0-4018-828c-4665c19683d4"><ix:nonFraction unitRef="gbpPerShare" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMS01LTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjowNjc0N2QyNzBmYjQ0ZmFiYmVlMmZjMDNmOTBlMzFmZV81NDk3NTU4MTM5MDY_f91c4667-0502-4178-8137-27f0d458386e">21,921.504</ix:nonFraction></ix:nonFraction> PAR VALUE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95405ef6eec44bbaac9fdee032a0137a_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xLTEtMS0xMDQxMzY_a33d6cec-8bc4-4bbe-8dcc-48a3a4b907c4">35,930,331</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95405ef6eec44bbaac9fdee032a0137a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0zLTEtMS0xMDQxMzY_1ec1e1ed-f0ad-41ba-8375-3a9ad747d0f2">367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78c91b535c5d4deab01c85d4d735656c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy01LTEtMS0xMDQxMzY_94f9608f-2f5e-4ed0-827e-0040d780c641">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c91b535c5d4deab01c85d4d735656c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy03LTEtMS0xMDQxMzY_0532dd6c-d69b-4ef8-9f6a-82dc29a32f74">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85a709a97804361a3e0501cf690f852_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy05LTEtMS0xMDQxMzY_f9f015f8-6342-4b94-aa70-8bd342e26c13">279,480</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e99a1e2762468ba33ad456ee6384e8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xMS0xLTEtMTA0MTM2_b0501a6a-12d4-46d3-952a-a3d36b52a851">14,585</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i946e6c79976c439793df16cc9ad150f0_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xMy0xLTEtMTA0MTM2_2b8bcdee-7ff1-4fec-9287-1bb455d96637">97,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7d6429579e4d5489d901de0c7b760d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xNS0xLTEtMTA0MTM2_3e62d78c-0c7a-43de-9e69-b5aac2194fc9">196,561</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39e7c838434a4743bb3511c468433615_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0xLTEtMS0xMDQxMzY_8c6dfb86-ad1a-47ed-bc70-afe045fcebe2">581,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e7c838434a4743bb3511c468433615_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0zLTEtMS0xMDQxMzY_dc88c932-d4b0-43f7-b5fe-fe6873c352d9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc87b096855342a28b7610a6c449b3cf_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC05LTEtMS0xMDQxMzY_11c6a71e-85e1-43b5-90fc-3008874860d7">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1066678671241ee8df1293eba5ee43f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0xNS0xLTEtMTA0MTM2_ebd4143c-83a0-4522-8a2e-e1fc1396fd70">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares due to options exercised in previous year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0xLTEtMS0xMDQxMzY_a550e5d7-4603-4973-8d8e-ea3e80e6d9cd">232,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0zLTEtMS0xMDQxMzY_a2a10398-9202-4883-8a2c-970d87e761b2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89069162ebf84150934609fed74281ea_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS05LTEtMS0xMDQxMzY_be9c9a9a-5644-4fd4-bdfa-2fd83c4fcef7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7a414f30d846af97155958e7d21aa6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0xNS0xLTEtMTA0MTM2_c00a6a06-8054-48fc-ae0b-57ab3e408a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ad4c5e2814404694ba16c54c9efd7a_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNi05LTEtMS0xMDQxMzY_9d0235da-9032-4a63-8c70-44840261c640">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNi0xNS0xLTEtMTA0MTM2_fcf302a4-52fc-48a8-af4e-c076e738aba7">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9e32ee38ba4810ab4493f286127787_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNy0xMS0xLTEtMTA0MTM2_1de63ce1-29f6-4ebf-8b32-1f4047122175">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNy0xNS0xLTEtMTA0MTM2_9295a7e7-be82-4888-b506-8947e5792281">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c8df0b02b474d6d9d1369e7470155ce_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOC0xMy0xLTEtMTA0MTM2_e2d48f0c-6512-4e87-ad0d-a585f24f0f8f">12,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOC0xNS0xLTEtMTA0MTM2_73331340-b8f9-430d-9b36-4c2b96bd80f3">12,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a5c404dbf07411487c062c65fb44ea2_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xLTEtMS0xMDQxMzY_3d955e87-7911-4d56-be51-a4bf29791fed">36,743,886</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5c404dbf07411487c062c65fb44ea2_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0zLTEtMS0xMDQxMzY_d83996f7-9801-474e-9c53-b548032716bd">376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic794b704bc624a2c8e82ca8a90a87e57_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS01LTEtMS0xMDQxMzY_f0ff17db-8937-4304-bacb-9bf7b71b98ab">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic794b704bc624a2c8e82ca8a90a87e57_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS03LTEtMS0xMDQxMzY_8e089cce-111a-4c76-8162-624686ab8fa4">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d35501a7b994b798bb3b150095bde6a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS05LTEtMS0xMDQxMzY_2425dc8b-2aec-4508-b900-a39717ef3df3">282,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56a347d696345219a31e7675ac71b27_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xMS0xLTEtMTA0MTM2_2c23afaf-17a7-4429-a971-41337a8cd992">16,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6755946d0ae7463594da91d4a5e9a57a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xMy0xLTEtMTA0MTM2_e71a75b8-f74c-41a0-a9d7-8c9c01e23690">110,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5925242606241eda223f30a9b342280_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xNS0xLTEtMTA0MTM2_5879bfb1-50a7-4e01-987f-05caad4bc1ec">188,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMS0xLTEtMTA0MTM2_0ecefd65-9dab-44ce-b43e-4d4d44866ea5">4,600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMy0xLTEtMTA0MTM2_4ba81a95-2184-424c-b88f-2eeaf8f9d365">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtOS0xLTEtMTA0MTM2_728dc90d-7a5b-453b-b3dc-d84f4ba330fc">154,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMTUtMS0xLTEwNDEzNg_f77c7abc-0264-465f-becb-6294ed0a67c8">154,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMS0xLTEtMTA0MTM2_eb6a4ad8-d4ee-418b-b481-804fbb60cd58">351,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMy0xLTEtMTA0MTM2_5dec8286-f175-4ef2-bb57-d1b8ea2dea50">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItOS0xLTEtMTA0MTM2_6b85f441-892e-43de-88dc-fc4d48b1aa63">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMTUtMS0xLTEwNDEzNg_00f91cdb-091d-4e66-a298-aa6f9348d807">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTMtOS0xLTEtMTA0MTM2_c98cc3ce-c3f6-41a3-9d7c-b409ffb062bc">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTMtMTUtMS0xLTEwNDEzNg_5effb0c9-f597-4212-bf18-464c3f4948a3">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48210596e684e8b87d26aeeb8c60c98_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTQtMTEtMS0xLTEwNDEzNg_38ca5d7a-71dc-4aaa-a071-93c71d08d0ec">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTQtMTUtMS0xLTEwNDEzNg_fd80f229-d0e9-47a5-a6f8-18e5ee223cdd">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib515d46f69b343fc9a56d22004bb2629_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTUtMTMtMS0xLTEwNDEzNg_636d062c-af43-4c15-b294-bb0a62216413">17,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTUtMTUtMS0xLTEwNDEzNg_afb4b9fb-55de-4f9a-9a87-42a7ce1b722d">17,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13bdb58279f54f18a78e5e0b660a5a40_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMS0xLTEtMTA0MTM2_78f55a2a-f754-4e93-846d-fdea3f06a1d4">41,695,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bdb58279f54f18a78e5e0b660a5a40_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMy0xLTEtMTA0MTM2_91ab6b22-a4a7-46d6-bf13-ce637f07bb49">431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98da39a461bd466bb89f458b884735f4_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtNS0xLTEtMTA0MTM2_0a7ff0c8-8351-4290-b321-704f11fec571">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98da39a461bd466bb89f458b884735f4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtNy0xLTEtMTA0MTM2_b85fef89-0f8b-407d-94d6-cb24a1fa9e20">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185ef63d08ed431a91fd1bb8a28346cc_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtOS0xLTEtMTA0MTM2_bf52a8f8-9fd5-4184-969d-0bdac12089ef">438,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c092cad9544d7182cc6b0f1ebbbbbd_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTEtMS0xLTEwNDEzNg_fa682380-e96c-40b1-84d3-654a212f2458">16,218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i060c433da7a748b5839bed1921540abe_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTMtMS0xLTEwNDEzNg_b62f9b70-d581-4403-9644-1af58d9313f5">128,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2f615c6fb3418d80683fcbc8681e63_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTUtMS0xLTEwNDEzNg_fa88e62a-f7ec-47bc-b21e-71bfd63c5592">327,360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMS0xLTEtMTA0NDIz_5ffa391c-3cde-4070-814a-c246a5cb4f67">23,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtOS0xLTEtMTA0NDIz_b78c0b61-cf02-4032-9462-114a64aa87fb">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTUtMS0xLTEwNDQyMw_67a7d01f-8c2e-47bc-901e-c1338b44af23">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMS0xLTEtMTA0NDE3_c78a02f2-348a-440a-b350-de09b93117aa">12,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMTUtMS0xLTEwNDQyMw_b5c87d0d-6c12-4381-877c-eca3dc2eb3af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtOS0xLTEtMTA0NDIz_89a1871e-7f3e-4392-a5d4-48c8b3e01c50">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMTUtMS0xLTEwNDQyMw_d6e541be-e01d-4e32-928d-87009580fd2c">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie12fd33674544d41aa2a56f391291315_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTEtMS0xLTEwNDQyMw_ba9aff18-9627-4e04-99ed-12206a8f1ce6">8,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTUtMS0xLTEwNDQyMw_a0b1bca2-f879-4e68-9fd0-c0401f0e9748">8,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06c40baf5bb840f4a2732edb5af34c95_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTMtMS0xLTEwNDQyMw_dcef3e3e-f53b-4615-9782-609d45889bf0">15,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTUtMS0xLTEwNDQyMw_8a50ed1a-6939-4a28-a4f0-006e654ad021">15,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMS0xLTEtMTA0NDE3_3ffb96b6-d94d-49bb-9779-9197d91d2fb4">41,731,180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMy0xLTEtMTA0NDIz_e08dc9e2-49bb-43d6-98ac-8f4760d61814">431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47c008660987437795f6004bdf3aa8f2_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtNS0xLTEtMTA0NDIz_a0158ac9-1d87-4a46-90ab-c8433ff75e3a">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c008660987437795f6004bdf3aa8f2_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtNy0xLTEtMTA0NDIz_64ffeada-3f47-4781-b221-48dd8c4bfb4b">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae288fd8ae146d4bc365c5abf5bc0d8_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtOS0xLTEtMTA0NDIz_66dedac3-d40c-4e2f-9e87-d4409bf0caf9">441,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9479266e364845e5bcca2f38d03e9949_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTEtMS0xLTEwNDQyMw_2b5f37bf-ea42-43b1-ae32-a4b0e4d2aaa4">7,817</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a02125e33964e9fa1af31b586645796_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTMtMS0xLTEwNDQyMw_b55f9530-8c1a-4230-8955-ca89d8cd023a">143,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTUtMS0xLTEwNDQyMw_8f39e818-9d81-4c7f-ae9b-effc2e0174c8">305,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.210%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ORDINARY SHARES &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA4NTg5L3RleHRyZWdpb246YWJmZWNmNDlkMDhkNDBmNzhiNzkzM2ZlM2MwODM1ZjNfMjE_5614bd2c-79d7-4b10-861e-96acf62d6f5f"><ix:nonFraction unitRef="gbpPerShare" contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA4NTg5L3RleHRyZWdpb246YWJmZWNmNDlkMDhkNDBmNzhiNzkzM2ZlM2MwODM1ZjNfMjE_84d60964-9626-4a3a-84b4-f2a4e1d6866d">0.008</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DEFERRED SHARES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PAR VALUE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctNS0xLTEtMTA4NTg5L3RleHRyZWdpb246YjA0ZjYwZWUzYWVjNDJiZDgxMmQ5MjA2NzRlZmUxNjhfNQ_2ca43e7e-4ac0-4018-828c-4665c19683d4"><ix:nonFraction unitRef="gbpPerShare" contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctNS0xLTEtMTA4NTg5L3RleHRyZWdpb246YjA0ZjYwZWUzYWVjNDJiZDgxMmQ5MjA2NzRlZmUxNjhfNQ_f91c4667-0502-4178-8137-27f0d458386e">21,921.504</ix:nonFraction></ix:nonFraction> PAR VALUE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99d27dd8120d4b11b43f64710a22d3ca_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMS0xLTEtMTA0MTM2_9c625471-5baa-4460-a360-c5fee4f5b67c">42,019,874</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d27dd8120d4b11b43f64710a22d3ca_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMy0xLTEtMTA0MTM2_658c30b4-5d12-46f8-892b-a9b13be97f28">435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792cfb0299e04fd8a2fdee2f25255774_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtNS0xLTEtMTA0MTM2_b90e013e-d1b1-4059-82cc-6d70da64d123">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792cfb0299e04fd8a2fdee2f25255774_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtNy0xLTEtMTA0MTM2_9389f9b6-ba37-4e31-aee6-5582645774b0">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125f25c0dca643febb4347815b8ad76f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtOS0xLTEtMTA0MTM2_1b8a5a72-684e-4311-81bd-ce2931afa359">444,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84383e2bd7e84205988fc419ca82f7c6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTEtMS0xLTEwNDEzNg_fb7a5dde-08ff-452f-94bd-25734bfee7ca">8,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c315e44b8bc431fa86ce4c0715a7db0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTMtMS0xLTEwNDEzNg_c3f66d18-3790-4455-92d5-d8d0b78b5794">169,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTUtMS0xLTEwNDEzNg_f8495499-1b0e-4616-ad5c-53459a36cbec">284,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMS0xLTEtMTA0MTM2_9f5c580c-05ed-4446-ae07-326a3cb18950">376,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMy0xLTEtMTA0MTM2_51d3eec9-a63f-48e0-8162-b691a571a13b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktOS0xLTEtMTA0MTM2_40060c5f-52a6-40d8-a48b-a835e3de3ac1">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMTUtMS0xLTEwNDEzNg_adb334ef-f2fd-45e3-a576-f3f36c5c8c6b">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMS0xLTEtMTA0MTM2_8ca55c24-7748-4efc-b9da-cf3f186e55a5">68,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMy0xLTEtMTA0MTM2_7ad4ceb2-559c-4f62-9cee-02543bef6b83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMTUtMS0xLTEwNDEzNg_3fc9d877-6c3c-4bbc-842d-8a423b90d8f9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtOS0xLTEtMTA0MTM2_3db08763-3461-4d5c-8862-12777c498c37">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTUtMS0xLTEwNDEzNg_7abe19cd-ee25-4445-8bb6-dbfabb9cb118">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebfc5653c5b8429d8f749dc4fedac7c8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTEtMS0xLTEwNDEzNg_806cc899-a60c-4b39-b7e6-d69464952fbb">7,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTUtMS0xLTEwNDEzNg_c71f3177-c5b6-4837-893f-f47458131375">7,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091b6e0de623464a98074345e2575290_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTMtMS0xLTEwNDEzNg_ada1816e-c590-45fc-bbed-3fcf97294e4e">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTUtMS0xLTEwNDEzNg_a84d114b-28ef-4c53-9710-374f06ce26b9">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMS0xLTEtMTA0MTM2_078f12e9-6094-4059-8c19-6e64c1c415d1">42,464,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMy0xLTEtMTA0MTM2_34ff4c55-f245-4719-a033-468ea1791a88">440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7dd95d805cd40f39509fb6515797148_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtNS0xLTEtMTA0MTM2_7f9dccc9-3b38-4ca2-b877-bc15d6366924">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7dd95d805cd40f39509fb6515797148_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtNy0xLTEtMTA0MTM2_825f9992-8a89-4271-9984-3c35c74bf0c5">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb224cca99b54f1db1729d2b867bfada_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtOS0xLTEtMTA0MTM2_2c3f0ecc-c64b-4a22-92ca-03e7aab0466c">448,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8bc5bae85b48c9924bda0d62dcbc4d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTEtMS0xLTEwNDEzNg_51b49bcf-e120-4f1e-bad5-42657713c9cb">1,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fb3a6d558d7437b86d516564947533b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTMtMS0xLTEwNDEzNg_beece4d0-d4e3-4efb-8702-621d4ac352b3">190,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666fe11914564071afc01b589931e866_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTUtMS0xLTEwNDEzNg_1bb4b2ce-6934-49bd-86ec-749618c0997f">259,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA0MTM2_cf3d922f-8305-4b94-be4d-5add5c8a17f3">55,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtOS0xLTEtMTA0MTM2_dc4ec43a-e5ec-4fa2-b036-f1c9148cd0b7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMTUtMS0xLTEwNDEzNg_4d39dff8-15d0-4135-bab0-216c6c90bc2c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctMS0xLTEtMTA0MTM2_c9e259af-4b98-4e89-bc3c-cf6270c303b6">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctMTUtMS0xLTEwNDEzNg_9dd4166f-20be-42bd-b8ef-066f40e91129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjgtOS0xLTEtMTA0MTM2_67af368c-bee3-4da0-8f62-30391ae63552">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjgtMTUtMS0xLTEwNDEzNg_b0d52ce8-f6e8-4ebf-9692-af83eab47ac5">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96551c10145d4467af80d00b2f8ec49e_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjktMTEtMS0xLTEwNDEzNg_0b6ca58a-2ca5-46bd-9cd8-a3742a2b2c12">17,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjktMTUtMS0xLTEwNDEzNg_753d72be-e9bb-4126-a461-55c28e9065c2">17,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib906b2d3cb24439f813b95288f8ba9ec_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzAtMTMtMS0xLTEwNDEzNg_f2ef9d28-fcd2-4e6a-8ac3-1ce3b65bb89e">21,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzAtMTUtMS0xLTEwNDEzNg_eec313d0-10d7-4bc4-a2ec-3c54a5633b11">21,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i040af099c030461699b8808e3daabecc_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMS0xLTEtMTA0MTM2_0788bb83-f540-43df-8414-f3cb43cdd6f5">42,522,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040af099c030461699b8808e3daabecc_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMy0xLTEtMTA0MTM2_8065656f-e2f5-4761-a4e9-d6f083dcae83">440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e0eac4c061d4c7fb0a29e209902295d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtNS0xLTEtMTA0MTM2_74ef385e-83d1-45b3-b582-08323f22c4ef">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0eac4c061d4c7fb0a29e209902295d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtNy0xLTEtMTA0MTM2_eccea79e-df47-493b-b316-7d44f0fe94dc">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie748da8f76a746f280de5263b489baed_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtOS0xLTEtMTA0MTM2_2fc6e7c7-6598-4440-96a5-2f61e7d38419">451,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a070c3e49fc4a47b4a3837aa83925d6_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTEtMS0xLTEwNDEzNg_9e196db3-ee7a-4661-9ea7-31da8abf327a">15,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic982ac60ad0243d6a23af0d1772047e6_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTMtMS0xLTEwNDEzNg_9153411b-9d7b-47c8-bc60-2c74c9bf1970">211,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4807ff1430444da1b1c019311c325e45_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTUtMS0xLTEwNDEzNg_796fdbf5-d366-4d45-bfec-f0375966c6b3">224,585</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDAtMS0xLTEtMTA0NTE3_d1913e00-952e-4393-bfe4-43c2752dd91e">29,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDEtMS0xLTEtMTA0NTE3_db6f145e-8cbe-4ddb-8bad-c1df15584a7c">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27028a6c13f4e2185c22066785a346c_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDItOS0xLTEtMTA0NTE3_95c52932-ebd3-48bb-9c38-0ebfb770d3d3">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDItMTUtMS0xLTEwNDUxNw_b25a2fae-b8ab-4001-a9b2-6f5a6d9961ac">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37af0655d52644088f3ca93ae36fddc8_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDMtMTEtMS0xLTEwNDUxNw_98b2736b-4622-47ca-9354-cc35be75e910">15,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDMtMTUtMS0xLTEwNDUxNw_a101e53f-afc9-495c-974a-5e674f3fe82f">15,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d0006602ef04e3ea9db6289df6795e2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDQtMTMtMS0xLTEwNDUxNw_f66def56-a8d5-4410-9437-1470b8e98a1d">18,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDQtMTUtMS0xLTEwNDUxNw_6488cd75-fe19-447c-9b8c-90727d214278">18,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMS0xLTEtMTA0NTE3_504fbfeb-d45b-434d-8f58-e23d5e8acbd0">42,554,384</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMy0xLTEtMTA0NTE3_94ce34b1-1ae2-4217-bf35-44d3f54138b9">440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3137c453e903495eaaf7d9ad3254c18d_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtNS0xLTEtMTA0NTE3_210e9fd4-5f2a-4161-9831-eb6943f04070">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3137c453e903495eaaf7d9ad3254c18d_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtNy0xLTEtMTA0NTE3_50fb3804-85d8-4931-955c-ecc1c2aed8fd">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4120f8256c42b8b85596ceb05ffa7b_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtOS0xLTEtMTA0NTE3_8a7163a1-dfea-420c-8910-b822663a5544">454,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e65128b96b64b4d953bc090ea8f9461_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTEtMS0xLTEwNDUxNw_d40c744d-7a3e-4d5e-8b1b-0b5d4f224181">30,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e8120c9d53e4a378e74d67421c6687c_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTMtMS0xLTEwNDUxNw_78e78aef-4ea0-4790-a925-2c524b5a800f">230,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTUtMS0xLTEwNDUxNw_83d1be6d-9637-47f7-b12b-5f79c3dfafaf">194,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_34"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMy0xLTEtMS0xMDQxMzY_22cb3161-7234-424d-882d-38dd1102240c">60,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMy0zLTEtMS0xMDQxMzY_3fd6568a-4da8-45f3-888b-38339ad9e26f">46,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNS0xLTEtMS0xMDQxMzY_d507603b-79dd-42bb-88b5-1a11a3ed3174">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNS0zLTEtMS0xMDQxMzY_abbb7d52-6417-4fef-80c7-264b7025e647">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain on foreign currency remeasurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNi0xLTEtMS0xMDQxMzY_1ff939c4-f6f3-413a-ad82-078797641521">3,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNi0zLTEtMS0xMDQxMzY_557d55dc-d773-4cc1-8097-380a923ae3ae">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNy0xLTEtMS0xMDQxMzY_431f39d6-ec2c-4222-b80e-e17b34ef8f94">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNy0zLTEtMS0xMDQxMzY_53bd9faa-2690-485c-b241-b2f48c4ddd16">5,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfOC0xLTEtMS0xMDQxMzY_be27045c-8d44-4542-9280-0fc51e91e1a4">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfOC0zLTEtMS0xMDQxMzY_f331d818-9fba-4eaf-9a6e-9b638d1c96e1">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTAtMS0xLTEtMTA0MTM2_112a445e-3b08-48ec-bdfc-c54cc1f3253f">30,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTAtMy0xLTEtMTA0MTM2_fdd04858-c2e0-4647-9f0f-815d374600ca">6,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and prepaid tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTEtMS0xLTEtMTA0MTM2_dae0cb0c-019c-46f8-a633-305f4ceb4597">1,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTEtMy0xLTEtMTA0MTM2_ad24df9a-d90a-4d25-a8a0-f988dc87a85b">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTItMS0xLTEtMTA0MTM2_7612f67d-75fb-4c5c-8839-99ce96410c36">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTItMy0xLTEtMTA0MTM2_041b7da8-9f23-4371-b5f3-d5577a3478ba">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTMtMS0xLTEtMTA0MTM2_bf911fff-1740-4cf9-b9b7-06054e398847">1,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTMtMy0xLTEtMTA0MTM2_e49324e2-3fbe-4be0-949b-dbbc26ddbcd5">1,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTQtMS0xLTEtMTA0MTM2_084cb555-f000-45a5-aca7-6ded4d9a064e">20,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTQtMy0xLTEtMTA0MTM2_6b44981a-5e12-4131-971b-58937b70bd2f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTUtMS0xLTEtMTA0MTM2_f17bbe0a-524e-4db7-b1ea-c2c85fdfdb9b">1,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTUtMy0xLTEtMTA0MTM2_2e1fa3f1-4540-4994-a619-8625e196047a">2,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTYtMS0xLTEtMTA0MTM2_5cef89c7-6adf-4048-9f7e-0fec616ec6dc">60,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTYtMy0xLTEtMTA0MTM2_6439c688-bcd5-4f44-9204-81f74dbf331d">45,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTgtMS0xLTEtMTA0MTM2_0d60f094-63c1-4d25-984a-ccca89a1a71c">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTgtMy0xLTEtMTA0MTM2_6e110c59-2db5-4998-9b51-b459ca81a2dd">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTktMS0xLTEtMTA0MTM2_1b01e089-4bfc-4925-9126-7999d8010c54">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTktMy0xLTEtMTA0MTM2_fab51ec0-a1a2-419c-91e3-fcf61e4bdb76">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjEtMS0xLTEtMTA0MTM2_a869377d-4138-479f-9af9-c70336c702d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjEtMy0xLTEtMTA0MTM2_dd712fad-a4b4-4cdf-af4c-9b38b43e9803">154,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjItMS0xLTEtMTA0MTM2_8daedac5-74e5-41be-ad9a-c6151682be4d">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjItMy0xLTEtMTA0MTM2_0be55ab0-abbc-4b14-a057-e1451cba9a86">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjQtMS0xLTEtMTA0MTM2_568d34be-930d-4258-809b-c981a138fca8">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjQtMy0xLTEtMTA0MTM2_ed463eb1-7b0c-495f-acf9-2f64093c1db7">155,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjUtMS0xLTEtMTA0MTM2_17dc2287-c9c7-4525-b810-105c4991c1b6">39,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjUtMy0xLTEtMTA0MTM2_5092b7f1-ccc3-4a79-968c-04441c9e6fd7">6,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease)/increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjYtMS0xLTEtMTA0MTM2_2e6ffacf-e3ab-4295-bebc-fa57eb0ff75a">100,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjYtMy0xLTEtMTA0MTM2_cac32d51-1ee0-4d6a-a7bd-b5f5d6ab6a98">103,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjctMS0xLTEtMTA0MTM2_1011cd01-96a9-4093-8f17-b2bc735c08a5">273,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7d6429579e4d5489d901de0c7b760d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjctMy0xLTEtMTA0MTM2_a481fc71-1f12-4663-b8b6-1eca4a7c7ac4">190,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjgtMS0xLTEtMTA0MTM2_45f68cd5-e87b-47c2-a5e6-96ea6199680f">173,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjgtMy0xLTEtMTA0MTM2_95331d09-059a-4f59-a87c-f48bd08ded9d">294,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzEtMS0xLTEtMTA0MTM2_1690e1ce-9182-4f43-90eb-24ebe7219f0a">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzEtMy0xLTEtMTA0MTM2_69eea733-55ea-49a6-9d1d-570aa40fa39f">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options were received and recorded in other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="cmps:ProceedsFromStockOptionsExercisedNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzItMS0xLTEtMTA2MjUx_e5d1bb1d-5ff4-4267-bc78-efe474efb99e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="cmps:ProceedsFromStockOptionsExercisedNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzItMy0xLTEtMTA2MjYw_8b12cae4-3947-4ea2-86d6-b955db22eb7f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs included in accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="cmps:DeferredOfferingCostsIncludedInAccruedExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzMtMS0xLTEtMTA2MjUx_f50685ef-3a86-403f-9f8d-69382fc0969a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="cmps:DeferredOfferingCostsIncludedInAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzMtMy0xLTEtMTA2MjYw_ada449a9-2325-4d12-aef2-5094600c5b7d">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the cash, cash equivalents and restricted cash balances as of each of the periods, shown above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMi0xLTEtMS0xMDQxMzY_0024bad3-4131-4e23-afbc-6d7bcc3f1153">173,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMi0zLTEtMS0xMDQxMzY_392839b2-b72f-4dbf-8781-c686c7e1e76b">293,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMy0xLTEtMS0xMDQxMzY_271861b0-1dbb-4b14-ad9a-256f5dbe0d4c">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMy0zLTEtMS0xMDQxMzY_0b2df24c-51c5-4b45-9d81-c5974d449574">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfNC0xLTEtMS0xMDQxMzY_f67887d2-cb18-4291-bbd3-f6645a77481d">173,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfNC0zLTEtMS0xMDQxMzY_7b6a20df-9aaf-41d9-8b7f-9e871e67b5af">294,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_37"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_40"></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfNDg4Mw_0bc260fb-95a7-4f68-9146-330c7e7e0e8e" continuedAt="ic4623c967fed41379a066a15f3a5d574" escape="true">Nature of Business </ix:nonNumeric></span></div><ix:continuation id="ic4623c967fed41379a066a15f3a5d574"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and more recently through the sale of American Depository Shares, or ADSs, in connection with the Company&#8217;s initial public offering, or the IPO, in September 2020, and its $<ix:nonFraction unitRef="usd" contextRef="i728c5692d6704623aa8c0fcc42770d12_D20210501-20210531" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjcyOQ_d225fc8b-9b1c-4ed6-a41f-cb8c4a6bec1e">154.8</ix:nonFraction>&#160;million May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="i7191433cf01d4df1bb228323c1facbe9_I20211008" decimals="-5" name="cmps:SaleOfStockMaximumAmountAllowableForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjc0NQ_3fa1e5b7-522d-45f6-8673-1cc969b76537">150.0</ix:nonFraction>&#160;million of its ADSs, each representing <ix:nonFraction unitRef="number" contextRef="i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjc2MQ_53422fe4-87b2-44fa-93bc-88299c000cb5">one</ix:nonFraction> ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. The Company has not yet sold any ADSs under this at-the-market offering. The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTY0OTI2NzQ0NjU4Mw_7bc31c66-f300-4e95-9ff3-a2de6d7d5562">60.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTY0OTI2NzQ0NjU4Nw_0eca619d-2848-48ff-a5d4-9758d5235179">46.1</ix:nonFraction> million for the nine months ended September 30, 2022 and 2021, respectively. In addition, as of September&#160;30, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib94f580649ab49a0896b34592f4b080d_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMjI5Mg_5577f8ca-63ac-4491-8dd3-5b80350722f0">230.2</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the cash and cash equivalents on hand as of September&#160;30, 2022 of $<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfNTQ5NzU1ODE4ODAy_749ebfda-ee34-4bd1-9984-9aa8a46f23d8">173.1</ix:nonFraction> million will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, the Company continues to assess its business plans and the additional impact which resurgences or the emergence of new variants of COVID-19 may have on its ability to advance the development and manufacturing of COMP360 as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom it relies, or to raise further financing to support the development of its investigational COMP360 psilocybin therapy. While many measures have been put in place to attempt to contain the spread of COVID-19 resurgences, including existing or future variants, no assurances can be given that the Company will avoid any future impact from the ongoing COVID-19 pandemic or the emergence of new variants, including any direct or indirect impacts arising as a result of downturns in business sentiment generally or in its sector in particular, impacts on global supply chains, or other effects. The Company cannot currently predict the scope and severity of any future potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies or with whom the Company conducts business were to experience additional shutdowns or other business disruptions, the Company&#8217;s ability to conduct its business in the manner and on the timelines presently planned could be materially and adversely impacted.</span></div></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_46"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDc_49ddd08c-05ae-4d44-b850-44a3890df322" continuedAt="i05693e5c01ec43f382403268a85373de" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i05693e5c01ec43f382403268a85373de" continuedAt="i6a9125b286de4846a32edcffda961900"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjA_14abe1a8-eb4b-4f0c-8577-af335d4b68c0" continuedAt="i5c6d8521322645779ae73a21067d847f" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September 30, 2022, the results of its operations and comprehensive loss for the three months and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c6d8521322645779ae73a21067d847f">The results for the three months and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 24, 2022.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDE_e185f8d7-f459-4fd9-933a-f6282ecacef3" continuedAt="i2680913fdd774850b1adf086a455f388" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2680913fdd774850b1adf086a455f388">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDg_a873f176-dfab-4643-80e2-5346ce2c20e4" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before the Company&#8217;s IPO, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDk_a7b2bc28-3cff-4453-b8e0-42f0b2adf0ee" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTA_73a36144-dca5-47c1-8f86-079f7b91cd71" continuedAt="ie935bbd56eaa4f4da00ea9be8eafaf5b" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie935bbd56eaa4f4da00ea9be8eafaf5b">Restricted cash as of September&#160;30, 2022 and December 31, 2021 represents a collateral deposit for employee credit cards.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDU_03556681-183a-409a-8117-ba093e294de3" continuedAt="iabbabff5294f4dbc8ad2599d1182c160" escape="true">Investment</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iabbabff5294f4dbc8ad2599d1182c160">The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.</ix:continuation> </span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjI_2c278394-aeea-4685-800e-e1462a0bfb30" continuedAt="i2e3838b53501401291fef8db0670df99" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the inputs for the first two are considered observable and the inputs for the last are considered unobservable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i6a9125b286de4846a32edcffda961900" continuedAt="i44ccbac4b39b4ea4912d6fe829f6ee8a"><ix:continuation id="i2e3838b53501401291fef8db0670df99"><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for the Company&#8217;s cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.</span></div></ix:continuation><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTE_817ab252-7b66-4f4d-8634-6d13861a4c7d" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTM_378c2af5-0e32-401c-bd23-594201533a4d" continuedAt="i46b3961db3244e1c9c2a7d057817dc25" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDI_85a4425a-4426-4fc5-b43d-d69d0b736ab0" continuedAt="ib59ddbde5cf349b898863a4f9dc8d0bf" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMS0xLTEtMS0xMDQxMzY_e202e67e-8ef1-4cc7-b614-dc182f03b2f5">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7276d186a62437988e54f6972e90adc_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMi0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjo2OGJmNWJlNDYwMDE0YmY1Yjg3MTY5ODliODk1ZjBjMl80_45735812-eb1d-44f2-a2dd-cfe2004299f7">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i58ad1f7848464166b04ff803b503d684_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMi0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjo2OGJmNWJlNDYwMDE0YmY1Yjg3MTY5ODliODk1ZjBjMl83_5733e5d9-98d0-45c6-9edc-186181368924">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ca94ba54c5c4d338293cf60580918bb_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMy0xLTEtMS0xMDQxMzY_c8258a9c-ceac-4ccc-98c7-2d61d3548b0b">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i46b3961db3244e1c9c2a7d057817dc25">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjM_b86e785b-09c3-4c80-9150-2de48bdab3e1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the nine months ended September 30, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDM_cbaa78fc-e2fe-4cf4-bbda-251dff0cb76d" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in <ix:nonFraction unitRef="region" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="cmps:NumberOfGeographicRegions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNzA1NQ_e4f2abe6-35ac-4a66-a217-aea5e402c7d6">two</ix:nonFraction> geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTQ_a00ae512-94f9-4fe2-b0f5-b9f3e5cbaf77" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i44ccbac4b39b4ea4912d6fe829f6ee8a" continuedAt="i2993ff518c994e9086b6febb37079b98"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTI_669de8f2-db27-4c53-8eb9-cffa813debfc" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDY_3cbdedb7-dc04-4753-a845-e22413d16dfd" continuedAt="i79e3c4918c064f2a898abad755ae2013" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimated the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 9 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the absence of an active market for the Company&#8217;s ordinary shares prior to the IPO, the Company and the board of directors of the Company, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s ordinary shares at the time of each grant of a stock-based award prior to the IPO. The grant date fair value of restricted ordinary shares and share options were calculated based on the grant date fair value of the underlying ordinary shares. The Company calculated the fair value of the ordinary shares in accordance with the guidelines in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the &#8220;Practice Aid&#8221;. The Company&#8217;s valuations of ordinary shares were prepared using a market approach, based on precedent transactions in the shares, to estimate the Company&#8217;s total equity value using an option-pricing method, or OPM. After the Company&#8217;s IPO, the fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i2993ff518c994e9086b6febb37079b98" continuedAt="ie6d9f5050a2e440dbe98e918740401ac"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79e3c4918c064f2a898abad755ae2013">The OPM derives an equity value such that the value indicated for ordinary shares is consistent with the investment price, and it provides an allocation of this equity value to each of the Company&#8217;s securities. The OPM treats the various classes of ordinary shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the share liquidation preferences of ordinary shares with senior preferences at the time of the liquidity event. Key inputs into the OPM calculation included the risk-free rate, expected time to liquidity and volatility. A reasonable discount for lack of marketability was applied to the total equity value to arrive at an estimate of the total fair value of equity on a non-marketable basis.</ix:continuation></span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTg_30fa741b-6d62-4821-b7a0-99268d59f8d7" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3abee071f8fa481083b1445474906b6a_I20210101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQ5NDg1_13012f3f-9425-4b1a-afdc-6ddeea3c90a0"><ix:nonFraction unitRef="usd" contextRef="i3abee071f8fa481083b1445474906b6a_I20210101" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQ5NDg1_be910471-07ed-4de4-a225-1e1d89eae346">1.0</ix:nonFraction></ix:nonFraction>&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 11 for right-of-use assets and liabilities recorded during the periods ended September 30, 2022 and 2021 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjE_f597368a-7282-479a-87c8-303bdbd11365" continuedAt="i4a20877679204e2ca20f30a21dc321cc" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is Pound Sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded foreign exchange gains of approximately $<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQzMDQ5_3e4595c9-26cf-4385-8de1-d9ac8dfddba1">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQzMDUz_3b850cdb-2d1f-4a9b-9452-93920786c894">3.4</ix:nonFraction> million for the three months ended September&#160;30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded a foreign exchange gain of $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfODI0NjMzNzIzNzYzNg_8df047ff-22bb-483b-80e2-dfa1058c995b">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfODI0NjMzNzIzNzY0MA_1df4ef5d-5810-4ebe-bf34-bb9ed956bcc8">2.2</ix:nonFraction> million respectively. These gains arise from U.S. dollars which are held in a financial institution in one of our UK subsidiaries that has a functional currency of Pound Sterling.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="ie6d9f5050a2e440dbe98e918740401ac" continuedAt="i520f71b2a8c645348075e02da4881eca"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a20877679204e2ca20f30a21dc321cc">For financial reporting purposes, the condensed consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting currency. The financial statements of entities are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other income, net are translated at the average exchange rates for the periods presented and shareholders&#8217; equity is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.</ix:continuation></span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTU_033473b7-85c4-4fe9-91db-19eccc0c7c86" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standard Update, or ASU, 2019-12, &#8220;Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740),&#8221; or ASU 740, which simplifies the accounting for income taxes. The new guidance removes certain exceptions to the general principles in ASC 740 such as recognizing deferred taxes for equity investments, the incremental approach to performing intra-period tax allocation and calculating income taxes in interim periods. The standard also simplifies accounting for income taxes under U.S. GAAP by clarifying and amending existing guidance, including the recognition of deferred taxes for goodwill, the allocation of taxes to members of a consolidated group and requiring that an entity reflect the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods thereafter; however, early adoption is permitted. The Company adopted this ASU as of January 1, 2021 and it has had no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of September 30, 2022 and December 31, 2021, the Company has not identified any uncertain tax positions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022 and December 31, 2021 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTY_f6c2c6a6-c76f-4c61-9cf8-a68474909b5d" continuedAt="i9a200ae370064ae484c20b9fa12adc06" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to <ix:nonFraction unitRef="number" contextRef="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930" decimals="INF" name="cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjE3NTM_8235adeb-4aa2-4ef4-8b60-c0429f271ed7">33.35</ix:nonFraction>% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to <ix:nonFraction unitRef="number" contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930" decimals="INF" name="cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjIxNzQ_e30e67df-d1f4-4446-8285-d1deb2c4d498">21.67</ix:nonFraction>%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i520f71b2a8c645348075e02da4881eca"><ix:continuation id="i9a200ae370064ae484c20b9fa12adc06"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;<ix:nonFraction unitRef="eur" contextRef="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930" decimals="-5" name="cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjM3ODg_17b1a91e-cf04-4def-a26c-e32c996d1e22">7.5</ix:nonFraction> million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;<ix:nonFraction unitRef="gbp" contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930" decimals="-5" name="cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjQ4MDc_bd94a939-ab07-4cd9-87aa-b16a4d4f6a61">5.0</ix:nonFraction> million plus an incremental <ix:nonFraction unitRef="number" contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930" decimals="2" name="cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjQ4Mzg_dcf62fc2-9d55-42b0-9059-f32ed8d17bd1">50</ix:nonFraction>% of UK taxable profits.</span></div></ix:continuation><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDQ_ba91260f-8928-4e8b-afd4-4be5e87f5bf2" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months and nine months ended September 30, 2022 and 2021, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTk_f2ebf9c7-4c88-4331-a7fa-89cd56dd8678" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into foreign currency contracts to reduce the risk that our cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying Consolidated Statement of Operations and Comprehensive Loss as Other income, net.</span></div></ix:nonNumeric></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_49"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80OS9mcmFnOjRkZDczZjE2ZjE1YjRiNGY5M2MwMTg5MGUwOTRlNTc4L3RleHRyZWdpb246NGRkNzNmMTZmMTViNGI0ZjkzYzAxODkwZTA5NGU1NzhfNDI3_1f29ce2e-793e-4a4f-a39f-8f69422e384b" continuedAt="i0e4690239b9840b5b79aecd080e8cb90" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0e4690239b9840b5b79aecd080e8cb90">There are no financial instruments measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021. Management believes that the carrying amounts of the Company&#8217;s condensed consolidated financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.</ix:continuation></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_52"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfMTA4OQ_37cb339d-a257-46b8-87a3-8365eefdd72a" continuedAt="ifef62f6e4e1848aebd57a0cab6022104" escape="true">Investment</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifef62f6e4e1848aebd57a0cab6022104">On March 6, 2020, the Company made a strategic investment of $<ix:nonFraction unitRef="usd" contextRef="i8952b53cbd2045e785cda206c0dbefa7_D20200306-20200306" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfODA_e50317f5-11d3-4e30-99c8-d4f1a89d666c">0.5</ix:nonFraction> million to acquire an <ix:nonFraction unitRef="number" contextRef="i291d3af8cf514f328ce6b2496870c764_I20200306" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfMTA1_cae1169a-a677-41b4-8d1e-66120ea3e021">8</ix:nonFraction>% (on a fully diluted basis) shareholding in Delix Therapeutics, Inc., a drug discovery and development company researching novel small molecules for use in Central Nervous System, or CNS, indications. The Company&#8217;s investment in Delix Therapeutics, Inc. does not provide it with significant influence over the investee. The investment does not have a readily determinable fair value and therefore will be measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This investment will be measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of September 30, 2022, no impairment loss was recognized.</ix:continuation></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_55"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RleHRyZWdpb246OTFmYTM5NzNhMDVjNDJhNWI2MWZlOWM4OTAzZjc2YjlfMTM1_a1a73091-2f2f-4a8a-8174-51ad12d9262d" continuedAt="i504a66cec95945f388c5226d8c94e13f" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="i504a66cec95945f388c5226d8c94e13f"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RleHRyZWdpb246OTFmYTM5NzNhMDVjNDJhNWI2MWZlOWM4OTAzZjc2YjlfMTM2_e9bceb2d-af82-4bb5-9eb3-08c7c26f8da7" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMi0xLTEtMS0xMDQxMzY_3d6993c9-c1f1-45d4-a71e-a73b14543c6a">16,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMi0zLTEtMS0xMDQxMzY_600a92c6-ff41-4177-b377-73cf63abeebd">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMy0xLTEtMS0xMDQxMzY_96290a14-386a-4be1-b996-91d2438d92e9">3,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMy0zLTEtMS0xMDQxMzY_4360025d-69e7-4f16-b41a-ebc728ad583b">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNC0xLTEtMS0xMDQxMzY_3fe3f00e-00fe-46a7-bcca-9cd5c22e4c89">22,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNC0zLTEtMS0xMDQxMzY_72d9b4c5-65b6-4eb5-aff0-cd13000aa52f">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNS0xLTEtMS0xMDQxMzY_67758edf-e78f-408d-86ae-b14d05280e66">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNS0zLTEtMS0xMDQxMzY_503b8204-d855-4669-8e26-b232bdf07440">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:DeferredCostsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNi0xLTEtMS0xMDQxMzY_dd3384c3-d5c8-443b-a4c6-4a35fb4fd302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:DeferredCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNi0zLTEtMS0xMDQxMzY_9d622fe7-3da8-405b-9d70-afa28da3fbe1">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNy0xLTEtMS0xMDQxMzY_b0aa2365-fff2-4a12-8a00-a32c982a8da1">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNy0zLTEtMS0xMDQxMzY_07ee2ca5-d0db-444e-826d-04d29c5c1447">274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOC0xLTEtMS0xMDQxMzY_30056477-6a63-4d99-94ff-f9f803008118">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOC0zLTEtMS0xMDQxMzY_471c29c3-638c-40d3-8418-4c57466db1ec">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOS0xLTEtMS0xMDQxMzY_ed1bd198-5f16-4591-889d-a74de828b5c2">44,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOS0zLTEtMS0xMDQxMzY_3153c9a7-a2fb-4916-9a8c-f372c68907bb">21,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_58"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfMzgy_3627741f-5f4b-4af4-8a98-2d0b91754575" continuedAt="i1bc8028e81bf4c9294cdf6cac9fc926d" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="ib59ddbde5cf349b898863a4f9dc8d0bf"><ix:continuation id="i1bc8028e81bf4c9294cdf6cac9fc926d" continuedAt="i44be2a9e4d9e4bafb5a3dc14970745b3"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76776d937084bb6b068aef14a3affac_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMi0xLTEtMS0xMDQxMzY_0d7e6878-1d5d-4519-81cd-8719f2e968a8">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71781fc181fd4d39bb070c8c01a27ba1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMi0zLTEtMS0xMDQxMzY_93ca124e-56fa-425a-9bd0-cb58569f425d">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief874743632e4333a3f835ba18d45264_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMy0xLTEtMS0xMDQxMzY_6fe7895b-4b48-4475-b682-18ce6a3b3532">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086cfe97e6384515ace3b2cd9e1a8caf_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMy0zLTEtMS0xMDQxMzY_592b6f51-a45a-4b96-b2c8-aecf31d5ef41">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b536a3e71446ef897b88f79dc31c3d_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNC0xLTEtMS0xMDQxMzY_9f7a7d1d-3ff7-444b-a388-1aece5638ed8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d60c51518a44be9b0594797b5f26453_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNC0zLTEtMS0xMDQxMzY_e44a6011-8705-4d0a-9087-2bf1651758e2">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb55899e87ce45a0a6e5f48a7d035dfb_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNS0xLTEtMS0xMDQxMzY_57a50318-bea7-43b9-ba96-0097484bdb5f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15077b2d3fd4730b187893fbb83cd38_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNS0zLTEtMS0xMDQxMzY_422fce3b-cf37-40aa-bc32-ce33462efa37">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNi0xLTEtMS0xMDQxMzY_00e82199-4887-472a-af50-e25180c7a57c">950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNi0zLTEtMS0xMDQxMzY_956f2491-8a02-4f2b-8670-069e9e4ae7c5">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNy0xLTEtMS0xMDQxMzY_9bb514a6-eaf7-430c-9077-c73b50aba974">395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNy0zLTEtMS0xMDQxMzY_a4b81b85-b19e-41e1-bea2-990314ee3842">358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfOC0xLTEtMS0xMDQxMzY_e78f53b4-e0ca-41d6-84c8-24f51a8b5bc6">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfOC0zLTEtMS0xMDQxMzY_ec80898a-9b7c-455a-a08e-4a4740b9f915">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i44be2a9e4d9e4bafb5a3dc14970745b3">Depreciation and amortization expenses were less than $<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDM1_4bcd7238-c9c9-428a-bd67-b18aa6a63c55">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDU5_48ed502e-9a9c-48e6-beb6-192ed7fe9143">0.2</ix:nonFraction>&#160;million for the three months and nine months ended September 30, 2022 respectively. For the three months and nine months ended September 30, 2021, depreciation and amortization expenses were also less than $<ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDQ4_34c8e843-4853-458f-8074-f1d9e002b05d">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDUz_2e5e941c-8d70-48c3-8fea-9d1107083e33">0.1</ix:nonFraction>&#160;million, respectively</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_61"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RleHRyZWdpb246NDk5OTJjY2VjOTdlNDJkODkzZGFmMzExMDQ4Njc1NjNfMTI5_8736fec2-f143-48cc-8238-b24840003c06" continuedAt="ib6493f9ccf424385bfb30848fa7c2837" escape="true">Accrued Expenses and Other Liabilities</ix:nonNumeric></span></div><ix:continuation id="ib6493f9ccf424385bfb30848fa7c2837"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RleHRyZWdpb246NDk5OTJjY2VjOTdlNDJkODkzZGFmMzExMDQ4Njc1NjNfMTMw_6f70d86e-c325-4d9c-853c-f52cd36cd477" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="cmps:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMi0xLTEtMS0xMDQxMzY_e529e842-af41-4ff6-9e5c-f94616146c74">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="cmps:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMi0zLTEtMS0xMDQxMzY_1284d311-e398-41b0-b5c4-ee6982ede95c">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMy0xLTEtMS0xMDQxMzY_4946e20d-0c9c-4750-8195-d65be679affe">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMy0zLTEtMS0xMDQxMzY_fb67e7da-68cd-47ab-a6a8-c260e449f993">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNC0xLTEtMS0xMDQxMzY_3997f1c2-aa79-4cfa-9d72-70c52350315c">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNC0zLTEtMS0xMDQxMzY_15e9401b-954b-4a5a-9717-c90f7802e28b">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNS0xLTEtMS0xMDQxMzY_7a2583ad-9fc1-49a9-9e1a-bb7b438b34fd">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNS0zLTEtMS0xMDQxMzY_3226a10c-1d44-425c-a327-8b62cab0c446">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNy0xLTEtMS0xMDQxMzY_baee9693-cf59-4cd0-9d47-5ddc3e1ed817">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNy0zLTEtMS0xMDQxMzY_7148a861-b11e-42df-984a-fcfd08d5c99b">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfOC0xLTEtMS0xMDQxMzY_b700ab0f-e389-4920-a9ed-2ce45ad60b31">7,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfOC0zLTEtMS0xMDQxMzY_ccea8097-ec9a-489c-8d10-44fb726faae4">10,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_70"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTQ0Ng_56a33d86-997c-4c70-bbf4-90b886ce2cf1" continuedAt="i9c5973e9c4954e8f98d821ff94d2e925" escape="true">Ordinary Shares</ix:nonNumeric></span></div><ix:continuation id="i9c5973e9c4954e8f98d821ff94d2e925"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company issued in total <ix:nonFraction unitRef="shares" contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NDk4_69a47d60-de3f-42db-b953-6259fc6eaf84">461,772</ix:nonFraction> ordinary shares to settle share options exercised by employees and non-employees compared to <ix:nonFraction unitRef="shares" contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTAy_61ccfcd2-bb0c-4995-85db-12e5e337ef3f">1,188,242</ix:nonFraction> in the nine months ended September 30, 2021. Of the shares issued in the nine months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i68a1067ba8c745c39aa70a7c93efb438_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg2MA_9fcd748b-3d1a-4adb-9345-93a79479e94d">232,227</ix:nonFraction> were related to options exercised in 2020 for which shares were delivered in 2021.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTYx_8f3b53b8-23c2-482f-af8c-5e7399b3dfad">72,738</ix:nonFraction> ordinary shares were issued in settlement of restricted share units, of which <ix:nonFraction unitRef="shares" contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTY1_673b3c36-3860-4402-a380-b78ecab6f778">14,863</ix:nonFraction> vested and were issued during the nine months ended September 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE2MTYx_4e754093-391c-463a-b862-1fdc9dc733c5">57,875</ix:nonFraction> vested but had not been issued at December 31, 2021. As of September 30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE2MjEw_fe86ffdb-4843-457e-b9db-c11809b9dc29">17,112</ix:nonFraction> restricted shares vested but not settled.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg3Nw_56b9ee19-7fa8-471d-8a1f-5b7b090fced7">56,887</ix:nonFraction> restricted share units vested, of which <ix:nonFraction unitRef="shares" contextRef="i4b33a16f531f4d5e8eb681ad202ab246_D20210813-20210813" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg4NQ_701a049d-294b-4f8b-9476-b93c4147808f">12,607</ix:nonFraction> ordinary shares were issued in settlement of the vested restricted shares units on August 13, 2021. <ix:nonFraction unitRef="shares" contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNzM0_0a0cf906-7c38-41a9-9bc9-26ad125a54f1">No</ix:nonFraction> ordinary shares were issued for the vested restricted share units of <ix:nonFraction unitRef="shares" contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYzMDE1NQ_3c5a5e5e-2913-4478-b1e8-9acd2c000169">44,280</ix:nonFraction> in the nine months ended September 30, 2021.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1e7b97b682754dbe8249580f1dc607a3_D20210504-20210504" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg5Mw_71e8fa2b-7af3-403b-ac4b-d3434bf6ec5f">4,000,000</ix:nonFraction> ordinary shares in connection with its follow-on offering. On May 19, 2021 the underwriters exercised their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i985155b2f2d949c18fb2718219f25234_D20210519-20210519" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkwNA_65057555-2250-4478-8903-772f1a4a5722">600,000</ix:nonFraction> ordinary shares. This capital raise resulted in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ifb10d785bf534ccd8a1515186b019eee_D20210504-20210519" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkxMw_642b500e-1638-4a9a-9401-94688c70ad92">154.8</ix:nonFraction>&#160;million after deducting underwriting fees and offering costs.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ordinary share entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i67cd6c80c90e48c2b80e5fc3ba599bcd_D20220101-20220930" decimals="INF" name="cmps:NumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkzOA_febdcf67-6938-4640-8cd7-e45119cf8751">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through September 30, 2022, <ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="cmps:CashDividendDeclaredOrPaidDuringPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkyOA_dfc028dd-c02b-4404-9802-f76575b84694">no</ix:nonFraction> cash dividends had been declared or paid by the Company.</span></div></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_73"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQzMw_e055bfd1-50b3-41e0-aab2-334270fdb8cc" continuedAt="if1d8c5f6df0f47879ec99ebe94e54b5d" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if1d8c5f6df0f47879ec99ebe94e54b5d" continuedAt="i06541c574b764809a2735a876b11f6af"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company was authorized to issue a total of <ix:nonFraction unitRef="shares" contextRef="i116fea83328e4122a910788f7882e8d5_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjI5Mw_7c394ed1-51ff-4c4b-9626-8b82b43ab323">1,602,117</ix:nonFraction> ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan, typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTAyNA_35a1f89c-3484-499d-8cd2-515ba09fe46d">three</span> or <ix:nonNumeric contextRef="ie927c44e5cb04850896477090264ffbc_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwOA_47804730-a4e6-46c5-8834-c108185a72b5">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="ic7fc213c5d7f4036bd82a5d59fa39b09_D20220101-20220930" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA1OA_4a4bd350-af21-484d-9ecc-61cf2e4b38b4">33.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjMyOQ_0cf4df8e-1bbb-4135-9fd9-55890b758771">25</ix:nonFraction>% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire <ix:nonNumeric contextRef="i8252967fea954920a4963de621717ddc_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDk0Ng_3999fb60-03bb-477a-8285-93c4e16f9686">10</ix:nonNumeric> years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a <ix:nonNumeric contextRef="i214715ae51834a1089d9817b0bf23379_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwOQ_f16e63bd-51d1-42ac-bb1a-7588348d7cca">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="i214715ae51834a1089d9817b0bf23379_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTMxMg_d7c37bf8-9de9-4e61-a217-44770b2c730a">25</ix:nonFraction>% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i06541c574b764809a2735a876b11f6af" continuedAt="i332fac16e0ee4f318eb814f33d1a518f"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to <ix:nonFraction unitRef="number" contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjMyMA_573a7b3c-dced-41d6-b952-aad2a079fe29">25</ix:nonFraction>% vesting upon the earlier occurrence of (i) the <ix:nonNumeric contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTY2OQ_814126e4-35b4-46ef-976b-f33702646ee0">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for <ix:nonNumeric contextRef="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDkyNA_8e905445-5255-4c02-b61a-6602733083dc">three years</ix:nonNumeric> for the remaining <ix:nonFraction unitRef="number" contextRef="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDkzOA_c921be18-01fc-4d4d-ada1-5a8f1233e61e">75</ix:nonFraction>% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to <ix:nonFraction unitRef="number" contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjQ3MA_38703a1c-78f9-46fd-8710-025346ab7a92">25</ix:nonFraction>% vesting upon the earlier of (i) the <ix:nonNumeric contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjUwOQ_947fb8f7-e5e0-4e75-870a-6a787f7cd4a1">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is <ix:nonFraction unitRef="number" contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjQyMw_5d45f934-1af7-4e56-807b-542b740665ac">20</ix:nonFraction>% higher than the listing price for at least <ix:nonFraction unitRef="day" contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjc2NA_20d244c3-ede8-43e1-94f1-4bd733a3c7fa">five</ix:nonFraction> consecutive trading days. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of <ix:nonFraction unitRef="shares" contextRef="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzI1OQ_9db7975a-7486-4661-b42b-cc433a07bc68">340,053</ix:nonFraction> ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzUzNQ_686ed94c-dcda-4f95-a12c-6a07b6113d90">1</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) <ix:nonFraction unitRef="shares" contextRef="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzYzMg_0a2fe94f-b83e-408e-87b8-1591d33d764f">510,080</ix:nonFraction> ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of <ix:nonNumeric contextRef="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzk0OA_6dc79a96-407f-4f01-b0bf-4f930e1e3b50">six months</ix:nonNumeric>, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a <ix:nonFraction unitRef="number" contextRef="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDA4MQ_244dc732-4b55-4ef8-ace3-380fe231ebb2">15</ix:nonFraction>% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire <ix:nonNumeric contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDY4MQ_bc7eea4f-f797-4a07-a0b6-efedb0442614">10</ix:nonNumeric> years from the date of grant and typically vest over a <ix:nonNumeric contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDczMw_cceee62f-384e-4ac7-99fa-7a35b12e3b92">4</ix:nonNumeric> year service period with <ix:nonFraction unitRef="number" contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDc2MQ_926389e5-61d8-41ea-a16b-52d8dec9ab5e">25</ix:nonFraction>% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="ib1a328d9f64c4104a3a8029417180e0a_I20200930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDkxOA_92ab1ba6-ffaa-4063-b778-5fa34ea1169f">2,074,325</ix:nonFraction> of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to <ix:nonFraction unitRef="number" contextRef="ib1a328d9f64c4104a3a8029417180e0a_I20200930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTE3NQ_fc680cf0-1c01-4dda-b450-01247809ef09">4</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is <ix:nonFraction unitRef="shares" contextRef="iec562706b0534cfeb692067a09d83c1b_I20220930" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTU4Ng_7b05c652-2b37-4398-8bab-8358ce4d863d">3,755,119</ix:nonFraction> shares as of September 30, 2022, of which <ix:nonFraction unitRef="shares" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjQyOA_bd029eda-411c-4098-81cd-da39f64b858a">761,700</ix:nonFraction> shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted in 2022 under the 2020 Plan to employees generally expire <ix:nonNumeric contextRef="i610168e4d50d4341abec1f5d08582cad_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTc2MA_6d3e6a0e-349d-4f83-a87c-70c0dbea50ad">10</ix:nonNumeric> years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) <ix:nonFraction unitRef="number" contextRef="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTg3NQ_2a03011f-b45e-411b-a68d-34ad1754dcfd">25</ix:nonFraction>% per year over <ix:nonNumeric contextRef="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNA_da3a5c70-dd4a-4f2e-9890-1df45cd6e121">four year</ix:nonNumeric> service period, (ii) <ix:nonNumeric contextRef="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODE5OQ_f22f5d19-907b-40ef-8625-185aa0849ceb">four year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTk0OA_7afa47d9-c7a0-4dda-b982-0246fcddf7aa">25</ix:nonFraction>% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over <ix:nonNumeric contextRef="i943a4addcd6943e98158e8fe064d19ae_D20220201-20220228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNQ_1dc0446a-e468-44c3-b870-80bc5fbce5c2">four year</ix:nonNumeric> service period.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company granted options to purchase <ix:nonFraction unitRef="shares" contextRef="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMjk5_5461617f-01b9-460f-bd24-8827641fc9cd"><ix:nonFraction unitRef="shares" contextRef="i1626078e6ffb423ca90396bef3017393_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMjk5_d560fb28-b87f-4192-b6d0-bce6969f1757">1,400,783</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib9d03b7f170b4a6d82400d749c8536c4_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzAz_3eb77821-7b90-4f55-8fe7-08c12796900b"><ix:nonFraction unitRef="shares" contextRef="i41471be5a1e8469eb1c6407abc7d16dd_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzAz_b1da32e5-f313-497e-a01e-37a9e91c5a37">752,702</ix:nonFraction></ix:nonFraction> ordinary shares to employees and non-employees, respectively.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i332fac16e0ee4f318eb814f33d1a518f" continuedAt="if224c5e151f24103be926a47a6df64a8"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company granted to our new chief executive officer a non-qualified share option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i168b4e16d7474cce8e24f284c7f15369_I20220801" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQxMA_47ddbb44-b5bb-41bb-9f18-06ae79bd256e">600,000</ix:nonFraction> ordinary shares as an inducement grant. The non-qualified share option has a <ix:nonNumeric contextRef="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQyMg_2e5123b9-7dac-4840-b2a4-f71b5a8a9512">10</ix:nonNumeric> year term and vests as to one-fourth on August 1, 2023 and as to the remaining three-fourths in equal monthly installments over the following <ix:nonNumeric contextRef="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDUzMQ_6aeb6da6-b581-4e1f-aa65-c5a65dd369f3">36</ix:nonNumeric> months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement. <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Restricted Share Units</span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwMg_431e06ec-2235-4c83-ae43-92124a01c637" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the nine months ended September 30, 2022 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if753486ce3c14daba4fcbe1f311b43da_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMS0xLTEtMS0xMDQxMzY_dfcb87da-6791-4717-b68d-ec27ef001f46">115,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if753486ce3c14daba4fcbe1f311b43da_I20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMS0zLTEtMS0xMDQxMzY_c050dc58-a941-4575-a0c6-1eae145c4c66">10.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMi0xLTEtMS0xMDQxMzY_87689731-0aee-4c4b-bb5c-a4453b28d437">143,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMi0zLTEtMS0xMDQxMzY_aa7f6941-9817-4cc7-97b2-2f76cfd1daf2">14.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMy0xLTEtMS0xMDQxMzY_374057cb-9a98-4b2c-87d5-dd062e8f7e9e">31,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMy0zLTEtMS0xMDQxMzY_7c9e046b-9a8d-40de-87e1-85cffc7b9ff1">9.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNC0xLTEtMS0xMDQxMzY_0ce5bf36-3ca1-42f2-80ff-75efb4c8551c">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNC0zLTEtMS0xMDQxMzY_5c76656c-195e-4db9-b5fb-daf00775d14f">14.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNS0xLTEtMS0xMDQxMzY_e305355d-febe-4aef-96e0-04d70875ffb6">226,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNS0zLTEtMS0xMDQxMzY_08ba17bf-2d23-4c4d-8213-ca03d4c147b2">11.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzg1_4f862328-4c46-41ff-9f28-10917cadb96a">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf3977e8c2424d11b3e78355783d2144_I20210930" decimals="1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzc5_f7db7e44-d2a9-47e8-b41e-7cae3ea9e9eb">1.6</ix:nonFraction> million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzk4_664da1d3-a101-4c3e-bd46-b62b6b18b9a2">3.0</ix:nonNumeric> years and <ix:nonNumeric contextRef="i732830fb1c7142c5a6f37a0707285a52_D20210101-20210930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzky_20be865e-b5a7-4418-bca3-017357d39fac">2.95</ix:nonNumeric> years, respectively. The exercise price of restricted share units is at a nominal value less than &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNjc5MA_09ec1ba6-c8d4-4b56-b180-59f33aa4f89c">0.01</ix:nonFraction> per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Share Options</span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwMw_d0be55c4-135c-48b7-b2bc-8926127a6d57" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the nine months ended September 30, 2022:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdbbcb43854149dfbf0bcce7cd02755f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS0xLTEtMS0xMDQxMzY_ec46961f-c90b-40e7-a76f-578ae5905719">3,915,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS0zLTEtMS0xMDQxMzY_d6ed5f18-fa33-442f-abed-4a20e782bbfa">13.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7964b739ce6343c381ccfca5dfb1ea6a_D20211231-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS01LTEtMS0xMDQxMzY_5c828b99-4be8-4f1e-bdf1-7cf6adcc339a">8.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS03LTEtMS0xMDQxMzY_c9fedd78-2417-4acb-bd26-b8f5e5087543">51,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMi0xLTEtMS0xMDQxMzY_414f7956-ad80-4620-9b96-306380fadaed">2,000,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMi0zLTEtMS0xMDQxMzY_ddb6138b-567b-4e60-9650-68356cfb2daf">13.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMy0xLTEtMS0xMDQxMzY_bd672159-da41-49fa-9b78-685aa42fff47">461,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMy0zLTEtMS0xMDQxMzY_86abfe9a-0604-495f-b609-e08de14be450">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNC0xLTEtMS0xMDQxMzY_4181c130-c958-4450-b90e-da3cc9040525">418,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNC0zLTEtMS0xMDQxMzY_dab595b1-1bc9-4604-b55a-840569e9da36">9.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS0xLTEtMS0xMDQxMzY_bb5eb1a8-69c6-40bb-8a6e-f97a8c3798a6">5,035,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS0zLTEtMS0xMDQxMzY_d3f4e1cf-41c5-476c-811f-f5ecaaf37e2d">14.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS01LTEtMS0xMDQxMzY_88467f77-d82a-44c8-a686-74673720aa77">8.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS03LTEtMS0xMDQxMzY_2582fcc4-1154-405b-bf19-1148208b488d">17,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi0xLTEtMS0xMDQxMzY_e734e521-9abf-40ad-8c8d-042681482bb2">2,106,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi0zLTEtMS0xMDQxMzY_1bc24e7e-5a56-4bd4-b1a9-21a7232fb51c">7.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi01LTEtMS0xMDQxMzY_eefe89c3-e6be-4cd4-81fd-a5290419b893">7.82</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi03LTEtMS0xMDQxMzY_536b85d6-d796-49ea-9ee2-63cad1fcf9d1">15,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy0xLTEtMS0xMDQxMzY_b00e3b48-2800-4fd5-9bab-bc09d0f40d1e">2,929,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy0zLTEtMS0xMDQxMzY_a3a6cd79-eb83-4ac2-87de-9c1dede25f8b">16.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy01LTEtMS0xMDQxMzY_9562f3fb-c108-424d-9a91-606e845809fe">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy03LTEtMS0xMDQxMzY_f1646331-37bf-497e-97a0-215f5159f280">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzAzNg_c3c5e021-e59b-490f-b7d8-99e221d1bb2b">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzA1MQ_d10f139c-e26f-42ac-875c-7e40629091c3">41.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzQzOA_1d4f8d9a-309d-4b95-b62d-b598361ef221">10.29</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzQ0NQ_251a4caf-66dd-4a5d-8cb5-5599673224e9">22.71</ix:nonFraction> per share during the nine months ended September 30, 2022, and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzU2NQ_068ab015-8600-4cd9-84fe-5f4c2d94fed4">30.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzU4MA_8eb6c220-8666-4ba9-b239-23912a9030b7">27.6</ix:nonFraction> million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i36db55c852ef4eaa89b999164b7a2a99_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzcyOQ_c6beceae-528f-498c-a5d4-8567310c444e">2.97</ix:nonNumeric> years and <ix:nonNumeric contextRef="ib34b90f4692c4d4f9bc74dd8fc80e8c5_D20210101-20210930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzc0Mg_fe6a4f8f-bbf9-4369-99a6-c1d9486371e3">3.2</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="if224c5e151f24103be926a47a6df64a8"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNg_f3d09911-3b35-4801-be1e-c00918b859f0" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2022, and 2021 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.345%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi0xLTEtMS0xMDQxMzY_4fca3fb5-c749-44cf-a15e-89ddc855f34d">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi0zLTEtMS0xMDQxMzY_22d5cb9f-24f2-4fa8-8e55-c42596a7ec76">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi01LTEtMS0xMDQxMzY_58902d12-6f60-4273-8dce-ea9308480a45">5.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi03LTEtMS0xMDQxMzY_86a1ee81-15f3-47d5-be07-0907f2486c79">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy0xLTEtMS0xMDQxMzY_55d13e37-623b-4283-9ed8-9d510fb61602">81.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy0zLTEtMS0xMDQxMzY_c24d4838-1f33-4b12-bb70-fb9c6658a764">66.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy01LTEtMS0xMDQxMzY_13067255-9a90-450a-b994-dac68a8c30dc">80.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy03LTEtMS0xMDQxMzY_83692d55-4d6d-416e-8c35-85bae9e4a088">67.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC0xLTEtMS0xMDQxMzY_2da2664b-c1aa-4d5f-a576-5b900a5e20aa">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC0zLTEtMS0xMDQxMzY_a8cce9b8-083f-4bce-845d-8b3aadbb136e">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC01LTEtMS0xMDQxMzY_561c20f0-73e9-4c2b-a60f-257262672bd9">2.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC03LTEtMS0xMDQxMzY_f6976557-b2c3-4007-8043-192bde21f31f">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS0xLTEtMS0xMDQxMzY_3393ba6f-7f63-403b-8293-01ab2f3e530c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS0zLTEtMS0xMDQxMzY_214dd960-e38e-4ad7-bc50-7e54051f094f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS01LTEtMS0xMDQxMzY_ef91130b-f186-4a46-ac6d-1eb60145e007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS03LTEtMS0xMDQxMzY_9c323e11-1d1e-4a38-88ce-352cb5909927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi0xLTEtMS0xMDQxMzY_f19e5393-8b2f-416e-a53c-8056d814182c">14.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi0zLTEtMS0xMDQxMzY_bb70038e-e3dd-4a9b-9d81-b0f6de5b3c93">34.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi01LTEtMS0xMDQxMzY_93ebe768-ffd8-4225-b5d1-bdad860d4a60">14.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi03LTEtMS0xMDQxMzY_aadc4436-351a-41fa-b269-44c216410418">37.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNw_bbbaf0eb-2086-4015-9c29-d3a4e0fc9ef2" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6d7c3a8be24750a3f82abce012253e_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi0xLTEtMS0xMDQxMzY_4434cd83-7d4f-4b05-9f15-94c8fb75de44">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70760bf78092452f9552082498923167_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi0zLTEtMS0xMDQxMzY_70d47b11-3ed6-4b4f-9533-3f4af56c32a8">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d9f56a071347a7afea2e8409054eaa_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi01LTEtMS0xMDQxMzY_0481c09d-f244-4f3b-87d8-49303c110373">5,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016ce66a6c4e4fc9aca63c6f704fddfc_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi03LTEtMS0xMDQxMzY_13a3d4e5-b8c1-493a-98a7-5effd00a9129">3,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd618f6b010d4a5f99e94d9218acf147_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy0xLTEtMS0xMDQxMzY_a19664ac-5c80-4661-a6f9-b5373e4f29a2">1,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ed6fe991c1471db93324917ceeb126_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy0zLTEtMS0xMDQxMzY_d7a10006-a1d7-4ae1-a48a-5d212daf59b1">999</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92840f8d4bd4abeb1cb6f957e873ca3_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy01LTEtMS0xMDQxMzY_e0ad6f76-48e3-4cfe-8717-7a520b844c9f">4,252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487b8d6412304b83aef12793165358c6_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy03LTEtMS0xMDQxMzY_3aa78e74-b9d7-4b7f-88a4-5de54cf2d886">2,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC0xLTEtMS0xMDQxMzY_e161dcaa-c6c3-435b-a4b5-4c84962248bc">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC0zLTEtMS0xMDQxMzY_156956c3-c287-4857-a57f-0e4c27729085">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC01LTEtMS0xMDQxMzY_6ff435f2-c972-4aa0-aad6-014ffea79a6c">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC03LTEtMS0xMDQxMzY_deafc390-4729-4969-b657-a8c300012ec8">5,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_79"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcx_f668b583-c5cd-4552-b968-8a6e35a4afe3" continuedAt="i6ed450ad26634ae084141e1376f8e222" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i6ed450ad26634ae084141e1376f8e222" continuedAt="icabe5e089ae74fe78b1ee857e1f211dd"><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcy_124cb557-0d9c-454c-9428-a7c7a2ad8b70" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy0xLTEtMS0xMDQxMzY_03aabefb-c945-4651-b385-727169d5ead2">18,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy0zLTEtMS0xMDQxMzY_176c8b32-4134-4c0d-bbc7-8d873a52cee2">15,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy01LTEtMS0xMDQxMzY_9171ab39-f2ea-456a-b6a1-6f406275c5ca">60,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy03LTEtMS0xMDQxMzY_be38a69b-81be-418b-8442-cd6750255b4d">46,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0xLTEtMS0xMDQxMzY_4d7e554b-f096-4bd7-920e-a13863785074"><ix:nonFraction unitRef="usd" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0xLTEtMS0xMDQxMzY_5e42ede0-9a0a-4beb-b7d0-d9c9bf6f43eb">18,371</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0zLTEtMS0xMDQxMzY_a7127675-1987-48ce-9573-7db972a40af9"><ix:nonFraction unitRef="usd" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0zLTEtMS0xMDQxMzY_c287ee3a-de37-4fd6-b6a0-6b649e4aa82f">15,849</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC01LTEtMS0xMDQxMzY_1ffeb0f7-e4c9-4267-bb85-ed461a8556cd"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC01LTEtMS0xMDQxMzY_b668c95c-b549-4b03-9ed6-851212585fe8">60,579</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC03LTEtMS0xMDQxMzY_0642f8fa-467c-44b6-8a2e-63ce67c2e093"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC03LTEtMS0xMDQxMzY_7a6d3969-65e8-4e68-b5d4-03a4672da3de">46,092</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0xLTEtMS0xMDQxMzY_654a50ec-2ddd-48d7-a1e2-d50104ee6478"><ix:nonFraction unitRef="shares" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0xLTEtMS0xMDQxMzY_ca99112a-07e8-4bf7-a7ac-ea41ca37aeb2">42,525,855</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0zLTEtMS0xMDQxMzY_7e54bb76-ad73-4107-9085-d2b160af957f"><ix:nonFraction unitRef="shares" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0zLTEtMS0xMDQxMzY_92468327-2860-40da-8a09-1be86802f571">41,708,220</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy01LTEtMS0xMDQxMzY_bc5fab98-60a4-4fbd-ac54-9be687211362"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy01LTEtMS0xMDQxMzY_bec6eda9-75ad-469b-b8cc-79e187cc7e33">42,377,895</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy03LTEtMS0xMDQxMzY_8ed7b287-b8aa-4220-a96e-9f0d5a8e6dab"><ix:nonFraction unitRef="shares" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy03LTEtMS0xMDQxMzY_a7c19b65-8d65-4ffd-8a2d-2e156954e15d">39,378,824</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0xLTEtMS0xMDQxMzY_217eea87-3d1d-4b9a-979c-84ebfb8a1d85"><ix:nonFraction unitRef="usdPerShare" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0xLTEtMS0xMDQxMzY_c1a38906-c693-451c-952e-faa8845bf844">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0zLTEtMS0xMDQxMzY_44e063f1-6aa3-49e8-8a28-62e5239d71c7"><ix:nonFraction unitRef="usdPerShare" contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0zLTEtMS0xMDQxMzY_9ef926fd-6e10-445d-864e-8e41a52d28af">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC01LTEtMS0xMDQxMzY_07765fb6-e529-4346-84e0-dbc8fbf7a75c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC01LTEtMS0xMDQxMzY_f14f42eb-7e80-4b82-896a-1952c23cced6">1.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC03LTEtMS0xMDQxMzY_40bbf056-510b-4870-9027-26a22bb27c96"><ix:nonFraction unitRef="usdPerShare" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC03LTEtMS0xMDQxMzY_a167e806-6620-4e73-9109-a6e0fd5be5cf">1.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="icabe5e089ae74fe78b1ee857e1f211dd"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcz_774b786b-5430-418a-88c7-304948e13a8c" continuedAt="i79a4aa3f0dfe41279b8dbeeab6fea407" escape="true">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months and nine months ended September 30, 2022 and 2021 because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><ix:continuation id="i79a4aa3f0dfe41279b8dbeeab6fea407"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87aefa457f98460d9ba72963b7697019_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi0xLTEtMS0xMDQxMzY_be296e97-7f0d-4245-a024-8e8840195e23">226,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f7c123bcb2043639356b3682899ec41_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi0zLTEtMS0xMDQxMzY_cab6c2ec-2bc6-4b10-8f3b-493533758e94">160,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b8dd5142c74e14af90b4df630e08e7_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi01LTEtMS0xMDQxMzY_41deafea-0a8e-4297-8a55-6d17fd56c824">226,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icefa4748348444fa952bab3678989dc2_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi03LTEtMS0xMDQxMzY_cca01fa2-8e57-4556-8f31-963daa3a228b">160,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested restricted share units, for which shares are not in issue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic18cd041e9674a2fa8a04ceae64ee78a_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy0xLTEtMS0xMDQxMzY_9ceb09f7-65ee-4ce4-93cf-c089d217dec0">17,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03df66d076904953a72557ea780c6f6a_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy0zLTEtMS0xMDQxMzY_2a055d21-2bba-47cf-8cf1-52727ce97947">44,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica9696938fd04b1da48bd8c16ddcb336_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy01LTEtMS0xMDQxMzY_f166ec8f-ad7c-4695-8b2c-e2742f08b088">17,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i187723a49dae400c970198d5678bbf0d_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy03LTEtMS0xMDQxMzY_f66b8f4a-4214-4a2f-93f3-4bb5686dc797">44,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d9eda1626844e1a4d7a56935aef2e0_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC0xLTEtMS0xMDQxMzY_fac3738b-a597-4078-9c37-314174471327">5,035,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0192aff8fc8a44639feb49e5ff26383e_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC0zLTEtMS0xMDQxMzY_57208019-3047-4c54-8241-5e772741ae19">4,092,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaf53ccfc8a04ca7aca822f4ae66c4bd_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC01LTEtMS0xMDQxMzY_897ff89e-f76a-4543-9343-d5ef1fd3ef1a">5,035,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3fc341a339e466c85a21126366804be_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC03LTEtMS0xMDQxMzY_9dc484d6-6076-4ba4-9dd1-eec3a516dbf8">4,092,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS0xLTEtMS0xMDgzMjY_01f1cc24-7361-4639-8d32-0206dd1f9699">5,279,430</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS0zLTEtMS0xMDgzMjY_6a37124e-d0bd-42e0-9f14-2daa3df14505">4,297,371</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS01LTEtMS0xMDgzMjY_58794458-8d2f-40af-8d74-95be5b0a0d3f">5,279,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS03LTEtMS0xMDgzMjY_6f9d59d3-28cd-4a7e-8986-18e12dbc7d16">4,297,371</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_82"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjE3NA_43b79b1a-877f-4c69-b84d-53d30103eddc" continuedAt="i007ea35cc82b42d9862ef30519489c2c" escape="true">Right of use of assets</ix:nonNumeric></span></div><ix:continuation id="i007ea35cc82b42d9862ef30519489c2c" continuedAt="i7d166c23614c4a5fa32c63b6be2799d1"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York, NY</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a lease with BioLabs for <ix:nonFraction unitRef="sqft" contextRef="i6445d031d3af49a6a06ea1db2dc1ffdd_I20190531" decimals="INF" name="us-gaap:NetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNjYy_62d962e4-01e0-42ce-b5b8-fcb76233e771">200</ix:nonFraction> rentable square feet of office space at 180 Varick Street, New York, New York 10014, United States. The lease is cancellable with <ix:nonNumeric contextRef="ibb6279cd6f4344d69acccb3e96e46e53_D20190501-20190531" name="cmps:LeaseCancellationNotificationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNzk1_49ecbb8b-a9a3-47b3-ba5d-da71bd6eee18">30</ix:nonNumeric> days&#8217; notice. This lease is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a <ix:nonNumeric contextRef="i8c93062327a04098856532f8d1e3bcff_I20220801" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjE3NQ_6b05c604-d61b-402d-92c6-61182913f4e6">twelve month</ix:nonNumeric> membership agreement with WeWork for rentable office space.  The membership is cancellable with <ix:nonNumeric contextRef="i2d32385fb8994518b1f04d199668f0e8_D20220801-20220831" name="cmps:LeaseCancellationNotificationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjEwNg_6f0e5bdb-261e-431a-9ba7-b379cd4f0cc4">90</ix:nonNumeric> days&#8217; notice.  This membership is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eastbourne Terrace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an operating lease located at 19 Eastbourne Terrace, London, UK. This lease commenced on January 1, 2020, and expired on December 31, 2021. Under the terms of the lease, the Company paid &#163;<ix:nonFraction unitRef="gbp" contextRef="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130" decimals="0" name="cmps:AnnualLeasePayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NTU1_5af9f6e9-4a04-4a1d-809f-1c5a7e69b127">780,000</ix:nonFraction> per year, and paid a refundable deposit of &#163;<ix:nonFraction unitRef="gbp" contextRef="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130" decimals="0" name="cmps:RefundableLeaseDepositPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NjAy_222fdaad-1db4-4418-8b21-060b45a92468">130,000</ix:nonFraction> upon signing the agreement. Additionally, in February 2021, the Company entered into an Amendment for rental relief in January and February 2021 for a total of &#163;<ix:nonFraction unitRef="gbp" contextRef="i1da6eb55524b416f9a934077e9e0964b_D20210201-20210228" decimals="0" name="cmps:LeaseRentalRelief" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NzY2_ffa7cf20-14a1-4a0d-8d64-4ca33522ae68">32,500</ix:nonFraction>, due to extended periods working from home as a result of the COVID-19 pandemic.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Soho, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a <ix:nonNumeric contextRef="ie5dcf53d81a142d5b2daa60f4b084c52_I20210731" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2OA_84b173a2-6e3a-49a5-9666-1ff313552f1c">two-year</ix:nonNumeric> operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is <ix:nonNumeric contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930" name="cmps:OperatingLeasesNoncancelableTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTE5Mw_bfcf2c8d-d021-488f-9019-238cd3bee189">24</ix:nonNumeric> months and there is no option to extend the lease. The recurring residency fee per month is &#163;<ix:nonFraction unitRef="gbp" contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930" decimals="0" name="cmps:OperatingLeaseMonthlyPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTI4OA_9d589904-2c4f-4eda-9b82-1eb25e435fee">136,200</ix:nonFraction>, and the Company paid a refundable deposit of &#163;<ix:nonFraction unitRef="gbp" contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930" decimals="0" name="cmps:RefundableLeaseDepositPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTMzNw_109fac5e-fc0a-4872-871b-036e59775c83">136,200</ix:nonFraction> at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee will be subject to an automatic inflation linked increase of the previous years&#8217; amount.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Francisco, CA </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an operating lease commencing in August 2021 for approximately <ix:nonFraction unitRef="sqft" contextRef="ia57eb47573b842caa7eb13f5560d4cce_I20210831" decimals="INF" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTY2Mw_71db437b-b92f-4865-b231-c726112da226">2,526</ix:nonFraction> rentable square feet located in San Francisco, California. The total monthly rent for the lease term is $<ix:nonFraction unitRef="usd" contextRef="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831" decimals="0" name="cmps:OperatingLeaseMonthlyPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTg0MQ_917717fa-ec5d-415a-ae0d-35398458962a">10,000</ix:nonFraction> per month, and the Company paid $<ix:nonFraction unitRef="usd" contextRef="ia57eb47573b842caa7eb13f5560d4cce_I20210831" decimals="0" name="us-gaap:AdvanceRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTg3Ng_294d36a9-2f3a-49d0-8e63-85c0dab624e7">9,000</ix:nonFraction> of advanced rent upon lease execution. Additionally, the Company paid a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831" decimals="0" name="cmps:RefundableLeaseDepositPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTk4Mg_24ad0cba-00c3-404b-92ff-1cf792fac04c">20,000</ix:nonFraction> upon execution of the lease.  In September 2022, the Company entered into a lease extension, which is set to expire on October 31, 2022.</span></div></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><ix:continuation id="i7d166c23614c4a5fa32c63b6be2799d1"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denmark Hill, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of <ix:nonNumeric contextRef="i8d6417d20a4747be9ada6c3270634e36_I20220621" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjMxMA_fcbb4732-f211-477a-9396-fea26bf05de5">five years</ix:nonNumeric>. The rent is &#163;<ix:nonFraction unitRef="gbp" contextRef="i397deef1a4764e6097cd7f14b27e8ec0_D20220101-20220930" decimals="0" name="cmps:OperatingLeaseAnnualPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjMyNg_2e8e24f1-5bc6-4f12-af40-065bb4ccd672">180,000</ix:nonFraction> per year, with no deposit payable, and payment dates occurring once per quarter.</span></div><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2NQ_454370b6-f3f5-4017-b937-130753ee8a6f" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our costs included in our condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through September 30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMy0xLTEtMS0xMDQxMzY_dfadba2e-0d09-4787-9926-3a13ba99e9aa">1,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMy0zLTEtMS0xMDQxMzY_d5ec1f2b-7b89-4250-b6ad-0b76217cda4d">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="cmps:VariableLeaseCostLeaseIncentiveReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNC0xLTEtMS0xMDQxMzY_268602bf-3b45-443d-866b-bb4260dca4ee">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="cmps:VariableLeaseCostLeaseIncentiveReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNC0zLTEtMS0xMDQxMzY_ec70b6c4-21a1-491d-9411-caf2b93426d7">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNS0xLTEtMS0xMDQxMzY_8cd14827-529f-4432-9de1-a56dace5a936">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNS0zLTEtMS0xMDQxMzY_05da1f9b-e076-4597-895b-bd1411c8d3da">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNi0xLTEtMS0xMDQxMzY_91c9d49e-756e-4322-809a-5b37f7d2728c">1,829</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNi0zLTEtMS0xMDQxMzY_283d8a3f-70ec-4457-9c4c-c676fccc3669">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOC0xLTEtMS0xMDQxMzY_f65ca081-6672-4dee-a5b0-b3ba67a1d054">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOC0zLTEtMS0xMDQxMzY_4595445a-de03-40db-9814-5a9c367abff8">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOS0xLTEtMS0xMDQxMzY_4c4fecba-dc62-400c-8411-7178da396cd1">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOS0zLTEtMS0xMDQxMzY_98601c76-7a6b-4acb-81c0-1d2f031d1e94">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTAtMS0xLTEtMTA0MTM2_42fa3ccb-3949-4533-b850-bfdecd11ca37">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTAtMy0xLTEtMTA0MTM2_25b33a13-3663-4152-9b27-83a07c9d3cc1">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTEtMS0xLTEtMTA0MTM2_8f28b521-37fd-4d1f-9017-4f72bc04b711">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTEtMy0xLTEtMTA0MTM2_124bf1b7-f620-4e78-84c4-3cf27f47ec88">4.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2Ng_304ed955-2416-450a-9556-80545b7fc79c" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of September 30, 2022, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:85.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfMi0xLTEtMS0xMDQxMzY_7fa29f84-f550-43fe-9e7a-fa40a57c4dd7">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfMy0xLTEtMS0xMDQxMzY_efbb915e-8f57-4875-baf2-0a5d1460317c">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNC0xLTEtMS0xMDQxMzY_0f94713d-6de1-47b9-8016-3220292bb953">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNS0xLTEtMS0xMDQxMzY_1b7e51ef-ad87-48f6-972e-8c8025748a5f">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNi0xLTEtMS0xMDQxMzY_5f237e62-ff50-420c-badc-cefbe83d9d48">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNy0xLTEtMS0xMDQxMzY_40379474-367f-4eec-84e4-f59ae92636cc">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfOC0xLTEtMS0xMDQxMzY_3b74f6ee-52a0-40aa-8453-d19e58303711">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfOS0xLTEtMS0xMDQxMzY_7bddd6a5-04b9-4e18-aa8c-35494e3a4549">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_85"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84NS9mcmFnOjNjNzA3NzZmMzIzMDRhYTM4ZTMwYjMxNTU5MjkzMWYzL3RleHRyZWdpb246M2M3MDc3NmYzMjMwNGFhMzhlMzBiMzE1NTkyOTMxZjNfMTMzNA_84ff6f37-c6f7-40da-867b-d749bd03135f" continuedAt="i2b19c9e36d404b58bb93446d120754f0" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i2b19c9e36d404b58bb93446d120754f0"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of September 30, 2022, or 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_88"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfNjg0_3e707c84-a1c4-4983-9a54-06963c9103fc" continuedAt="i9e499ab3b6aa48af99148c983de61bdf" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i9e499ab3b6aa48af99148c983de61bdf"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the UK, the Company makes contributions to private defined contribution pension schemes on behalf of its employees. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE2Nw_eafff74a-f275-4397-bef3-a471bcf1bd49">0.2</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE4Mw_62a4a9fc-999d-4e6e-b930-fee074c55f44">0.1</ix:nonFraction> million in contributions for the nine months ended September 30, 2022, and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE4OQ_77ca2358-21b2-4c30-bfe0-5313f2edf607">0.1</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE5OQ_0cd7605b-1a76-4202-8406-2d322c9b8df1">0.1</ix:nonFraction> million in contributions in the nine months ended September 30, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i2c038f1b3ae34b9980fe150878abee2f_91"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_97"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS&#160;OF&#160;OPERATIONS</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_100"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the related notes to those statements included earlier in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. &#8220;Risk Factors&#8221; and the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;  </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;the Company&#8221; refer to COMPASS Pathways plc. </span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which COMP360 psilocybin is administered in conjunction with psychological support, which we refer to as COMP360 psilocybin therapy. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the current treatment paradigm. Early signals from academic studies, using formulations of psilocybin not developed by us, have shown that psilocybin therapy may have the potential to improve outcomes for patients suffering with TRD, with rapid reductions in depression symptoms and effects lasting up to six months, after administration of a single high dose. We have developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. In 2019, we completed a Phase 1 clinical trial administering COMP360, along with psychological support, to 89 healthy volunteers. In this trial, we observed that COMP360 was generally well-tolerated and supported continued progression of Phase 2b studies. On November 9, 2021, we announced positive top-line results from our Phase 2b clinical trial evaluating COMP360 in conjunction with psychological support for the treatment of treatment-resistant depression. This was the largest, randomized, controlled, double-blind psilocybin therapy clinical trial ever completed. The top-line results from the 233-participant trial showed a rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support. The trial achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a statistically significant (p&lt;0.001) and clinically relevant reduction in depressive symptom severity after three weeks compared with the COMP360 1mg arm. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the world&#8217;s leading peer-reviewed medical journal, published the positive results from our Phase 2b trial of COMP360 psilocybin therapy for TRD.  We believe that COMP360 psilocybin therapy &#8211; combining COMP360 psilocybin with psychological support from specially trained therapists &#8211; could offer a new approach to depression care.  </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate the initiation of a Phase 3 program in the fourth quarter of 2022.  The Phase 3 program is composed of three clinical trials, two pivotal trials and one long-term follow-up. The pivotal program design is as follows:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Pivotal trial 1 (COMP 005) (n=378): a single dose (25mg) monotherapy compared with placebo. This trial is designed to replicate the treatment response seen in the Company&#8217;s Phase 2b trial (n=233).  We expect top-line data by the end of 2024.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Pivotal trial 2 (COMP 006) (n= 568): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate if a second dose can increase treatment responders and/or improve response seen in the Company&#8217;s Phase 2b trial and explore the potential for a meaningful treatment response from repeat administration of COMP360 10mg.  We expect top-line data by mid-2025.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     The primary endpoint in both pivotal trials is the change from baseline in MADRS total score at Week 6.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond TRD, we have on-going Phase 2 trials in anorexia nervosa and PTSD.  We are conducting a double-blind randomised controlled Phase 2 clinical trial investigating the efficacy of COMP360 psilocybin, administered with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">psychological support, in people with anorexia nervosa. It is a multicenter study and will enroll 60 patients.  We are conducting a Phase 2 clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in PTSD. It is a multicenter, fixed-dose open label study and will enroll 20 participants.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our formation, we have devoted substantially all of our resources to conducting preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We do not have any therapeutic candidates approved for sale and have not generated any revenue. We have funded our operations to date primarily with proceeds from the sale of convertible preferred shares, convertible loan notes, our initial public offering, or IPO, and our follow-on offering completed in May 2021, or Follow-On Offering, of American Depositary Shares, or ADSs, representing our ordinary shares in September 2020 and May 2021, respectively. Through September 30, 2022, we had received net cash proceeds of $116.4 million from sales of our convertible preferred shares and convertible loan notes, $132.8 million from sales of ADSs in our IPO and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$154.8 million from sales of ADSs in our Follow-On Offering. In October 2021, we entered into a Sales Agreement with Cowen and Company, LLC, under which we may issue and sell from time to time up to $150.0 million of our ADSs at market prices. We have not yet sold any ADSs under this at-the-market facility.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception. We incurred total net losses of $60.6 million and $46.1 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $230.2 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access, commercialization and business development activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our operating losses stem primarily from development of our investigational COMP360 psilocybin therapy for TRD, and we expect they will continue to increase as we increase our headcount and commence our Phase 3 program in TRD for our investigational COMP360 psilocybin therapy candidate and conduct our Phase 2 studies for anorexia nervosa and PTSD and, potentially including expanding into additional indications, and initiate preclinical and clinical development of additional programs for different therapeutic candidates, as well as using digital technologies and solutions to enhance our therapeutic offering. Furthermore, since the completion of our IPO, we have incurred additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of therapeutic candidates, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our ability to raise additional funds may also be adversely impacted by macroeconomic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the COVID-19 pandemic, the hostilities in Ukraine, and increasing interest rates and rates of inflation. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that our current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had cash and cash equivalents of $173.1 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our existing cash and cash equivalents will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources&#8212;Funding Requirements&#8221; below.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the ongoing impacts of current macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, the hostilities in Ukraine, increasing rates of inflation, rising interest rates and fluctuations in foreign exchange rates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic continues to evolve, and we will continue to monitor any developments. The extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains uncertain, and will depend on certain contingencies, including the evolution of the disease and spread of new variants of COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The COVID-19 pandemic or other public health crises could in the future delay enrollment in and completion of our clinical trials, interrupt our clinical trial activities, our supply chain, our employees or the employees of research sites and service providers, such as therapists, suppliers, contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_103"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue and do not expect to generate any revenue from the sale of therapeutic candidates in the foreseeable future. If our development efforts for our investigational COMP360 psilocybin therapy are successful and result in regulatory approval of COMP360, we may generate revenue in the future.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      development costs, including expenses incurred under agreements with CROs and CMOs, investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services, as well as manufacturing scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies and clinical trials and laboratory and trial site supplies and equipment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      personnel expenses, including salaries, related benefits and travel expense for employees engaged in research and development functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      non-cash share-based compensation expenses resulting from equity awards granted to employees engaged in research and development functions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      other expenses, including costs of outside consultants, including their fees and related travel expenses, allocated facility-related expenses such as direct depreciation costs, allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as a prepaid expense or accrued research and development expenses.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product or therapeutic candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product manufacturing expenses. As a result, we expect that our research and development expenses will continue to increase over the next several years as we: (i) seek to complete the clinical development for our investigational COMP360 psilocybin therapy for TRD; (ii) fund research for our investigational COMP360 psilocybin therapy in other neuropsychiatric indications, including anorexia nervosa and PTSD; (iii) seek to develop digital technologies to complement and augment our therapies, and seek to access other novel drug candidates for development in neuropsychiatric and related indications; (iv) improve the efficiency and scalability of our third-party manufacturing processes and supply chain; and (v) build our third-party or in-house process development, analytical and related capabilities, increase personnel costs and prepare for regulatory filings related to our potential or future therapeutic candidates.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of our investigational COMP360 psilocybin therapy is highly uncertain. This is due to the numerous risks and uncertainties associated with development and commercialization, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials and preclinical studies, including our Phase 3 clinical trials in TRD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials and our ability to raise capital on favorable terms or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 psilocybin therapy and any future therapeutic candidates in the intended populations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and scaling up, through third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any therapeutic candidates are approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin therapy and our future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our current and future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our investigational COMP360 psilocybin therapy and our future therapeutic candidates following approval.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of our investigational COMP360 psilocybin therapy in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of our investigational COMP360 psilocybin therapy. For example, if the FDA, the European Medicines Agency, or EMA, the Medicines and Healthcare products Regulatory Agency, or MHRA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to commit significant additional financial resources and time on the completion of clinical development of that therapeutic candidate.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel expenses, including salaries and related benefits, travel and other expenses incurred by personnel in certain executive, finance and administrative functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">non-cash share-based compensation expenses resulting from the equity awards granted to employees engaged in certain executive, finance and administrative functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal and professional fees, including consulting, accounting and audit services; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other expenses, including depreciation costs, allocated expenses for rent and maintenance of facilities, director and officer insurance and other operating costs.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will continue to increase in the future as we increase our headcount to support our continued research activities and development of our investigational COMP360 psilocybin therapy.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate we will continue to incur increased accounting, audit, legal, regulatory and compliance costs, as well as investor and public relations expenses associated with being a public company and as a result of our loss of Foreign Private Issuer, or FPI, status and resulting transition to a U.S. domestic filer effective January 1, 2022. Additionally, if and when we believe a regulatory approval of a therapeutic candidate appears likely, we anticipate an increase in payroll and other expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our therapeutic candidate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income relates to interest earned on cash balances.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains consist of foreign exchange impacts arising from foreign currency transactions, primarily related to U.S. dollars maintained in a bank account in a Pounds Sterling functional currency entity.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Research and Development Tax Credit</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from R&amp;D tax credit consists of the R&amp;D tax credit received in the UK, which is recorded within other income, net. As a company that carries out extensive research and development activities, we seek to benefit from the Small and Medium Enterprise, or SME, Program. Qualifying expenditures largely comprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which we do not receive income.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by His Majesty&#8217;s Revenue and Customs, or HMRC, a portion of expenditures being carried in relation to our pipeline research and development, clinical trial management and third-party manufacturing development activities were eligible for the SME regime for the three months and nine months ended September 30, 2022 and 2021. We expect such elements of expenditure will also continue to be eligible for the SME regime for future accounting periods.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK R&amp;D tax credit is fully refundable to us and is not dependent on current or future taxable income. As a result, we have recorded the entire benefit from the UK research and development tax credit as a benefit which is included in our net loss before income tax and, accordingly, not reflected as part of the income tax provision. If, in the future, any UK R&amp;D tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate taxation in the United States and the UK. Due to the nature of our business, we have generated losses since inception and have therefore not paid UK corporation tax. Our income tax expense represents only income taxes in the United States.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely and may be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits. After accounting for tax credits receivable, we had accumulated trading losses for carry forward in the UK of $144.0 million and $53.0 million as of December 31, 2021 and 2020, respectively, which is offset by a full valuation allowance.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company recorded a tax provision of $0.3 million and $0.1 million, related to its income tax obligations of its operating company in the US, which generates a profit for tax purposes. The Company&#8217;s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate (&#8220;AETR&#8221;), adjusted for the effect of discrete items arising in that quarter. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. For the nine months ended September 30, 2022 and 2021, the Company excluded the UK from the calculation of the AETR as the Company anticipates an ordinary loss in this jurisdiction for which no tax benefit can be recognized.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_106"></div><div style="margin-bottom:4pt;margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison For The Nine Months Ended September 30, 2022 and 2021</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,898)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,263)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,992)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,271)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,579)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,092)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,487)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses incurred for the nine months ended September 30, 2022 and 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $14.8 million to $45.3 million for the nine months ended September 30, 2022, from $30.4 million for the nine months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in research and development expenses was primarily attributable to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $4.5 million in external development expenses, which primarily related to $3.1 million for the cost of preclinical studies, $1.3 million in drug development and manufacturing costs, $0.4 million in costs for digital activities and $0.2 million in therapist training costs, offset by a $0.5 million decrease in clinical trial expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $5.1 million in personnel expenses, primarily as a result of hiring additional personnel in our research and development departments to support the expansion of our digital, preclinical and clinical activities; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.5 million in non-cash share-based compensation expense due to increased staffing levels year over year, and the inducement grant awarded to our new chief executive officer in August 2022, in addition to a company-wide option grant in February 2022. There was no similar company-wide grant in 2021; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.7 million in other expenses, which was primarily related to increased external consulting expenses relating to pre-commercial and therapist training projects.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to continue to increase substantially in the near future, consistent with our plan to begin our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 3 program for COMP360 psilocybin therapy in TRD by the end of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative  </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the nine months ended September 30, 2022, and 2021 (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $8.5 million to $33.0 million for the nine months ended September 30, 2022 from $24.5 million for the nine months ended September 30, 2021. The increase in general and administrative expenses was primarily attributable to the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.1 million in personnel expenses, primarily due to an increase in headcount related to the hiring of additional personnel in general, administrative and commercial departments to support our growth initiatives, including operating as a public compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.4 million in non-cash share-based compensation expense due to increased staffing levels year on year, and the inducement grant awarded to our new chief executive officer in August 2022, in addition to a company-wide option grant in February 2022. There was no similar company-wide grant in 2021;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $3.7 million in legal and professional fees, primarily related to expenses associated with external consulting, public relations, patent applications and legal advice as well as continuing costs associated with operating as a public company, and other corporate activities as we continue to grow our business; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.2 million in facilities and other expenses, mainly attributable to an increase of $0.9 million in information technology costs, in addition to increases of $0.3 million associated with Centers of Excellence costs, $0.3 million in office rental costs as a result of continued growth and $0.3 million in charitable donations and other expenses, offset by a decrease of $0.6 million in insurance and listing expenses.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these general and administrative expenses to substantially increase consistent with our plans to increase our headcount as a result of ongoing requirements as a public company, in addition to ongoing research and development growth initiatives.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $3.6 million for the nine months ended September 30, 2022 and less than $0.1 million for the nine months ended September 30, 2021. The increase in other income primarily related to increased interest income as a result of higher interest rates on cash deposits in addition to a gain of $2.6 million recognized in connection with a forward exchange contract that we entered into and settled in the third quarter of 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains increased by $2.2 million to a gain of $4.4 million for the nine months ended September 30, 2022 from a gain of $2.2 million for the nine months ended September 30, 2021, primarily related to gains arising from the translation of cash balances generated from the IPO proceeds and the Follow-On Offering proceeds that were maintained in U.S. dollars, which is different from the legal entity&#8217;s functional currency (Pound Sterling) giving rise to foreign currency gains. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our U.S. dollar balances are held in a Pound Sterling functional currency legal entity and converted as required into Pound Sterling because the predominant cash outflows are Pound Sterling. As our operating model and business develops we will continually monitor and assess our legal entity structure and whether our future cash outflows continue to be reported in Pounds Sterling or in U.S. dollars, as well as the continuing impact of foreign exchange rates on our results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Research and Development Tax Credit</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, we recognized an R&amp;D tax credit from the UK as a benefit within other income, net of $10.0 million and $6.7 million, respectively. The tax credit receivable increased by $3.3 million in 2022 compared to 2021 in line with increased research and development activities.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense was $0.3 million for the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and less than $0.1 million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The income tax expense was related to income tax obligations of our operating company in the United States, which generates a profit for tax purposes.</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison For The Three Months Ended September 30, 2022 and 2021</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,786)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,371)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,849)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,522)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses incurred for the three months ended September 30, 2022 and 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.8 million to $14.0 million for the three months ended September 30, 2022, from $12.2 million for the three months ended September 30, 2021. The increase in research and development expenses was primarily attributable to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $0.8 million in development expenses due to increases of  $1.2 million in preclinical costs and $0.3 million in drug development expenses, offset by a decrease of $2.3 million in clinical trial expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.8 million in personnel expenses, as a result of hiring additional personnel in our research and development departments to support the expansion of our digital, preclinical and clinical activities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.6 million in non-cash share-based compensation expense due to increased staffing levels year over year, and the inducement grant awarded to our new chief executive officer in August 2022, in addition to a company-wide option grant in February 2022. There was no similar company-wide grant in 2021; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.1 million in other expenses, which was primarily related to increased external consulting expenses relating to pre-commercial and therapist training projects.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to continue to increase substantially in the near future, consistent with our plan to advance our investigational COMP360 psilocybin therapy through clinical development.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative  </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the three months ended September 30, 2022, and 2021 (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $2.0 million to $11.6 million for the three months ended September 30, 2022 from $9.6 million for the three months ended September 30, 2021. The increase in general and administrative expenses was primarily attributable to the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.4 million in personnel expenses, primarily due to an increase in headcount related to the hiring of additional personnel in general, administrative and commercial functions to support our growth initiatives, including operating as a public compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.6 million in non-cash share-based compensation expense due to increased staffing levels year on year, and the inducement grant awarded to our new chief executive officer in August, 2022, in addition to a company-wide option grant in February 2022. There was no similar company-wide grant in 2021;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.6 million in legal and professional fees, primarily related to expenses associated with external consulting, public relations, patent applications and legal advice as well as continuing costs associated with operating as a public company, and other corporate activities as we continue to grow our business; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.4 million in facilities and other expenses, mainly attributable to an increase of $0.4 million in information technology expenses and an increase in Centers of Excellence costs of $0.1 million, offset by a decrease in listing expenses of $0.1 million.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these general and administrative expenses to substantially increase consistent with our plans to increase our headcount as a result of ongoing requirements as a public company, in addition to ongoing research and development growth initiatives.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $3.2 million for the three months ended September 30, 2022 and $0 for the three months ended September 30, 2021. The increase in other income primarily related to increased interest income as a result of higher interest rates in addition to a gain of $2.6 million recognized in connection with a forward exchange contract that we entered into and settled in the third quarter of 2022. </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains decreased by $2.3 million to a gain of $1.1 million for the three months ended September 30, 2022 from a gain of $3.4 million for the three months ended September 30, 2021, primarily related to gains arising from the translation of cash balances generated from the IPO proceeds and the Follow-On Offering proceeds that were maintained in U.S. dollars, which is different from the legal entity&#8217;s functional currency (Pound Sterling) giving rise to foreign currency gains. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our U.S. dollar balances are held in a pound sterling functional currency legal entity and converted as required into Pound Sterling because the predominant cash outflows are Pound Sterling. As our operating model and business develops we will continually monitor and assess our legal entity structure and whether our future cash outflows continue to be reported in Pounds Sterling or in U.S. dollars, as well as the continuing impact of foreign exchange rates on our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Research and Development Tax Credit</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, we recognized an R&amp;D tax credit from the UK as a benefit within other income, net of $3.0 million and $2.6 million, respectively. The tax credit receivable increased by $0.4 million in 2022 compared to 2021 in line with increased research and development activities.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense was $0.1 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September 30, 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and less than $0.1 million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The income tax expense was related to income tax obligations of our operating company in the United States, which generates a profit for tax purposes.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_109"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage mental health care company and we have not yet generated any revenue to date. We have incurred significant operating losses since our formation. We have not yet commercialized any therapeutic candidates and we do not expect to generate revenue from sales of any therapeutic candidates for the foreseeable future, if at all. We have funded our operations to date primarily with proceeds from the sale of convertible preferred shares, convertible loan notes and ADSs in our IPO and our Follow-On Offering. Through September 30, 2022, we had received net cash proceeds of $116.4 million from sales of our convertible preferred shares and convertible loan notes, $132.8 million in net proceeds from sales of ADSs through our IPO, and $154.8 million in net proceeds from our Follow-On Offering. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash balance of $173.1 million at September 30, 2022 will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,376)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease)/increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, net cash used in operating activities was $60.1 million, primarily resulting from our net loss of $60.6 million offset by a non-cash gain on foreign currency remeasurement of $3.9 million, non-cash share-based compensation expenses of $9.8 million, depreciation and amortization of $0.2 million, and non-cash lease expenses of $1.6 million. The net loss was also adjusted by $15.0 million related to changes in components of working capital, including a $30.1 million increase in prepaid expenses and other current assets which primarily related to the R&amp;D tax credit receivable and prepaid research and development expense, a $0.3 million increase in other assets related to increased implementation costs and a $20.0 million increase in accounts payable which primarily relates to research and development invoices received in the quarter, in addition to a $1.2 million decrease in accrued expenses and other liabilities, a $1.6 million decrease in operating lease liabilities and a decrease in deferred and prepaid tax assets of $1.8 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">During the nine months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">, net cash used in operating activities was $45.4&#160;million, primarily resulting from our net loss of $46.1&#160;million offset by non-cash share-based compensation expense of $5.9&#160;million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">non-cash lease expenses of $1.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> and depreciation and amortization of $0.1 million. The net loss was also adjusted by $6.3 million related to changes in components of working capital, including a $6.8&#160;million increase in prepaid expenses and other current assets which primarily related to the R&amp;D tax credit receivable and prepaid research and development expense, a $0.6 million increase in deferred tax assets, a $0.2 million increase in other assets which primarily related to the security deposit for our new London office lease and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a $1.0 million decrease in operating lease liabilities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> offset by a $2.3 million increase in accrued expenses and other liabilities primarily related to an increase in clinical trial costs and legal and professional fees, primarily related to expenses associated with operating as a public company and other corporate activities as we continue to grow our business.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, net cash used in investing activities was $0.5 million and $0.2 million respectively, primarily driven by our purchases of property and equipment, which largely consisted of lab and office equipment.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, net cash provided by financing activities was $0.4 million and $155.8 million, respectively, primarily related to the proceeds from exercise of options and issuance of our shares through our Follow On Offering.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 the effect of exchange rate changes on cash, cash equivalents and restricted cash resulted in an exchange loss of $39.9 million compared with a loss of $6.5 million in the same period in the prior year, primarily driven by movements in exchange rates from period to period, resulting in exchange losses on cash balances which are held in entities with Pound Sterling functional currencies and translated to U.S. dollars, the reporting currency.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to continue to increase substantially in connection with our ongoing activities, particularly as we begin our Phase 3 clinical program of COMP360 in TRD and continue to advance the preclinical activities, manufacturing and Phase 2 clinical trials of COMP360. In addition, we expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our expenses will also increase as we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the clinical development of our investigational COMP360 psilocybin therapy in active clinical trial sites across Europe and North America, including costs associated with conducting our Phase 3 program in TRD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct Phase 2 studies evaluating the safety and tolerability of COMP360 psilocybin therapy in patients suffering with anorexia nervosa and PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish relationships with the network of public healthcare institutions and private clinics that will administer our investigational COMP360 psilocybin therapy, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the training of qualified therapists, psychiatrists and other healthcare professionals to deliver our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates, therapy sessions, or digital support, for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our commercialization strategy in Europe and North America, including using digital technologies and solutions to enhance our therapeutic offering;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the research and development program for our other preclinical stage therapeutic candidates and discovery-stage programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and/or develop additional therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any therapeutic candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue necessary scheduling-related decisions to enable us to commercialize any therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore external business development opportunities through acquisitions, partnerships, licensing deals to enhance our pipeline and add additional therapeutic candidates to our portfolio;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operations in the United States, Europe and potential other geographies</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as a public company listed in the United States; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">work to accelerate research of emerging psychedelic therapies through our partnership with Sheppard Pratt.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$173.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at September 30, 2022 will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. As we progress with our development programs and the regulatory review process, we expect to incur significant commercialization expenses related to product manufacturing, pre-commercial activities and commercialization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and completion of our Phase 3 clinical program  for COMP360 for the treatment of TRD, and for indications outside of TRD or any future therapeutic candidates outside of TRD, including anorexia nervosa and PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the United States Drug Enforcement Agency, or DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential new therapeutic candidates we identify and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with establishing and maintaining Centers of Excellence to serve as research facilities and innovation labs, in line with our ambition to create a new mental health care model;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved with hiring additional personnel in our research and development department to support the expansion of our digital activities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our investigational COMP360 psilocybin therapy and future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements raised by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or future therapeutic candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any of our future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our investigational COMP360 psilocybin therapy and future therapeutic candidates, if approved; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available at all or on acceptable terms. To the extent that we raise additional capital through the sale of equity, current ownership interests will be diluted. If we raise additional funds through government or third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish future revenue streams, research programs or therapeutic candidates or grant licenses on terms that may not be favorable to us. Debt financing, if available, may involve high interest rates or agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_112"></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our significant accounting policies or&#8239;critical&#8239;accounting&#8239;estimates during the first nine months of 2022. For a complete discussion, see the &#8220;Critical Accounting Policies and Significant Judgments and Estimates&#8221; section of the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation in our Form 10-K.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_115"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the market value of shares held by non-affiliates on June 30, 2022, we are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act and will exit &#8220;large accelerated filer&#8221; status as of December 31, 2022. We may take advantage of certain of the scaled disclosures available to smaller reporting companies. These include, but are not limited to, reduced disclosure obligations regarding executive compensation and an exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures. As a smaller reporting company with annual revenues of less than $100.0 million, we are also not required to provide an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will be able to take advantage of these scaled disclosures and exemptions for so long as (i) our voting and non-voting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_121"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_124"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2022. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the&#160;Exchange Act&#160;is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2c038f1b3ae34b9980fe150878abee2f_127"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_130"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation or claims that we believe, if determined adversely to us, would have a material adverse effect on our business, operating results, financial condition or cash flows. From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_133"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors as well as the other information included in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our condensed consolidated financial statements and related notes thereto. Any of the following risks could materially and adversely affect our business, financial condition, or results of operations. The selected risks described below, however, are not the only risks facing us. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially and adversely affect our business, financial condition, or results of operations. The summary of the material risks associated with our business is included in the &#8220;Special Note Regarding Forward Looking Statements&#8221; on page 4 above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage mental health care company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage mental health care company and we have not generated any revenue to date. We have incurred significant operating losses since our formation. We incurred total net losses of $60.6 million, and $46.1 million, respectively, for the nine months ended September 30, 2022 and September 30, 2021. As of September 30, 2022, we had an accumulated deficit of $230.2 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access, commercialization and business development activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our expected losses, among other things, may continue to cause our working capital and shareholders&#8217; equity to decrease. We anticipate that our expenses will increase substantially if and as we, among other things: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the clinical development of our investigational COMP360 psilocybin therapy for the treatment of TRD, anorexia nervosa and PTSD, including our plan to begin our Phase 3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program for COMP360 psilocybin therapy in TRD by the end of 2022;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in the development of prodrug candidates and psychedelic compounds that could be developed into therapies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the training of therapists to deliver our investigational COMP360 psilocybin therapy in our clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in funding investigator-initiated studies, or IISs, including the IIS co-sponsored by King&#8217;s IoPPN and South London and Maudsley NHS Foundation Trust that will use COMP360 psilocybin therapy to explore how psilocybin affects specific brain pathways in autistic adults;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates for which we may obtain regulatory approval, including COMP360; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and expand the network of public healthcare institutions and private clinics that administer our investigational COMP360 psilocybin therapy in conjunction with psychological support;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our commercialization strategy in North America and Europe, including using digital technologies to enhance our proposed therapeutic offering; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research additional indications for our investigational COMP360 psilocybin therapy and discover and develop any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in our Discovery Center and Centers of Excellence; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any future therapeutic candidates that successfully complete clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience heightened regulatory scrutiny;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue necessary scheduling-related decisions to enable us to commercialize any future therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore external business development opportunities through acquisitions, partnerships, licensing deals to add future therapeutic candidates and technologies to our portfolio;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">experience any delays or encounter any issues with respect to any of the above, including failed studies, ambiguous trial results, safety issues or other regulatory challenges, including, for example, delays and other impacts as a result of a resurgence or emergence of new COVID-19 variants;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operations in the United States, Europe and potential other geographies in the future; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as an English-domiciled public company listed in the U.S.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have funded our operations through private placements of equity and convertible notes and, since our initial public offering, or IPO, in 2020, through public equity offerings. To become and remain profitable, we will need to continue developing and eventually commercialize therapies that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials of COMP360 or any future therapeutic candidates, and initiating new clinical trials, including our planned Phase 3 trial in TRD, training a sufficient number of qualified therapists to deliver our investigational COMP360 psilocybin therapy, using digital technologies and solutions to enhance our therapeutic offering, establishing and/or collaborating with providers to develop &#8220;Centers of Excellence&#8221; where we can conduct trainings for therapists, discovering and developing any future therapeutic candidates, obtaining regulatory approval for COMP360 psilocybin therapy and any future therapeutic candidates that successfully complete clinical trials, and establishing marketing capabilities. Even if COMP360 psilocybin therapy or any of the future therapeutic candidates that we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing COMP360 or any other approved future therapeutic candidate. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, the MHRA, or other comparable foreign authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to require substantial additional funding in the future to sufficiently finance our operations and advance development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. We expect that our cash and cash equivalents of $173.1 million as of September 30, 2022, will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, such as rising inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and completion of our planned Phase 3 clinical program for our current investigational COMP360 psilocybin therapy program for TRD, our Phase 2 studies in anorexia nervosa, PTSD, and our preclinical activities and clinical trials for future indications or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the U.S. Drug Enforcement Administration, or the DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential future therapeutic candidates we identify and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, including increasing personnel costs; </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing sales and marketing capabilities to target public and private healthcare providers and clinic networks in major markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of training and certifying therapists to administer our investigational COMP360 psilocybin therapy in our clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing our Centers of Excellence and the Center for Mental Health Research, which includes conducting clinical trials, including proof of concept studies, to refine our therapeutic model; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generating and collecting data and advancing our intellectual property portfolio; and strengthening our regional presence as a scientific and clinical resource;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing, testing and deploying digital technology solutions to improve the patient experience and therapeutic process;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements or invalidity raised by third parties; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or any future therapeutic candidates, and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty payments from future sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, recent volatility in capital markets and lower market prices for many securities may affect our ability to raise additional funding through sales of our ADSs or issuance of indebtedness, which may harm our liquidity, may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our investigational COMP360 psilocybin therapy or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, geopolitical tensions resulting from conflict between Ukraine and Russia, increasing inflation and interest rates and the related U.S. and global economic impact or other economic or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our ADSs, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to COMP360 or any future therapeutics candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, heightened regulatory scrutiny could have a negative impact on our ability to raise capital. Our business activities rely on developing laws and regulations in multiple jurisdictions. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding our investigational COMP360 psilocybin therapy or any future therapeutic candidates may adversely affect our business and operations, including without limitation, our ability to raise additional capital.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited history as a clinical stage company may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were formed in 2016 and to date, we have invested most of our resources in developing our investigational COMP360 psilocybin therapy, building our intellectual property portfolio, conducting business planning, raising capital and providing administrative support for these operations. Although we will soon be initiating our Phase 3 clinical program for our COMP360 psilocybin therapy for TRD, we have not yet demonstrated an ability to conduct later-stage clinical trials, obtain regulatory approvals, manufacture a commercial-scale product, conduct sales and marketing activities necessary for successful product commercialization or obtain reimbursement in the countries of sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. If and when we receive regulatory approval for our COMP360 psilocybin therapy or any future product candidate, we will  need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to holders of our ordinary shares or ADSs, restrict our operations or require us to relinquish rights to COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. Any indebtedness we incur would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual property rights, declare dividends, make capital expenditures and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic collaborations and alliances, licensing arrangements or monetization transactions with third parties, we may have to relinquish valuable rights to our investigational COMP360 psilocybin therapy or any future therapeutic candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our investigational COMP360 psilocybin therapy or any future therapeutic candidates that we would otherwise prefer to develop and market ourselves. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Development, Clinical Testing and Commercialization of Our Investigational COMP360 Psilocybin Therapy and Any Future Therapeutic Candidates</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the successful development of our investigational COMP360 psilocybin therapy. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no therapies that are approved for commercial sale and may never be able to develop marketable therapies. We expect that a substantial portion of our efforts and expenditures over the next several years will be devoted to our investigational COMP360 psilocybin therapy, which is currently our only therapeutic candidate in development. Accordingly, our business currently depends on the successful regulatory approval of COMP360 and the commercialization of our investigational COMP360 psilocybin therapy. We cannot be certain that COMP360 will receive regulatory approval or that our therapy will be successfully commercialized even if we receive regulatory approval. If we were required to discontinue development of our investigational COMP360 psilocybin therapy, or if COMP360 does not receive regulatory approval or fails to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing, and distribution of psilocybin is, and will remain, subject to comprehensive regulation by the FDA, the DEA, the EMA, the MHRA and foreign regulatory authorities. Failure to obtain regulatory approval in the United States, Europe or other jurisdictions will prevent us from commercializing and marketing our investigational COMP360 psilocybin therapy in such jurisdictions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we were to successfully obtain approval from the FDA, the EMA, the MHRA and foreign regulatory authorities for COMP360, any approval might contain significant limitations related to use, as well as restrictions for specified age groups, warnings, precautions or contraindications. Furthermore, even if we obtain regulatory approval for COMP360, we will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize including securing availability of third-party therapy sites for the appropriate administration of our investigational COMP360 psilocybin therapy, secure adequate manufacturing, train and secure access to qualified therapists, establish a commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including government healthcare programs. If we, or any future collaborators, are unable to successfully commercialize our investigational COMP360 psilocybin therapy, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our investigational COMP360 psilocybin therapy and any future therapeutic candidates will depend on several factors, including the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successful completion of clinical trials, including our Phase 3 program in TRD, and preclinical studies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful patient enrollment in and completion of clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 and any future therapeutic candidates in the intended populations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if COMP360 or any future therapeutic candidates are approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting, training and certifying therapists to administer our investigational COMP360 psilocybin therapy in our clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin therapy and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining and defending patent and trade secret protection and/or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of COMP360 and any future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of COMP360 and any future therapeutic candidates following approval;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with companies developing and commercializing other therapies in the indications which our investigational COMP360 psilocybin therapy targets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining the strength of our reputation; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with laws and regulations, including laws applicable to controlled substances, data privacy, and pre-commercial activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates we develop, which would materially harm our business. If we do not receive marketing approvals for COMP360 and any future therapeutic candidates, we may not be able to continue our operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMP360 psilocybin therapy is, and any future therapeutic candidates we may develop in the future may be, subject to controlled substance laws and regulations in the territories where the product will be marketed, such as the United States, the UK and the rest of Europe, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition. In addition, during the review process of COMP360 psilocybin therapy, and prior to approval, the FDA and/or other regulatory bodies may require additional data, including with respect to whether COMP360 has abuse or misuse potential. This may delay approval and any potential rescheduling process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, psilocybin and its active metabolite, psilocin, are listed by the DEA as &#8220;Controlled Substances&#8221; or scheduled substances, under the Comprehensive Drug Abuse Prevention and Control Act of 1970, also known as the Controlled Substances Act, or CSA specifically as a Schedule I substance. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example, they may not be refilled without a new prescription and may have a black box warning. Further, most, if not all, state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocybin to be available for commercial marketing in the United States, psilocybin and psilocin must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Commercial marketing in the United States will also require scheduling-related legislative or administrative action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance. Therefore, while psilocybin and psilocin are Schedule I controlled substances, products approved by the FDA for medical use in the United States that contain psilocybin or psilocin should be placed in Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement. If and when COMP360 receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed to patients in the United States. This scheduling determination will be dependent on FDA approval and the FDA&#8217;s recommendation as to the appropriate schedule. During the review process, and prior to approval, the FDA may determine that it requires additional data, either from non-clinical or clinical studies, including with respect to whether, or to what extent, the substance has abuse or misuse potential. This may introduce a delay into the approval and any potential rescheduling process. That delay would be dependent on the quantity of additional data required by the FDA. This scheduling determination will require DEA to conduct notice and comment rule making including issuing an interim final rule. Such action will be subject to public comment and requests for hearing which could affect the scheduling of these substances. There can be no assurance that the DEA will make a favorable scheduling decision. Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such substances would also require scheduling determinations under state laws and regulations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved by the FDA, and if the finished dosage form of COMP360 is listed by the DEA as a Schedule II, III, or IV controlled substance, its manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use will continue to be subject to a significant degree of regulation by the DEA. In addition, the scheduling process may take significantly longer than the 90-day deadline set forth in the CSA, thereby delaying the launch of our investigational COMP360 psilocybin therapy in the United States. Furthermore, the FDA, DEA, or any foreign regulatory authority could require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the cost and/or delay the launch of our investigational COMP360 psilocybin therapy and any future therapeutic candidates containing controlled substances. In addition, therapeutic candidates containing controlled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DEA registration and inspection of facilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result in delay of the importation, manufacturing or distribution of COMP360. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">State-controlled substances laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule COMP360. While some states automatically schedule a drug based on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal action, other states schedule drugs through rule making or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or our partners must also obtain separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because our investigational COMP360 psilocybin therapy contains psilocybin, to conduct clinical trials with COMP360 in the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense COMP360 and to obtain the product from our importer. If the DEA delays or denies the grant of a researcher registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites. The importer for the clinical trials must also obtain a Schedule I importer registration and an import permit for each import. We do not currently conduct any manufacturing or repackaging/relabeling of either COMP360 or its active ingredients (i.e., psilocybin) in the United States. COMP360 is imported in its fully-finished, packaged and labeled dosage form.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Importation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If COMP360 is approved and classified as a Schedule II, III or IV substance, an importer can import it for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority, including specific quantities, could affect the availability of COMP360 and have a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible that adverse comments may delay the grant of an importer registration. If COMP360 is approved and classified as a Schedule II controlled substance, federal law may prohibit the import of the substance for commercial purposes. If COMP360 is listed as a Schedule II substance, we will not be allowed to import the drug for commercial purposes unless the DEA determines that domestic supplies are inadequate or there is inadequate domestic competition among domestic manufacturers for the substance as defined by the DEA. Moreover, Schedule I controlled substances, including psilocybin and psilocin, have never been registered with the DEA for importation for commercial purposes, only for scientific and research needs. Therefore, if neither COMP360 nor its drug substance could be imported, COMP360 would have to be wholly manufactured in the United States, and we would need to secure a manufacturer that would be required to obtain and maintain a separate DEA registration for that activity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacture in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the United States, our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements. Additionally, regardless of the scheduling of COMP360, the active ingredient in the final dosage form is currently a Schedule I controlled substance and would be subject to such quotas as this substance could remain listed on Schedule I. The annual quota allocated to us or our contract manufacturers for the active ingredient in COMP360 may not be sufficient to complete clinical trials or meet commercial demand. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&#8217;, procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Distribution in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If COMP360 is scheduled as Schedule II, III or IV, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute COMP360 and any future therapeutic candidates. These distributors would need to obtain Schedule II, III or IV distribution registrations. This limitation in the ability to distribute COMP360 more broadly may limit commercial uptake and could negatively impact our prospects. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result in increased costs to us. If COMP360 is a Schedule II drug, participants in our supply chain may have to maintain enhanced security with alarms and monitoring systems and they may be required to adhere to recordkeeping and inventory requirements. This may discourage some pharmacies from carrying the product. In addition, COMP360 could be determined to have a high potential for abuse and therefore required to be administered at our trial sites, which could limit commercial uptake. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse, such as the requirement that physicians consult a state </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drug monitoring program, may make physicians less willing to prescribe, and pharmacies to dispense, Schedule II products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Psilocybin and psilocin are &#8220;controlled drugs&#8221; in the UK, as they are listed under Schedule 1 of the UK&#8217;s Misuse of Drugs Regulations 2001 and are classified as Class A controlled substances under the Misuse of Drugs Act 1971. Substances listed under Schedule 1 of the Misuse of Drugs Regulations 2001 are considered to have little or no therapeutic benefit and are the most strictly controlled. These substances can therefore only be imported, exported, produced and supplied under a license issued by the UK Government&#8217;s Home Office. Psilocybin and psilocin may never be rescheduled under the Misuse of Drugs Regulations 2001, or reclassified under the UK&#8217;s Misuse of Drugs Act 1971.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The potential reclassification of psilocybin and psilocin in the United States could create additional regulatory burdens on our operations and negatively affect our results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If psilocybin and/or psilocin, other than the FDA-approved formulation, is rescheduled under the CSA as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), the ability to conduct research on psilocybin and psilocin would most likely be improved. However, rescheduling psilocybin and psilocin may materially alter enforcement policies across many federal agencies, primarily the FDA and DEA. The FDA is responsible for ensuring public health and safety through regulation of food, drugs, supplements, and cosmetics, among other products, through its enforcement authority pursuant to the Federal Food, Drug, and Cosmetic Act, or the FDCA. The FDA&#8217;s responsibilities include regulating the ingredients as well as the marketing and labeling of drugs sold in interstate commerce. Because it is currently illegal under federal law to produce and sell psilocybin and psilocin, and because there are no federally recognized medical uses, the FDA has historically deferred enforcement related to psilocybin and psilocin to the DEA. If psilocybin and psilocin were to be rescheduled to a federally controlled, yet legal, substance, the FDA would likely play a more active regulatory role. The DEA would continue to be active in regulating manufacturing, distribution and dispensing of such substances. The potential for multi-agency enforcement post-rescheduling could threaten or have a materially adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMP360 contains controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current or future investigational therapies using psilocybin may negatively influence the success of these therapies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapies containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, COMP360 and any future therapeutic candidates we may develop. Opponents of these therapies may seek restrictions on marketing and withdrawal of any regulatory approvals. In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community to reject these therapies. For example, we may face media-communicated criticism directed at our clinical development program. Adverse publicity from psilocybin misuse may adversely affect the commercial success or market penetration achievable by our investigational COMP360 psilocybin therapy. Anti-psychedelic protests have historically occurred and may occur in the future and generate media coverage. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict the introduction and marketing of, our investigational COMP360 psilocybin therapy or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If COMP360 or any future therapeutic candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of the safety and quality of our therapies. We may face limited adoption if third-party therapy sites, therapists, and patients are unwilling to try such a novel treatment. There has been a history of negative media coverage regarding psychedelic substances, including psilocybin, which may affect the public&#8217;s perception of our therapies. In addition, psilocybin elicits intense psychological experiences, and this could deter patients from choosing this course of treatment. We could be adversely affected if we were subject to negative publicity or if any of our therapies or any similar therapies distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perception, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our therapies or any similar therapies distributed by other companies could have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adverse events in research into depression and mental health diseases on which we focus our research efforts, or the pharmaceutical industry more generally, could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our therapies. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for COMP360 or any future therapeutic candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of COMP360 or any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates on a timely basis or at all, which will adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in initiating and completing our Phase 3 clinical program of COMP360 psilocybin therapy in TRD, completing our ongoing Phase 2 clinical trials in anorexia nervosa and PTSD and initiating or completing additional clinical trials. We may also experience numerous unforeseen events, and in some cases have experienced such events, during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to obtain regulatory approval to commence or modify a trial, including the imposition of a temporary or permanent clinical hold by regulatory authorities for a number of reasons, including after review of an Investigational New Drug Application, or IND, or amendment, clinical trial application, or CTA, or amendment, or equivalent application or amendment, as a result of a finding that the trial presents unreasonable risk to clinical trial participants or a negative finding from an inspection of our clinical trial operations or study sites, or the occurrence of a suspected, unexpected serious adverse reaction, or SUSAR, which we have experienced in the past, or serious adverse reaction, or SAE, during our clinical trials or investigator-initiated studies, or IISs, using COMP360; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to obtain institutional review board, or IRB, or ethics committee approval at each site; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to recruit and enroll a sufficient number of suitable patients to participate in a trial; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in studies given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of adequately trained therapists and appropriate third-party clinical trial sites for the administration of COMP360 psilocybin therapy, including preparation, psilocybin administration and integration of the therapeutic experience;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of any supporting digital services that may form part of the preparation, integration or long-term follow-up relating to any therapy we develop;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to contract for the manufacture of sufficient quantities of the underlying therapeutic substance for use in clinical trials in a timely manner; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party actions claiming infringement by our investigational COMP360 psilocybin therapy or any future therapeutic candidates in clinical trials and obtaining injunctions interfering with our progress; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or tolerability concerns which could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower than anticipated retention rates of patients and patients in clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in establishing the appropriate dosage levels in clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in our clinical trials due to the ongoing COVID-19 pandemic, due to factors such as a decrease in the willingness or availability of patients to enroll in our clinical trials and challenges in procuring sufficient supplies of the underlying therapeutic substance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality or stability of the underlying therapeutic substance falling below acceptable standards; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, pandemics, or failures or significant downtime of our information technology systems resulting from cyber-attacks on such systems or otherwise.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs of the institutions in which such trials are being conducted or ethics committees, by the Data Review Committee, or DRC, or Data Safety Monitoring Board for such trial or by the FDA, the EMA, the MHRA or other regulatory authorities or if the DEA registration of an investigator or site conducting the clinical trial is revoked. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA, the MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including any SUSARs or SAEs which have in the past or may in the future occur in our trials or any IISs or other studies using COMP360 and those relating to the class to which COMP360 or any future therapeutic candidates belong, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, on June 18, 2018, the FDA placed COMP360 on clinical hold after it reviewed our initial IND submission, citing the need for additional information regarding the structure of the psilocybin sessions, study personnel, and criteria for discharge. We submitted responsive information to our IND, and the FDA removed the clinical hold on August 8, 2018. If we experience delays in the completion of, or termination of, any clinical trial of COMP360 or any future therapeutic candidates, the commercial prospects of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will be harmed, and our ability to generate revenue from any such therapeutic candidates will be delayed. In addition, any delays in completing our clinical trials will likely increase our costs, slow down COMP360 or any future therapeutic candidate development and approval process and jeopardize our ability to commence sales and generate revenue. Moreover, if we make changes to COMP360 or any future therapeutic candidates, we may need to conduct additional studies to bridge such modified therapeutic candidates to earlier versions, which could delay our clinical development plan or marketing approval for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Significant clinical trial delays could also allow our competitors to bring therapies to market before we do or shorten any periods during which we have the exclusive right to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and impair our ability to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and may harm our business and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of COMP360 or any future therapeutic candidates or result in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates being stopped early. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of COMP360 or any future product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of our investigational COMP360 psilocybin therapy or future therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that the applicable therapeutic candidate is both safe and effective for use in each target indication. A therapeutic candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process and, because our investigational COMP360 psilocybin therapy is in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our investigational COMP360 psilocybin therapy. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same therapeutic candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of COMP360, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with COMP360, we may be delayed in obtaining marketing approval, or we may never obtain marketing approval. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of COMP360 in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are successfully completed, preclinical and clinical data are often susceptible to varying interpretations and analyses and we cannot guarantee that the FDA, the EMA or comparable foreign regulatory authorities will interpret the results as we do. Accordingly, more trials could be required before we submit COMP360 for approval. To the extent that the results of the trials are not satisfactory to the FDA, the EMA or comparable foreign regulatory authorities for support of a marketing application, approval of COMP360 may be significantly delayed, or we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of COMP360. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. Due to the inherent risk in the development of therapeutic substances, there is a significant likelihood that COMP360 and any future therapeutic candidates will not successfully complete development and receive approval. Many other companies that believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the marketing of their therapy. If we do not receive regulatory approvals for COMP360 or future therapeutic candidates, we may not be able to continue our operations. Even if regulatory approval is secured for COMP360 or any future therapeutic candidate, the terms of such approval may limit the scope and use of a specific therapeutic candidate, which may also limit its commercial potential.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. These data may not be sufficient to support regulatory submissions or approvals.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past published and, from time to time in the future we may publish, interim, top-line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a certain number or percentage of subjects have been enrolled, but before completion of the trial. Similarly, we may report top-line or preliminary results of primary and key secondary endpoints before the final trial results are completed. Interim, top-line and preliminary data from our clinical trials may change as more patient data or analyses become available. Preliminary, top-line or interim data from our clinical trials are not necessarily predictive of final results. Interim, top-line and preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular therapeutic candidate and our company in general, and regulatory agencies may request further data from us. In addition, you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular therapeutic candidate. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize COMP360 or any future product candidate, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process of the FDA, the EMA, the MHRA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for COMP360 and any future therapeutic candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a new drug application, or NDA, to the FDA, or a marketing authorization application, or MAA, to the EMA or the MHRA. Before obtaining regulatory approvals for the commercial sale of COMP360 or any future therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that COMP360 and any future therapeutic candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and, because COMP360 is in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA, the EMA, the MHRA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a therapeutic candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for COMP360. It is possible that neither COMP360 nor any future therapeutic candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMP360 or any future therapeutic candidates could fail to receive regulatory approval from the FDA, the EMA, the MHRA or comparable foreign regulatory authorities or be precluded from commercial marketing for many reasons, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with, question or request changes in the design or implementation of our clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may determine that COMP360 or any future therapeutic candidates are not safe and effective, only moderately effective, or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA, the MHRA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our investigational COMP360 psilocybin therapy or any future therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may not be sufficient to support the submission of an NDA or other submission, or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential risk of our novel therapy and delivery method, including the use of third-party clinical trial sites and therapists.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any COMP360 or any future therapeutic candidates, which would significantly harm our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, results of operations and prospects. The FDA, the EMA, the MHRA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of COMP360 or any future therapeutic candidates. Even if we believe the data collected from clinical trials of COMP360 or any future therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, the MHRA or any other regulatory authority. If COMP360 or any future therapeutic candidates fails to obtain approval on the basis of any applicable condensed regulatory approval process, this will prevent such therapeutic candidate from obtaining approval on a shortened time frame, or at all, resulting in increased expenses which would materially harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory or pricing authorities may approve COMP360 or any future therapeutic candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our therapies, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a therapeutic candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that therapeutic candidate. For example, esketamine, a drug targeting major depressive disorder, or MDD, is only available through a Risk Evaluation and Mitigation Strategy, or REMS, program, under the applicable FDA regulations. Any of the foregoing scenarios may have a negative impact on the commercial prospects for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if COMP360 or any future therapeutic candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA, the EMA, the MHRA or a comparable foreign regulatory authority approves COMP360 or any future therapeutic candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the therapy and underlying therapeutic substance will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices, or cGMPs, and with good clinical practices, or GCPs, for any clinical trials that we conduct post-approval, as well as applicable product tracking and tracing requirements, all of which may result in significant expense and limit our ability to commercialize such therapies. Additionally, a company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Later discovery of previously unknown problems with any approved therapeutic candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the labeling, distribution, marketing or manufacturing of COMP360 or any future therapeutic candidates, withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled and warning letters, or holds on clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA, the EMA, the MHRA or other foreign regulatory body to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on coverage by third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of the product; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any regulatory approvals that we receive for COMP360 or any future therapeutic candidates may also be subject to limitations on the approved indicated uses for which the therapy may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of such therapeutic candidates. For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations. REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin therapy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are changes in the application of legislation, regulations or regulatory policies, or if problems are discovered with our investigational COMP360 psilocybin therapy or our manufacture of an underlying therapeutic substance, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the therapeutic or its manufacture and requiring us to recall or remove the therapeutic from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our therapeutic labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such therapy may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMP360 and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of COMP360 or any future therapeutic candidates or following approval, if any, we may need to abandon our development of such therapeutic candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects that may be caused by COMP360 or any future therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials or result in clinical holds and could result in a more restrictive label, a requirement that we implement a REMS plan to ensure that the benefits of the therapy outweigh its risks, or the delay or denial of regulatory approval by the FDA, the EMA, the MHRA or other comparable foreign authorities. We or regulatory authorities may also learn of and take similar actions based on side effects related to COMP360 or compounds similar to COMP360 or any future therapeutic candidates in studies not conducted by us, including in IISs or studies conducted by other sponsors, from spontaneous reports of use of psilocybin outside of the clinical trial setting or from safety reports in literature.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of future clinical studies may show that COMP360 or any future therapeutic candidates cause undesirable or unacceptable side effects or even death. For example, there were a number of treatment emergent adverse events reported with the results of our Phase 2 clinical trial in TRD. There can be no assurance that deaths or serious side effects will not occur, even in a clinical setting. In the event serious side effects occur, our trials could be suspended or terminated and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of COMP360 or any future therapeutic candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, because of the high variability in how different individuals react to psilocybin, certain patients may have negative experiences with the treatment that could subject us to liability or, if publicized, reputational harm. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Even if we receive regulatory approval for COMP360 or any future therapeutic candidates, we will have tested them in only a limited number of patients during our clinical trials. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the therapy used to determine whether, on a potentially statistically significant basis, the planned safety and efficacy of any such therapeutic candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of COMP360 or any future therapeutic candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to such therapeutic candidate for a longer duration, may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. If our applications for marketing are approved and more patients begin to use our therapy, new risks and side effects associated with our therapies may be discovered. There have been other products and therapies that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of therapies from the market, and our investigational COMP360 psilocybin therapy and any future therapeutic candidates may be subject to similar risks. We might have to withdraw or recall our investigational COMP360 psilocybin therapy and any future therapeutic candidates from the marketplace. We may also experience a significant drop in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the potential future sales of our investigational COMP360 psilocybin therapy or any future therapeutic candidates if and when regulatory approvals for such therapy are obtained, experience harm to our reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved therapeutic candidates, if any, or substantially increase the costs and expenses of commercializing and marketing our investigational COMP360 psilocybin therapy and any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our investigational COMP360 psilocybin therapy or any future therapeutic candidates receive marketing approval and we or others later identify undesirable or unacceptable side effects caused by such therapeutic candidates, a number of potentially significant negative consequences could result, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such therapies and require us to take our approved therapeutic candidates, if any, off the market;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of the therapeutic candidate outweigh its risks;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the therapy is administered, conduct additional clinical trials or change the labeling of the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the therapy may decrease significantly;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of the affected therapeutic candidate or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA, EMA or MHRA approval for COMP360 or any future therapeutic candidates that we may identify and pursue in the United States, Europe or the UK, we may never obtain approval to commercialize any such therapeutic candidates outside of those jurisdictions, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a therapeutic candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeking foreign regulatory approval could result in difficulties and costs and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our investigational COMP360 psilocybin therapy and any future therapeutic candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA, EMA or MHRA approval. We do not have any therapeutic candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets for COMP360 or any future therapeutic candidates. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our investigational COMP360 psilocybin therapy and any future therapeutic candidates will be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early-stage clinical trials of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of COMP360 or any future therapeutic candidates. There is a high failure rate for drugs proceeding through clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery and development of new drugs targeting central nervous system, or CNS, disorders are particularly difficult and time-consuming, evidenced by the higher failure rate for new drugs for CNS disorders compared with most other areas of drug discovery. Any such setbacks in our clinical development could have a material adverse effect on our business and operating results. In addition, our later stage clinical trials may present challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of the human brain and the central nervous system, it can be difficult to predict and understand why a drug, including COMP360, may have a positive effect on some patients but not others and why some individuals may react to the drug differently from others. The population of those suffering with TRD is large and heterogenous and individuals may have different levels of severity of TRD. These differences may further result in different reactions to impact the effectiveness of our investigational COMP360 psilocybin therapy. All of these factors may make it difficult to assess the prior use or the overall efficacy of our investigational COMP360 psilocybin therapy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on enrollment of patients in our clinical trials for COMP360 and any future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying and enrolling eligible patients, including those willing to discontinue use of their existing medications; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical protocol and the patient eligibility and exclusion criteria for the trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety profile, to date, of the therapeutic candidate under study;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials, including due to the perceived risks and benefits, stigma or other side effects of use of a controlled substance;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials, including due to any public health crisis such as the emergence of  new COVID-19 variants;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of our approach to treatment of indication;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to clinical sites;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of competing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of new drugs approved for the indication the clinical trial is investigating;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the drug being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any negative results we may report in clinical trials of COMP360 or any future therapeutic candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same therapeutic candidate. Delays in the enrollment for any clinical trial of COMP360 or any future therapeutic candidates will likely increase our costs, slow down COMP360 approval process and delay or potentially jeopardize our ability to commence sales of our investigational COMP 360 psilocybin therapy and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of COMP360 or any future therapeutic candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics. For example, our clinical trial sites may be located in regions currently or in the future affected by the COVID-19 pandemic or which may in the future be impacted by other pandemics. For example, in the past, enrollment in our trials was adversely affected by limiting the availability of participants, the inability of patients, therapists or physicians to participate in our trials, interruptions in supply chains and delays with regulators and other similar bodies. The global outbreak of COVID-19 continues to evolve and the conduct of our trials may continue to be adversely affected, despite efforts to mitigate this impact.<br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently assembling a sales and marketing infrastructure, we have limited organizational experience in the sale or marketing of therapeutic candidates. To achieve commercial success for any approved therapy, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into partnerships. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our investigational COMP360 psilocybin therapy is approved for commercial sale, we plan on establishing our own market access and commercialization capabilities in primary markets in North America and in the EU. In select geographies, we might also consider relying on the support of a Contract Sales Organization, or CSO, or enter into commercialization arrangements with companies with relevant commercialization capabilities. There are risks involved in establishing our own sales and marketing capabilities, as well as with entering into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch our therapies effectively or to market our therapies effectively since we have limited organizational experience in the sales and marketing of therapeutic substances. In addition, recruiting and training a sales force is expensive and time-consuming, and could delay any therapeutic launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our therapies on our own include: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to train an adequate number of therapists to meet the demand for psilocybin therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our therapists to perform their roles consistently with our training and our guidelines for the administration of our investigational COMP360 psilocybin therapy;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain effective market access and commercial personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of commercial personnel to obtain access to or educate adequate numbers of physicians on the benefits of prescribing any future therapies; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to identify a sufficient number of treatment centers in third-party therapy sites to meet the demands of our therapies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary therapies to be offered by our commercial personnel, which may put us at a competitive disadvantage relative to companies with more extensive therapeutic lines; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent market access and commercial organization; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of market access and commercialization above those anticipated by us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform market access and commercial services for any approved therapies, the revenue or the profitability of these revenues to us could be lower than if we were to commercialize any therapies that we develop ourselves. Such collaborative arrangements may place the commercialization of any approved therapies outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our therapies or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. We may not be successful in entering into arrangements with third parties to commercialize our therapies or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to commercialize our therapies effectively, to set up sufficient number of treatment centers in third-party therapy sites, or to recruit, train and retain adequate number of therapists to administer our therapies. In addition, we are exploring ways in which we can use digital technology to improve the patient experience and therapeutic outcomes of our therapies. Commercialization partners may lack incentives to promote our digital technology and we may face difficulties in implementing our digital technologies in third-party therapy sites through such third parties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not establish commercial capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our therapies, which in turn would have a material adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The future commercial success of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never have a therapy that is commercially successful. To date, we have no therapy authorized for marketing. Our investigational COMP360 psilocybin therapy requires further clinical investigation, regulatory review, significant market access and marketing efforts and substantial investment before it can produce any revenue. Furthermore, if approved, our therapy may not achieve an adequate level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large, and we may not become profitable. The level of acceptance we ultimately achieve may be affected by negative public perceptions and historical media coverage of psychedelic substances, including psilocybin. Because of this history, efforts to educate the medical community and third-party payors and health technologies assessment bodies on the benefits of our investigational COMP360 psilocybin therapy may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of our future therapies by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number of factors, many of which are beyond our control, including, but not limited to, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by healthcare professionals, patients and healthcare payors of each therapy as safe, effective and cost-effective; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any therapeutic candidate; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of sales, marketing and distribution support; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic candidate&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternative therapies; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events or publicity; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of therapeutic characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with our therapy in relation to alternative treatments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the steps that prescribers and dispensers must take, given that COMP360 includes a controlled substance, as well as the perceived risks based upon its controlled substance status;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manufacture our product in sufficient quantities and yields;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try, and of healthcare professionals to prescribe, the therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any potential unfavorable publicity, including negative publicity associated with recreational use or abuse of psilocybin;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use, sale or distribution of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, including through REMS;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which therapies are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our therapies are designated under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line or last-line therapy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our investigational COMP360 psilocybin therapy or any future therapeutic candidates fail to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large enough to allow us to generate significant revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and commercialization strategy depends on our ability to identify, qualify, prepare, certify and support third-party therapy sites to administer COMP360 psilocybin therapy. If we are unable to do so, our commercialization prospects would be limited and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are able to commercialize our investigational COMP360 psilocybin therapy or future therapies, our success will be dependent upon our ability to identify, qualify, prepare, certify and support third-party therapy sites that offer and administer our therapies. Our commercial model of delivering our investigational COMP360 psilocybin therapy will also involve third-party therapists before, during and after the COMP360 psilocybin administration session, which will be hosted in one of the third-party therapy sites. We intend to commercialize our investigational COMP360 psilocybin therapy and any future therapeutic candidates by building close relationships with qualified third-party therapy sites where these therapists will administer our investigational COMP360 psilocybin therapy. Because we intend to work only with third-party sites and providers who agree to adhere strictly to our treatment protocols, we may face limitations on the number of sites available to administer our investigational COMP360 psilocybin therapy. Any such limitations could make it impracticable or impossible for some potential patients to access our investigational COMP360 psilocybin therapy, if approved, which could limit the overall size of our potential patient population and harm our future results of operations. Although we plan to develop Centers of Excellence to train and certify such third-party therapy sites, conduct further research on and continuously improve our treatment protocol, we expect this to involve significant costs, time and resources, and our efforts may not be successful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish a sufficient network of third-party therapy sites certified under applicable standards, including regional, national, state or other applicable standards as needed to render psilocybin therapeutic services, including the certifications that such third-party therapy sites may require, it would have a material adverse effect on our business and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to grow and would adversely affect our results of operations and commercialization efforts. We expect the therapists to be employed by the third-party therapy sites where the therapists administer our therapies. Third-party therapy sites could, for a number of reasons, demand higher payments for our therapies or take other actions to increase their income from selling our therapies, which could result in higher costs for payors and for our patients to get access to our therapies. For example, legal regimes may have higher levels of licensure which force us to contract with third-party therapy sites that demand higher payment rates to provide psilocybin therapeutic services. In addition, third-party therapy sites may have difficulty meeting regulatory or accreditation requirements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the novel nature of our treatment, third-party therapy sites may face additional financial and administrative burdens in order to deliver any approved therapy, including adhering to a REMS plan in the United States or a Risk Management Program, or RMP, in Europe. The process for a third-party therapy site to obtain a certificate under a REMS plan can be very costly and time-consuming, which could delay a third-party therapy site&#8217;s ability to provide our therapies and materially adversely affect our commercialization trajectory. Furthermore, third-party therapy sites will need to ensure that they have the necessary infrastructure and equipment in order to deliver our investigational COMP360 psilocybin therapy, such as adequate audio-visual equipment, ancillary equipment and sufficient treatment rooms. This may deter third-party therapy sites from providing our therapeutic candidate and reduce our ability to expand our network and generate revenue. Our ability to develop and maintain satisfactory relationships with third-party therapy sites may otherwise be negatively impacted by other factors not associated with our operations and, in some instances, outside of our direct or indirect control, such as negative perceptions regarding the therapeutic use of psilocybin, changes in Medicare and/or Medicaid or commercial payors reimbursement levels and other pressures on healthcare providers and consolidation activity among hospitals, physician groups and the providers. Reimbursement levels may be inadequate to cover third-party therapy sites&#8217; costs of delivering our investigational COMP360 psilocybin therapy. The failure to maintain or to secure new cost-effective contracts with third-party therapy sites may result in a loss of or inability to grow our network of third-party therapy sites, patient base, higher costs to our patients and us, healthcare provider network disruptions and/or difficulty in meeting regulatory or accreditation requirements, any of which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on qualified therapists working at third-party clinical trial sites to administer our investigational COMP360 psilocybin therapy in our clinical trials and we expect this to continue upon approval, if any, of COMP360 or any future therapeutic candidates. If third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently administer our investigational COMP360 psilocybin therapy in our clinical trials through qualified third-party therapists working at third-party clinical trial sites. However, there are currently not enough trained therapists to carry out our investigational COMP360 psilocybin therapy at a commercial scale, and our efforts to facilitate training and certification programs for therapists, including through our planned Centers of Excellence, may be unsuccessful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently provide training to the therapists and expect to continue providing trainings in the future (either directly or indirectly through third-party providers), we do not currently employ the therapists who deliver our therapies to patients and do not intend to do so in the future. Such therapists are typically employed by the third-party therapy sites. If our investigational COMP360 psilocybin therapy or any future therapeutic candidates are approved for commercialization, third-party therapy sites may demand substantial financial resources from us to recruit and retain a team of qualified therapists to administer our investigational COMP360 psilocybin therapy or any future therapeutic candidates. If the third-party therapy sites fail to recruit, train and retain sufficient number of therapists or if a competitor develops a similar product that is effective without the use of therapists, our ability to offer and administer our therapies will be greatly harmed, which may in turn reduce the market acceptance rate of our therapies or limit our ability to grow our business. If this occurs, our commercialization prospects would be negatively affected and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently provide training and expect to continue providing training to the therapists (directly or through third-party providers), we generally rely on qualified and certified third-party therapy sites to manage the therapists and monitor the administration of our therapies and ensure that the administration process of our therapies comply with our established protocols. However, if not properly managed and supervised, there is a risk that therapists may deviate from our training protocols, fail to follow the guidelines we have established, or abuse patients during psilocybin administration sessions. The therapists might also administer unauthorized therapies to patients using illegal psilocybin compounds in &#8220;underground&#8221; clinics. Such illegal activities would put the patients at risk and subject us to potential liabilities, litigations, regulatory proceedings and reputational harm. If this were to occur, we may face serious setbacks for our commercialization process and our financial condition and results of operations would be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our COMP360 psilocybin therapy or other therapeutic candidates is dependent on our relationships with affiliated professional entities, which we do not own, to provide physician services, and our business would be adversely affected if those relationships were disrupted.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk that U.S. state authorities in some jurisdictions may find that our contractual relationships with our affiliated providers and our Centers of Excellence violate laws prohibiting the corporate practice of medicine and certain other health professions. These laws generally prohibit the practice of medicine and certain other health professions by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing the professional judgment of clinicians and other health care practitioners. The professions subject to corporate practice restrictions and the extent to which each jurisdiction considers particular actions or contractual relationships to constitute improper influence of professional judgment vary across jurisdictions and are subject to change and evolving interpretations by state boards of medicine and other health professions and enforcement agencies, among others. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of the corporate practice laws will not further circumscribe our business operations. State corporate practice restrictions also often impose penalties on health professionals for aiding a corporate practice violation, which could discourage clinicians or other licensed professionals from participating in our network of providers or Centers of Excellence. Any difficulty securing clinicians to participate in our network could impair our ability to provide therapies and could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate practice restrictions exist in some form, whether by statute, regulation, professional board or attorney general guidance, or case law, in at least 42 U.S. states, though the broad variation between jurisdictions with respect to the application and enforcement of the doctrine makes establishing an exact count difficult. Because of the prevalence of corporate practice restrictions on medicine, we contract for provider services and other services provided by the Centers for Excellence through various agreements, such as service agreements, rather than employ providers. We expect that these relationships will continue, but we cannot guarantee that they will. The arrangement in which we have entered to comply with state corporate practice of medicine doctrines could subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state fraud and abuse laws. In addition, a material change in our relationship with the Providers, whether resulting from a dispute among the entities, a change in government regulation, or the loss of these affiliations, could impair our ability to provide therapies and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As therapeutic candidates are developed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes and results. Any of these changes could cause our investigational COMP360 psilocybin therapy or any future therapeutic candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of COMP360 or any future therapeutic candidates and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy designation by the FDA for COMP360 or any future therapeutic candidates may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our investigational COMP360 psilocybin therapy or any future therapeutic candidates will receive marketing approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Breakthrough Therapy designation for COMP360 for the treatment of TRD and may seek it for any future therapeutic candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe any future therapeutic candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for COMP360 and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future therapeutic candidates may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even though COMP360 has been designated as a breakthrough therapy, the FDA may later decide that it, or any future therapeutic candidates that are designated by FDA as breakthrough therapies, no longer meet the conditions for qualification. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek Fast Track designation for any of our therapeutic candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular therapeutic candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we receive Fast Track designation for any future therapeutic candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track designation for any therapeutic candidate that is granted Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future enter into collaborations for the discovery, development and/or commercialization of additional therapeutic candidates or research programs. Such collaborations may not result in the development of commercially viable therapeutic candidates or the generation of significant future revenue, or we may fail to enter into profitable relationships.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into collaborations with pharmaceutical companies or others for the discovery, development and/or commercialization of future therapeutic candidates or research programs. For example, we are expanding our Discovery Center, a sponsored research agreement with University of the Sciences (Pennsylvania), through collaborations with academic laboratories at the University of California San Diego, School of Medicine (California), the Medical College of Wisconsin (Wisconsin), and Dr. Matthias Grill, CEO of MiHKAL GmbH (Switzerland). If we fail to enter into or maintain collaborations on reasonable terms, our ability to discover and develop future therapeutic candidates and research programs could be delayed or become more costly. Any future collaborations may subject us to a number of risks, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to control the amount and timing of resources that our collaboration partner devotes to our future research programs and therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for collaboration agreements where we may be solely or partially responsible for funding development expenses through a defined milestone event, we may never recoup the costs of these investments if the therapeutic candidate fails to achieve regulatory approval or commercial success; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may rely on the information and data received from third parties regarding their research programs and therapeutic candidates without independent verification; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have control of the process conducted by the third party in gathering and composing data regarding their research programs and therapeutic candidates and we may not have formal or appropriate guarantees with respect to the quality and the completeness of such data; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have sufficient funds to satisfy any milestone, royalty or other payments we may owe to any third party collaborator;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration agreements may contain non-competition provisions which place restrictions on our business operations and the therapeutic candidates and/or indications we may pursue; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborative partner may develop or commercialize a competing therapeutic candidate either by itself or in collaboration with others, including one or more of our competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborative partners&#8217; willingness or ability to complete their obligations under our collaboration arrangements may be adversely affected by business combinations or significant changes in a collaborative partner&#8217;s strategy; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborative partners may experience delays in, or increases in the costs of, the discovery and development of our future therapeutic candidates and research programs and we may be required to pay for any cost increases; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have disagreements with collaborative partners, including disagreements over proprietary rights, selection of lead therapeutic candidates, contract interpretation or the preferred course of development that might cause delays or termination of the research, development or commercialization of therapeutic candidates, might lead to additional responsibilities for us with respect to therapeutic candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborative partners may not properly obtain, maintain, defend or enforce intellectual property rights; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborative partners may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a collaborative partnership depends, among other things, upon our assessment of a potential collaborator&#8217;s resources and expertise, the terms and conditions of the proposed partnership and the potential collaborator&#8217;s evaluation of a number of factors. Proposing, negotiating, and implementing collaborations, licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. We have limited institutional knowledge and experience with respect to such activities and we may also not realize the anticipated benefits of any such transaction or arrangement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of the foregoing risks materialize, any collaborations we enter into could fail to result in the development of commercially viable therapeutic candidates or the generation of future revenue, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business strategy includes developing Centers of Excellence, which we expect will involve significant costs, time and resources. If our efforts are unsuccessful, our business, prospects and financial condition would be adversely affected.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A key element of our business strategy involves setting up research facilities and innovation labs, which we refer to as Centers of Excellence, in key markets. We announced the establishment of our first Center of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, in January 2021. In March 2022, we announced a strategic collaboration with King&#8217;s College London and South London and Maudsley NHS Foundation Trust, or SLAM, to establish The Center for Mental Health Research and Innovation with an overarching goal of accelerating patient access to evidence-based innovation in mental health care by driving forward research in psychedelic therapies through, among other things, the development of working model psychedelic treatment clinics, therapist training programs, conducting clinical trials, and data analysis.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to use these Centers to gather evidence to optimize our therapy model, train and certify therapists, conduct clinical trials, including proof of concept studies, develop and test digital technology solutions to improve patient experience and outcomes and pursue other activities to refine our approach to delivering our investigational COMP360 psilocybin therapy safely and cost-effectively. Our efforts to design, build and staff these Centers of Excellence, or identify suitable third parties with whom we may collaborate to open these centers, will involve significant time, costs, including potential capital expenditures to acquire and develop facilities, and other resources, and may divert our management team&#8217;s focus from executing on other key elements of our business strategy. If we fail to enter into or maintain agreements with third parties to develop and operate these Centers of Excellence on reasonable terms, or at all, our ability to develop our future research programs and therapeutic candidates could be delayed, the commercial potential of our therapies could change and our costs of development and commercialization could increase. If our efforts to develop these Centers of Excellence are unsuccessful, it will have a materially adverse impact on our business, future prospects and financial position.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our investigational COMP360 psilocybin therapy or any future therapeutic candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of therapeutic substances. Currently, we have no therapies that have been approved for commercial sale; however, the current and future use of our investigational COMP360 psilocybin therapy or any future therapeutic candidates by us and our corporate collaborators in clinical trials, and the potential sale of any approved therapies in the future, may expose us to liability claims. These claims might be made by patients who receive our investigational COMP360 psilocybin therapy in clinical trials and if regulatory approval is obtained, by patients who receive and by healthcare providers, pharmaceutical companies, our corporate collaborators or other third parties that sell COMP360 psilocybin therapy or any future therapeutic candidates. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our investigational COMP360 psilocybin therapy or any future therapeutic candidates or any prospects for commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Although the clinical trial process is designed to identify and assess potential side effects, it </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If COMP360 or any future therapeutic candidates causes adverse side effects during clinical trials or after regulatory approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with warnings that identify known potential adverse effects and describe which patients should not use COMP360 or any future therapeutic candidates. Regardless of the merits or eventual outcome, liability claims may cause, among other things, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our therapies due to negative public perception; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend or settle the related litigation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue from therapeutic sales; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial therapies if we obtain marketing approval for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability claims resulting from any of the events described above could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Psilocybin and psilocin are listed as Schedule I controlled substances under the CSA in the United States, and similar controlled substance legislation in other countries and any significant breaches in our compliance with these laws and regulations, or changes in the laws and regulations, may result in interruptions to our development activity or business continuity. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psilocybin and psilocin are categorized as Schedule I controlled substances under the CSA, Schedule 1 drugs under the UK&#8217;s Misuse of Drugs Regulations 2001 and are similarly categorized by most states and foreign governments. Even assuming that COMP360 or any future therapeutic candidates containing psilocybin or psilocin are approved and scheduled by regulatory authorities to allow their commercial marketing, the ingredients in such therapeutic candidates would likely continue to be Schedule I, or the state or foreign equivalent. Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges and penalties, including, but not limited to, disgorgement of profits, cessation of business activities, divestiture, or prison time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial position, operating results, profitability or liquidity or the market price of our publicly traded ADSs. In addition, it is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or our final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet such activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment, fines and/or imprisonment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various federal, state, provincial and local laws govern our business in the jurisdictions in which we operate or currently plan to operate, and to which we export or currently plan to export our products, including laws relating to health and safety, the conduct of our operations, and the production, storage, sale and distribution of our products. Complying with these laws requires that we comply concurrently with complex federal, state, provincial and/or local laws. These laws change frequently and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need to invest significant financial and managerial resources. It is impossible for us to predict the cost of such laws or the effect they may have on our future operations. A failure to comply with these laws could negatively affect our business and harm our reputation. Changes to these laws could negatively affect our competitive position and the markets in which we operate, and there is no assurance that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we or third parties were to conduct activities in compliance with U.S. state or local laws or the laws of other countries and regions in which we conduct activities, potential enforcement proceedings could involve significant restrictions being imposed upon us or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on our business, revenue, operating results and financial condition as well as on our reputation and prospects, even if such proceedings conclude successfully in our favor. In the extreme case, such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure of corporate assets, and consequently, our inability to continue business operations. Strict compliance with state and local laws with respect to psilocybin and psilocin does not absolve us of potential liability under U.S. federal law, EU law or English law, nor provide a defense to any proceeding which may be brought against us. Any such proceedings brought against us may adversely affect our operations and financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the current status of psilocybin and psilocin as Schedule I controlled substances in the United States, there may be changes in the status of psilocybin or psilocin under the laws of certain U.S. cities or states. For instance, the city of Denver voted to decriminalize the possession of psilocybin in 2019, and in Oregon, Measure 109 was passed in November 2020 to pave the way for the legal medical use of &#8220;psilocybin products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with registered therapists. Similar legislation has been passed in Washington, D.C. (November 2020), Somerville, Massachusetts (January 2021), Cambridge, Massachusetts (February 2021), and Northampton, Massachusetts (April 2021). The legalization of psilocybin without regulatory oversight may lead to the setup of clinics without proper therapeutic infrastructure or adequate clinical research, which could put patients at risk and bring reputational and regulatory risk to the entire industry, making it harder for us to achieve regulatory approval. Furthermore, the legalization of psilocybin could also impact our commercial sales if we receive regulatory approval as it would reduce the barrier to entry and could increase competition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin therapy or any future therapeutic candidates outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the UK Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, a financial or other advantage to government officials or other persons to induce them to improperly perform a relevant function or activity (or reward them for such behavior).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We, along with those acting on our behalf and our commercial partners, operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the UK and the U.S., and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin therapy or any future therapeutic candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by UK, U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to U.S. federal and state forfeiture laws which could negatively impact our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, seizure of assets, disgorgement of profits, cessation of business activities or divestiture. As an entity that conducts business involving psilocybin and psilocin, we are potentially subject to federal and state forfeiture laws (criminal and civil) that permit the government to seize the proceeds of criminal activity. Civil forfeiture laws could provide an alternative for the federal government or any state (or local police force) that wants to discourage residents from conducting transactions with psilocybin- and psilocin-related businesses but believes criminal liability is too difficult to prove beyond a reasonable doubt. Also, an individual can be required to forfeit property considered to be the proceeds of a crime even if the individual is not convicted of the crime, and the standard of proof in a civil forfeiture matter is lower than the standard in a criminal matter. Depending on the applicable law, whether federal or state, rather than having to establish liability beyond a reasonable doubt, the federal government or the state, as applicable, may be required to prove that the money or property at issue is proceeds of a crime only by either clear and convincing evidence or a mere preponderance of the evidence.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors located in jurisdictions where psilocybin and psilocin remains illegal may be at risk of prosecution under conspiracy, aiding and abetting, and money laundering statutes, and be at further risk of losing their investments or proceeds under forfeiture statutes. Many jurisdictions remain fully able to take action to prevent the proceeds of psilocybin and psilocin businesses from entering their state. Our investors and prospective investors should be aware of these potentially relevant laws in considering whether to invest in us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain tax risks and treatments that could negatively impact our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 280E of the Internal Revenue Code of 1986, as amended, or the Code, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the CSA). The U.S. Internal Revenue Service, or IRS, has invoked Section 280E in tax audits against various businesses in the United States that are permitted under applicable state laws. Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative and federal courts challenging these restrictions, there is no guarantee that these courts will issue an interpretation of Section 280E favorable to psilocybin and psilocin businesses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a UK incorporated and tax resident entity, we are subject to UK corporate taxation on tax-adjusted trading profits. Due to the nature of our business, we have generated losses since inception and therefore have not paid any UK corporation tax. We had accumulated trading losses for carry forward in the UK of $144.0 million and $53.0 million as of December 31, 2021 and 2020, respectively. Subject to any relevant utilization criteria and restrictions (including those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half of our ordinary shares and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits. The use of loss carryforwards in relation to UK profits incurred on or after April 1, 2017 will be limited each year to &#163;5.0 million per group plus, broadly, an incremental 50% of UK taxable profits. In addition, if we were to have a major change in the nature of the conduct of our trade, loss carryforwards may be restricted or extinguished.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, we seek to benefit from the UK research and development tax relief programs, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Under the SME Program, we may be able to surrender the trading losses that arise from our qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditures or carried forward for potential offset against future profits (subject to relevant restrictions). The majority of our research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. We may not be able to continue to claim payable research and development tax credits in the future if we cease to qualify as a SME, based on size criteria concerning employee headcount, turnover and gross assets. The SME Program has been amended by the Finance Act 2021 which came into force in April 2021.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This legislation introduced a cap on claims under the SME Program to a multiple of payroll taxes (broadly, to a maximum payable credit equal to &#163;20,000 plus three times the total PAYE and NICs liability of the company) subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may benefit in the future from the UK&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. We own two UK patents which cover our investigational COMP360 psilocybin therapy, and accordingly, future upfront fees, milestone fees, product revenue and royalties could be eligible for this deduction. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term rate of corporation tax lower than the statutory to apply to us. If, however, there are unexpected adverse changes to the UK research and development tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and could have a material adverse effect on our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the EU and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that changes and challenges to the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, and additional downward pressure on the price that we receive for our products and any future approved product. On July 9, 2021, President Biden issued an executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and identify and address any efforts to impede generic drug competition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New laws and additional health reform measures may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and affordability for our investigational COMP360 psilocybin therapy and any future therapeutic candidates and, accordingly, the results of our financial operations. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any therapies on the market, our current and future operations may be directly, or indirectly through our relationships with investigators, health care professionals, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute or the federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any therapies for which we obtain marketing approval. These laws impact, among other things, our research activities and proposed sales, marketing and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals who participate in our clinical research program, healthcare professionals and others who recommend, purchase, or provide our approved therapies, and other parties through which we market, sell and distribute our therapies for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including European data protection authorities). Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including licensing, extensive record-keeping, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of our Centers for Excellence conduct clinical studies, we may face risks relating to operating a clinical trial site. Such risks may include research misconduct and patient injury. In addition, we may end up possessing a large amount of individually identifiable health information. Such activities are subject to a wide variety of laws, such as the aforementioned HIPAA.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with health and data protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any potential collaborators may be subject to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, which are subject to privacy and security requirements under HIPAA, as amended by HITECH. To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018, or CCPA, which came into effect on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020. The CCPA provides new data privacy rights for consumers (as that term is broadly defined) and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. In particular, the CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has resulted in an increase in data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. There continues to be uncertainty surrounding the enforcement and implementation of the CCPA, exemplifying the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a new California ballot initiative, the California Privacy Rights Act, or &#8220;CPRA,&#8221; was passed in November 2020. Effective starting on January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Certain other state laws impose similar privacy obligations, and we anticipate that more states may enact legislation similar to the CCPA, which provides consumers with new privacy rights and increases the privacy and security obligations of entities handling certain personal information of such consumers. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and foreign privacy and data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European data collection is governed by restrictive privacy and security regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial activity conducted within the Member States of the EEA is regulated by the GDPR. The collection, use, storage, disclosure, transfer, or other processing of personal data (including health data processed in the context of clinical trials) (i) regarding individuals in the EU, and/or (ii) carried out in the context of the activities of our establishment in any EU Member State, is subject to the GDPR which became effective on May 25, 2018, as well as other national data protection legislation in force in relevant Member States (including the Data Protection Act 2018 in the UK). </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR is wide-ranging in scope and imposes numerous additional requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenue, whichever is greater. The GDPR provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR provides that EEA Member States may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to evolving and strict rules on the transfer of personal data out of the EEA to the United States. The EU-U.S. and the Swiss-U.S. Privacy Shield frameworks allowed U.S. companies that self-certify to the U.S. Department of Commerce and publicly commit to comply with specified requirements to import personal data from the EU and Switzerland. In 2020, the Court of Justice of the EU ruled that the EU-U.S. Privacy Shield is an invalid transfer mechanism, which was one of the primary mechanisms used by U.S. companies to import personal information from Europe in compliance with the GDPR&#8217;s cross-border data transfer restrictions, and raised questions about whether the European Commission&#8217;s Standard Contractual Clauses, or SCCs, one of the primary alternatives to the Privacy Shield, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner has opined that the Swiss-U.S. Privacy Shield is inadequate for transfers of data from Switzerland to the U.S, and the UK Information Commissioner&#8217;s Office has stated that the Privacy Shield framework is inadequate for transfers from the UK to the U.S. Furthermore, on June 4, 2021, the European Commission issued new forms of standard contractual clauses for data transfers from controllers or processors in the EEA (or otherwise subject to the GDPR) to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controllers or processors established outside the EEA. The new forms of standard contractual clauses have replaced the standard contractual clauses that were adopted previously under the Data Protection Directive. We will be required to transition to the new forms of standard contractual clauses and doing so may require significant effort and cost. The new standard contractual clauses may also impact our business as companies based in Europe may be reluctant to utilize the new clauses to legitimize transfers of personal information to third countries given the burdensome requirements of transfer impact assessments and the substantial obligations that the new standard contractual clauses impose upon exporters. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition, and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR. While we have taken steps to comply with the GDPR, and implementing legislation in applicable EU Member States, including by seeking to establish appropriate lawful bases for the various processing activities we carry out as a controller or joint controller, reviewing our security procedures and those of our vendors and collaborators, and entering into data processing agreements with relevant vendors and collaborators, we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty regarding data protection regulation in the United Kingdom. Following the United Kingdom&#8217;s withdrawal from the EU on January 31, 2020, pursuant to the transitional arrangements agreed to between the United Kingdom and EU, the GDPR continued to have effect in law in the United Kingdom, and continued to do so until December 31, 2020 as if the United Kingdom remained a Member State of the EU for such purposes. Following December 31, 2020, and the expiry of those transitional arrangements, the data protection obligations of the GDPR continue to apply to United Kingdom-related processing of personal data in substantially unvaried form under the so-called &#8220;UK GDPR&#8221; (i.e., the GDPR as it continues to form part of law in the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments, etc) (EU Exit) Regulations 2019)). However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, could limit our ability to market those therapies and decrease our ability to generate revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford therapies such as our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved. As Schedule I substances under the CSA, psilocybin and psilocin are deemed to have no accepted medical use and therapies that use psilocybin or psilocin are precluded from reimbursement in the United States. Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially marketed. Our ability to achieve acceptable levels of coverage and reimbursement for therapies by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, and attract additional collaboration partners to invest in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. There is limited clinical data on the long-term efficacy of psilocybin on treating TRD. Certain patients may need repeated treatments </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over their lifetime to avoid relapse. This may increase treatment costs, making it more difficult for us to secure reimbursement. Even if we obtain coverage for a given therapy by third-party payors, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients may find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, Europe or elsewhere will be available for any therapy that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our investigational COMP360 psilocybin therapy or future therapeutic candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for COMP360 or our future therapeutic candidates, we will be subject to rules and regulations in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some foreign countries, particularly certain countries in Europe, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our investigational COMP360 psilocybin therapy or our future therapeutic candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a therapeutic candidate. In addition, market acceptance and sales of our investigational COMP360 psilocybin therapy or future therapeutic candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our investigational COMP360 psilocybin therapy or future therapeutic candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging prices charged for therapeutic substances and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our investigational COMP360 psilocybin therapy or any future therapeutic candidates as substitutable and only offer to reimburse patients for the less expensive therapy. Even if we show improved efficacy or improved convenience of administration with our investigational COMP360 psilocybin therapy or any future therapeutic candidates, pricing of existing drugs may limit the amount we will be able to charge. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed therapies at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, and may not be able to obtain a satisfactory financial return on therapeutic candidates that we may develop. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved therapies. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug therapies exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug therapies can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our therapies to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the state level, local governments have been very aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our therapies or put pressure on our therapeutic pricing, which could negatively affect our business, results of operations, financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, and other countries has and will continue to put pressure on the pricing and usage of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In many countries, the prices of medical therapies are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical therapies, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Accordingly, in markets outside the United States, the reimbursement for our therapies may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU-wide, law and policy. The medicines regulatory regime in respect of the EU applies to the EEA. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of therapies in that context. In general, however, the healthcare budgetary constraints in many EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with increasing EU and national regulatory burdens on those wishing to develop and market therapies, this could prevent or delay marketing approval of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize any therapies for which we obtain marketing approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU drug marketing regulation may materially affect our ability to market and receive coverage for our therapies in the EU Member States. Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal therapies is also prohibited in most countries within the EU. The provision of benefits or advantages to induce or reward improper performance generally is typically governed by the national anti-bribery laws of EU Member States, and in respect of the UK (which is no longer a member of the EU), the Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in individual EU Member States and the particular requirements can therefore vary widely amongst the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in most foreign countries, including many EU Member States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, individual Member States in the EU have the ability to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our investigational COMP360 psilocybin therapy or any of our future therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapies. Historically, therapies launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our therapies is unavailable or limited in scope or amount, our revenue from sales and the potential profitability of our investigational COMP360 psilocybin therapy or any of our future therapeutic candidates in those countries would be negatively affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the EU, the United States and elsewhere to cap or reduce healthcare costs may cause such organizations to limit coverage and the level of reimbursement for newly approved therapies and, as a result, they may not cover or provide adequate payment for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific therapies. We expect to experience pricing pressures in connection with the sale of our investigational COMP360 psilocybin therapy or any future therapeutic candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could experience difficulty enforcing our contracts.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our business and the fact that some of our contracts involve psychedelics including psilocybin and psilocin, the use of which is not legal under U.S. federal law and in certain other jurisdictions, we may face difficulties in enforcing our contracts in U.S. federal and state courts. The inability to enforce any of our contracts could have a material adverse effect on our business, operating results, financial condition or prospects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to manage our contracts with contractors, we ensure that such contractors are appropriately licensed at the state and federal level in the United States, and at the appropriate level in other territories. Were such contractors to operate outside the terms of these licenses, we may experience an adverse effect on our business, including the pace of development of our investigational COMP360 psilocybin therapy, any future therapeutic candidate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and other intellectual property rights to protect our investigational COMP360 psilocybin therapy, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for COMP360, any future therapeutic candidates and associated therapies, digital therapies, methods used to manufacture the underlying therapeutic substances, and the methods for treating patients using those substances and therapies, or on licensing in such rights. Failure to obtain, maintain protect, enforce or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our investigational COMP360 psilocybin therapy and any future therapeutic candidates. We also rely on trade secrets and know-how to develop and maintain our proprietary and intellectual property position. Any failure to protect our trade secrets and know-how could adversely affect our operations and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of companies like </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ours is generally uncertain because it involves complex legal and factual considerations. The standards applied by the European Patent Office, the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in pharmaceutical patents. Consequently, patents may not issue from our pending patent applications, and even if they do issue, such patents may not issue in a form that effectively prevents others from developing or commercializing competing therapies. As such, we do not know the degree of future protection that we will have on our proprietary therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, complex and time-consuming, and we and our current or future third party partners, licensors, licensees, or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of research, development or commercialization activities before it is too late to pursue patent protection on them. In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published until and unless granted. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly we cannot be certain that for any licensed patents or pending patent applications, the named applicant(s) were the first to make the inventions claimed in such patents or pending patent applications or that the named applicant(s) were the first to file for patent protection for such inventions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our therapies, in whole or in part, or that effectively prevent others from commercializing competitive technologies and therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaboration partners. If our current or future licensors, licensees or collaboration partners fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaboration partners are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent examination process may require us or our licensors, licensees or collaboration partners to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Even if patents do successfully issue and even if such patents cover COMP360 and any future therapeutic candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation proceedings in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. For example, in December 2021, a third party filed two petitions requesting post grant review of two of our patents (U.S. Patent 10,947,257 and U.S. Patent 10,954,259) before the Patent Trial &amp; Appeal Board of the U.S. Patent and Trademark Office, or the USPTO Board. On June 22, 2022, the USPTO Board issued decisions in both cases denying institution of post grant review on the merits of the arguments presented in each of the challenges. On July 22, 2022, the third-party challenger filed a request with the USPTO Board for rehearing of the USPTO Board&#8217;s decision. We cannot provide any assurances that we will successfully defend ourselves against this challenge or any future patent challenges.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition, patents and other intellectual property rights also will not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protect our technology, COMP360 and any future therapeutic candidates if third parties, including our competitors, design around our protected technology and our investigational COMP360 psilocybin therapy and any future therapeutic candidates without infringing, misappropriating or otherwise violating our patents or other intellectual property rights. Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing therapies and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current or future licensors, licensees or collaborators were or will be the first to file any patent application related to a therapeutic candidate. Furthermore, if patent applications of third parties have an effective filing date before March 16, 2013, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If patent applications of third parties have an effective filing date on or after March 16, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, we may be subject to third-party challenges regarding our exclusive ownership of our intellectual property. If a third party were successful in challenging our exclusive ownership of any of our intellectual property, we may lose our right to use such intellectual property, such third party may be able to license such intellectual property to other third parties, including our competitors, and our competitors could market competing therapies and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering one or more of our investigational therapeutics could be found invalid or unenforceable if challenged in court. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#8217; or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the UK, EU and the United States. We may fail in enforcing our rights, in which case our competitors and other third parties may be permitted to use our therapies without payment to us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, litigation involving our patents carries the risk that one or more of our patents will be narrowed, held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our therapies, and then compete directly with us, without payment to us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our investigational therapies, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the European Patent Office or the USPTO or made a misleading statement, during prosecution. Third parties may also raise challenges to the validity of our patent claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (i.e., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover COMP360 or any future therapeutic candidates. The outcome following legal assertions of invalidity and unenforceability during patent litigation or other proceedings is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on COMP360 or one or more of any future therapeutic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. Such a loss of patent protection could have a material adverse impact on our business financial condition, results of operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the European Patent Office, the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The European Patent Office, the USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our collaboration partners to pay these fees due to United States and comparable foreign patent agencies and take the necessary action to comply with such requirements with respect to our intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our investigational therapies, third parties, including our competitors might be able to enter the market with similar or identical therapies or technologies, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our investigational therapies, our business may be materially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, if all maintenance fees are paid on time, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our investigational therapies, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive therapies. Given the amount of time required for the development, testing and regulatory review of new investigational therapies, patents protecting such candidates and concomitant therapies might expire before or shortly after such candidates and concomitant therapies are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing therapies similar or identical to ours. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of COMP360 and any future therapeutic candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the EU. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term loss during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method of manufacturing it may be extended. However, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will not be lengthened and third parties, including our competitors, may obtain approval to market competing therapies sooner than we expect. As a result, our revenue from applicable therapies could be materially reduced and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds or develop digital assets that are the same as or similar to our investigational COMP360 psilocybin therapy, any future therapeutic candidates and digital assets but that are not covered by the claims of the patents that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of third parties may have an adverse effect on our business; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to file patent applications covering certain of our inventions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing misappropriating or otherwise violating our intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current and future pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by third parties; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive therapies for sale in our major commercial markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our therapies or technologies could use the intellectual property of others without obtaining a proper license; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional technologies that are patentable; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property, or otherwise develop similar know-how.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our consultants, advisors and employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Some of these individuals executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we intend that our consultants, advisors and employees do not use proprietary information or know-how of their former employers while working for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer. Litigation may be necessary to defend against these claims. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our therapies. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract our management from its day-to-day activities. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights of third parties could adversely affect our ability to compete or commercialize our investigational therapies, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational therapies. Such litigation or licenses could be costly or not available on commercially reasonable terms. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market, and sell any investigational therapies that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In the past, we have been subject to, and in the future we may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to COMP360 or any future therapeutic candidates. If the outcome of any such proceeding or litigation is adverse to us, it may affect our ability to compete effectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our therapies or elements thereof, our manufacture or uses relevant to our development plans, the targets of COMP360 or any future therapeutic candidates, or other attributes of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In such cases, we may not be in a position to develop or commercialize such therapeutic candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms or at all. In the event that a patent has not expired at the time of approval of such investigational therapies or therapeutic candidate and the patent owner were to bring an infringement action against us, we may have to argue that our investigational therapies or the manufacture or use of the underlying therapeutic substances do not infringe a valid claim of the patent in question. Alternatively, if we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would need to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. The same applies to other jurisdictions. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. In the event that a third party successfully asserts its patent against us such that such third party&#8217;s patent is found to be valid and enforceable and infringed by our investigational therapies, unless we obtain a license to such patent, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize our investigational therapies. Similarly, the targets for our investigational COMP360 psilocybin therapy have also been the subject of research by other companies, which have filed patent applications or have patents on aspects of the targets or their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, or at all, and any such litigation would be costly and time-consuming. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we have failed, and in the future may fail, to identify relevant patents or applications that may be asserted against us. For example, certain U.S. applications filed after November 29, 2000 can remain confidential until and unless issued as patents, provided that inventions disclosed in the applications have not and will not be the subject of a corresponding application filed outside the United States. In general, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapies could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our therapies or the use of our therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party intellectual property right holders, including our competitors, may actively bring infringement, misappropriation or violation claims against us based on existing or future intellectual property rights, regardless of their merit. We may not be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful defending in any such claim, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our investigational therapies that were held to be infringing. If possible, we might be forced to redesign our investigational COMP360 psilocybin therapy or any future therapeutic candidates so that we no longer infringe the intellectual property rights of third parties, or we may be required to seek a license to any such technology that we are found to infringe, which license may not be available on commercially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable terms or at all. Even if we or our licensors or collaboration partners obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaboration partners and it could require us to make significant licensing and royalty payments. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaboration partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future investigational therapies. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities, harming our reputation and our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development and commercialization activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to COMP360 or any future therapeutic candidates through acquisitions and in-licenses. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, our programs may require the use of proprietary rights held by third parties, and the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest in such patents. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for COMP360 or any future therapeutic candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of an investigational therapy or program, we may have to abandon development of that investigational therapy or program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable investigational therapy or program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights to or from third parties, or otherwise experience disruptions to our business relationships with our licensors, licensees or collaborators, we could lose the rights to intellectual property that are important to our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are or may become a party to third-party agreements under which we grant or are granted rights to intellectual property that are potentially important to our business and we expect that we may need to enter into additional license or collaboration agreements in the future. Our existing third-party agreements impose, and we expect that future license agreements will impose, various obligations related to, among other things, therapeutic development and payment of royalties and fees based on achieving certain milestones. In addition, under several of our collaboration agreements, we are prohibited from developing and commercializing therapies that would compete with the therapies licensed under such agreements. If we fail to comply with our obligations under these agreements, our licensor or collaboration partner may have the right to terminate the agreement, including any licenses included in such agreement. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The termination of any license or collaboration agreements or failure to adequately protect such license agreements or collaboration could prevent us from commercializing our investigational COMP360 psilocybin therapy or any future therapeutic candidates covered by the agreement or licensed intellectual property. For example, we may rely on license agreements which grant us rights to certain intellectual property and proprietary materials that we use in connection with the development of our therapies. If this agreement were to terminate, we would be unable to timely license similar intellectual property and proprietary materials from an alternate source, on commercially reasonable terms or at all, and may be required to conduct additional bridging studies on our investigational COMP360 psilocybin therapy or any future therapeutic candidates, which could delay or otherwise have a material adverse effect on the development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our existing license agreements are sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we must rely on our licensor to comply with its obligations under the primary license agreements under which such third party obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which it may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a license or collaboration agreement, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the agreement and other interpretation-related issues; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor or collaboration partner that is not subject to the agreement; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any current or future collaboration relationships; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaboration partners; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our third-party agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidate, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business. We rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect this type of information against disclosure or appropriation by third parties and our competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or confidential know-how. Also, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our trade secrets and confidential know-how to our competitors and other third parties or breach such agreements, and we may not be able to obtain an adequate remedy for such breaches. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is difficult, expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor or other third party lawfully obtained or independently developed any of our trade secrets or confidential know-how, we would have no right to prevent such competitor or other third party from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain or maintain trade secrets or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on therapeutic candidates in all countries and jurisdictions throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside of the UK and the United States, could be less extensive than those in the UK and the United States, assuming that rights are obtained in the UK and the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the UK and the United States, or from selling therapies or importing therapeutic substances made using our inventions in and into the UK and the United States, or other jurisdictions. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same therapeutic candidate or technology. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may use our and our licensors&#8217; or collaboration partners&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own therapies and, further, may export otherwise infringing therapies to territories where we and our licensors or collaboration partners have patent protection, but enforcement is not as strong as that in the UK and the United States. These therapies may compete with COMP360 or any future therapeutic candidates, and our and our licensors&#8217; or collaboration partners&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the UK and the United States, and companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors or collaboration partners is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our and our licensors&#8217; or collaboration partners&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217; or collaboration partners&#8217; efforts and attention from other aspects of our business, regardless of whether we or our licensors or collaboration partners are successful, and could put our and our licensors&#8217; or collaboration partners&#8217; patents at risk of being invalidated or interpreted narrowly. In addition, such proceedings could put our and our licensors&#8217; or collaboration partners&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaboration partners. We or our licensors or collaboration partners may not prevail in any lawsuits that we or our licensors or collaboration partners initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply and manufacture the psilocybin and psilocin incorporated in COMP360 and expect to continue to rely on third parties to supply and manufacture any future therapeutic candidates, and we will rely on third parties to manufacture these substances for commercial supply, if approved. If any third-party provider fails to meet its obligations manufacturing COMP360 or our future therapeutic candidates, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substances and the commercialization of any therapies, if approved, could be stopped, delayed or made commercially unviable, less profitable or may result in enforcement actions against us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability necessary to manufacture COMP360 or any future therapeutic candidates, including the psilocybin and psilocin incorporated into such therapeutic candidates. We rely on, and expect to continue to rely on, CMOs for the development, manufacture and production of the psilocybin and psilocin used in our investigational therapies administered in our clinical trials and will continue to rely on such CMOs for the development, manufacture and production of any commercial supply, if our investigational therapies are approved. Currently, we engage with multiple different CMOs in the UK for all activities relating to the development, manufacture and production of all components incorporated in COMP360. Reliance on third-party providers, such as CMOs, exposes us to more risk than if we were to manufacture COMP360, or any future therapeutic candidates. We do not control the manufacturing processes of the CMOs we contract with and are dependent on those third parties for the production of COMP360 or any future therapeutic candidates in accordance with relevant regulations (such as the FDA&#8217;s good laboratory practices, or GLP, cGMPs or similar regulatory requirements outside the US) for the manufacture of drug substances, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Some of the suppliers currently engaged in the production process of COMP360, including our current supplier of API, have not in the past been subject to inspection by the FDA and/or EMA and there can be no assurance that they are in compliance with all applicable regulations. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of COMP360 or any future therapeutic candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of COMP360 or any future therapeutic candidates and harm our business and results of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for COMP360 or any future therapeutic candidates, we could experience delays in our research or planned clinical studies or commercialization. In addition, quality issues may arise during scale-up activities. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. For example, the COVID-19 pandemic created supply constraints generally globally. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, may significantly delay our clinical studies and the commercialization of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">therapies, if approved, which would materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In complying with the manufacturing regulations of the FDA, the DEA, the EMA, the MHRA and other comparable foreign authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the therapies meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of therapies and shutting down of production, any of which could materially adversely affect our business, prospects, financial condition and results of operations. We and any of these third-party suppliers may also be subject to audits by the FDA, the DEA, the EMA, the MHRA or other comparable foreign authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the therapies could suffer significant interruptions. We face risks inherent in relying on a limited number of CMOs, as any disruption, such as a fire, natural hazards or vandalism at the CMO could significantly interrupt our manufacturing capability. We currently do not have disaster recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all, and we would likely experience months of manufacturing delays as we build or locate replacement facilities and seek and obtain necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis or at all. In addition, operating any new facilities may be more expensive than operating our current facility, and business interruption insurance may not adequately compensate us for any losses that may occur, in which case we would have to bear the additional cost of any disruption. In such a scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For these reasons, a significant disruptive event of the manufacturing facility could have a material adverse effect on our business, including placing our financial stability at risk. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, academic collaborators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, academic collaborators and third-party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA, the MHRA and comparable foreign regulatory authorities for all of our therapies in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we, our investigators, academic collaborators or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure, or the failure of our third-party contractors and CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators, academic collaborators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our investigational COMP360 psilocybin therapy or any future therapeutic candidates and clinical trials. If independent investigators, academic collaborators or CROs fail to devote sufficient resources to the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. In addition, investigators, academic collaborators and CROs may have difficulty staffing, undergo changes in priorities or become financially distressed or form relationships with other entities, some of which may be our competitors, any of which materially adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a limited number of third-party service providers that specialize in or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs, academic collaborators or investigators on commercially reasonable terms or at all. If CROs, academic collaborators or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. As a result, our results of operations and the commercial prospects for our investigational COMP360 psilocybin therapy or any future therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding additional CROs (or investigators) involves additional cost and requires management time and focus. In addition, delays occur during the natural transition period when a new CRO commences work, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business or financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are a number of third parties that conduct IISs using COMP360 provided by us. We do not sponsor these IISs, and encourage the open publication of all IIS findings. Any failure by a third party to meet its obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may delay or impair our ability to obtain regulatory approval for COMP360. IISs of COMP360 or any future therapeutic candidates may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360 and any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of academic and private non-academic institutions that conduct and sponsor clinical trials relating to COMP360. We do not control the design or conduct of the IISs, and the FDA or comparable foreign regulatory authorities could determine that these IISs do not provide adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the studies, safety concerns or other study results. Third-party investigators may design IISs that are underpowered, use clinical endpoints that are not widely accepted, questionable, or more difficult to achieve, or in other ways increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. In addition, these IISs may be conducted using different populations or indications than are used in our clinical trials, including milder or more severe patient populations. We also do </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not have control over academic or private non-academic institutions&#8217; disclosure of information, and these parties may disclose sensitive information or results of studies without our approval or consent.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these IISs, we will receive certain information rights with respect to the IISs, including access to and the ability to use and reference the resulting data, including for our own regulatory filings. However, we do not have control over the timing and reporting of the data from IISs, nor do we necessarily own or control the data from the IISs. If we are unable to confirm or replicate the results from the IISs or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of COMP360 or any future therapeutic candidates. Any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials. Any data perceived to be negative, however, could harm our ability to advance the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, and we may not be able to investigate whether such negatively perceived data reflects issues with the design and/or conduct of the IIS or if it actually reflects characteristics of our therapeutic approach. Moreover, we rely on our investigators and institutions to provide us timely information. We have in the past, and may in the future, experience delays in receiving notice of reportable adverse events or SUSARs from IISs. For example, we were informed in September 2020 of a SUSAR in an IIS at the University of Zurich that had occurred a few weeks earlier, despite an obligation by the site investigator to report such an event to us immediately. Such delays, or any failures to provide contractually required information, could negatively impact us or cause delays in our reporting requirements to applicable regulatory authorities. Further, if investigators or institutions breach their obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the IISs been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA or comparable foreign regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these IISs, or our interpretation of preclinical, manufacturing or clinical data from these IISs. If so, the FDA or other comparable foreign regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Managing Growth and Employee Matters</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A pandemic, epidemic, or outbreak of an infectious disease, such as the ongoing COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to risks related to public health crises such as the on-going COVID-19 pandemic. The pandemic and policies and regulations implemented by governments in response to the pandemic, most of which have been lifted, have had a significant impact, both direct and indirect, on businesses and commerce. For example, although restrictions in the United Kingdom and the United States have generally been lifted, restrictions have been reimposed in the People&#8217;s Republic of China and additional indirect effects such as worker shortages and supply chain constraints continue to impact segments of the economy. Other global health concerns could also result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The future extent of the impact of the COVID-19 pandemic on our preclinical studies or clinical trial operations, our supply chain and manufacturing and our office-based business operations, will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the emergence of additional or more infectious variants, or the effectiveness of actions to contain and treat coronavirus. For example, at the onset of the COVID-19 pandemic, we paused the enrollment of new patients into our clinical trials. In the future, we could also experience  significant and material disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of COMP360 and any future therapeutic candidates. Future developments are inherently hard to predict and there can be no guarantee we will not face difficulties or additional costs in enrolling patients in our Phase 3 trials for TRD or future clinical trials, that we will be able to achieve full enrollment of our studies within the timeframes we anticipate, or at all, or that an supply disruptions would not adversely impact our ability to initiate and complete preclinical studies or clinical trials.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has also affected, and may in the future affect, employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. As new variants of the COVID-19 virus continue to emerge and spread around the globe, we may experience additional disruptions that could severely impact our business and clinical trials, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of sites or facilities serving as our clinical trial sites and staff supporting the conduct of our clinical trials, including our trained therapists, or absenteeism due to the COVID-19 pandemic that reduces site resources;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state or national governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events or patient withdrawals from our trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on conducting our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption in global shipping that may affect the transport of clinical trial materials, such as the COMP360 used in our clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or the discontinuation of the clinical trials altogether;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions or delays in preclinical studies due to restricted or limited operations at research and development laboratory facilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA, the EMA, the MHRA or the other regulatory bodies to accept data from clinical trials in affected geographies outside the United States or the EU or other relevant local geography.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any negative impact the COVID-19 pandemic has on patient enrollment or treatment or the development of our investigational COMP360 psilocybin therapy and any future therapeutic candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved, increase our operating expenses, and have a material adverse effect on our financial results. The COVID-19 pandemic, among other factors, has also in the past caused significant volatility in public equity markets and disruptions to the United States and global economies. Increased volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. We cannot currently predict the scope and severity of any potential future business shutdowns or disruptions, should they occur. If we or any of the third parties with whom we engage, however, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial conditions. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also heighten many of the other risks </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth and ability to compete effectively depends on our ability to manage senior management changes and our ability to retain our key personnel and recruit additional qualified personnel, and on the key personnel employed by our collaborative partners. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continued contributions of our key management, scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our board of directors and certain executive officers. We do not currently maintain any key person insurance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we announced the separation of the Chief Executive Officer and chair of the board of directors positions, the appointment of Kabir Nath as our new Chief Executive Officer and the appointment of our co-founder George Goldsmith, who was our Chief Executive Officer until August 1, 2022, as Executive Chairman of the board of directors and Mr. Goldsmith will continue as the chair of the board of directors. There is a transition period as we adjust to our new leadership structure and as our new Chief Executive Officer, who does not have prior experience as a Chief Executive Officer of a publicly traded company, is fully integrated into his role and our company. Leadership transitions are often difficult and create uncertainty. If we are not successful in managing this leadership transition or any future changes in senior management, it could negatively impact our corporate culture, negatively impact our relationships with employees, investors, suppliers, CROs, principal investigators, key opinion leaders, regulators and other key stakeholders, or otherwise disrupt our business operations, which could have a material adverse effect on our business and prospects. In addition, we have had other senior management changes within the past year, including hiring a new chief financial officer and general counsel, as well as the resignation of our president and Chief Operating Officer, whom we do not intend to replace. Further, these changes also increase our dependency on other members of our executive team and key managers and senior scientists. The loss of other key executives, managers and senior scientists could delay our research and development activities. In addition, our ability to compete in the highly competitive pharmaceutical industry depends upon our ability to attract and retain highly qualified management, scientific and medical personnel. Many other companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Therefore, we might not be able to attract or retain these key persons on conditions that are economically acceptable. Moreover, some qualified prospective employees may choose not to work for us due to negative perceptions regarding the therapeutic use of psilocybin or other objections to the therapeutic use of a controlled substance. Furthermore, we will need to recruit new managers and qualified scientific personnel to develop our business if we expand into fields that will require additional skills. Our inability to attract and retain these key persons could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the area of sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain key academic and scientific personnel play a pivotal role in our collaborative partners&#8217; research and development activities. If any of those key academic and scientific personnel who work on development of our research programs, our investigational COMP360 psilocybin therapy and any future therapeutic candidates leave our collaborative partners, the development of our research programs, our investigational COMP360 psilocybin therapy and any future therapeutic candidates may be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party therapy sites, therapists and collaboration partners and third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party therapy sites, therapists and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and negligent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct or unauthorized activities that violate, among other things: (i) the regulations of the FDA, the EMA, the MHRA and other comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercialization model also entails the risk of malpractice and professional liability claims against both our third-party therapy sites and us as a result of actual or alleged therapist misconduct. Although we, and the third-party therapy sites with which we engage, carry insurance covering malpractice and professional liability claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful malpractice or professional liability claims could result in substantial damage awards that exceed the limits of our insurance coverage and our third-party therapy sites&#8217; insurance coverage. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our services. As a result, adequate professional liability insurance may not be available to our providers or to us in the future at acceptable costs or at all. Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our third-party therapy sites from our operations, which could have a material adverse effect on our business, financial condition and results of operations. In addition, any such claims may materially and adversely affect our business or reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter misconduct by employees and other third parties, including our therapists, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition and our competitors may discover, develop or commercialize therapies before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and psychedelic industry is intensely competitive and subject to rapid and significant technological change. Our competitors include multinational pharmaceutical companies, universities and other research institutions. We also face competition from 501(c)(3) non-profit medical research organizations, including the Usona Institute. Such non-profits may be willing to provide psilocybin-based products at cost or for free, undermining our potential market for COMP360. In addition, a number of for-profit biotechnology companies or institutions are specifically pursuing the development of psilocybin to treat mental health illnesses, including TRD. In addition, an increasing number of companies are stepping up their efforts in discovery of new psychedelic compounds. It is also probable that the number of companies seeking to develop psychedelic products and therapies for the treatment of mental health illnesses, such as depression, will increase. If any of our competitors is granted an NDA for their psychedelic-assisted therapies before us and manages to obtain approval for a broader indication, and thus access a wider patient population, we may face more intensified competition from such potential psychedelic-assisted therapies and increased difficulties in winning market acceptance of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. All of these risks are heightened because psilocybin, which is a naturally occurring substance and therefore not subject to patent protection, may be deemed an appropriate substitute for COMP360.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from major pharmaceutical, biopharmaceutical and biotechnology companies who have developed or are developing non-psilocybin or psychedelic based therapies for the treatment of MDD and TRD, and will face future competition for any other indications we may seek to treat with our investigational COMP360 psilocybin therapy. There are a number of companies that currently market and sell products or therapies, or are pursuing the development of products or therapies, for the treatment of depression, including antidepressants such as SSRIs and serotonergic norepinephrine reuptake inhibitors, or SNRIs, antipsychotics, cognitive behavioral therapy, or CBT, esketamine and ketamine, repeat transcranial magnetic stimulation, or rTMS, electroconvulsive therapy, or ECT, vagus nerve stimulation, or VNS, and deep brain stimulation, or DBS, among others. Many of these pharmaceutical, biopharmaceutical and biotechnology competitors have established markets for their therapies and have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market superior products or therapies. In addition, many of these competitors have significantly greater experience than we have in undertaking preclinical studies and human clinical trials of new therapeutic substances and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA, EMA or MHRA approval for alternative or superior products. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field in which we operate is characterized by a growing and shifting understanding of disease biology, changing technologies, and strong intellectual property barriers to entry, and many companies are involved in the creation, development and commercialization of novel therapeutics and technology platforms. Our competitors may develop therapies that are more effective, more convenient, more widely used and less costly or have a better safety profile than our therapies and these competitors may also be more successful than we are in manufacturing and marketing their therapies. Additionally, there can be no assurance that our competitors are not currently developing, or will not in the future develop, technologies and therapies that are equally or more economically attractive as our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Competing alternative therapies or technology platforms may gain faster or greater market acceptance than our therapies or technology platforms and medical advances or rapid technological development by competitors may result in our investigational COMP360 psilocybin therapy or any future therapeutic candidates or technology platforms becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we are unable to compete effectively against these companies, then we may not be able to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates or achieve a competitive position in the market. This would materially and adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face intense and increasing competition as new treatments enter the market. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions and investments could result in operating difficulties, dilution and other harmful consequences that may adversely impact our business, financial condition and results of operations. Additionally, if we are not able to identify and successfully acquire suitable businesses, our operating results and prospects could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future make additional acquisitions or investments to add employees, complementary companies, therapies, products, solutions, technologies, or revenue. These transactions could be material to our business, financial condition and results of operations. We also expect to continue to evaluate and enter into discussions regarding a wide array of potential strategic transactions. The identification of suitable acquisition or investment candidates can be difficult, time-consuming and costly, and we may not be able to complete acquisitions or investment on favorable terms, if at all. The process of integrating an acquired company, business or technology and managing our future investments may create unforeseen operating difficulties and expenditures. The areas where we face risks include:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of key employees of the acquired company and other challenges associated with integrating new employees into our culture, as well as reputational harm if integration is not successful;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to addressing acquisition integration and investment management challenges;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high uncertainty with respect to any investment in companies engaging in early stage drug discovery and development with limited proof of concept, which might result in significant investment loss;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in identifying suitable investment opportunities in the digital health market and diversion of management time and resources to integrate such investments into our business due to our lack of experience in such market; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementation or remediation of controls, procedures, and policies at any acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in integrating and managing the combined operations, technologies, technology platforms and products of any acquired companies and realizing the anticipated economic, operational and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical or financial problems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integration of the acquired company&#8217;s accounting, human resource and other administrative systems, and coordination of product, engineering and sales and marketing function;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assumption of contractual obligations that contain terms that are not beneficial to us, require us to license or waive intellectual property rights, or increase our risk for liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully further develop the acquired technology or realize our intended business strategy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on unfamiliar affiliates and partners of acquired businesses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainty of entry into markets in which we have limited or no prior experience or in which competitors have stronger market positions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs associated with pursuing investments or acquisitions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to find commercial success with the products or services of the acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty of transitioning the acquired technology onto our existing platforms and maintaining the security standards for such technology consistent with our other solutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">responsibility for the liabilities of acquired businesses, including those that were not disclosed to us or exceed our estimates, as well as, without limitation, liabilities arising out of their failure to maintain effective data protection and privacy controls and comply with applicable regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to maintain our internal standards, controls, procedures, and policies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to generate the expected financial results related to an acquisition in a timely manner or at all;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in complying with antitrust and other government regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in integrating and auditing the financial statements of acquired companies that have not historically prepared financial statements in accordance with U.S. GAAP;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential accounting charges to the extent intangibles recorded in connection with an acquisition, such as goodwill;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trademarks, client relationships or intellectual property, are later determined to be impaired and written down in value; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to accurately forecast the impact of an acquisition transaction.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may rely heavily on the representations and warranties provided to us by the sellers of acquired companies or strategic partners, including as they relate to creation of, and ownership and rights in, intellectual property, existence of open source and compliance with laws and contractual requirements. If any of these representations and warranties are inaccurate or breached, such inaccuracy or breach could result in costly litigation and assessment of liability for which there may not be adequate recourse against such sellers, in part due to contractual time limitations and limitations of liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future acquisitions and investments could also result in expenditures of significant cash, dilutive issuances of our equity securities, the incurrence of debt, restrictions on our business, contingent liabilities, amortization expenses or write-offs of goodwill, any of which could harm our financial condition. In addition, any acquisitions or investments we announce could be viewed negatively by collaborative partners, employees, vendors, patients, shareholders, or investors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, competition within our industry for acquisitions of business, technologies and assets may become heightened. Even if we are able to identify an acquisition or investment that we would like to consummate, we may not be able to complete the acquisition or investment on commercially reasonable terms or the target may be acquired by another </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company. We may enter into negotiations for acquisitions or investments that are not ultimately consummated. Those negotiations could result in diversion of management time and significant out-of-pocket costs. If we fail to evaluate and execute acquisitions or investments successfully, we may not be able to realize the benefits of these acquisitions or investments, and our operating results could be harmed. If we are unable to successfully address any of these risks, our business, financial condition and results of operations could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to maintain and enhance our reputation and brand recognition, our business, financial condition and results of operations will be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing and future third-party therapy sites, therapists, patients and collaborators, and to our ability to attract clinics to become our third-party therapy sites offering our therapies. The promotion of our brand has required and may continue to require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing and other initiatives may become increasingly difficult and expensive. Brand promotion and marketing activities may not be successful or yield increased revenue, to the extent we generate any future revenue, and to the extent that these activities yield increased future revenue, the increased revenue may not offset the expenses we incur and our business, financial condition and results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our network of third-party therapy sites, therapists and patients, could harm our reputation and brand and make it substantially more difficult for us to attract new third-party therapy sites, therapists and patients. If we do not successfully maintain, protect or enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with third-party therapy sites, therapists and patients, which would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and potential future digital technologies may not be successful, which may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently employ or are developing digital technologies to collect data, educate patients and therapists, collect digital phenotyping information, and harness artificial intelligence. We are expanding our research into digital technology to complement and augment our current or future investigational therapies, and may work with technology companies or other third parties to acquire or develop new technologies. Our efforts to develop or acquire these technologies will involve significant time, costs, and other resources, and may divert our management team&#8217;s attention and focus from executing on other key elements of our strategy. If our efforts to develop or acquire these digital technologies are unsuccessful, it may have a materially adverse impact on our business, future prospects and financial position.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future digital technology solutions could compromise sensitive information related to our business, patients, healthcare professionals, therapists, third-party therapy sites and collaborators, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current and future digital technology solutions may involve the collection, storage, usage or disclosure of sensitive data, including protected health information, or PHI, and other types of personal data or personally identifiable information, or PII. For example, as part of our clinical trials, we may use digital technology solutions to record and analyze therapeutic sessions. We may also process and store, and use additional third parties to process and store, sensitive information including intellectual property and other proprietary business information of ours and our third-party collaborators.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be highly dependent on information technology networks and systems, including the internet and external cloud providers, to securely process, transmit and store this critical information. Security incidents or breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, and employee or contractor error, negligence or malfeasance, could create system disruptions, shutdowns or unauthorized disclosure or modifications of confidential information, causing patient health information to be accessed, acquired or altered without authorization or to become publicly available. We utilize third-party service providers for important aspects of the collection, storage and transmission of patient information, and other confidential and sensitive information as well as encryption of data at rest and in transit, along with appropriate system logging and access controls, and therefore rely on third parties to manage functions that have material cybersecurity risks. We take certain administrative and technological safeguards to address these risks, such as by requiring outsourcing contractors who handle or subcontract the handling of patient information for us to enter into agreements that contractually obligate those contractors and any subcontractors to use reasonable efforts to safeguard PHI, other PII, and other sensitive information. Measures taken to protect our systems, those of our subcontractors, or the PHI, other PII, or other sensitive data we or our subcontractors process or maintain, may not adequately protect us from the risks associated with the collection, storage and transmission of such information. Although we take steps to help protect confidential and other sensitive information from unauthorized access or disclosure, our information </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology and infrastructure may be vulnerable to attacks by hackers or viruses, failures or breaches due to third-party action, employee negligence or error, malfeasance or other disruptions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, patient information, including PHI or other PII, or other sensitive information we or our subcontractors maintain or otherwise process, could harm our reputation, compel us to comply with breach notification laws, cause us to incur significant costs for remediation, fines, penalties, notification to individuals and for measures intended to repair or replace systems or technology and to prevent future occurrences, potential increases in insurance premiums, and require us to verify the accuracy of database contents, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, or if it is perceived that we have been unable to do so, our operations could be disrupted, we may be unable to provide access to our digital technology solutions and tools, and our ability to conduct our clinical trials may be negatively impacted, including patient enrollment in clinical trials and therapist recruitment for our clinical trials, and we may suffer loss of reputation, adverse impacts on patients, physicians, clinical trial sites and investor confidence, financial loss, governmental investigations or other actions, regulatory or contractual penalties, and other claims and liability. In addition, security breaches and other inappropriate access to, or acquisition or processing of, information can be difficult to detect, and any delay in identifying such incidents or in providing any notification of such incidents may lead to increased harm.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such breach or interruption of our systems or any of our third-party information technology partners, could compromise our networks or data security processes and sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption of access, improper or unauthorized access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws and regulations that protect the privacy of patient information or other personal information, such as HIPAA, and the GDPR, the CCPA, and regulatory penalties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct clinical trials for COMP360 psilocybin therapy or any future therapeutic candidates, obtain regulatory approval of and commercialize COMP360 psilocybin therapy or any future therapeutic candidates, conduct research and development activities, collect, process, and prepare company financial information, provide information about our current and future therapeutic candidates. Any such breach could also result in the compromise of our trade secrets and other proprietary information or that of third parties whose information we maintain, which could adversely affect our business and competitive position. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are headquartered in one location, and we or the third parties upon whom we depend may be adversely affected by natural disasters, as well as occurrences of civil unrest, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business operations are headquartered in our offices in London, UK, with additional offices in New York and San Francisco in the United States. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents, including events of civil unrest that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates or interruption of our business operations. Such natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. For risks in connection with the COVID-19 pandemic, see &#8220; &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital and our ability to conduct regular business and our financial results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot ensure that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our investigational COMP360 psilocybin therapy or any future therapeutic candidates are being developed to treat, and we may use appropriate social media in connection with our commercialization efforts of our investigational COMP360 psilocybin therapy following approval of COMP360 or future therapeutic candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve, and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to certain prohibited activities. For example, patients may use social media channels to comment on their experience in an ongoing clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations, or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational COMP360 psilocybin therapy or any future therapeutic candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Ownership of Our ADSs</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our ADSs has been and will likely continue to be volatile and you could lose all or part of your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our ADSs has been and may continue to be highly volatile and could be subject to large fluctuations in response to the risk factors discussed in this section, and others beyond our control, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative results of testing and clinical trials by us, strategic partners or competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in entering into strategic relationships with respect to development or commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into strategic relationships on terms that are not deemed to be favorable to us; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations or commercial therapeutic introductions by competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government regulations and healthcare payment systems; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning proprietary rights, including patent and litigation matters; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern relating to the commercial value or safety of any of our investigational COMP360 psilocybin therapy or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative publicity or public perception of the use of psilocybin therapy as a treatment therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financing or other corporate transactions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trading volume of our ADSs on Nasdaq;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our ADSs by us, members of our senior management and directors or our shareholders or the anticipation that such sales may occur in the future;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">general economic, political, geopolitical and market conditions, including the recent significant increases in inflation in the United States, U.K. and Europe, and overall market volatility in the United States or the UK as a result of, among other factors, macroeconomic conditions and the conflict between Russia and Ukraine or similar events; and </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the stock markets, and particularly the stock of pharmaceutical and biotechnology companies, at times have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of affected companies. Broad market and industry factors may significantly affect the market price of our common stock unrelated to our actual operating performance. Since our ADSs were sold in our IPO at a price of $17.00 per ADS, our ADS price has fluctuated significantly, ranging from an intraday low of $6.54 to an intraday high of $61.69 for the period beginning September 18, 2020, our first day of trading on The Nasdaq Global Market, through September 30, 2022. If the market price of our ADSs does not exceed the price at which you acquired them, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and certain significant shareholders own a substantial number of our ordinary shares (including ordinary shares represented by ADSs) and, as a result, may be able to exercise control over us, including the outcome of shareholder votes. Certain of our directors and officers hold interests in one of these shareholders and these shareholders may have different interests from us or your interests. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our ordinary shares outstanding as of April 19, 2022, our executive officers, directors, greater than five percent shareholders and their affiliates beneficially own approximately 45% of our ordinary shares and ADSs. Depending on the level of attendance at our general meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our Articles of Association. Among other consequences, this concentration of ownership may prevent or discourage unsolicited acquisition proposals that our shareholders may believe are in their best interest as shareholders. Some of these persons or entities may have interests that are different than those of our other shareholders. For example, because many of these shareholders purchased their ordinary shares at prices substantially below the price at which ADSs were sold in our initial public offering have held their ordinary shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want us to pursue strategies that deviate from the interests of other shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information regarding our principal shareholders and their affiliated entities, see the sections titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Certain Relationships and Transactions with Related Parties&#8221; in our definitive proxy statement for the 2022 Annual General Meeting of Shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we have no present intention to pay dividends on our ordinary shares for the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be your sole source of gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs at or above the price at which you purchased them. Any recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition (including losses carried forward), results of operations, legal requirements and other factors. We are unlikely to pay dividends or other distributions in the foreseeable future. If the price of our ADSs declines before we pay dividends, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not continue to publish research or publish inaccurate research or unfavorable research about our business, the price of our ADSs and trading volume could decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market of our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have control over these analysts. If one or more of the analysts who covers us downgrades our ADSs or publishes incorrect or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our ADSs could decrease, which could cause the price of our ADSs or trading volume to decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our ADSs are not treated as holders of our ordinary shares. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying our ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our ADSs will not have the same voting rights as the holders of our ordinary shares, and may not receive voting materials or any other documents that would need to be provided to our shareholders pursuant to English corporate law, including the UK Companies Act 2006, or Companies Act 2006, in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described in the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon our request, the depositary shall distribute to the holders as of the record date (i) the notice of the meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in which instructions may be given by the holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. As a result, ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested or if their shares cannot be voted. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many members of our senior management and certain members of our board of directors are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtain in U.S. courts against them or us based on civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether the courts of England and Wales would entertain original actions brought in the UK against us or our directors or senior management predicated upon securities laws of the U.S. or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ADSs trade on the Nasdaq Global Select Market in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may result in temporary differences between the value of our ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of ADSs would receive upon the sale in the UK of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in euros on our ordinary shares represented by ADSs could also decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may not be able to participate in equity offerings we may conduct from time to time. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain shareholders and holders of ADSs, including those in the United States, may, even in the case where preferential subscription rights have not been cancelled or limited, not be entitled to exercise such rights, unless the offering is registered or the ordinary shares are qualified for sale under the relevant regulatory framework. As a result, there is the risk that investors may suffer dilution of their holdings should they not be permitted to participate in preference right equity or other offerings that we may conduct in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement governing our ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ADSs or the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and our ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our articles of association, or Articles, provide that the courts of England and Wales are the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the United States District Court for the Southern District of New York is the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles provide that, unless we consent by ordinary resolution to the selection of an alternative forum, the courts of England and Wales shall, to the fullest extent permitted by law, be the exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us; (c) any action or proceeding asserting a claim arising out of any provision of the Companies Act 2006 or our Articles (as may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs, or the England and Wales Forum Provision. The England and Wales Forum Provision does not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Articles further provide that unless we consent by ordinary resolution to the selection of an alternative forum, the United States District Court for the Southern District of New York is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act, or the U.S. Federal Forum Provision. In addition, our Articles provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to the England and Wales Forum Provision and the U.S. Federal Forum Provision; provided, however, that our shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The England and Wales Forum Provision and the U.S. Federal Forum Provision in our Articles may impose additional litigation costs on our shareholders in pursuing any such claims. Additionally, the forum selection clauses in our Articles may limit the ability of our shareholders to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including the courts of England and Wales and other courts within the United States, will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. The U.S. Federal Forum Provision may also impose additional litigation costs on our shareholders who assert that the provision is not enforceable or invalid. The courts of England and Wales and the United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were classified as a passive foreign investment company, it would result in adverse U.S. federal income tax consequences to U.S. holders. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. Holder (as defined below under &#8220;Taxation&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;) holds our ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional reporting requirements. No assurances regarding our PFIC status can be provided for the current taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering. Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. Holders</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, if a non-U.S. corporation owns at least one U.S. subsidiary, under current law, any current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries of the non-U.S. corporation will be treated as CFCs, regardless of whether the non-U.S. corporation is treated as a CFC. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the value or total combined voting power of all classes of stock entitled to vote of such corporation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our review of beneficial ownership reports filed with the SEC, we do not believe that we were classified as a CFC for the 2021 taxable year. However, the determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with CFC reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any Ten Percent Shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the CFC rules of the Code. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur increased costs as a result of operating as an English-domiciled public company listed in the United States, and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an English domiciled public company listed in the United States, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements on foreign reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors, management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations have increased and will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, each year in our annual reports on Form 10-K, we are required to furnish a report by management on, among other things, the effectiveness of our internal control over financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reporting. However, we will not require an attestation report on internal control over financial reporting issued by our independent registered public accounting firm for the year ending December 31, 2022, because, based on our public float at June 30, 2022, we qualify as a smaller reporting company and will be considered a non-accelerated filer as of December 31, 2022. In order to achieve and maintain compliance with Section 404, we have documented and evaluated our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, have engaged outside consultants and adopted a detailed work plan to continually assess and document the adequacy of internal control over financial reporting, taken steps to improve control processes as appropriate, validated through testing that controls are functioning as documented and have implemented a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk in any given year that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. Moreover, if in future years an attestation report on internal control over financial reporting issued by our independent registered public accounting firm may be required and if our independent registered public accounting firm were to be unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected, and we could become subject to investigations by the SEC or other regulatory authorities or to stockholder litigation, which could have an adverse impact on the market price or our common stock and cause us to incur additional expenses.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our securities less attractive to investors.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning with this Quarterly Report on Form 10-Q, we have qualified as a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $560.0 million as of June 30, 2022, and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We will continue to be a smaller reporting company for so long as (i) our voting and non-voting shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. As a smaller reporting company, we may take advantage of many of the same exemptions from disclosure requirements as an emerging growth company, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited, because we are incorporated under the laws of England and Wales, conduct most of our operations outside the United States and many members of our senior management and certain members of our board of directors reside outside the United States.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated and have our registered office in, and are currently existing under the laws of, England and Wales. In addition, most of our tangible assets are located, and many members of our senior management and certain of our directors reside, outside of the United States. As a result, it may not be possible to serve process within the United States on certain directors or us or to enforce judgments obtained in U.S. courts against such directors or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether courts of England and Wales would entertain original actions brought in England and Wales against us or our directors or senior management predicated upon the securities laws of the U.S. or any state in the U.S. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is subject to determination by the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As an English domiciled public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">English law provides that a board of directors may only allot shares (or grant rights to subscribe for or to convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five years, each as specified in the articles of association or relevant ordinary resolution passed by shareholders at a general meeting. Such authority from our shareholders to allot additional shares for a period of five years from September 11, 2020 was included in the ordinary resolution passed by our shareholders on September 11, 2020, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, but not longer than the duration of the authority to allot shares to which this disapplication relates or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). Such authority from our shareholders to disapply preemptive rights for a period of five years was included in the special resolution passed by our shareholders on September 11, 2020, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder protections found in provisions under the UK City Code on Takeovers and Mergers, or the Takeover Code, will not apply if our place of central management and control remains outside of the UK (or the Channel Islands or the Isle of Man). </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our place of central management and control is not currently in the UK (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are not currently subject to the Takeover Code and, as a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules regarding mandatory takeover bids.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, or Takeover Panel, changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the UK), the Takeover Code may apply to us in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Takeover Code provides a framework within which takeovers of companies which are subject to the Takeover Code are regulated and conducted. The following is a brief summary of some of the most important rules of the Takeover Code:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When any person acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares already held by that person and an interest in shares held or acquired by persons acting in concert with him or her) carry 30% or more of the voting rights of a company that is subject to the Takeover Code, that person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights in that company to acquire the balance of their interests in the company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When any person who, together with persons acting in concert with him or her, is interested in shares representing not less than 30% but does not hold more than 50% of the voting rights of a company that is subject to the Takeover Code, and such person, or any person acting in concert with him or her, acquires an additional interest in shares which increases the percentage of shares carrying voting rights in which he or she is interested, then such person is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of that company to acquire the balance of their interests in the company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A mandatory offer triggered in the circumstances described in the two paragraphs above must be in cash (or be accompanied by a cash alternative) and at not less than the highest price paid within the preceding 12 months to acquire any interest in shares in the company by the person required to make the offer or any person acting in concert with him or her.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In relation to a voluntary offer (i.e., any offer which is not a mandatory offer), when interests in shares representing 10% or more of the shares of a class have been acquired for cash by an offeror (i.e., a bidder) and any person acting in concert with it in the offer period and the previous 12 months, the offer must be in cash or include a cash alternative for all shareholders of that class at not less than the highest price paid for any interest in shares of that class by the offeror and by any person acting in concert with it in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a cash alternative must be made available at not less than the highest price paid for any interest in the shares of that class.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If, after making an offer for a company, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All shareholders must be given the same information.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated under the laws of England and Wales. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by the laws of England and Wales, including the provisions of the Companies Act 2006, and by our Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See the information under the heading &#8220;Description of Share Capital and Articles of Association&#8212;Differences in Corporate Law&#8221; in our prospectus dated September 17, 2020, filed with the SEC pursuant to Rule 424(b), which information is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporated herein by reference, for a description of the principal differences between the provisions of the Companies Act 2006 applicable to us and, for example, the Delaware General Corporation Law relating to shareholders&#8217; rights and protections.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal differences include the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under English law and our Articles, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under English law and our Articles, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the UK, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares (including those represented by ADSs) will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares (including those represented by ADSs) voting at the meeting for approval.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under English law and our Articles, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The quorum requirement for a shareholders&#8217; meeting is one or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least thirty-three and one-third percent (33 &#8531;%) in number of the issued shares (excluding any shares held as treasury shares) entitled to attend and vote on the business to be transacted. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and results of operations may be negatively impacted by the UK&#8217;s withdrawal from the EU.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2016, the UK held a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, however it is possible that these regimes will diverge in the future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. For example, the new Clinical Trials Regulation which became effective in the EU on January 31, 2022 and provides for a streamlined clinical trial application and assessment procedure covering multiple EU Member States has not been implemented into UK law, and a separate application will need to be submitted for clinical trial authorization in the UK. In addition, as we are headquartered in the UK, it is possible that Brexit may impact some or all of our current operations. For example, Brexit will impact our ability to freely move employees from our headquarters in the UK to other locations in the EU and it will impact the ability of EU therapists to move freely to the UK in order to complete part of their training or work on our clinical trials there. Furthermore, if other EU Member States pursue withdrawal, barrier-free access among the EEA overall could be diminished or eliminated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term effects of Brexit will depend in part on how the terms of the TCA continue to take effect in practice and the terms of any further agreements the UK makes with the EU. Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the UK&#8217;s access to the European single market for goods, capital, services and labor, or single market, and the wider commercial, legal and regulatory environment, will impact our future operations (including business activities conducted by third parties and contract manufacturers on our behalf) and clinical activities in the UK in the long term. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Controls Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, testing required to be conducted by us in connection with Section 404, and subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously identified material weaknesses in our internal control over financial reporting. We may identify future material weaknesses in our internal control over financial reporting. If we are unable to remedy these material weaknesses, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our ADS price.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the preparation of our 2019 financial statements, management identified three material weaknesses in our internal control over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically we identified that we lacked a sufficient number of trained professionals with an appropriate level of accounting knowledge, training and experience to: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design and maintain formal accounting policies, procedures and controls over the fair presentation of our financial statements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analyze, record and disclose complex accounting matters timely and accurately, including share-based compensation arrangements and other non-routine transactions; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design and maintain controls over the preparation and review of account reconciliations, journal entries and financial statements including maintaining appropriate segregation of duties.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the material weaknesses, we have since recruited an experienced finance team, which is further supported by appropriately qualified external advisers, including third-party professional accounting consulting firms to advise on accounting for and presentation of technical and complex non-routine transactions, as well as the calculation and review of tax liabilities and research and development tax credits. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has designed and now maintains formal accounting policies, procedures and controls to ensure the fair presentation of our financial statements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is now identifying, analyzing, recording and disclosing complex accounting matters in a timely and accurate manner; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has designed and is maintaining controls over the preparation and review of account reconciliations, journal entries and financial statements including maintaining appropriate segregation of duties.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These enhancements to our internal controls over financial reporting have operated for a sufficient period of time, and management&#8217;s evaluation of such controls indicates that such controls are effective. Although we have determined that the previously identified material weaknesses were remediated as of December 31, 2020, we cannot assure you that we will not identify other material weaknesses or deficiencies, which could negatively impact our results of operations in future periods.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, if we are unable to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose confidence in our reported financial information. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to the Ownership of Our ADSs&#8212;We have incurred and will continue to incur increased costs as a result of operating as an English public company listed in the United States, and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information, and the trading price of our stock may decline.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the international scope of our operations, our assets, earnings, expenses and cash flows are influenced by movements in exchange rates of several currencies, particularly the U.S. dollar, the Pound Sterling and the euro. Our reporting currency is denominated in U.S. dollars and our functional currency is the Pound Sterling (except that the functional currency of our U.S. subsidiary is the U.S. dollar) and the majority of our operating expenses are paid in Pound Sterling. We also regularly acquire services, consumables and materials in U.S. dollars, Pound Sterling and the euro. Further potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs has been affected and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">may in the future be affected by fluctuations in foreign exchange rates between the Pound Sterling and these other currencies, which may also have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. See Note 2 in the notes to our annual financial statements for a description of foreign exchange risks. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the possible abandonment of the euro by one or more members of the European Union, or the EU, could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">states from the EU or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Key national economies, including the United States and UK, have been affected from time to time by economic downturns or recessions, supply chain constraints, rising inflation, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies, rising interest rates and overall uncertainty with respect to the economy. For example, while we do not have activities in Russia and Ukraine, the ongoing conflict and any further escalation of geopolitical tensions related to this conflict, including the imposition of sanctions by the United States and other countries, has and could result in, among other things, supply disruptions, fluctuations in foreign exchange rates and increased volatility in financial markets. Any of these disruptions could adversely affect our businesses, results of operations and financial condition. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A deterioration in the global economy and financial markets could result in a variety of risks to our business. In addition, due to the international scope of our operations, our financial condition is and will continue to be influenced by movements in exchange rates of several currencies because our functional currency is the Pound Sterling, but we report our financial results in U.S. dollars. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in many years. Increased inflation may result in further currency fluctuations, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. In addition, increased interest rates or a general economic downturn or recession could reduce our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, supply disruptions or international trade disputes could also strain our third-party suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current and future economic climate and financial market conditions could adversely impact our business.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business globally and file income tax returns in multiple jurisdictions. Our consolidated effective income tax rate could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms being implemented or under consideration (such as those related to the Organisation for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on our balance sheets, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, His Majesty&#8217;s Revenue &amp; Customs, or HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8216;&#8216;permanent establishment&#8217;&#8217; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new therapies from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new therapies can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. In February 2022, FDA announced it would resume routine domestic inspections. Ongoing travel restrictions and other uncertainties continue to impact oversight operations abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (i.e., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as of May 26, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations. These laws and regulations govern, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among other things, the controlled use, manufacture, handling, release and disposal of and the maintenance of a registry for, hazardous materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. Furthermore, if we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous materials and, as a result, may incur material liability as a result of such release or exposure. Environmental, health and safety laws and regulations are becoming more stringent. We may incur substantial expenses in connection with any current or future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely affected. In the event of an accident involving such hazardous materials, an injured party may seek to hold us liable for damages that result.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general or prevent us from obtaining patents and thereby impair our ability to protect our investigational therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other companies in our industry, our success is heavily dependent on our intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve technological and legal complexity. Therefore, obtaining and enforcing patents for therapeutics is costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, the America Invents Act, or the AIA, enacted in the United States in 2012 and 2013, has resulted in significant changes to the U.S. patent system. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the enactment of the AIA, assuming that other requirements for patentability are met, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 16, 2013, under the AIA, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention regardless of whether a third party was the first to invent the claimed invention. On or after that date, a third party that files a patent application in the USPTO before us could be awarded a patent covering an invention of ours even if we made the invention before the third party. The AIA will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide additional opportunities for third parties to challenge any pending patent application or issued patent in the USPTO. Such opportunities include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and derivation proceeding. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim in our patents invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to economic, political, regulatory and other risks associated with international operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, political instability in particular in foreign economies and markets, and the effect of the COVID-19 pandemic, including the emergence of any variants or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future mitigation efforts and current or future economic effects;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements for drug approvals; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing jurisdictions potentially presenting different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially reduced protection for intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in currency exchange rates of the euro, U.S. dollar, Pound Sterling and currency controls; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative consequences from changes in tax laws or practice; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States and EU; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war, terrorism, pandemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber security or cyber security of our collaborators, vendors and other partners.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our reliance on technological infrastructure, we continue to evaluate internal security measures and policies. Our internal computer systems, which are managed partially by a third party, and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, pandemics and telecommunications and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our therapeutic development programs. In addition, our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. Cyber incidents have been increasing in sophistication and frequency and can include third parties gaining access to employee or customer data using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks, ransomware, card skimming code, and other deliberate attacks and attempts to gain unauthorized access. Whilst we conduct periodic penetration testing and perform continuous security monitoring, as the techniques used by computer programmers who may attempt to penetrate and sabotage our network security or our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, it is also possible that unauthorized access to customer data may be obtained through inadequate use of security controls by customers, suppliers or other vendors. While we are not currently aware of any material impact from recent attacks such as SolarWinds, Log4j, and Kaseya, new information on the scope of such attacks is continuing to emerge. While we continue to devote time and resources on the remediation of such risks, there is the possibility of a material impact from such an attack in the future.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not, to our knowledge, experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of COMP360 or any future therapeutic candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates could be hindered or delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Although we maintain cyber liability insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all.</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_136"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of IPO Proceeds </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2020, the Registration Statement on Form S-1 (File No. 333-248484) relating to our IPO was declared effective by the SEC. There has been no material change in the planned use of proceeds from our IPO as described in our IPO prospectus. </span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_139"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_142"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_145"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_148"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed in the Exhibit Index of this Quarterly Report are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.410%"><tr><td style="width:1.0%"></td><td style="width:8.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporation by reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule/Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000162828020013522/exhibit32f-1a1xformofa.htm">Articles of Association of COMPASS Pathways plc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-248484</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9/14/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1472033/000119380520001149/e619934_ex99-a.htm">Deposit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-6/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-248514</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.(A)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9/17/2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of American Depositary Receipt (included in exhibit 4.1).</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q3xex311ceo302certifi.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Executive Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q3xex312cfo302certifi.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Finance Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q3xex321ceoxcfosectio.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">_________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i2c038f1b3ae34b9980fe150878abee2f_151"></div><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c038f1b3ae34b9980fe150878abee2f_7">Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934 the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS PATHWAYS PLC</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 3, 2022</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 3, 2022</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Falvey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Falvey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="12" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cmps-q3xex311ceo302certifi.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i98dbd6e8b8844e54b1d9f3ba6ce52b5f_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Kabir Nath, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cmps-q3xex312cfo302certifi.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iad0844a8ddef42e487aa9770f03ab544_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Michael Falvey, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>cmps-q3xex321ceoxcfosectio.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia53ef9cb652b444fbe6da5597c5a80e7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Kabir Nath, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended September 30, 2022 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Michael Falvey, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended September 30, 2022 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and it is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cmps-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cmps="http://compasspathways.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://compasspathways.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://compasspathways.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://compasspathways.com/role/NatureofBusiness">
        <link:definition>0000007 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://compasspathways.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investment" roleURI="http://compasspathways.com/role/Investment">
        <link:definition>0000010 - Disclosure - Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>0000011 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://compasspathways.com/role/PropertyandEquipmentNet">
        <link:definition>0000012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilities" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities">
        <link:definition>0000013 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinaryShares" roleURI="http://compasspathways.com/role/OrdinaryShares">
        <link:definition>0000014 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://compasspathways.com/role/ShareBasedCompensation">
        <link:definition>0000015 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://compasspathways.com/role/NetLossPerShare">
        <link:definition>0000016 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Rightofuseofassets" roleURI="http://compasspathways.com/role/Rightofuseofassets">
        <link:definition>0000017 - Disclosure - Right of use of assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://compasspathways.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://compasspathways.com/role/EmployeeBenefitPlans">
        <link:definition>0000019 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>0000022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://compasspathways.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000023 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesTables" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables">
        <link:definition>0000024 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://compasspathways.com/role/ShareBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://compasspathways.com/role/NetLossPerShareTables">
        <link:definition>0000026 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsTables" roleURI="http://compasspathways.com/role/RightofuseofassetsTables">
        <link:definition>0000027 - Disclosure - Right of use of assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://compasspathways.com/role/NatureofBusinessDetails">
        <link:definition>0000028 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentNarrativeDetails" roleURI="http://compasspathways.com/role/InvestmentNarrativeDetails">
        <link:definition>0000031 - Disclosure - Investment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000032 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://compasspathways.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000033 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesDetails" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>0000034 - Disclosure - Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesDetails" roleURI="http://compasspathways.com/role/OrdinarySharesDetails">
        <link:definition>0000035 - Disclosure - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2017EquityIncentivePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails">
        <link:definition>0000036 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails">
        <link:definition>0000037 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020ShareOptionPlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails">
        <link:definition>0000038 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2022InducementGrantOptionAwardDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails">
        <link:definition>0000039 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedShareUnitDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails">
        <link:definition>0000040 - Disclosure - Share-Based Compensation - Restricted Share Unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationShareOptionsDetails" roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails">
        <link:definition>0000041 - Disclosure - Share-based Compensation - Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofValuationAssumptionsDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails">
        <link:definition>0000042 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>0000043 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>0000044 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>0000045 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsNarrativeDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Right of use of assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails">
        <link:definition>0000047 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails">
        <link:definition>0000048 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1">
        <link:definition>0000048 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://compasspathways.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000049 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_VariableLeaseCostLeaseIncentiveReceived" abstract="false" name="VariableLeaseCostLeaseIncentiveReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_EastbourneTerraceLondonUKMember" abstract="true" name="EastbourneTerraceLondonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_NumberOfOrdinarySharesConversionRatio" abstract="false" name="NumberOfOrdinarySharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cmps_GrantDateJune302020Member" abstract="true" name="GrantDateJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_SohoLondonUKMember" abstract="true" name="SohoLondonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_LeaseRentalRelief" abstract="false" name="LeaseRentalRelief" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_A2020ShareOptionPlanMember" abstract="true" name="A2020ShareOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_OptionsGrantedBeforeJune302020Member" abstract="true" name="OptionsGrantedBeforeJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_DeferredOfferingCostsIncludedInAccruedExpenses" abstract="false" name="DeferredOfferingCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_CashDividendDeclaredOrPaidDuringPeriod" abstract="false" name="CashDividendDeclaredOrPaidDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareOptionsMember" abstract="true" name="ShareOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_OperatingLeaseAnnualPayment" abstract="false" name="OperatingLeaseAnnualPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_A2020AwardMember" abstract="true" name="A2020AwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_OperatingLeaseMonthlyPayment" abstract="false" name="OperatingLeaseMonthlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" abstract="false" name="RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" abstract="false" name="ResearchAndDevelopmentTaxCreditCashRebatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_UnvestedRestrictedShareUnitsMember" abstract="true" name="UnvestedRestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionOneMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_WeWorkMember" abstract="true" name="WeWorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_A2017EquityIncentivePlanMember" abstract="true" name="A2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PrepaidExpenseResearchAndDevelopmentCurrent" abstract="false" name="PrepaidExpenseResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" abstract="false" name="BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cmps_LeaseCancellationNotificationPeriod" abstract="false" name="LeaseCancellationNotificationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_SaleOfStockMaximumAmountAllowableForSale" abstract="false" name="SaleOfStockMaximumAmountAllowableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OrdinarySharesMember" abstract="true" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_A2021AwardMember" abstract="true" name="A2021AwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_DenmarkHillLondonUKMember" abstract="true" name="DenmarkHillLondonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ProceedsFromStockOptionsExercisedNotReceived" abstract="false" name="ProceedsFromStockOptionsExercisedNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_SanFranciscoCAMember" abstract="true" name="SanFranciscoCAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_AnnualLeasePayment" abstract="false" name="AnnualLeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cmps_NumberOfGeographicRegions" abstract="false" name="NumberOfGeographicRegions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_DelixTherapeuticsIncMember" abstract="true" name="DelixTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_RefundableLeaseDepositPayments" abstract="false" name="RefundableLeaseDepositPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" abstract="true" name="UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" abstract="false" name="ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_NewYorkNYMember" abstract="true" name="NewYorkNYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_A2022InducementGrantOptionAwardMember" abstract="true" name="A2022InducementGrantOptionAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_NumberOfVotes" abstract="false" name="NumberOfVotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_OperatingLeasesNoncancelableTerm" abstract="false" name="OperatingLeasesNoncancelableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" abstract="false" name="ResearchAndDevelopmentTaxCreditTotalAidClaimable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" abstract="true" name="UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cmps-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42c1f645-f7e8-4b0f-869f-846921ca2685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_50a36322-e56f-4aaa-b85e-ea02517e87be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42c1f645-f7e8-4b0f-869f-846921ca2685" xlink:to="loc_us-gaap_CommonStockValue_50a36322-e56f-4aaa-b85e-ea02517e87be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_902a248c-e7df-4088-8e0a-ec7f4c569769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42c1f645-f7e8-4b0f-869f-846921ca2685" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_902a248c-e7df-4088-8e0a-ec7f4c569769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5f4f094a-95a2-424b-b76f-e81c8676226f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42c1f645-f7e8-4b0f-869f-846921ca2685" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5f4f094a-95a2-424b-b76f-e81c8676226f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5a6fabf0-e28c-4d08-8d21-10c10c2ac31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42c1f645-f7e8-4b0f-869f-846921ca2685" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5a6fabf0-e28c-4d08-8d21-10c10c2ac31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_683c86ab-ebbc-4f8e-9b9d-ff1d1e3050dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f53a1ad5-8eb8-4c6a-9ad6-62fbaa7f7244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_683c86ab-ebbc-4f8e-9b9d-ff1d1e3050dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f53a1ad5-8eb8-4c6a-9ad6-62fbaa7f7244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6dac8e72-5211-4c82-9fa5-a82fc5e2a0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_683c86ab-ebbc-4f8e-9b9d-ff1d1e3050dc" xlink:to="loc_us-gaap_LiabilitiesCurrent_6dac8e72-5211-4c82-9fa5-a82fc5e2a0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd038493-3c8d-4d9a-8e5d-cd98ac037acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25848355-c1c4-4580-a0ec-c4e7b086e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd038493-3c8d-4d9a-8e5d-cd98ac037acc" xlink:to="loc_us-gaap_Liabilities_25848355-c1c4-4580-a0ec-c4e7b086e0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1ba80902-4872-4767-a0c3-b21d4362aae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd038493-3c8d-4d9a-8e5d-cd98ac037acc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1ba80902-4872-4767-a0c3-b21d4362aae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_01119f9d-2a30-465b-9e8a-7ae79e3f2671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd038493-3c8d-4d9a-8e5d-cd98ac037acc" xlink:to="loc_us-gaap_StockholdersEquity_01119f9d-2a30-465b-9e8a-7ae79e3f2671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b707c176-4cfa-429d-b643-0d63a4bbc71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b707c176-4cfa-429d-b643-0d63a4bbc71e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1ac0f691-97ff-4612-96c4-91b6d2c94dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1ac0f691-97ff-4612-96c4-91b6d2c94dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc2f62fd-8233-4dd7-8b09-fb8f7fd243af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc2f62fd-8233-4dd7-8b09-fb8f7fd243af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44567ec0-2a39-4e45-9c76-092c9dbfdf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_AssetsCurrent_44567ec0-2a39-4e45-9c76-092c9dbfdf13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3cfaebcd-7915-46e5-9779-a26dda548b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3cfaebcd-7915-46e5-9779-a26dda548b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5272edac-cc92-4c98-a994-a09482b9d41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4221f08f-89a9-4514-a337-5a18216533bb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5272edac-cc92-4c98-a994-a09482b9d41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e9de9bd-105f-4b9a-a4a7-57eb34583d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_64dc4d69-6ed2-4dc7-89d7-862a8a9c8730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e9de9bd-105f-4b9a-a4a7-57eb34583d7d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_64dc4d69-6ed2-4dc7-89d7-862a8a9c8730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d925870-16fa-4bbf-a175-6733b712f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e9de9bd-105f-4b9a-a4a7-57eb34583d7d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d925870-16fa-4bbf-a175-6733b712f2bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_bada9a23-9c03-45db-aab1-721548e966e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e9de9bd-105f-4b9a-a4a7-57eb34583d7d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_bada9a23-9c03-45db-aab1-721548e966e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_0f7dd4f0-d9c2-4571-989e-463cf226815a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e9de9bd-105f-4b9a-a4a7-57eb34583d7d" xlink:to="loc_us-gaap_PrepaidTaxes_0f7dd4f0-d9c2-4571-989e-463cf226815a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d097d396-a3b8-440b-b6d6-7fa0f3825193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1bfcf6f3-d9c9-41e5-8114-8a735fb6c108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d097d396-a3b8-440b-b6d6-7fa0f3825193" xlink:to="loc_us-gaap_AccountsPayableCurrent_1bfcf6f3-d9c9-41e5-8114-8a735fb6c108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7612ee2f-cf37-4862-b934-31ad684bba29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d097d396-a3b8-440b-b6d6-7fa0f3825193" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7612ee2f-cf37-4862-b934-31ad684bba29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6de874c-622f-4c9c-a11d-f0853df7510d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d097d396-a3b8-440b-b6d6-7fa0f3825193" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6de874c-622f-4c9c-a11d-f0853df7510d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2c69965f-ed8a-40ce-9758-a64a4ea03d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b003cb33-f1e2-49a1-a780-d579c28ec2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2c69965f-ed8a-40ce-9758-a64a4ea03d89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b003cb33-f1e2-49a1-a780-d579c28ec2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14c15bce-ad3f-4eb1-9638-f9dc6c07a493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2c69965f-ed8a-40ce-9758-a64a4ea03d89" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14c15bce-ad3f-4eb1-9638-f9dc6c07a493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0140162d-575b-452f-a5a6-9cdd99fd8bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2e5555f4-8ae5-4663-953c-7dd0b34d8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0140162d-575b-452f-a5a6-9cdd99fd8bba" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2e5555f4-8ae5-4663-953c-7dd0b34d8c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6f03d884-cc09-43a5-bfde-4414a0bafd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0140162d-575b-452f-a5a6-9cdd99fd8bba" xlink:to="loc_us-gaap_OperatingIncomeLoss_6f03d884-cc09-43a5-bfde-4414a0bafd16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_006b81ee-e18d-4655-9f68-cfdacefe0874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3f879f0b-fa48-4ca1-b49b-a2d66f0ccd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_006b81ee-e18d-4655-9f68-cfdacefe0874" xlink:to="loc_us-gaap_NetIncomeLoss_3f879f0b-fa48-4ca1-b49b-a2d66f0ccd69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_896917a5-b3d5-49a6-a79c-91109d5b9835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_006b81ee-e18d-4655-9f68-cfdacefe0874" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_896917a5-b3d5-49a6-a79c-91109d5b9835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1565fea9-47bb-4341-b606-e1f90e33c5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a402625d-c885-45cb-9550-855254d07264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1565fea9-47bb-4341-b606-e1f90e33c5e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a402625d-c885-45cb-9550-855254d07264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ed8f25c-a970-49fc-9b15-0cc6e60bd8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1565fea9-47bb-4341-b606-e1f90e33c5e5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1ed8f25c-a970-49fc-9b15-0cc6e60bd8ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_49d51375-2fd1-4f75-b834-fef50bb4506f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_263c7ddd-b14d-40da-86b5-79992e4c33a7" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49d51375-2fd1-4f75-b834-fef50bb4506f" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_263c7ddd-b14d-40da-86b5-79992e4c33a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_e3756856-ded3-471d-a246-8f521d6b4995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49d51375-2fd1-4f75-b834-fef50bb4506f" xlink:to="loc_us-gaap_OtherNonoperatingIncome_e3756856-ded3-471d-a246-8f521d6b4995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9003cef4-1308-4388-bda4-9ad72e1e0d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49d51375-2fd1-4f75-b834-fef50bb4506f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9003cef4-1308-4388-bda4-9ad72e1e0d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_840b2657-90db-425c-bc92-1713dd648127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7c8a0f44-1ef0-41ac-b1cf-331fb82f83f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_840b2657-90db-425c-bc92-1713dd648127" xlink:to="loc_us-gaap_OperatingExpenses_7c8a0f44-1ef0-41ac-b1cf-331fb82f83f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0678017-e5ce-4c6a-a4a2-5e45774ecf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2bf80a62-e743-4624-96d0-0cbfaedb6c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0678017-e5ce-4c6a-a4a2-5e45774ecf2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2bf80a62-e743-4624-96d0-0cbfaedb6c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_96bf7bdd-902b-4f73-8c3d-54ff28680c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0678017-e5ce-4c6a-a4a2-5e45774ecf2f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_96bf7bdd-902b-4f73-8c3d-54ff28680c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0c11ca0-0080-430d-a721-8dd2c3af02d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3685c86b-20ff-42c2-9d5b-3e93c606dcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0c11ca0-0080-430d-a721-8dd2c3af02d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3685c86b-20ff-42c2-9d5b-3e93c606dcc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a22abe9a-9fc3-4985-b218-c3cac9655577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0c11ca0-0080-430d-a721-8dd2c3af02d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a22abe9a-9fc3-4985-b218-c3cac9655577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4412b88a-51da-4624-9b05-fb2e3947ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0c11ca0-0080-430d-a721-8dd2c3af02d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4412b88a-51da-4624-9b05-fb2e3947ddc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad24d835-340a-479b-9a5d-a44edcb3cffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0c11ca0-0080-430d-a721-8dd2c3af02d1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad24d835-340a-479b-9a5d-a44edcb3cffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23e4d371-e478-4d7f-9ec5-d1e9ba5cb06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbe6d7cd-67b2-40c1-9e89-e774c8d19d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23e4d371-e478-4d7f-9ec5-d1e9ba5cb06c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbe6d7cd-67b2-40c1-9e89-e774c8d19d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b421c3b9-6e92-4157-baa3-2ea16c398703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23e4d371-e478-4d7f-9ec5-d1e9ba5cb06c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b421c3b9-6e92-4157-baa3-2ea16c398703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0de392a5-9ab8-479e-a701-2da281a802fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_900808fa-102d-4600-914b-18b1ef48780d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0de392a5-9ab8-479e-a701-2da281a802fc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_900808fa-102d-4600-914b-18b1ef48780d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_648f6f86-bc34-4816-b434-7cb4683fada4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_648f6f86-bc34-4816-b434-7cb4683fada4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_99558a6e-ec33-4931-9e6c-1f7f333c98f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_99558a6e-ec33-4931-9e6c-1f7f333c98f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_480d2638-3af1-4433-bc0e-f2da15b50966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_480d2638-3af1-4433-bc0e-f2da15b50966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3c7a920b-10c8-4228-9d70-0b4e58e81c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3c7a920b-10c8-4228-9d70-0b4e58e81c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_72f95669-0c54-45ba-b628-9abace6457b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_72f95669-0c54-45ba-b628-9abace6457b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2b79f86a-e16f-47c4-99eb-60e4ce284154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2b79f86a-e16f-47c4-99eb-60e4ce284154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3246a096-eaf8-463a-a50d-adc12908d425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_ShareBasedCompensation_3246a096-eaf8-463a-a50d-adc12908d425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_db68ed35-baf2-479e-b407-b4609fc04de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_db68ed35-baf2-479e-b407-b4609fc04de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_00df4a21-27a3-4034-96d4-ab942fc09b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_00df4a21-27a3-4034-96d4-ab942fc09b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d56dba0f-de6e-4506-96b9-bd642ac92090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d56dba0f-de6e-4506-96b9-bd642ac92090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5bb99ee0-baaf-41a1-a2d5-f3d0ffccd536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_698418f2-e0d1-4f36-bf5d-5742ffa2bd56" xlink:to="loc_us-gaap_NetIncomeLoss_5bb99ee0-baaf-41a1-a2d5-f3d0ffccd536" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_6eccc645-a4bc-4f95-94e4-3ce7f2a67cab" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_6eccc645-a4bc-4f95-94e4-3ce7f2a67cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_817be5b5-2516-4160-b05b-a446282038a1" xlink:href="cmps-20220930.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_817be5b5-2516-4160-b05b-a446282038a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_72530caf-87ef-47e9-9200-f41cbee89f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_us-gaap_OtherAssetsCurrent_72530caf-87ef-47e9-9200-f41cbee89f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_8b545b4c-cdff-4017-bc7e-0a0f24a0d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_us-gaap_DepositsAssetsCurrent_8b545b4c-cdff-4017-bc7e-0a0f24a0d14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_c5a5fc43-f05e-405c-a633-704a8627f899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_c5a5fc43-f05e-405c-a633-704a8627f899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_987d9865-100f-4738-a033-d3c144286c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_us-gaap_PrepaidInsurance_987d9865-100f-4738-a033-d3c144286c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_ac7d1851-8396-4674-9e50-0544f9082e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e202fbc2-229a-403b-8dc4-a16e672d2c1c" xlink:to="loc_us-gaap_DeferredCostsCurrent_ac7d1851-8396-4674-9e50-0544f9082e32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a05ce5a-b3d4-43b0-979d-520b26ffeb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f25518d1-b16a-4c92-ad9e-986ab6fc0780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a05ce5a-b3d4-43b0-979d-520b26ffeb94" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f25518d1-b16a-4c92-ad9e-986ab6fc0780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_274250ac-5977-494f-991c-9c6d7da592cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a05ce5a-b3d4-43b0-979d-520b26ffeb94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_274250ac-5977-494f-991c-9c6d7da592cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_25c6bcc0-a253-45e8-b2ec-9f65e642faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_25c6bcc0-a253-45e8-b2ec-9f65e642faf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_83133d4c-9d38-4721-880c-acbe5fbd4509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_83133d4c-9d38-4721-880c-acbe5fbd4509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cd36ac1f-58fa-4873-a99b-3a377331adf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cd36ac1f-58fa-4873-a99b-3a377331adf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_044ad76c-056d-4552-9c3b-375edebdd484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_044ad76c-056d-4552-9c3b-375edebdd484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_a9c6a427-f191-4938-b7db-72f1dc58e568" xlink:href="cmps-20220930.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93498662-8922-4bdf-91a6-5ad44e5db5ee" xlink:to="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_a9c6a427-f191-4938-b7db-72f1dc58e568" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5a33cb1c-6ba4-44dc-94a3-3a2fb6b27eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_050ee221-8550-42c1-bc2f-70607f974fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5a33cb1c-6ba4-44dc-94a3-3a2fb6b27eb4" xlink:to="loc_us-gaap_OperatingLeaseCost_050ee221-8550-42c1-bc2f-70607f974fa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9a8101f6-8838-4ffc-acd6-4268e58cc210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5a33cb1c-6ba4-44dc-94a3-3a2fb6b27eb4" xlink:to="loc_us-gaap_ShortTermLeaseCost_9a8101f6-8838-4ffc-acd6-4268e58cc210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VariableLeaseCostLeaseIncentiveReceived_863de3c6-2bd7-40c4-8b26-c6b66529d42f" xlink:href="cmps-20220930.xsd#cmps_VariableLeaseCostLeaseIncentiveReceived"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5a33cb1c-6ba4-44dc-94a3-3a2fb6b27eb4" xlink:to="loc_cmps_VariableLeaseCostLeaseIncentiveReceived_863de3c6-2bd7-40c4-8b26-c6b66529d42f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_81175b8c-3c4a-45ba-a981-dfff652971df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_81175b8c-3c4a-45ba-a981-dfff652971df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f40f5f9c-9f6f-46fc-8694-153d03592463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f40f5f9c-9f6f-46fc-8694-153d03592463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5569f2e9-25aa-454b-9cd0-7cfe37d645df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5569f2e9-25aa-454b-9cd0-7cfe37d645df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2b26e0db-d728-4d99-b3e8-e6214e4bcfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2b26e0db-d728-4d99-b3e8-e6214e4bcfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d00fff8d-0c8b-4c7b-8936-b78f21ab530c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97d7d1b8-d67a-4216-abdc-782327c41046" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d00fff8d-0c8b-4c7b-8936-b78f21ab530c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07876636-3c10-4eff-9cae-9908e9370bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6f581e1d-59a3-4ace-8f06-bd562ee92fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07876636-3c10-4eff-9cae-9908e9370bb0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6f581e1d-59a3-4ace-8f06-bd562ee92fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a7581d8-652f-4a30-8c3e-afa4b39b905a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07876636-3c10-4eff-9cae-9908e9370bb0" xlink:to="loc_us-gaap_OperatingLeaseLiability_4a7581d8-652f-4a30-8c3e-afa4b39b905a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cmps-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i286223b3f9ef4dd3a3b7686c19fffbdf_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:to="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a13dff97-7ace-4dee-b2e1-9e32edaa3bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a13dff97-7ace-4dee-b2e1-9e32edaa3bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aad6f8c3-a3e7-46d7-af20-538168a8332f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aad6f8c3-a3e7-46d7-af20-538168a8332f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_29d4ded4-fc20-416b-909e-c61a2841817a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_PrepaidTaxes_29d4ded4-fc20-416b-909e-c61a2841817a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4cce825a-878d-4228-b782-498ffa46f214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4cce825a-878d-4228-b782-498ffa46f214" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b6023cd4-c52c-4316-a1cd-14f761c676e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_AssetsCurrent_b6023cd4-c52c-4316-a1cd-14f761c676e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2caba26-958b-4c61-8e2a-34f7f36a3704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2caba26-958b-4c61-8e2a-34f7f36a3704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53435269-8ea0-4120-b75d-23b899971f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53435269-8ea0-4120-b75d-23b899971f6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_182809d8-e4b9-49c3-976f-66a3732282b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_182809d8-e4b9-49c3-976f-66a3732282b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bfa96418-079b-459a-83dc-36d43570ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bfa96418-079b-459a-83dc-36d43570ba1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_38793cef-fc07-4c98-841a-de6f71ed71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_38793cef-fc07-4c98-841a-de6f71ed71f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d9a34694-3a16-4063-8bb3-aa236b86f260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_Assets_d9a34694-3a16-4063-8bb3-aa236b86f260" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f3deb187-7adf-40ad-8fbc-fcf3a825560e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_AccountsPayableCurrent_f3deb187-7adf-40ad-8fbc-fcf3a825560e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_26a35bb7-3ab7-4e22-aa36-d3d0a88b76bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_26a35bb7-3ab7-4e22-aa36-d3d0a88b76bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cd51a20-fba6-4ae6-88ab-28f02b6275ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cd51a20-fba6-4ae6-88ab-28f02b6275ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e687a564-a35e-4940-923a-d24c7e676961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_LiabilitiesCurrent_e687a564-a35e-4940-923a-d24c7e676961" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1729a470-db4f-4c78-b2de-1dbf37677623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1729a470-db4f-4c78-b2de-1dbf37677623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d66ea1c6-e0a5-4916-921f-2a14768c0cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_Liabilities_d66ea1c6-e0a5-4916-921f-2a14768c0cc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e9caed26-3c1f-48cd-ae8a-3564475425da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e9caed26-3c1f-48cd-ae8a-3564475425da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f28ac965-2d5e-4a19-bb04-2f286876047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_CommonStockValue_f28ac965-2d5e-4a19-bb04-2f286876047d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_96efd044-3361-4514-9cb3-aa9b77ca7de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_AdditionalPaidInCapital_96efd044-3361-4514-9cb3-aa9b77ca7de5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8cea43f-a8e5-4e0a-8501-b18e44ecd1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8cea43f-a8e5-4e0a-8501-b18e44ecd1ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33e38e8d-a308-489e-b976-d69348962568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33e38e8d-a308-489e-b976-d69348962568" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff70b6c7-6b29-45f4-9299-a845349eaace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_StockholdersEquity_ff70b6c7-6b29-45f4-9299-a845349eaace" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8114e5d-b939-4d10-9ec3-3e045636c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8114e5d-b939-4d10-9ec3-3e045636c0cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:to="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7291fdbc-9576-407b-993e-caab4ae625fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:to="loc_us-gaap_ClassOfStockDomain_7291fdbc-9576-407b-993e-caab4ae625fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:to="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_8d97eb03-8f6f-4b03-a126-e6b77d012e18" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:to="loc_cmps_OrdinarySharesMember_8d97eb03-8f6f-4b03-a126-e6b77d012e18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_38ed20b5-2f7e-4ba6-8587-b1c60db75a57" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:to="loc_cmps_DeferredSharesMember_38ed20b5-2f7e-4ba6-8587-b1c60db75a57" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie0ed9076d3d6430dbc1f956f40e4bd4d_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f0806e3f-b68c-46ec-9b3c-7b14eccb1f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f0806e3f-b68c-46ec-9b3c-7b14eccb1f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1cd63eef-03d0-4320-9a5e-05a30e849457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1cd63eef-03d0-4320-9a5e-05a30e849457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_76345d83-b555-4851-96e9-7042eb97bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesIssued_76345d83-b555-4851-96e9-7042eb97bf17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3e9903c-f7ed-4007-9263-b37924ee261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3e9903c-f7ed-4007-9263-b37924ee261b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_37df949a-3ac2-4f86-8423-99cd26e03cd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:to="loc_us-gaap_ClassOfStockDomain_37df949a-3ac2-4f86-8423-99cd26e03cd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:to="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_c39e9819-4216-4b43-9f46-669c7a0b5974" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:to="loc_cmps_OrdinarySharesMember_c39e9819-4216-4b43-9f46-669c7a0b5974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_dbb69059-461f-406c-9538-2e67129ee57d" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:to="loc_cmps_DeferredSharesMember_dbb69059-461f-406c-9538-2e67129ee57d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="ifb2c6b22fdb940d39df396ac3ac3738d_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_890ff4f6-f6fc-46ef-95b0-649ac048ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_890ff4f6-f6fc-46ef-95b0-649ac048ada9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fba82b0-9874-4bf8-9595-19a9f675a5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockholdersEquity_7fba82b0-9874-4bf8-9595-19a9f675a5af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd101b71-3439-42cf-b1c6-19e5fc4df5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd101b71-3439-42cf-b1c6-19e5fc4df5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed27d8e9-4996-47e5-a954-2ea785186825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed27d8e9-4996-47e5-a954-2ea785186825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a0a1d6b-e5f7-4cb5-af9b-43f374839fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a0a1d6b-e5f7-4cb5-af9b-43f374839fee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b222b0d4-4db1-4ebf-9fe5-c7d1e32762ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b222b0d4-4db1-4ebf-9fe5-c7d1e32762ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3062b860-307b-48c9-9a18-cf62fe838a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3062b860-307b-48c9-9a18-cf62fe838a7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_165e9548-56a0-45e9-941b-e50bc54fc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_165e9548-56a0-45e9-941b-e50bc54fc72e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d496588-37e7-42a0-b9b0-c422b67534da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d496588-37e7-42a0-b9b0-c422b67534da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_5586f141-c439-4092-8cc5-9533697285af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_5586f141-c439-4092-8cc5-9533697285af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd19779e-f5d1-4a56-9473-d0518dfbb23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_NetIncomeLoss_bd19779e-f5d1-4a56-9473-d0518dfbb23e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0c1254a0-763b-4ac2-a574-772a738db46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9984525-87ee-4ffc-8746-2f5a1aff0917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9e65b6a-366f-4d6f-9407-8053af153233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9e65b6a-366f-4d6f-9407-8053af153233" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba7b983e-b018-4607-8353-ef983675c369_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:to="loc_us-gaap_ClassOfStockDomain_ba7b983e-b018-4607-8353-ef983675c369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:to="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_f472ad02-00b6-40e5-ad89-f85245b92ef0" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:to="loc_cmps_OrdinarySharesMember_f472ad02-00b6-40e5-ad89-f85245b92ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_6a69b4d2-a2b6-474d-bd6c-702a5490cc0b" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:to="loc_cmps_DeferredSharesMember_6a69b4d2-a2b6-474d-bd6c-702a5490cc0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3de950b9-421d-4000-b3fa-dc1d4a13a48c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:to="loc_us-gaap_EquityComponentDomain_3de950b9-421d-4000-b3fa-dc1d4a13a48c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:to="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a6a7a53e-bfe9-454c-bc0e-6ce1660c6402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_CommonStockMember_a6a7a53e-bfe9-454c-bc0e-6ce1660c6402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e683f882-8c4e-461e-9d37-21c77c81bff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e683f882-8c4e-461e-9d37-21c77c81bff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79a8bc82-8765-44bc-bf93-7b92d74c1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79a8bc82-8765-44bc-bf93-7b92d74c1ea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1a167334-271c-43d9-b6a6-edaf9553e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_RetainedEarningsMember_1a167334-271c-43d9-b6a6-edaf9553e02d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_18fcbb20-d6be-41e0-bc75-a89116c1d9bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:to="loc_us-gaap_AwardDateDomain_18fcbb20-d6be-41e0-bc75-a89116c1d9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:to="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2021AwardMember_a3baef7a-6153-459c-a06f-e19cbe6b3499" xlink:href="cmps-20220930.xsd#cmps_A2021AwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:to="loc_cmps_A2021AwardMember_a3baef7a-6153-459c-a06f-e19cbe6b3499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020AwardMember_dab86eb9-a377-4a6c-a078-737cab862018" xlink:href="cmps-20220930.xsd#cmps_A2020AwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:to="loc_cmps_A2020AwardMember_dab86eb9-a377-4a6c-a078-737cab862018" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended" id="ieb942c10f0c140baa2f5c23beaebf646_NatureofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19926ea2-7dd5-4c22-9d99-c825135122b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19926ea2-7dd5-4c22-9d99-c825135122b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_cfb8553a-febc-4077-a92e-2eb6986c5f87" xlink:href="cmps-20220930.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_cfb8553a-febc-4077-a92e-2eb6986c5f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_2bb6288b-5bd9-44bc-bb22-fb83b4561bd6" xlink:href="cmps-20220930.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_2bb6288b-5bd9-44bc-bb22-fb83b4561bd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80fbf802-5b7d-4971-87dc-bf44ebe158bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_NetIncomeLoss_80fbf802-5b7d-4971-87dc-bf44ebe158bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aa312df-b676-479b-9d3e-cf687295d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aa312df-b676-479b-9d3e-cf687295d6c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2b1d229-08e7-4cd4-969e-ae81438fa60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2b1d229-08e7-4cd4-969e-ae81438fa60c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95317cd6-1597-4668-bf59-a439034e2d90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95317cd6-1597-4668-bf59-a439034e2d90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f02a0a2c-f2ef-427e-9409-2c92e6dbb0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:to="loc_us-gaap_IPOMember_f02a0a2c-f2ef-427e-9409-2c92e6dbb0c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3aafb76a-1b16-44b5-a421-49e66dd52060_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:to="loc_us-gaap_ClassOfStockDomain_3aafb76a-1b16-44b5-a421-49e66dd52060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:to="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_6ffbaee9-6c27-4bb3-bca0-e03b2f060d43" xlink:href="cmps-20220930.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:to="loc_cmps_AmericanDepositarySharesMember_6ffbaee9-6c27-4bb3-bca0-e03b2f060d43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended" id="i032023ad3c0d456aab98a64aea226b07_SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259c13e9-4f36-458c-9cd5-b073676a1a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259c13e9-4f36-458c-9cd5-b073676a1a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fb18e1ee-8e19-4699-86ce-43189a315630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_EquipmentMember_fb18e1ee-8e19-4699-86ce-43189a315630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_039c1d63-d589-44bb-9fc7-be8d0bdccc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_OfficeEquipmentMember_039c1d63-d589-44bb-9fc7-be8d0bdccc8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_023c355b-2e91-41c2-ac2f-835ace6389c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_023c355b-2e91-41c2-ac2f-835ace6389c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:to="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e68397a9-e058-4681-9c9f-60f12a030494_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:to="loc_srt_RangeMember_e68397a9-e058-4681-9c9f-60f12a030494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:to="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3793335a-bee1-47b9-885e-38d500d0ea45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:to="loc_srt_MinimumMember_3793335a-bee1-47b9-885e-38d500d0ea45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cab31ba-f873-475d-8a3a-3fab9f2cb24d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:to="loc_srt_MaximumMember_6cab31ba-f873-475d-8a3a-3fab9f2cb24d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i4383e389ba764b2c9dd4fab0af863c58_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions_2aedee4d-0a88-4636-a8b5-1bbc9d3690b4" xlink:href="cmps-20220930.xsd#cmps_NumberOfGeographicRegions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_NumberOfGeographicRegions_2aedee4d-0a88-4636-a8b5-1bbc9d3690b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_99c285c0-1ce4-454a-b373-fcf18f1c24b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_99c285c0-1ce4-454a-b373-fcf18f1c24b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfcc3670-e46c-490f-929a-c4dc69d2e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfcc3670-e46c-490f-929a-c4dc69d2e7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f4a75cf7-3d94-4ea5-83d2-a70469339096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f4a75cf7-3d94-4ea5-83d2-a70469339096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_30c127ad-714d-49e9-b6d5-1b053aa3f6cc" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_30c127ad-714d-49e9-b6d5-1b053aa3f6cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_a098387d-4dee-4703-81a9-038d41746597" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_a098387d-4dee-4703-81a9-038d41746597" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_f76b5e0e-4cf6-4b04-90df-ec6ec04118ab" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_f76b5e0e-4cf6-4b04-90df-ec6ec04118ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_8429601f-abc0-42c8-a31c-eb67bedeab63" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_8429601f-abc0-42c8-a31c-eb67bedeab63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_03655324-cba7-47b2-9c48-fe10c66ea6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_03655324-cba7-47b2-9c48-fe10c66ea6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_c16e31de-09d6-4841-9e5e-74d1c77bfa57" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_c16e31de-09d6-4841-9e5e-74d1c77bfa57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_368216e4-c079-4b20-b935-5c88a3a0785a" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_368216e4-c079-4b20-b935-5c88a3a0785a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fbffce2d-e26c-4706-bd48-167389daaa9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fbffce2d-e26c-4706-bd48-167389daaa9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_7cea2679-4046-4159-8653-c722bb70a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_7cea2679-4046-4159-8653-c722bb70a179" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/InvestmentNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#InvestmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/InvestmentNarrativeDetails" xlink:type="extended" id="icbf1040c05eb4a3182192184787e83bc_InvestmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4da748f4-e65f-4ed2-8004-8612274cc14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4da748f4-e65f-4ed2-8004-8612274cc14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8cb859e1-ac52-4c60-a57b-40e3210b2d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8cb859e1-ac52-4c60-a57b-40e3210b2d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5fa4f9ff-e4c3-460b-9f08-841705e11fc0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5fa4f9ff-e4c3-460b-9f08-841705e11fc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DelixTherapeuticsIncMember_ddcc413a-5e5e-40b5-8893-01baf90377ec" xlink:href="cmps-20220930.xsd#cmps_DelixTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:to="loc_cmps_DelixTherapeuticsIncMember_ddcc413a-5e5e-40b5-8893-01baf90377ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:to="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_43227dc2-1b5a-4bb3-b845-9b85b71a5f97_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:to="loc_srt_OwnershipDomain_43227dc2-1b5a-4bb3-b845-9b85b71a5f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:to="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DelixTherapeuticsIncMember_ece54014-f54f-4094-91a8-22b6eb409b8d" xlink:href="cmps-20220930.xsd#cmps_DelixTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:to="loc_cmps_DelixTherapeuticsIncMember_ece54014-f54f-4094-91a8-22b6eb409b8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i56150b4762a8427cba2237df3fbae35f_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1bd017fe-9967-4e4c-8d4d-ee47471ddc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1bd017fe-9967-4e4c-8d4d-ee47471ddc7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2eb9a9e-0d58-4e55-9c54-d59c3407471b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2eb9a9e-0d58-4e55-9c54-d59c3407471b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_62232070-5787-48e0-b5fb-beae1621cbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_62232070-5787-48e0-b5fb-beae1621cbc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4e90fc82-80b0-4bff-80f9-e0080051fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4e90fc82-80b0-4bff-80f9-e0080051fdb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0071304d-9e4c-4000-9cf4-924717f0a601_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0071304d-9e4c-4000-9cf4-924717f0a601_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5d8b120b-bafd-4d5c-8d3b-6dcdd0e7f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_EquipmentMember_5d8b120b-bafd-4d5c-8d3b-6dcdd0e7f082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4d22a691-805d-477e-b18a-435a9658609e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_OfficeEquipmentMember_4d22a691-805d-477e-b18a-435a9658609e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5ded3b57-822e-477e-b470-0321aba022b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5ded3b57-822e-477e-b470-0321aba022b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b07e5d5b-e7a2-4eb9-8c8f-98a666220b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b07e5d5b-e7a2-4eb9-8c8f-98a666220b66" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#OrdinarySharesDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="extended" id="i60f8879125464abab02b4a73b208a87e_OrdinarySharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27b06bf5-4176-4df5-8cbf-07ff312433bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27b06bf5-4176-4df5-8cbf-07ff312433bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2de600a8-003b-4f5f-9ffa-df890614ee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2de600a8-003b-4f5f-9ffa-df890614ee4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_51041402-de2c-49bd-b305-f212d483d110" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_51041402-de2c-49bd-b305-f212d483d110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ec61483e-56db-4902-83ef-93583b3674da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ec61483e-56db-4902-83ef-93583b3674da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_b828253e-96e1-4f7f-ba6f-78f4319e1ca3" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_b828253e-96e1-4f7f-ba6f-78f4319e1ca3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e14a4da-37de-4831-ab32-37be581c78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e14a4da-37de-4831-ab32-37be581c78c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c689d6f-0bce-4137-96af-48d5b4bd9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c689d6f-0bce-4137-96af-48d5b4bd9e64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8115f635-4708-4c05-8f95-3c7ce5e26f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8115f635-4708-4c05-8f95-3c7ce5e26f02" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVotes_c5b45737-a384-454b-b8d9-298a3d74b8a2" xlink:href="cmps-20220930.xsd#cmps_NumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_NumberOfVotes_c5b45737-a384-454b-b8d9-298a3d74b8a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod_5655d1d9-8d9f-46af-a2db-8fae60da7759" xlink:href="cmps-20220930.xsd#cmps_CashDividendDeclaredOrPaidDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod_5655d1d9-8d9f-46af-a2db-8fae60da7759" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f92041f-ba06-4ded-a027-9e2c11b164e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:to="loc_us-gaap_ClassOfStockDomain_4f92041f-ba06-4ded-a027-9e2c11b164e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:to="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_331cd471-2ae7-49ca-805c-5dd1c1b23694" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:to="loc_cmps_OrdinarySharesMember_331cd471-2ae7-49ca-805c-5dd1c1b23694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d631a98-4ab0-4f80-9309-39864e20d76b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:to="loc_us-gaap_EquityComponentDomain_3d631a98-4ab0-4f80-9309-39864e20d76b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:to="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f77da4e-17ab-4be3-bb9a-00b26297c632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:to="loc_us-gaap_CommonStockMember_0f77da4e-17ab-4be3-bb9a-00b26297c632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_30afcbb2-67b5-424b-bad3-3851308b47da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:to="loc_us-gaap_AwardDateDomain_30afcbb2-67b5-424b-bad3-3851308b47da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:to="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020AwardMember_15bcdeb4-4852-4775-9500-fa7aadc1f698" xlink:href="cmps-20220930.xsd#cmps_A2020AwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:to="loc_cmps_A2020AwardMember_15bcdeb4-4852-4775-9500-fa7aadc1f698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4558820-a277-43bf-9164-9b4fe868e881_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4558820-a277-43bf-9164-9b4fe868e881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41192db-42ca-4927-bf4f-e4f73d8cbe05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41192db-42ca-4927-bf4f-e4f73d8cbe05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ec7b30f-4848-4ace-97f3-c6264069291d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ec7b30f-4848-4ace-97f3-c6264069291d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7a9498e7-4967-44d5-ac3c-ab572a6f991d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:to="loc_us-gaap_IPOMember_7a9498e7-4967-44d5-ac3c-ab572a6f991d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended" id="ia21e8e968f004a6e99cae3359f78fd77_ShareBasedCompensation2017EquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_691293ee-6e26-4b70-bf41-1b59068f5213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_691293ee-6e26-4b70-bf41-1b59068f5213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eea2dd6e-4806-4452-9ca1-e69537cf6d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eea2dd6e-4806-4452-9ca1-e69537cf6d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7e67f28e-5d5d-45ec-9b19-dd1c4da023e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7e67f28e-5d5d-45ec-9b19-dd1c4da023e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_86a08004-48d4-4bb5-b3d6-a21a68feaafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_86a08004-48d4-4bb5-b3d6-a21a68feaafe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_66f823da-4f40-4d12-991f-2fc14f003f1c" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_66f823da-4f40-4d12-991f-2fc14f003f1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_c4ddc6ee-092d-4a94-9490-de9e9a9200db" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_c4ddc6ee-092d-4a94-9490-de9e9a9200db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8762323-d614-45e0-b926-f1da21930467_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8762323-d614-45e0-b926-f1da21930467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_6e54cd73-2686-4ce5-8d50-a038667ba634" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_cmps_OrdinarySharesMember_6e54cd73-2686-4ce5-8d50-a038667ba634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5beede4e-76fb-4051-aa67-c995e17c7552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5beede4e-76fb-4051-aa67-c995e17c7552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34abd334-86ee-4001-bb2c-7bc7b859a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34abd334-86ee-4001-bb2c-7bc7b859a4dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_14910590-b5b4-48d9-9526-2b02b15e1410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:to="loc_us-gaap_PlanNameDomain_14910590-b5b4-48d9-9526-2b02b15e1410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:to="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_5b430d04-1c16-4329-954e-983499cb51f7" xlink:href="cmps-20220930.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_5b430d04-1c16-4329-954e-983499cb51f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c11065c-6335-4d1e-ba83-e5d4b1bcef90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:to="loc_srt_RangeMember_0c11065c-6335-4d1e-ba83-e5d4b1bcef90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:to="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f37cf96d-98cb-4581-a64b-a897cf5658d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:to="loc_srt_MinimumMember_f37cf96d-98cb-4581-a64b-a897cf5658d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5431513c-d634-4365-b70b-3d9d7ffb599a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:to="loc_srt_MaximumMember_5431513c-d634-4365-b70b-3d9d7ffb599a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b9c13522-8204-4747-8a59-ca6504d218e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:to="loc_us-gaap_VestingDomain_b9c13522-8204-4747-8a59-ca6504d218e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:to="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c218e148-5fb5-4c8c-a05b-449a0c07ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c218e148-5fb5-4c8c-a05b-449a0c07ce02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_152ecb2f-c1fd-4917-953e-1d1da9985d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_152ecb2f-c1fd-4917-953e-1d1da9985d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:to="loc_us-gaap_AwardDateDomain_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:to="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_65f99a16-b3c7-4813-a4ec-567707bb1e60" xlink:href="cmps-20220930.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_65f99a16-b3c7-4813-a4ec-567707bb1e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_dad842b4-1843-4725-901c-d396c70cce53" xlink:href="cmps-20220930.xsd#cmps_GrantDateJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:to="loc_cmps_GrantDateJune302020Member_dad842b4-1843-4725-901c-d396c70cce53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_97b9b0ac-f821-488f-ad9d-a7b5281ad774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_97b9b0ac-f821-488f-ad9d-a7b5281ad774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_698dfd10-238d-43bc-a3be-47ea6f53e695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_698dfd10-238d-43bc-a3be-47ea6f53e695" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended" id="ide938cdbaf0a42e8bb421c1693dd21d2_ShareBasedCompensation2020EmployeeSharePurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24732752-dcbf-4542-ad31-e327fd889c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24732752-dcbf-4542-ad31-e327fd889c9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_9b757ca4-3d3d-456d-a37b-621ceaf4ead3" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_9b757ca4-3d3d-456d-a37b-621ceaf4ead3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_9f91425f-b307-460b-9365-c4eb48755723" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_9f91425f-b307-460b-9365-c4eb48755723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_26857a57-d4a8-4d03-8b66-0148175f3190" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_26857a57-d4a8-4d03-8b66-0148175f3190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3c25741a-9ba4-49f3-b43a-f1b8b22ca358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3c25741a-9ba4-49f3-b43a-f1b8b22ca358" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:to="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60bd7f84-f6d6-4009-99db-2e68ff2c23d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60bd7f84-f6d6-4009-99db-2e68ff2c23d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bed9bd41-2101-4fd6-acdd-f9b357b7411a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:to="loc_us-gaap_EmployeeStockMember_bed9bd41-2101-4fd6-acdd-f9b357b7411a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended" id="ib5a8a47559ae4047befaf9467d53a61d_ShareBasedCompensation2020ShareOptionPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b688ddf-ef9c-4fc9-b717-18d25ce3a092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b688ddf-ef9c-4fc9-b717-18d25ce3a092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f6f3768-6e92-4f7f-be29-72777c2722f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f6f3768-6e92-4f7f-be29-72777c2722f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e25302a9-62c5-475a-b22d-4706fc07a485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e25302a9-62c5-475a-b22d-4706fc07a485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5efe5af9-e5fe-42b5-bffd-378f312af13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5efe5af9-e5fe-42b5-bffd-378f312af13f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99825dcb-d2e0-476a-97fc-31f7c2c153d8" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99825dcb-d2e0-476a-97fc-31f7c2c153d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_714ff679-8786-4cb6-81f0-28a78fbebbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharesIssued_714ff679-8786-4cb6-81f0-28a78fbebbd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_476c7eba-86da-490c-bec3-4ce75263c9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_476c7eba-86da-490c-bec3-4ce75263c9d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f382a325-c235-41f0-a0c5-25f98fe5c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f382a325-c235-41f0-a0c5-25f98fe5c8fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b765c736-059e-4099-b7bf-184cd7e26c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b765c736-059e-4099-b7bf-184cd7e26c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_85a981ed-371b-4381-b70d-92a63cca08dc" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_cmps_OrdinarySharesMember_85a981ed-371b-4381-b70d-92a63cca08dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7e85723a-ff99-4bb7-b3bd-ef49f47348fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_us-gaap_EmployeeStockMember_7e85723a-ff99-4bb7-b3bd-ef49f47348fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonEmployeeMember_98c0dd78-1890-490b-88e4-cb49d26b67b0" xlink:href="cmps-20220930.xsd#cmps_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_cmps_NonEmployeeMember_98c0dd78-1890-490b-88e4-cb49d26b67b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac03abda-e82f-4d63-b632-a1c67c913c18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:to="loc_us-gaap_PlanNameDomain_ac03abda-e82f-4d63-b632-a1c67c913c18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:to="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_ac93821a-49f5-4708-85fb-96a8940fb2f8" xlink:href="cmps-20220930.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:to="loc_cmps_A2020ShareOptionPlanMember_ac93821a-49f5-4708-85fb-96a8940fb2f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9337e56e-ee18-49ec-9ebb-60fb3e94494f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:to="loc_us-gaap_ClassOfStockDomain_9337e56e-ee18-49ec-9ebb-60fb3e94494f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:to="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_161e4a37-3385-4e7a-8458-0f4a9f9a435a" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:to="loc_cmps_OrdinarySharesMember_161e4a37-3385-4e7a-8458-0f4a9f9a435a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5160fbfc-cfc1-404c-b457-8c8ba64e7241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:to="loc_us-gaap_VestingDomain_5160fbfc-cfc1-404c-b457-8c8ba64e7241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:to="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_78d09f68-2842-4608-bbd5-8b14647083c8" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_78d09f68-2842-4608-bbd5-8b14647083c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_22b7b181-32c6-4a9f-b715-7e3cba73d55a" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_22b7b181-32c6-4a9f-b715-7e3cba73d55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_9bb6806e-c49d-4677-9686-a626fcf49840" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_9bb6806e-c49d-4677-9686-a626fcf49840" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended" id="i850d30ed98f74f4e8af7722276a5e1bf_ShareBasedCompensation2022InducementGrantOptionAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7a7ff29-c72c-4c50-99ee-399673b41887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7a7ff29-c72c-4c50-99ee-399673b41887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_328f112b-5bf2-422a-990d-20bd5ecfebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_328f112b-5bf2-422a-990d-20bd5ecfebfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5a8a98bb-1165-45d5-a6fb-3fdd7d450775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5a8a98bb-1165-45d5-a6fb-3fdd7d450775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0887427-fcd4-4586-b593-04b7bea89cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0887427-fcd4-4586-b593-04b7bea89cff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7e2d94be-01e9-4f23-9e79-7d0aa5350e96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:to="loc_us-gaap_PlanNameDomain_7e2d94be-01e9-4f23-9e79-7d0aa5350e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:to="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_23b7091d-ec72-45bb-8598-ce9c91be78b2" xlink:href="cmps-20220930.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_23b7091d-ec72-45bb-8598-ce9c91be78b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cdee1816-5350-4978-9eb0-09c3aa458199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:to="loc_us-gaap_VestingDomain_cdee1816-5350-4978-9eb0-09c3aa458199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:to="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a456021d-1d59-4281-b40c-0fa5eee0deeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a456021d-1d59-4281-b40c-0fa5eee0deeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_72387ad7-7dad-4a96-afcc-9aaed400aaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_72387ad7-7dad-4a96-afcc-9aaed400aaeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7277421a-349d-43a8-91df-632d96bed744_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:to="loc_us-gaap_ClassOfStockDomain_7277421a-349d-43a8-91df-632d96bed744_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:to="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_e47ae2f0-0457-47eb-bb8d-72a0ae567463" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:to="loc_cmps_OrdinarySharesMember_e47ae2f0-0457-47eb-bb8d-72a0ae567463" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationRestrictedShareUnitDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails" xlink:type="extended" id="i40ef9bd45b41450ca7261712195626c1_ShareBasedCompensationRestrictedShareUnitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_601e52be-f1df-4c46-b0ed-52925f503f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_601e52be-f1df-4c46-b0ed-52925f503f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ae6b9350-d9e6-43e8-a8bb-570bdcc9f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ae6b9350-d9e6-43e8-a8bb-570bdcc9f3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906f13b2-7c56-44ed-b777-20758469b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906f13b2-7c56-44ed-b777-20758469b1e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b98a4955-4159-4792-9ecf-51fb338c9379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b98a4955-4159-4792-9ecf-51fb338c9379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_90552da7-a41b-4a9c-a504-8912ab16e5b4" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_90552da7-a41b-4a9c-a504-8912ab16e5b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_8ff58880-448c-42a5-97ab-4fdb0b6d1a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_8ff58880-448c-42a5-97ab-4fdb0b6d1a67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_9dc3d8b0-4f48-4389-8180-ad81f837705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_9dc3d8b0-4f48-4389-8180-ad81f837705c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1cecfe9f-062b-4ea8-8f53-9f5e8e5f9265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1cecfe9f-062b-4ea8-8f53-9f5e8e5f9265" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_61a7520c-ac5c-42fa-9250-9eb8e007d136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_61a7520c-ac5c-42fa-9250-9eb8e007d136" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3b37e7cd-1aa2-4a80-a095-519b91faec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3b37e7cd-1aa2-4a80-a095-519b91faec0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_bc580387-8237-4e0f-a2b2-e058db0b9239" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_bc580387-8237-4e0f-a2b2-e058db0b9239" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:to="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e58cd9a-43f2-4c6d-95ae-c467cc586559_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e58cd9a-43f2-4c6d-95ae-c467cc586559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0afa14-2078-4ff8-8ee0-5c9f1ca3037f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0afa14-2078-4ff8-8ee0-5c9f1ca3037f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SharebasedCompensationShareOptionsDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="extended" id="i8d710b480aae485f9b274e8b2f57980e_SharebasedCompensationShareOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_205980f6-bc4c-45df-8dc5-c6b502da3aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_205980f6-bc4c-45df-8dc5-c6b502da3aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e644050-5785-4e88-8590-60d1aacb83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e644050-5785-4e88-8590-60d1aacb83cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f131797-423a-4ffc-ad26-c984c48286b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f131797-423a-4ffc-ad26-c984c48286b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e75fb121-320f-46d6-b456-521a9b6f8d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e75fb121-320f-46d6-b456-521a9b6f8d77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_169d1061-b438-44bd-a94d-6e9ac6e5e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_03e0ce45-96e0-4296-bd3f-67c2e518c838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_03e0ce45-96e0-4296-bd3f-67c2e518c838" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fc003072-4edd-407b-bce9-4933d8470d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fc003072-4edd-407b-bce9-4933d8470d4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc121d53-0e50-4b97-b0a7-b961e5c83c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc121d53-0e50-4b97-b0a7-b961e5c83c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_79b7b0df-5d16-4994-92b2-96b5c6878b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_79b7b0df-5d16-4994-92b2-96b5c6878b85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24ad4faf-a42b-4afb-8968-c25958aeb23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24ad4faf-a42b-4afb-8968-c25958aeb23b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fede6213-1dc5-40da-878a-1a9ee1523219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fede6213-1dc5-40da-878a-1a9ee1523219" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f62d4aa1-27ed-4a40-bb4e-8aec79df8392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b8ec4d77-25c5-4c10-8882-8bc3be5b4993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b8ec4d77-25c5-4c10-8882-8bc3be5b4993" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1afc7665-d281-48e1-a7a4-c5c922ca30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1afc7665-d281-48e1-a7a4-c5c922ca30fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d6005a6c-25fc-4f1a-b3d5-82cc52eb1a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d6005a6c-25fc-4f1a-b3d5-82cc52eb1a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dea8285-167a-40de-b743-18c6267e5180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dea8285-167a-40de-b743-18c6267e5180" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_b44a8a8b-1c38-4d49-ab42-644282b11158" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_b44a8a8b-1c38-4d49-ab42-644282b11158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0002f142-04ca-442e-8ba7-4e83006f3868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0002f142-04ca-442e-8ba7-4e83006f3868" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0dd015d6-05e2-4740-8372-bba0d1f9929c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0dd015d6-05e2-4740-8372-bba0d1f9929c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27a33388-67f1-43de-b690-06e4a57f7f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27a33388-67f1-43de-b690-06e4a57f7f16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4dddbbe7-bd0a-4868-b7a6-5c41883bbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4dddbbe7-bd0a-4868-b7a6-5c41883bbc7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3ef4529-4ef1-4fb1-b9c2-8ab24a09f893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3ef4529-4ef1-4fb1-b9c2-8ab24a09f893" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_542ff40b-d1a1-453e-8a1a-dbbdd446cac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_542ff40b-d1a1-453e-8a1a-dbbdd446cac6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bb145a3c-9a27-437c-841b-1b1b4576eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bb145a3c-9a27-437c-841b-1b1b4576eee9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:to="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b912d3a-06c4-443e-9517-71ebd80bfb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b912d3a-06c4-443e-9517-71ebd80bfb4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_133ea24b-45e8-4f45-b358-7d22d77bbf75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:to="loc_us-gaap_ClassOfStockDomain_133ea24b-45e8-4f45-b358-7d22d77bbf75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:to="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_cbeed9e9-9722-4cbc-86c8-503504670e0e" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:to="loc_cmps_OrdinarySharesMember_cbeed9e9-9722-4cbc-86c8-503504670e0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="ie0d9284981fb47408dad048efd81b79d_ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_91808cbc-199a-4bd6-b050-3d5f715ae2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_91808cbc-199a-4bd6-b050-3d5f715ae2fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2dc41d3a-c55f-466f-8034-d491509c76db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2dc41d3a-c55f-466f-8034-d491509c76db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e13f32b8-5c16-4edc-a86c-5e147add89a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e13f32b8-5c16-4edc-a86c-5e147add89a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47d4603d-863c-40b4-ab24-42d442830aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47d4603d-863c-40b4-ab24-42d442830aeb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i220f1dc298ff4075ad60f43776e060ec_NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_da923fbc-8b86-4da5-89a6-c9d6095feef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_da923fbc-8b86-4da5-89a6-c9d6095feef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9903eb8a-0b31-4315-b0b7-89c9c16145ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9903eb8a-0b31-4315-b0b7-89c9c16145ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_6fb970c0-aeca-4011-b423-81d5762e7194" xlink:href="cmps-20220930.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_6fb970c0-aeca-4011-b423-81d5762e7194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fe244373-b131-49c7-98c1-c40540391c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fe244373-b131-49c7-98c1-c40540391c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_525fa151-91cb-405d-a719-5b04bf325aff" xlink:href="cmps-20220930.xsd#cmps_ShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_cmps_ShareOptionsMember_525fa151-91cb-405d-a719-5b04bf325aff" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="extended" id="i66406812c65242b7b17c458a1c125e2d_RightofuseofassetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_41638c62-377b-4a78-8737-704faf6f60c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_NetRentableArea_41638c62-377b-4a78-8737-704faf6f60c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod_c035941a-3e90-4ba9-b09c-580874cabf5e" xlink:href="cmps-20220930.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_LeaseCancellationNotificationPeriod_c035941a-3e90-4ba9-b09c-580874cabf5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc0bc798-3c73-4068-ae8f-537c78bc680b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc0bc798-3c73-4068-ae8f-537c78bc680b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AnnualLeasePayment_b1478c9b-089c-479d-a1c0-f4469036043e" xlink:href="cmps-20220930.xsd#cmps_AnnualLeasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_AnnualLeasePayment_b1478c9b-089c-479d-a1c0-f4469036043e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_40794cd2-7db8-4596-a9dc-6f390c084f0b" xlink:href="cmps-20220930.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_RefundableLeaseDepositPayments_40794cd2-7db8-4596-a9dc-6f390c084f0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseRentalRelief_6f6ebb41-b038-4904-9469-013aa64db44d" xlink:href="cmps-20220930.xsd#cmps_LeaseRentalRelief"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_LeaseRentalRelief_6f6ebb41-b038-4904-9469-013aa64db44d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_7580db36-e25e-418d-bd3b-5db876167bbb" xlink:href="cmps-20220930.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_7580db36-e25e-418d-bd3b-5db876167bbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_e71f0d11-55ef-4c4f-a758-7c1e915db867" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_e71f0d11-55ef-4c4f-a758-7c1e915db867" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRent_fabbd3d1-61e4-49e0-bb8c-33b39dccbbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_AdvanceRent_fabbd3d1-61e4-49e0-bb8c-33b39dccbbef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment_a06bc7f3-5bd6-4be4-a3da-5afd6edd60fc" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeaseAnnualPayment_a06bc7f3-5bd6-4be4-a3da-5afd6edd60fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:to="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56548ec5-6a86-4688-81b9-5909a9a2a705_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56548ec5-6a86-4688-81b9-5909a9a2a705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EastbourneTerraceLondonUKMember_ad9ecbb7-371c-4738-92b8-49217cf53c5a" xlink:href="cmps-20220930.xsd#cmps_EastbourneTerraceLondonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_EastbourneTerraceLondonUKMember_ad9ecbb7-371c-4738-92b8-49217cf53c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NewYorkNYMember_d60c3f1f-49d9-4947-a0b1-fe069f301af3" xlink:href="cmps-20220930.xsd#cmps_NewYorkNYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_NewYorkNYMember_d60c3f1f-49d9-4947-a0b1-fe069f301af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember_67b2bb27-b6e5-467b-908c-40abcd200e3e" xlink:href="cmps-20220930.xsd#cmps_SohoLondonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_SohoLondonUKMember_67b2bb27-b6e5-467b-908c-40abcd200e3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SanFranciscoCAMember_5e53bb71-68ce-4bfc-b84d-fa3be736250b" xlink:href="cmps-20220930.xsd#cmps_SanFranciscoCAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_SanFranciscoCAMember_5e53bb71-68ce-4bfc-b84d-fa3be736250b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember_73d274f2-f550-474a-bf45-526dea58b442" xlink:href="cmps-20220930.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_DenmarkHillLondonUKMember_73d274f2-f550-474a-bf45-526dea58b442" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember_cadd73d1-152c-48fb-8c00-e11856516619" xlink:href="cmps-20220930.xsd#cmps_WeWorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_WeWorkMember_cadd73d1-152c-48fb-8c00-e11856516619" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cmps-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_6d915264-619f-492e-81b7-41001e61eb19_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in pound sterling per share)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_eb3c2d35-0a45-4c53-ac7b-fba0e514cb21_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_78151877-575e-4a43-85d1-350b4177559a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ae2b6777-c0d8-4b19-bece-91f569a3e4a7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b9eec472-9bb9-41f3-9a06-ba199a52e46c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_4fcabe28-e925-4d72-9ab8-1dfae5caeeae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2f86095f-9649-4f08-9046-eb0adbffa164_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_600040fc-0760-4c3e-8d13-dfedfd807a3e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_e5699810-4b1a-4180-84d3-2f59ffae3c8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a22d7e09-438d-4548-bd2c-a679dd270cb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_8aa73e40-48ab-48c9-809f-99ad3c8a8e5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INCOME, NET:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_343414c9-fb78-4d8b-ab33-dbf47990a649_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_aa76552e-6c0e-445a-a45d-2c7866b74b2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_58d61f80-7547-4ea0-9821-a1c02580ae35_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd1304ac-7daf-4329-b3d8-8a28797eb5eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4a90c8c9-f50f-45fc-93ad-f868215ec7a0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3d0d50ee-d3b9-4c2a-ad3c-905462fe4f9e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3dd61533-884d-4457-8c6d-7bb32bced5cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_394f0416-bba6-46c0-a805-3106658b1770_terseLabel_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary share conversion ratio</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_label_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_documentation_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:href="cmps-20220930.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:to="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_6d8cfaab-6422-4672-b58a-775d72e3e6f5_terseLabel_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:href="cmps-20220930.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:to="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_0d9b373e-9883-41e4-ac9f-d68f74a00e1d_terseLabel_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember" xlink:href="cmps-20220930.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2017EquityIncentivePlanMember" xlink:to="lab_cmps_A2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cfa455ed-31d0-41b7-98ac-a977ee9a4400_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_269711af-e54a-4acc-8a03-f8bcca92d7cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0af2e482-9133-44c6-a4a5-ffa617c491df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_cb4d1396-dfcf-4aea-a9d9-cbcd6bafa18a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_237e6591-db1d-4745-9b44-fba99667b49f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_984e0404-9409-46bb-b80d-e8fc4c96fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_60b656e3-6135-4db0-9d57-c56a801722b1_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aid claimable</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Total Aid Claimable</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Total Aid Claimable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_ffe0f947-66d7-4f2c-8fb6-6f60a79d8993_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance premium</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_97f90384-cacd-4319-befe-0beea21f0c43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_277c99f6-74a2-49c9-861f-88d87f579cf2_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ae0976dc-f3f8-4319-baab-9a49fff6125d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting percentage (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cb42ae71-0595-49eb-bce2-d5c40c8d1baa_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e29ed9d8-c26f-4c21-882e-1f17a3ade73e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c5c61c26-bd5c-4d94-baa1-8bd0944ded48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1e27a07e-43b2-44d3-84e0-d27b80c120a1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e2796261-6a25-4a20-aec4-f6a67bc7b5da_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7a0eebf-726f-47c1-adb4-8944a81a074e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_424df56e-fd3e-4065-a385-8cb4c642e89e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0b5680fe-52e7-48d4-9d37-d440d9061977_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ae7b7d6f-6328-4a94-833d-88ce782c2e5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4ae6b364-b334-4b6a-a44a-d93a5f465333_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_962ebe69-4d5d-4409-8739-42fcdb0d3686_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Contract Costs, Prepayments and Accruals</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1eed3996-6c56-43f8-9669-8886391f8b88_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_360f53b1-f71a-4646-993c-237f86db4f8c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f72b09d-6c5c-4389-9be8-a497ffa88941_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cb8910f9-d615-4348-9d84-b627287023ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SanFranciscoCAMember_78f675e8-9fb1-433d-b38e-f02716d2cfaa_terseLabel_en-US" xlink:label="lab_cmps_SanFranciscoCAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco, CA</link:label>
    <link:label id="lab_cmps_SanFranciscoCAMember_label_en-US" xlink:label="lab_cmps_SanFranciscoCAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco, CA [Member]</link:label>
    <link:label id="lab_cmps_SanFranciscoCAMember_documentation_en-US" xlink:label="lab_cmps_SanFranciscoCAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco, CA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SanFranciscoCAMember" xlink:href="cmps-20220930.xsd#cmps_SanFranciscoCAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SanFranciscoCAMember" xlink:to="lab_cmps_SanFranciscoCAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_aa9b9128-8ab5-4f0a-9226-5a45b89497b8_terseLabel_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted share units</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_label_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Share Units [Member]</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Share Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:href="cmps-20220930.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:to="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_84554804-74b5-4650-a29b-e32fed9c13d3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8d0f890f-eca9-4a6d-ad6a-06321aa4bbf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_87049b98-9db0-4e5b-81ee-d5b5bf983820_terseLabel_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_label_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME) [Member]</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_documentation_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:to="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72268bf1-10db-44c0-baeb-68ea7bd48c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2020AwardMember_05d94a97-6bb5-450b-b7e4-91b69885118b_terseLabel_en-US" xlink:label="lab_cmps_A2020AwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Award</link:label>
    <link:label id="lab_cmps_A2020AwardMember_label_en-US" xlink:label="lab_cmps_A2020AwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Award [Member]</link:label>
    <link:label id="lab_cmps_A2020AwardMember_documentation_en-US" xlink:label="lab_cmps_A2020AwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020AwardMember" xlink:href="cmps-20220930.xsd#cmps_A2020AwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2020AwardMember" xlink:to="lab_cmps_A2020AwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRent_36ead220-811d-4d71-b14f-0344b7e885e8_terseLabel_en-US" xlink:label="lab_us-gaap_AdvanceRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance rent upon lease execution</link:label>
    <link:label id="lab_us-gaap_AdvanceRent_label_en-US" xlink:label="lab_us-gaap_AdvanceRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRent" xlink:to="lab_us-gaap_AdvanceRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808697cf-8bdd-4589-a1fa-9bcb02c0ef35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LeaseRentalRelief_2a4b732a-958a-434c-849f-5d108b887355_terseLabel_en-US" xlink:label="lab_cmps_LeaseRentalRelief" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease rental relief</link:label>
    <link:label id="lab_cmps_LeaseRentalRelief_label_en-US" xlink:label="lab_cmps_LeaseRentalRelief" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Rental Relief</link:label>
    <link:label id="lab_cmps_LeaseRentalRelief_documentation_en-US" xlink:label="lab_cmps_LeaseRentalRelief" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Rental Relief</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseRentalRelief" xlink:href="cmps-20220930.xsd#cmps_LeaseRentalRelief"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LeaseRentalRelief" xlink:to="lab_cmps_LeaseRentalRelief" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5711d3c1-adeb-437a-9d5f-4c045ce6e970_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2761fe0c-43cb-4e7a-9fc2-b4329020588f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d297dfc-bcd0-4808-8460-160fe8d2944a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fa1833dc-136e-4dd5-9b1d-3734c3e5d819_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7cd49b42-06ba-42bd-8c90-12dc16364504_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_346aebb2-17b6-43f5-9358-afdb1be4d2ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_31a70dae-37b8-4106-ab36-a4290c399bfc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cf368c0e-cf1b-4d01-a5b1-99b6d83d8435_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1549bb74-4ce4-4384-a23d-dfc674a492fb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_2888f087-f61b-43b0-b021-a1c0a5b13e75_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, noncancelable term</link:label>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_label_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Noncancelable Term</link:label>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_documentation_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Noncancelable Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm" xlink:href="cmps-20220930.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeasesNoncancelableTerm" xlink:to="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf66e78-656a-4958-a104-cb1f2ceec439_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_d24b8e87-e3e3-420e-a302-ff20a5308c83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_1f362c1c-eb0c-484e-b077-70e50ea43258_terseLabel_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashFlowLesseeAbstract" xlink:href="cmps-20220930.xsd#cmps_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_CashFlowLesseeAbstract" xlink:to="lab_cmps_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_183b29a4-014b-4049-bb9a-503010746831_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OrdinarySharesMember_8810e7b9-6100-4cdc-9e2a-a50915c18630_terseLabel_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_label_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_documentation_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OrdinarySharesMember" xlink:to="lab_cmps_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_85b273f9-43a2-4017-b232-752d42443c3f_terseLabel_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_label_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan [Member]</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_documentation_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember" xlink:href="cmps-20220930.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2020ShareOptionPlanMember" xlink:to="lab_cmps_A2020ShareOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4d9caf15-68e0-4c0b-9d15-e37223bab7c0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e523bff8-cc1f-4f9b-b24e-61991a667550_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0cecbbc9-2dee-4a0f-956b-cd706d236b48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_bd58d7c5-c083-422f-9506-f67abe33bad2_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan, offering period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8786be10-fa9a-47cb-8cd5-bbd5e857e736_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1531038d-c932-4498-9392-f3ed97536f90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_d96cc72c-dfa5-4fc1-8db7-4fe382ea83e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_e7971659-d74b-433d-8da6-109b1fcb80a9_terseLabel_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_label_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_documentation_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:href="cmps-20220930.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:to="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1b82bd73-40c0-422f-a014-b13eb94af769_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_9ab3e869-f360-4a6d-8798-8fed8ae1b518_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems" xlink:to="lab_us-gaap_ConversionOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_85226815-b0e1-45e8-8a69-5035dde28716_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_3743209a-cb7f-497b-94e6-6745f3b9a98b_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, annual payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_label_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_documentation_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeaseAnnualPayment" xlink:to="lab_cmps_OperatingLeaseAnnualPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_c84db42b-8e58-4a33-a87e-43593c5f3511_terseLabel_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK</link:label>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_label_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK [Member]</link:label>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_documentation_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember" xlink:href="cmps-20220930.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DenmarkHillLondonUKMember" xlink:to="lab_cmps_DenmarkHillLondonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3192e65e-f730-4cdc-945d-53cf47049c20_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_06c95f5c-2aa9-49ef-b4f6-91b4d338e856_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_42191adb-dd13-4314-a053-2ea68b27c4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_92b65b6c-1159-439f-8190-cbdf96d05bad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4adc1ccb-4a9b-45bf-a0c4-c81e45f87ba8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b42bd51-cf2b-464d-9c05-bf63e4ccb567_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44ada5f8-22fa-44cd-bbc1-2b0fd50e434e_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13d57776-d9ee-49a3-9f46-b29b248228cf_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a8c5009e-270d-4daf-b046-664b596a355c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9039a7b2-54d9-4f96-ba74-3e6988fd7038_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_25d4bfd2-d3a4-4747-9a94-29164440887d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_96621142-0e17-457f-ba79-588d25dd1aec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be2f602e-ece5-4889-a6e1-eda1d98422e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_07c72902-17ed-4915-b6d9-286d3ddf5381_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, monthly payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_label_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_documentation_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeaseMonthlyPayment" xlink:to="lab_cmps_OperatingLeaseMonthlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d53cdc87-0f0b-48ce-826d-2de308a76aa0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b0a708c-531c-4eb7-8f7b-d7a870644763_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d9f33713-5482-4dc8-be7b-e4e6245246d4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e5f1ee7d-2c51-4206-bd6e-194c3856fbdb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6d681ffc-13ec-459a-8188-8fa50548bf1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NewYorkNYMember_c9fdb707-f1c8-4b8f-8c3a-da1a515a91f2_terseLabel_en-US" xlink:label="lab_cmps_NewYorkNYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York, NY</link:label>
    <link:label id="lab_cmps_NewYorkNYMember_label_en-US" xlink:label="lab_cmps_NewYorkNYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York, NY [Member]</link:label>
    <link:label id="lab_cmps_NewYorkNYMember_documentation_en-US" xlink:label="lab_cmps_NewYorkNYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York, NY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NewYorkNYMember" xlink:href="cmps-20220930.xsd#cmps_NewYorkNYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NewYorkNYMember" xlink:to="lab_cmps_NewYorkNYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a734d1e2-1489-4707-9bea-eec211323ff4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_79b8c20c-9e15-46c5-a10e-d7f47875b905_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_0a772028-1cc8-4775-8083-5a4be7b69ee2_terseLabel_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred issuance costs included in accrued expenses</link:label>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_label_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accrued Expenses</link:label>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_documentation_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:href="cmps-20220930.xsd#cmps_DeferredOfferingCostsIncludedInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:to="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1140f4b5-a924-4b6f-a641-1d18091e194c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1156a40a-43c6-43d6-8201-ecb221552589_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2fbaa724-1ddf-4b18-ba20-bf75a54eb895_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_00f9f5d4-d416-442b-9915-0fe2cc26b496_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14d74a61-5cd9-43fb-90b8-7307a9ad9c0a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_980e786c-7fdf-4ba8-ac8f-57d0cce3fbc7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5cc1fe8a-90cf-41c0-b839-79904a170472_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_637b1d58-ad43-4c7a-b153-0ac574f742ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in GBP per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7bb38691-c0b1-43f2-855d-c9be26b703a0_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1dacd434-76e0-4323-b684-bd831fa8e570_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_97a65a3b-f12e-4143-8101-544b0528b0dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_be587671-618f-4813-aa26-f921b359b6f6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6f1aec2d-bad3-4567-bf77-414f4753ecff_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_bf384673-f565-41f6-8d36-0f165c76f099_terseLabel_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cancellation notification period (in days)</link:label>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_label_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cancellation Notification Period</link:label>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_documentation_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cancellation Notification Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod" xlink:href="cmps-20220930.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LeaseCancellationNotificationPeriod" xlink:to="lab_cmps_LeaseCancellationNotificationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_116b0679-a50c-4cc0-b6ca-31bc90cf63af_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_bdf8b7cf-38f0-4ebc-b206-4e4e56870281_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units for which no shares were issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1da2eb5d-2a6d-40d4-aa4c-d81157a88343_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8bcff287-24d0-4e6b-9931-495e8713ce4b_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_fbeb0196-4f50-4d75-af50-e1aac43fb8d5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7b096bbd-4141-4c57-bf46-6cafc97240bf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ca48993-f08d-4d49-ba6e-6dde9ddddcdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SohoLondonUKMember_c2dcf0e5-6181-45f7-987e-ab15b7b31f64_terseLabel_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK</link:label>
    <link:label id="lab_cmps_SohoLondonUKMember_label_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK [Member]</link:label>
    <link:label id="lab_cmps_SohoLondonUKMember_documentation_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember" xlink:href="cmps-20220930.xsd#cmps_SohoLondonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SohoLondonUKMember" xlink:to="lab_cmps_SohoLondonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_660d4c0e-fda4-4147-bc14-ceec3d27af9b_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT recoverable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_49f6e5d3-0a41-4f27-8bb0-2ed4b6821e1b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7bf4fc08-18e6-424b-9e35-860e930e07fc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_GrantDateJune302020Member_0940d55a-790e-45d4-ba07-5c405afd2cee_terseLabel_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_label_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_documentation_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member" xlink:href="cmps-20220930.xsd#cmps_GrantDateJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_GrantDateJune302020Member" xlink:to="lab_cmps_GrantDateJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a3a6bf77-e283-443d-8815-4d848dd2740f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eab0a41b-fce8-4530-95b4-4d19dabd6ded_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ab57a19a-e424-46f4-96d2-32c9ae9d28f0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1aa69d46-2429-44a8-a815-335d509bc1f5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5a3ed496-9c16-40ac-ba7d-2ba4a1d59cab_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9a6a8e17-9d82-457b-9d23-28d3e3fad788_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c0907947-c767-4cf2-b668-dac285532df7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_8a89e856-7917-469b-88bc-2e716a3c00bb_negatedTerseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_5255a74c-4112-42ae-ad37-a786e1e5adab_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_cad608da-b833-483f-84d4-a2127aa6bff6_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6d9c4d71-1dcd-43b7-97ec-cf1eb8a3fef2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_074d1ee6-40a1-4170-a8c5-d8f27f35996b_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition one</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7ef6bb19-9b7e-441d-842c-ba67eeb59fbf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2e463fcd-b9f9-46ca-a88f-39885d0f09ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DeferredSharesMember_0ca1b38a-fd6f-41fd-a26b-96ead7a4a7cb_terseLabel_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEFERRED SHARES</link:label>
    <link:label id="lab_cmps_DeferredSharesMember_label_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_cmps_DeferredSharesMember_documentation_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DeferredSharesMember" xlink:to="lab_cmps_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_8e04da66-c992-45c6-9154-f7c14d074574_terseLabel_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_label_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award [Member]</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_documentation_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:href="cmps-20220930.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:to="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_5519388b-0c1f-44c6-8732-883724ee3cd0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_WeWorkMember_0544731e-6cd3-4c42-a495-f114d2cdc398_terseLabel_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork</link:label>
    <link:label id="lab_cmps_WeWorkMember_label_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork [Member]</link:label>
    <link:label id="lab_cmps_WeWorkMember_documentation_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember" xlink:href="cmps-20220930.xsd#cmps_WeWorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_WeWorkMember" xlink:to="lab_cmps_WeWorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e5af2486-617f-4a7c-a5dd-6f91d5c00d0c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f1d13a3b-eaba-41fe-bda6-98f03af3657f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_9eb9b928-7943-4943-9d5f-cb3a29451d1b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e39bf1dc-9e0a-4510-896c-c075b5165710_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c1770867-e362-44f7-bca9-e67f985bde33_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Costs Included in Operating Expenses Related To Right of Use Assets</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_EastbourneTerraceLondonUKMember_536bff3b-6179-4fbf-8f84-231e447396cb_terseLabel_en-US" xlink:label="lab_cmps_EastbourneTerraceLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eastbourne Terrace, London, UK</link:label>
    <link:label id="lab_cmps_EastbourneTerraceLondonUKMember_label_en-US" xlink:label="lab_cmps_EastbourneTerraceLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eastbourne Terrace, London, UK [Member]</link:label>
    <link:label id="lab_cmps_EastbourneTerraceLondonUKMember_documentation_en-US" xlink:label="lab_cmps_EastbourneTerraceLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eastbourne Terrace, London, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EastbourneTerraceLondonUKMember" xlink:href="cmps-20220930.xsd#cmps_EastbourneTerraceLondonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_EastbourneTerraceLondonUKMember" xlink:to="lab_cmps_EastbourneTerraceLondonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20c53918-ff78-48db-bc02-8da23ffad438_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f7de846e-11a0-4489-b7cb-6aeb682b5071_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NonEmployeeMember_cd2ae905-9c2d-428e-b02e-3d99f8fc6d7a_terseLabel_en-US" xlink:label="lab_cmps_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee</link:label>
    <link:label id="lab_cmps_NonEmployeeMember_label_en-US" xlink:label="lab_cmps_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee [Member]</link:label>
    <link:label id="lab_cmps_NonEmployeeMember_documentation_en-US" xlink:label="lab_cmps_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonEmployeeMember" xlink:href="cmps-20220930.xsd#cmps_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NonEmployeeMember" xlink:to="lab_cmps_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_394d1629-e05f-4af7-8a08-d5fc9fc3c48d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Share Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e1a8ef2d-6919-44d0-bed0-b6cb5a661e74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d6858768-828b-4d5e-bf90-bd7c6fd526fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0e887e5e-aa17-4351-b8dd-c144399be3c8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockTable_14710b19-27eb-4d59-84a6-afef68732614_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable" xlink:to="lab_us-gaap_ConversionOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f7ccaa59-8a3c-4131-9a85-1f75a691f8e1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_26838cbe-0671-46f8-973e-2e4d113fa294_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a48e9da9-5b8b-4543-bbfe-044a62279932_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_9b9f1211-676e-4ec3-99f2-6f3433ce5bde_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_31d018c0-02e2-4086-996e-575dc36b14e2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption_e1f890be-19d3-4a2d-b599-512b76969c6d_terseLabel_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption_label_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adioption</link:label>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption_documentation_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adioption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:href="cmps-20220930.xsd#cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:to="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d0edb884-c5ac-4c74-b95a-045058db5e77_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cd22a5d9-8388-4674-92e8-54e6f0b0a5eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_56081ec9-1d8c-4b90-91d5-90a1a5c5a6e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_94473129-8a0a-4082-b9dc-75894a2df5d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1d87b5d6-29a7-411e-b9dc-95343de6fd3f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2a380289-2635-43ee-9a39-6060c860254a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_20d8f233-7824-48ea-9cc4-99f1d1088307_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d26ece71-bfc0-4ab1-927d-2e9e2bc1a5c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ef5a4554-7f13-40eb-9d4b-556459560a31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareOptionsMember_8a18aeb7-94da-41d8-bfa3-82187fe0e827_terseLabel_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_label_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options [Member]</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_documentation_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember" xlink:href="cmps-20220930.xsd#cmps_ShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareOptionsMember" xlink:to="lab_cmps_ShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9e927af2-70bf-49ae-8ceb-cd32630d1a17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e0b6c0b3-fd02-4ed9-bdb6-96419ad42f84_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c62043b0-1385-4267-8f11-c422257a2130_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_68ba3b14-ef19-4702-bafa-97eb2e019d51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent" xlink:to="lab_us-gaap_DeferredCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ea7bf886-5537-4466-8c94-a836c581360c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_48917cac-9ca9-46b4-966c-a3e2a82d72b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_44fef95a-1f00-4293-91de-69b512270059_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_24ab1810-842d-4996-8650-56c55b0318dd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9f3c5b10-8f5a-41b1-8152-934a69d371c6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a0b8e6ba-2dc7-4d7d-949d-80f466303b13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_554771f5-85be-4104-81f4-d285cadec0d4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS FROM OPERATIONS:</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_bbd8160e-5780-4a52-9715-bb1828f01beb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f524b3b5-7602-4f5c-be97-6f1b0dab6820_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_21f3e05f-7857-4320-bf13-412057c602cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_99d7e429-b933-4dfa-af0d-8d181e9e8bfd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_e3dd5bb5-550e-4a03-b6f4-dc47a2cb734c_terseLabel_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable lease deposit</link:label>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_label_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Lease Deposit, Payments</link:label>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_documentation_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Lease Deposit, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments" xlink:href="cmps-20220930.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_RefundableLeaseDepositPayments" xlink:to="lab_cmps_RefundableLeaseDepositPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_da8afe3b-5158-4cbf-bc9f-ea7eeb0c4cb9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income tax</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a82c9dfe-67fa-463c-9837-8b81c982c62f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6e6a55ca-3993-411a-88a3-4a357fc0ccc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_5bf8daef-2473-4f79-9eeb-dba4a5b2462b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c3ae7073-aa03-4aff-9572-9e35c2f68640_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfGeographicRegions_cc62ddb8-dbf1-4eff-9ed4-4d4dd06f4fa2_terseLabel_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of geographic regions</link:label>
    <link:label id="lab_cmps_NumberOfGeographicRegions_label_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Regions</link:label>
    <link:label id="lab_cmps_NumberOfGeographicRegions_documentation_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Regions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions" xlink:href="cmps-20220930.xsd#cmps_NumberOfGeographicRegions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfGeographicRegions" xlink:to="lab_cmps_NumberOfGeographicRegions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6e188584-e35c-4360-bc30-44ec86d117f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_3ab7196b-54c3-40df-bc87-7f6af95e5553_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_25bfa6f1-7ac8-4094-9e41-fef5416e0bb9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_24fd305e-a383-4246-b90f-d906bd8bb7f6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f36fb43f-6265-4d66-bb89-cde72111edae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7682b7bd-66ca-48a3-9a49-876955b0fd2d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_437c9565-d38c-4d07-8a09-53e00da0aef8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_965b9ab5-8409-4c5e-b4cd-e5601263a6a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_9c0c022c-3264-4f45-96d3-4d6aea00d689_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c16b7fec-dbea-4969-8ec1-c576e6040409_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f49bd0b1-cbdb-438f-b762-b5e899a465c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d62217ec-d466-4bf3-8256-48186e827569_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_1dc994da-48d1-4aa7-a926-ad133d35ecb7_terseLabel_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options were received and recorded in other current assets</link:label>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_label_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised, Not Received</link:label>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_documentation_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised, Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:href="cmps-20220930.xsd#cmps_ProceedsFromStockOptionsExercisedNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:to="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_09a11b90-b79a-4421-b5a2-4c833b5fd5e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary and deferred shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f865b8c4-37d5-4022-982d-6eaad205ffe1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6b6e1823-6f25-4e3f-b33a-8a53181ecb95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_60acb5ba-60cd-4032-a1b2-9b90ee5321cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a447fa95-fb4a-4df5-9fc3-dd44ac2a1aeb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2aaa53fb-b3f0-4c2b-aef7-802a6c8e4483_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05a7e78b-13fb-41a3-b05a-9cab37011189_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5e82ffc4-0f68-4b61-9aee-7b7c84722d0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_531e7d01-a579-4041-826c-ed385c9566d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_120bd388-28f7-4fe2-9b5b-2eeba5978a6a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24de9ebe-0920-4e7d-a622-acd1315841bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6ba5c2ae-8c42-416f-a74a-208c546b731d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2ca06a3e-4ac9-4416-850a-d7afddb02a7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_bbf6de12-1b22-40bb-a86d-d359a2bfdfa1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_ded9d1bb-95da-4f22-b2da-588042b6cdbf_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition three</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c80d13a8-d371-4952-bc7c-04f691026fae_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2886646a-eb15-4e21-a296-6f71a390e357_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8d6f5cf6-7ee2-496f-adbb-0299898785ec_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cb8285dc-38d9-4451-af62-68cf3234cc5b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a58d99ec-be89-464e-93c7-d706de2800de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_46d98795-83f3-4bdb-84c6-e57a4a6d5bf0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_716834bb-b903-47e3-ba80-684eb4db1e2a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_91cf8b08-e324-4e6a-83f7-9425c5863432_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UK R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_023ff13a-b528-43a0-ad33-c3a9db116ab0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_05901641-dbed-4043-95c4-a77e2acb5911_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3249f10d-8686-4b87-b9bd-17c3a3705f0f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d5800b40-fd3e-4cbd-b68c-e0074528a00e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5285920-b344-4efd-ba5e-0ae95a547ab4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bf6e9669-609a-4985-a73a-62834b5f70df_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod_27efaaf5-fcc9-482a-ac18-3a323429ede0_terseLabel_en-US" xlink:label="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared or paid</link:label>
    <link:label id="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod_label_en-US" xlink:label="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Dividend Declared Or Paid During Period</link:label>
    <link:label id="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod_documentation_en-US" xlink:label="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Dividend Declared Or Paid During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:href="cmps-20220930.xsd#cmps_CashDividendDeclaredOrPaidDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:to="lab_cmps_CashDividendDeclaredOrPaidDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_198f507a-ea0e-4c47-8e5b-1ff0d6114ee3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7f86149e-c366-4852-a7dc-d9a98381ffd1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fd6daa03-d0ed-4c81-850b-04cbd71b0bac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4bf1ff3e-3a50-4281-9302-e52c0500c41f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ef650d73-99ca-4cb3-9917-26dc949581ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_9165a15d-06ff-4aa3-8e02-c6a10a6ed426_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage amount closing price is higher than listing price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c8186fa4-dfa7-47d8-878b-3b96ecdbced0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_31f14d4a-ad61-4c1f-b6a5-2e018ef54206_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4c30bc9f-97b9-4e70-8e07-9197e4aea355_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_780eaa47-0ef6-4fbe-aac3-f24857edc4a5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8939af52-ac3d-4cf7-9100-275592f47f4f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_50235739-c093-484d-804b-eb5587091dd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8f2f3d1e-1a5d-4a76-9016-c124fca07c54_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9827191b-43be-4225-a3ce-456f94f03ca0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_03b7aae1-4113-4cee-858e-f7d8ae08e611_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_603140a3-bf07-44ef-b862-a848ba8d2c80_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested restricted share units, for which shares are not in issue</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_07334b54-096a-46ab-9b4f-931ecbfeee9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_7b996620-d11b-4326-ac02-9fa0bb7a5025_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net rentable area</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3095373f-2875-4a74-81af-3173ad113b5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_dfb80bcd-bb20-4282-8406-8384f7a085aa_terseLabel_en-US" xlink:label="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="cmps-20220930.xsd#cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="lab_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_c065dc81-768e-414e-8b61-57cdbaa6702d_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e234b643-9cf8-4391-8bd1-9f16cf065801_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3de65873-1b8e-4275-b492-ee6d25e29119_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7f55d18c-1a77-49fd-8ac2-ab9747f14ceb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AnnualLeasePayment_2983f580-53ff-4b57-8ae4-94bbe9052583_terseLabel_en-US" xlink:label="lab_cmps_AnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual lease payment</link:label>
    <link:label id="lab_cmps_AnnualLeasePayment_label_en-US" xlink:label="lab_cmps_AnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Lease Payment</link:label>
    <link:label id="lab_cmps_AnnualLeasePayment_documentation_en-US" xlink:label="lab_cmps_AnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Lease Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AnnualLeasePayment" xlink:href="cmps-20220930.xsd#cmps_AnnualLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AnnualLeasePayment" xlink:to="lab_cmps_AnnualLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_90e0effc-a88c-4a2c-91c7-ab4091960744_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_e5dc688b-8106-47ba-89bc-b0fc57198f00_terseLabel_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of stock that may be sold</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_label_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_documentation_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:href="cmps-20220930.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:to="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f2c5dead-6d09-469d-bd56-b6b10d3a3386_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss)/income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_904b92f7-442f-4a36-8264-09ff4325d1c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2969b17e-c8e4-4ba2-9c0f-fda97546b8dc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8787c5ca-8639-47d4-95a5-03e3b25d9370_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a229940c-843d-4d6c-bc7b-90a6c8bdc4ac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d137a67e-4b82-4e7a-85a5-d9b1aec3925a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_08ecba43-2f29-41b0-8f64-9f60b1a93e89_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bb8ae0e0-c8f6-448b-8d10-4a50a8d19314_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7cb90982-8a28-4f8e-ae1d-1b36f16bd3d7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b466a895-dd32-42ee-8ed6-0a396f0e61fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b67c1502-b387-4b0f-92fb-511722419e02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_bf7e5335-cf82-49ca-a2ac-d5f4d437293c_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_89d78b3b-8ce0-46b2-aaec-35e05e645268_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_e3b770fd-165b-4f0c-a580-1780121fabcc_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition two</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_3624657a-7f8a-4730-a3b1-701e9c8cbfd2_terseLabel_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense</link:label>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="cmps-20220930.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a7142d-fc25-41a1-ae3b-5ee1870da2ef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_316e559b-c700-46b4-8a75-d85e53fc3b84_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_06c5f966-f570-44d1-856d-9583c8bed72b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_424878b9-fb1d-4155-aa91-55b9ee859e91_terseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units vested, not settled (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested Not Settled</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested Not Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2936e5f9-22ad-4fe6-9bf3-fa3dc96e4cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_45f3e0db-3207-4180-a543-220c23a096fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_02f4a8ee-5f9d-4b0d-a49f-b1e009648c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_1cb2bdc5-d1c4-4aac-a151-c9932f218748_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_9d5829bf-e23f-42df-b941-61f5d3305e3a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b93ec89-6e53-4805-827f-0a03f54344fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8904f154-0129-452c-9102-b25f1a4075fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_517e7604-afb0-4480-bbd9-23ab86f4b159_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_ef480faf-235b-49a5-85a2-97d12ad6214f_terseLabel_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research and Development Tax Credit Regime</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_label_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime [Member]</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_documentation_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:to="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e7add8d-5c0c-4fa5-b274-c38446f912b7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dfbbaaab-7337-4844-b23a-46f3d7fe9dc7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4b363011-635a-43f6-ac9b-434fa76ea2ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_6f15f10b-c37e-4b59-9760-6422bcbaf150_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0c4e5222-7ae5-4957-ae57-996b5406127a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9de5958c-47e0-47c7-b131-4fc731567f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9166df27-98fa-44a4-acd6-7fbea149b22f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b76b8ec-666e-4008-967a-49822608d5fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f998d39f-6d3d-4b14-b8b6-00f688f9f831_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_be7510e7-44fe-439a-a107-504d2fc71a43_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13404ec7-f04d-42df-82c0-6ecc7f4ddc16_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb050790-b3c5-42b8-a2a7-72d27da408bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e9c8787f-88d2-42e7-b1e1-9694d9775848_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f2cacdfc-3f48-4644-a2e7-3f1f0cee3427_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_VariableLeaseCostLeaseIncentiveReceived_9ffd3a94-e448-4c20-83d4-4da567725031_negatedTerseLabel_en-US" xlink:label="lab_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_cmps_VariableLeaseCostLeaseIncentiveReceived_label_en-US" xlink:label="lab_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease Cost, Lease Incentive Received</link:label>
    <link:label id="lab_cmps_VariableLeaseCostLeaseIncentiveReceived_documentation_en-US" xlink:label="lab_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease Cost, Lease Incentive Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:href="cmps-20220930.xsd#cmps_VariableLeaseCostLeaseIncentiveReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:to="lab_cmps_VariableLeaseCostLeaseIncentiveReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e16bec9-9188-4f2d-84a7-1f13818cae46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_9787b9ef-a0e9-4c2f-88d6-1853a130d170_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_05ad2a3c-7091-40f1-8355-13bd5a3140f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_408ba349-ef9b-4af0-a060-761e03ca5741_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3415d693-ce02-4986-8342-eafff7311d12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_069f7988-56af-4d3d-b350-65ad71319081_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred and prepaid tax assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1c281333-6ab5-4cc1-a639-c310e1c1c23f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b9c81b5a-6a5d-4169-b502-03ed2035ab8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_85e5b8a8-6a55-4c53-9df5-c7fc79cb0f2b_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash rebate percent (in percent)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Percent</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_7ae51ef4-f339-432b-a398-05f8c96d7be4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_269e8c7d-3938-446c-8670-24802a621f24_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8f63292b-959d-4091-b04e-a9864c609978_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash gain on foreign currency remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_17efa347-9f0e-4cd7-ad05-40524f30a3dd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_282ddf45-2256-420a-bf74-6cf78d934572_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95ecbc3c-7348-4700-a831-633097f48da9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e3a2aa58-7f13-4001-9180-f64edb9b96f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_b072371d-e3a9-4e83-8cb2-b489d8808d1f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c0d4e907-9b15-4f69-b952-0ff03da0a16d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8649d56e-956c-462b-af47-3913594d606b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_9b704029-d342-4b6d-94b0-ab18fafedb41_terseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued and vested in period (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Issued And Vested In Period</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Issued And Vested In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cebc4e9e-85c1-4af4-9627-3a352ff36945_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6a70d01b-0902-4128-b8be-690e490887bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_00d924cf-99ac-450d-a1ee-f7a2cdee0f44_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage in Delix Therapeutics, Inc (in percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b713957f-5933-4725-8fe6-a516fe65e938_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_1887a813-953a-4c70-96de-0d54e436713d_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in years)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_7490039c-e877-4a47-9962-87ae142bbef0_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum increase in shares available for issuance (in shares)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_13546abf-5e8e-468b-9caf-0875fe464a65_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_da435e16-5a16-4659-b0c0-719919104c56_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_93450265-64e1-4240-87fb-47f23cda0ac0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcee5b7a-4a20-4b0c-ab02-f38bcd42a553_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DelixTherapeuticsIncMember_96712f61-7245-4c11-85ea-eba9c5c835fa_terseLabel_en-US" xlink:label="lab_cmps_DelixTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delix Therapeutics, Inc.</link:label>
    <link:label id="lab_cmps_DelixTherapeuticsIncMember_label_en-US" xlink:label="lab_cmps_DelixTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delix Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_cmps_DelixTherapeuticsIncMember_documentation_en-US" xlink:label="lab_cmps_DelixTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delix Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DelixTherapeuticsIncMember" xlink:href="cmps-20220930.xsd#cmps_DelixTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DelixTherapeuticsIncMember" xlink:to="lab_cmps_DelixTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_21c213d3-41fc-42ca-b249-f4bde96a3e33_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Due Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_12e733c7-51ce-41f4-bb85-a83015a87f9c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_8cabc9fe-3fe6-4a7b-8259-69309e6dba6f_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual offset amount</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:to="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_0cba92b8-dec8-4694-8d0d-3ec5ac33d813_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of taxable profits (in percent)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:to="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c37e82ff-348c-4dda-80f3-dd9ce4fc3d38_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ccdc708f-a41b-4637-b40b-d6d14d25bef7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0366419b-a6cf-43f2-9860-5e809a141f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_f040d17e-8a99-426d-a930-a295211c2db2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_cf7722c6-efad-4e02-b69f-39cf59519b35_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions on behalf of the employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6cde1d1d-dbb5-4188-a42c-290e084dcd13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2310567c-fc8b-4ee7-9ca5-de4fb8683d5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_bbccf145-afe3-4787-9b61-cfcbf3833fad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saving period (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_9cc104cf-ddd0-495e-a87a-694289ae85d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfVotes_9eedfc20-b38e-47d5-a1de-9eaff1f71f3b_terseLabel_en-US" xlink:label="lab_cmps_NumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_cmps_NumberOfVotes_label_en-US" xlink:label="lab_cmps_NumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes</link:label>
    <link:label id="lab_cmps_NumberOfVotes_documentation_en-US" xlink:label="lab_cmps_NumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVotes" xlink:href="cmps-20220930.xsd#cmps_NumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfVotes" xlink:to="lab_cmps_NumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd80dc79-9967-40a1-ada4-0c70c982835a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease)/increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f2d34159-7e53-4402-87ee-f6eaf7ee8fcb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_61f57e7e-b15a-4314-b763-9b9c4b3d9b8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2021AwardMember_f865afef-caab-4f6d-ba90-8e3bc7250a17_terseLabel_en-US" xlink:label="lab_cmps_A2021AwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Award</link:label>
    <link:label id="lab_cmps_A2021AwardMember_label_en-US" xlink:label="lab_cmps_A2021AwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Award [Member]</link:label>
    <link:label id="lab_cmps_A2021AwardMember_documentation_en-US" xlink:label="lab_cmps_A2021AwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2021AwardMember" xlink:href="cmps-20220930.xsd#cmps_A2021AwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2021AwardMember" xlink:to="lab_cmps_A2021AwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_93fbab65-3a47-42fb-a292-ca1588d6cd32_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d405aa5-f4d5-45ab-9406-121ab7eb65a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_958f1369-6d5b-4318-9aee-3c970c99b395_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7380c51e-023f-4385-a2ad-12751f140655_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b0fd2c85-3bb5-4e18-9862-f71a72acdc89_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_572464b1-4867-4159-9cce-8266513a5502_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d57d650e-dd51-47c0-aea4-413fd9bd7ae5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_aa667004-e318-47d2-a9da-89bcb51e0ea9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_585213ca-525a-40e8-ad68-7d105cca159d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_26d3ed98-e451-464d-9efa-8d13efe396c0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_595e3ac5-119b-4a3e-9769-0e4319fe200b_terseLabel_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from Research and Development Tax Credit</link:label>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit From Research And Development Tax Credit, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit From Research And Development Tax Credit, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:href="cmps-20220930.xsd#cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:to="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_0fc2c5a6-a806-4b9a-bd12-26290df16972_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89c72af0-f0f7-47cb-a379-25fe97a2b453_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_520d05f6-b134-40b2-bdc0-2d8f80dd2b8a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_fed930c7-532b-4b4d-82d2-1c7203a090ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_15d21a60-dce5-456f-be26-8eefac7f2a26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0646d946-1402-423b-b3fa-d5710b50110b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_b930de13-1359-4149-9fef-0d70b32f266f_terseLabel_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember" xlink:href="cmps-20220930.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AmericanDepositarySharesMember" xlink:to="lab_cmps_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2119e33f-70f6-44cf-8ea7-1610f8461eeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_61f409f6-dc84-4583-8411-4473da41bf52_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7fe7112b-a94d-4deb-8960-3f110d2e3c6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f8110767-e421-4088-8970-682cf789bbeb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_d06ef178-705f-427a-b879-395b53dd81e0_negatedTerseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cmps-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c5389c96-2c12-4697-80ce-9dae433c59a1,g:e7d46793-04e4-4d1f-af55-4f0c408b25da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/Cover" xlink:type="simple" xlink:href="cmps-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5a5fbee7-26f7-4f08-b72c-cb14cbc486a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentType_5a5fbee7-26f7-4f08-b72c-cb14cbc486a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_29cc409b-fe52-4d61-96ce-b029727d12a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentQuarterlyReport_29cc409b-fe52-4d61-96ce-b029727d12a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_21e7ef4b-90ff-4e6b-b948-f4645ed91524" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentPeriodEndDate_21e7ef4b-90ff-4e6b-b948-f4645ed91524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a72df148-7918-4cba-896c-3a2bf76ad00d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentTransitionReport_a72df148-7918-4cba-896c-3a2bf76ad00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9acf4082-51c7-4555-8d2f-4dbc8ba64380" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityFileNumber_9acf4082-51c7-4555-8d2f-4dbc8ba64380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_29b8fead-00a6-4795-81e3-689121271edc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityRegistrantName_29b8fead-00a6-4795-81e3-689121271edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_086c7276-4038-4e75-9c13-2b35643cc693" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_086c7276-4038-4e75-9c13-2b35643cc693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a96da951-e5f8-4dcc-9aa7-a733bc773427" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityAddressAddressLine1_a96da951-e5f8-4dcc-9aa7-a733bc773427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cd2f4709-8066-4cf8-9e75-a90195475235" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityAddressCityOrTown_cd2f4709-8066-4cf8-9e75-a90195475235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_be593c53-e68b-4278-b064-784e983a958a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityAddressPostalZipCode_be593c53-e68b-4278-b064-784e983a958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_2a7b614d-2de3-4f01-96a0-54bf4ff9957c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityAddressCountry_2a7b614d-2de3-4f01-96a0-54bf4ff9957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bcce6515-207e-43af-a0eb-2c7de108ace1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_CityAreaCode_bcce6515-207e-43af-a0eb-2c7de108ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_33d47be6-b948-47e8-b9ee-e59397438a86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_LocalPhoneNumber_33d47be6-b948-47e8-b9ee-e59397438a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37388a9f-5388-473f-b842-ac9eb34ffafa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_Security12bTitle_37388a9f-5388-473f-b842-ac9eb34ffafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_98dadbf5-7fb6-4775-b810-c101612fcfe0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_TradingSymbol_98dadbf5-7fb6-4775-b810-c101612fcfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6224c43b-82b3-439c-9329-c3e77735639a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_SecurityExchangeName_6224c43b-82b3-439c-9329-c3e77735639a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_92c7e919-3d3b-4b20-be5f-781bb2867342" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityCurrentReportingStatus_92c7e919-3d3b-4b20-be5f-781bb2867342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0c62257f-9609-4605-a4d3-f50e74afbd12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityInteractiveDataCurrent_0c62257f-9609-4605-a4d3-f50e74afbd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_378cd0b1-6f45-48a2-9a39-f603bc025e9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityFilerCategory_378cd0b1-6f45-48a2-9a39-f603bc025e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1845191a-3311-4fff-8a51-e921680034f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntitySmallBusiness_1845191a-3311-4fff-8a51-e921680034f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9463b739-594f-4c3c-89ca-976d856b7c04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityEmergingGrowthCompany_9463b739-594f-4c3c-89ca-976d856b7c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9917aaca-9011-44d5-b8fc-7fd08e422156" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityShellCompany_9917aaca-9011-44d5-b8fc-7fd08e422156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9ab46252-2165-4973-aaaa-540013e97d7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9ab46252-2165-4973-aaaa-540013e97d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c4c4988c-2b63-4203-9b87-43dc52a7465e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_EntityCentralIndexKey_c4c4988c-2b63-4203-9b87-43dc52a7465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d8e8cb3e-5615-4bda-a09a-c5a659fbdd94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentFiscalYearFocus_d8e8cb3e-5615-4bda-a09a-c5a659fbdd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_80d01ea0-81c2-4d0a-9c7c-a10d66eaac4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_80d01ea0-81c2-4d0a-9c7c-a10d66eaac4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b06e2b10-e16d-46b6-9601-53e5189d2556" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_AmendmentFlag_b06e2b10-e16d-46b6-9601-53e5189d2556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a5bf6bd0-eb39-45b8-9ee8-b163c431803f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e7a77cd7-f46e-4e55-be03-098037ebf73c" xlink:to="loc_dei_CurrentFiscalYearEndDate_a5bf6bd0-eb39-45b8-9ee8-b163c431803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7e0d69f2-6dda-4177-a40e-e44b26d70357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e0d69f2-6dda-4177-a40e-e44b26d70357" xlink:to="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7291fdbc-9576-407b-993e-caab4ae625fc" xlink:to="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_8d97eb03-8f6f-4b03-a126-e6b77d012e18" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:to="loc_cmps_OrdinarySharesMember_8d97eb03-8f6f-4b03-a126-e6b77d012e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_38ed20b5-2f7e-4ba6-8587-b1c60db75a57" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edcfed46-91f3-4b92-bf70-b45752a2f425" xlink:to="loc_cmps_DeferredSharesMember_38ed20b5-2f7e-4ba6-8587-b1c60db75a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_522f0536-71c5-4a20-ae34-68d234dff87f" xlink:to="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:to="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a13dff97-7ace-4dee-b2e1-9e32edaa3bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a13dff97-7ace-4dee-b2e1-9e32edaa3bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aad6f8c3-a3e7-46d7-af20-538168a8332f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aad6f8c3-a3e7-46d7-af20-538168a8332f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_29d4ded4-fc20-416b-909e-c61a2841817a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_PrepaidTaxes_29d4ded4-fc20-416b-909e-c61a2841817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4cce825a-878d-4228-b782-498ffa46f214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4cce825a-878d-4228-b782-498ffa46f214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b6023cd4-c52c-4316-a1cd-14f761c676e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9291f2fb-b0c6-4a00-9145-8aa70062551a" xlink:to="loc_us-gaap_AssetsCurrent_b6023cd4-c52c-4316-a1cd-14f761c676e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2caba26-958b-4c61-8e2a-34f7f36a3704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2caba26-958b-4c61-8e2a-34f7f36a3704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53435269-8ea0-4120-b75d-23b899971f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53435269-8ea0-4120-b75d-23b899971f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_182809d8-e4b9-49c3-976f-66a3732282b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_182809d8-e4b9-49c3-976f-66a3732282b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bfa96418-079b-459a-83dc-36d43570ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bfa96418-079b-459a-83dc-36d43570ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_38793cef-fc07-4c98-841a-de6f71ed71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_26f83714-f5cf-448e-9f17-31c6e248f1bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_38793cef-fc07-4c98-841a-de6f71ed71f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d9a34694-3a16-4063-8bb3-aa236b86f260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75108fef-d057-4c21-8bb7-eb734d1e5416" xlink:to="loc_us-gaap_Assets_d9a34694-3a16-4063-8bb3-aa236b86f260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6fd53c52-8172-4c73-af89-6704cf7a8e58" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f3deb187-7adf-40ad-8fbc-fcf3a825560e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_AccountsPayableCurrent_f3deb187-7adf-40ad-8fbc-fcf3a825560e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_26a35bb7-3ab7-4e22-aa36-d3d0a88b76bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_26a35bb7-3ab7-4e22-aa36-d3d0a88b76bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cd51a20-fba6-4ae6-88ab-28f02b6275ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cd51a20-fba6-4ae6-88ab-28f02b6275ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e687a564-a35e-4940-923a-d24c7e676961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc44f81d-9057-4980-87eb-abb76d0eca00" xlink:to="loc_us-gaap_LiabilitiesCurrent_e687a564-a35e-4940-923a-d24c7e676961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1729a470-db4f-4c78-b2de-1dbf37677623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4636a195-c869-4721-acf0-64113c80faf2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1729a470-db4f-4c78-b2de-1dbf37677623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d66ea1c6-e0a5-4916-921f-2a14768c0cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_Liabilities_d66ea1c6-e0a5-4916-921f-2a14768c0cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e9caed26-3c1f-48cd-ae8a-3564475425da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e9caed26-3c1f-48cd-ae8a-3564475425da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f28ac965-2d5e-4a19-bb04-2f286876047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_CommonStockValue_f28ac965-2d5e-4a19-bb04-2f286876047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_96efd044-3361-4514-9cb3-aa9b77ca7de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_AdditionalPaidInCapital_96efd044-3361-4514-9cb3-aa9b77ca7de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8cea43f-a8e5-4e0a-8501-b18e44ecd1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8cea43f-a8e5-4e0a-8501-b18e44ecd1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33e38e8d-a308-489e-b976-d69348962568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33e38e8d-a308-489e-b976-d69348962568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff70b6c7-6b29-45f4-9299-a845349eaace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d097da20-0898-4c81-ae22-0def72337a79" xlink:to="loc_us-gaap_StockholdersEquity_ff70b6c7-6b29-45f4-9299-a845349eaace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8114e5d-b939-4d10-9ec3-3e045636c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5531e4b8-9481-4ac4-addb-12ef1c00de88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8114e5d-b939-4d10-9ec3-3e045636c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_af119ebd-0b61-49cc-8ee2-2be79c004898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af119ebd-0b61-49cc-8ee2-2be79c004898" xlink:to="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37df949a-3ac2-4f86-8423-99cd26e03cd1" xlink:to="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_c39e9819-4216-4b43-9f46-669c7a0b5974" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:to="loc_cmps_OrdinarySharesMember_c39e9819-4216-4b43-9f46-669c7a0b5974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_dbb69059-461f-406c-9538-2e67129ee57d" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7f85e03-ecad-4640-9c61-03528a49ff8f" xlink:to="loc_cmps_DeferredSharesMember_dbb69059-461f-406c-9538-2e67129ee57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bc6da070-ac73-49a3-8889-64ea2de3e2d7" xlink:to="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f0806e3f-b68c-46ec-9b3c-7b14eccb1f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f0806e3f-b68c-46ec-9b3c-7b14eccb1f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1cd63eef-03d0-4320-9a5e-05a30e849457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1cd63eef-03d0-4320-9a5e-05a30e849457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_76345d83-b555-4851-96e9-7042eb97bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesIssued_76345d83-b555-4851-96e9-7042eb97bf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3e9903c-f7ed-4007-9263-b37924ee261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3e2542f-b11f-462d-8ebf-1068da4ebd7f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3e9903c-f7ed-4007-9263-b37924ee261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6db74ee1-41d0-496f-843a-38911a0d4775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6db74ee1-41d0-496f-843a-38911a0d4775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1418c099-6225-453f-9297-ba6cdfde327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6db74ee1-41d0-496f-843a-38911a0d4775" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1418c099-6225-453f-9297-ba6cdfde327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_85512176-90f8-4953-852c-dbda41e27625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6db74ee1-41d0-496f-843a-38911a0d4775" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_85512176-90f8-4953-852c-dbda41e27625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a1ebc14-5ee0-4030-9d64-27ac45d71f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6db74ee1-41d0-496f-843a-38911a0d4775" xlink:to="loc_us-gaap_OperatingExpenses_1a1ebc14-5ee0-4030-9d64-27ac45d71f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a3d40d9-91db-4a9d-a4eb-fbd632508790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_OperatingIncomeLoss_8a3d40d9-91db-4a9d-a4eb-fbd632508790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_5efcbdb7-650e-463b-8361-fb2e37aac6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:to="loc_us-gaap_OtherNonoperatingIncome_5efcbdb7-650e-463b-8361-fb2e37aac6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c1bcd27f-74ef-47b8-8800-4cfb364f1458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c1bcd27f-74ef-47b8-8800-4cfb364f1458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_b1577f92-dfaf-4567-966b-71c487c2b6ce" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_b1577f92-dfaf-4567-966b-71c487c2b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0caf5b96-4d40-4974-b03d-a53456c9aeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6602dc24-8de9-4be3-8a44-d0bd16b245c1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0caf5b96-4d40-4974-b03d-a53456c9aeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d7660e8-af53-4683-941f-dea16ef397cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d7660e8-af53-4683-941f-dea16ef397cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6163f9fc-8329-4a23-a05d-da8636b366c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6163f9fc-8329-4a23-a05d-da8636b366c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cbe07af7-fba0-414d-a8bb-9c4b7324d78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_NetIncomeLoss_cbe07af7-fba0-414d-a8bb-9c4b7324d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_58e96dc3-84d1-496e-952f-1b713feb2d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_58e96dc3-84d1-496e-952f-1b713feb2d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8c153c6a-aaa7-4f33-b7bb-f29231c776fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_58e96dc3-84d1-496e-952f-1b713feb2d31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8c153c6a-aaa7-4f33-b7bb-f29231c776fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1d0ac202-7679-4593-b505-adebd66ae844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1d0ac202-7679-4593-b505-adebd66ae844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0743b983-b0ed-4f87-8c1c-a6447de27956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_EarningsPerShareBasic_0743b983-b0ed-4f87-8c1c-a6447de27956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c21584f2-6066-4ea0-bb30-74952b931b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c21584f2-6066-4ea0-bb30-74952b931b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e003236d-937b-4019-8639-08a4f59853f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e003236d-937b-4019-8639-08a4f59853f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_26984d70-f14b-438c-8f65-473cb7f8b716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_616e58c5-a532-4d1c-a9a7-471043688ef6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_26984d70-f14b-438c-8f65-473cb7f8b716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9f5f002c-2028-4110-9c11-01c4413d7c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9f5f002c-2028-4110-9c11-01c4413d7c3b" xlink:to="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7b983e-b018-4607-8353-ef983675c369" xlink:to="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_f472ad02-00b6-40e5-ad89-f85245b92ef0" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:to="loc_cmps_OrdinarySharesMember_f472ad02-00b6-40e5-ad89-f85245b92ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_6a69b4d2-a2b6-474d-bd6c-702a5490cc0b" xlink:href="cmps-20220930.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bbf222fb-544b-4bd5-911c-8f292a52ff42" xlink:to="loc_cmps_DeferredSharesMember_6a69b4d2-a2b6-474d-bd6c-702a5490cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3de950b9-421d-4000-b3fa-dc1d4a13a48c" xlink:to="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a6a7a53e-bfe9-454c-bc0e-6ce1660c6402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_CommonStockMember_a6a7a53e-bfe9-454c-bc0e-6ce1660c6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e683f882-8c4e-461e-9d37-21c77c81bff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e683f882-8c4e-461e-9d37-21c77c81bff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79a8bc82-8765-44bc-bf93-7b92d74c1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79a8bc82-8765-44bc-bf93-7b92d74c1ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1a167334-271c-43d9-b6a6-edaf9553e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b6b4b5b-021a-441d-bcac-b13018b504a7" xlink:to="loc_us-gaap_RetainedEarningsMember_1a167334-271c-43d9-b6a6-edaf9553e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_18fcbb20-d6be-41e0-bc75-a89116c1d9bb" xlink:to="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2021AwardMember_a3baef7a-6153-459c-a06f-e19cbe6b3499" xlink:href="cmps-20220930.xsd#cmps_A2021AwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:to="loc_cmps_A2021AwardMember_a3baef7a-6153-459c-a06f-e19cbe6b3499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020AwardMember_dab86eb9-a377-4a6c-a078-737cab862018" xlink:href="cmps-20220930.xsd#cmps_A2020AwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_9680c45a-25c4-4209-bcbb-492b7061e427" xlink:to="loc_cmps_A2020AwardMember_dab86eb9-a377-4a6c-a078-737cab862018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b673159b-0195-433e-b32e-887d6982f820" xlink:to="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_890ff4f6-f6fc-46ef-95b0-649ac048ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_890ff4f6-f6fc-46ef-95b0-649ac048ada9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fba82b0-9874-4bf8-9595-19a9f675a5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockholdersEquity_7fba82b0-9874-4bf8-9595-19a9f675a5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd101b71-3439-42cf-b1c6-19e5fc4df5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd101b71-3439-42cf-b1c6-19e5fc4df5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed27d8e9-4996-47e5-a954-2ea785186825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed27d8e9-4996-47e5-a954-2ea785186825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a0a1d6b-e5f7-4cb5-af9b-43f374839fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a0a1d6b-e5f7-4cb5-af9b-43f374839fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b222b0d4-4db1-4ebf-9fe5-c7d1e32762ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b222b0d4-4db1-4ebf-9fe5-c7d1e32762ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3062b860-307b-48c9-9a18-cf62fe838a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3062b860-307b-48c9-9a18-cf62fe838a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_165e9548-56a0-45e9-941b-e50bc54fc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_165e9548-56a0-45e9-941b-e50bc54fc72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d496588-37e7-42a0-b9b0-c422b67534da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d496588-37e7-42a0-b9b0-c422b67534da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_5586f141-c439-4092-8cc5-9533697285af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_5586f141-c439-4092-8cc5-9533697285af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd19779e-f5d1-4a56-9473-d0518dfbb23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_NetIncomeLoss_bd19779e-f5d1-4a56-9473-d0518dfbb23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0c1254a0-763b-4ac2-a574-772a738db46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0c1254a0-763b-4ac2-a574-772a738db46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9984525-87ee-4ffc-8746-2f5a1aff0917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_StockholdersEquity_d9984525-87ee-4ffc-8746-2f5a1aff0917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9e65b6a-366f-4d6f-9407-8053af153233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361451f7-dede-428b-adaf-bf720f40b3e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9e65b6a-366f-4d6f-9407-8053af153233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d86de9a9-63bd-48b1-8575-e01d23219b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:to="loc_us-gaap_NetIncomeLoss_d86de9a9-63bd-48b1-8575-e01d23219b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebe8b2d5-acde-4680-aca3-03d8ff35da66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebe8b2d5-acde-4680-aca3-03d8ff35da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d9508f66-40f7-4f39-a0c4-61902568e0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d9508f66-40f7-4f39-a0c4-61902568e0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aabbb351-e104-4cf1-a6d1-eca7783c099c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:to="loc_us-gaap_ShareBasedCompensation_aabbb351-e104-4cf1-a6d1-eca7783c099c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_35691058-ede0-4184-a001-2a7ad61980bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c05ee093-adc7-4064-a75a-047361cb37cf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_35691058-ede0-4184-a001-2a7ad61980bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_88b558be-39c8-4e25-b5d2-9edf7ddcdb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_88b558be-39c8-4e25-b5d2-9edf7ddcdb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d7dbce2c-b299-471b-8f28-abe93463c7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d7dbce2c-b299-471b-8f28-abe93463c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e290c683-08a2-4687-8dc2-1f0c0e5bf55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e290c683-08a2-4687-8dc2-1f0c0e5bf55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a0e337bd-f4eb-42a8-ad91-379517d888fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a0e337bd-f4eb-42a8-ad91-379517d888fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fcc7369-1146-4e37-8e5f-bd68c7bd62fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fcc7369-1146-4e37-8e5f-bd68c7bd62fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_966d0638-3553-4bf6-bd79-19386298c979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_17efbca6-b363-44a2-baf7-8866f99e604b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_966d0638-3553-4bf6-bd79-19386298c979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d366a884-5651-41b9-9b1f-85b52f615c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18c54083-4c59-41fb-8f51-b7e534b7a0e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d366a884-5651-41b9-9b1f-85b52f615c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5956af1-4118-4718-9558-81f28838e555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5956af1-4118-4718-9558-81f28838e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26364987-b87d-4faf-9227-e2b077b85de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5956af1-4118-4718-9558-81f28838e555" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26364987-b87d-4faf-9227-e2b077b85de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f29a65f-64a1-43e8-9c90-effb14970630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5956af1-4118-4718-9558-81f28838e555" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f29a65f-64a1-43e8-9c90-effb14970630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ecb69e8-7993-4073-8ac7-6bb535fbe603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ecb69e8-7993-4073-8ac7-6bb535fbe603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca0bbe90-9155-40bb-950f-1eb1b67aed24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ecb69e8-7993-4073-8ac7-6bb535fbe603" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca0bbe90-9155-40bb-950f-1eb1b67aed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_67a4a06d-1ff3-4345-b374-3c2d104cc409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ecb69e8-7993-4073-8ac7-6bb535fbe603" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_67a4a06d-1ff3-4345-b374-3c2d104cc409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a8a4794-af18-42ca-bc3d-a27612f5e493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ecb69e8-7993-4073-8ac7-6bb535fbe603" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a8a4794-af18-42ca-bc3d-a27612f5e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ddf2905-2c80-4888-8e39-5f6f3dac6185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ddf2905-2c80-4888-8e39-5f6f3dac6185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf6a2e8d-928e-4509-8f00-1e74b47389b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf6a2e8d-928e-4509-8f00-1e74b47389b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233575be-dce2-4dfe-8c8d-a5e78464538d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233575be-dce2-4dfe-8c8d-a5e78464538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_256e1cf4-54c5-4a98-bb43-1ec76c41631d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_256e1cf4-54c5-4a98-bb43-1ec76c41631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_36677c29-fd11-45ee-9a21-008774275be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_36677c29-fd11-45ee-9a21-008774275be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption_a7be93c6-27b5-466f-a477-a581fa85ba39" xlink:href="cmps-20220930.xsd#cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36677c29-fd11-45ee-9a21-008774275be1" xlink:to="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption_a7be93c6-27b5-466f-a477-a581fa85ba39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived_2f809831-1c99-4697-9e61-31b114491704" xlink:href="cmps-20220930.xsd#cmps_ProceedsFromStockOptionsExercisedNotReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36677c29-fd11-45ee-9a21-008774275be1" xlink:to="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived_2f809831-1c99-4697-9e61-31b114491704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_33876d72-a9e4-4aa9-8486-754a1a7377b8" xlink:href="cmps-20220930.xsd#cmps_DeferredOfferingCostsIncludedInAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36677c29-fd11-45ee-9a21-008774275be1" xlink:to="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_33876d72-a9e4-4aa9-8486-754a1a7377b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5eac2cf8-08c6-4ad7-b584-fdd36ca9a0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1d30d189-32d0-460c-990d-1f09417999cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5eac2cf8-08c6-4ad7-b584-fdd36ca9a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6aacd60e-3d07-4ae2-8e5e-49078d1980cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5eac2cf8-08c6-4ad7-b584-fdd36ca9a0c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6aacd60e-3d07-4ae2-8e5e-49078d1980cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0c461172-5e2a-482d-9555-9e8ddc64cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5eac2cf8-08c6-4ad7-b584-fdd36ca9a0c5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0c461172-5e2a-482d-9555-9e8ddc64cfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aebe9bec-5394-4e49-94cd-07e4a13819eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5eac2cf8-08c6-4ad7-b584-fdd36ca9a0c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aebe9bec-5394-4e49-94cd-07e4a13819eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusiness" xlink:type="simple" xlink:href="cmps-20220930.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_641e9a5d-28b5-4dac-8acb-ac01a0e51c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a14ad94c-cc41-4aa8-ae00-78101ca5a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_641e9a5d-28b5-4dac-8acb-ac01a0e51c2e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a14ad94c-cc41-4aa8-ae00-78101ca5a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf6172ae-75ac-43b1-bf70-ed3f7b910d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_96a2f1f9-155d-453d-846c-95d9dbc4bc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf6172ae-75ac-43b1-bf70-ed3f7b910d50" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_96a2f1f9-155d-453d-846c-95d9dbc4bc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cmps-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ffb63e9-3579-4a79-85c9-26fef333c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_918a5c36-08f5-4b7a-8f06-35e4ffd08c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ffb63e9-3579-4a79-85c9-26fef333c4f2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_918a5c36-08f5-4b7a-8f06-35e4ffd08c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/Investment" xlink:type="simple" xlink:href="cmps-20220930.xsd#Investment"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Investment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6a7700be-9c41-491d-b7c4-9c1cf0b0ae7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_b2a75473-be1c-466c-8f54-6fcf37445d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6a7700be-9c41-491d-b7c4-9c1cf0b0ae7f" xlink:to="loc_us-gaap_InvestmentTextBlock_b2a75473-be1c-466c-8f54-6fcf37445d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="cmps-20220930.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5ed94dca-b5b0-449c-a816-41a38722822d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_8437c712-198a-4dc0-b69e-b349a2dc77cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5ed94dca-b5b0-449c-a816-41a38722822d" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_8437c712-198a-4dc0-b69e-b349a2dc77cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="cmps-20220930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_78ccb813-e742-46c4-b4dc-199aa7e2cedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a3cd713f-5d8b-41c8-9e4f-7373d5aa6be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_78ccb813-e742-46c4-b4dc-199aa7e2cedd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a3cd713f-5d8b-41c8-9e4f-7373d5aa6be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities" xlink:type="simple" xlink:href="cmps-20220930.xsd#AccruedExpensesandOtherLiabilities"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8318dd68-ae45-41b4-b987-8fa43f6b167c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ddc52787-5bc0-4c5b-a247-4b7d766e2a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8318dd68-ae45-41b4-b987-8fa43f6b167c" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ddc52787-5bc0-4c5b-a247-4b7d766e2a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinaryShares" xlink:type="simple" xlink:href="cmps-20220930.xsd#OrdinaryShares"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/OrdinaryShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8f6f89bb-7762-40df-bd1e-5f8c1ab5f5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ba59105-5802-4e56-9c86-a303d8e2c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8f6f89bb-7762-40df-bd1e-5f8c1ab5f5b2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ba59105-5802-4e56-9c86-a303d8e2c0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a901f69-e4ee-4180-a3d2-3aea7900feab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58028141-f1b4-4842-9ec0-31566db12e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a901f69-e4ee-4180-a3d2-3aea7900feab" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58028141-f1b4-4842-9ec0-31566db12e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cmps-20220930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b6c8da72-1b5f-45d8-9347-e6b705008a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a892ef8c-e7a0-42f9-8178-9f9b3df48ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6c8da72-1b5f-45d8-9347-e6b705008a38" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a892ef8c-e7a0-42f9-8178-9f9b3df48ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/Rightofuseofassets" xlink:type="simple" xlink:href="cmps-20220930.xsd#Rightofuseofassets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Rightofuseofassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_93e3dc8e-4833-4633-800f-ce938c08c332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5f114ee5-d33c-4f08-b22a-35a1f2d77c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93e3dc8e-4833-4633-800f-ce938c08c332" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5f114ee5-d33c-4f08-b22a-35a1f2d77c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cmps-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bdc48b4-2532-4ecd-a94a-86916c4bcd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ecebafca-b804-4c82-bb66-924c9437a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bdc48b4-2532-4ecd-a94a-86916c4bcd79" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ecebafca-b804-4c82-bb66-924c9437a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cmps-20220930.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fefbadf8-5a00-4a93-ae93-1b52ffe1c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1882b10f-a209-4351-912d-62fa313346a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fefbadf8-5a00-4a93-ae93-1b52ffe1c1e5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1882b10f-a209-4351-912d-62fa313346a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3de4fc14-8f41-495c-8a6a-4f8bcfd59f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3de4fc14-8f41-495c-8a6a-4f8bcfd59f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e3d44466-b632-40c4-aa4c-aebb82476f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e3d44466-b632-40c4-aa4c-aebb82476f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eeb664fa-b7e0-4f72-9593-93532a7bf984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_UseOfEstimates_eeb664fa-b7e0-4f72-9593-93532a7bf984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_142df5c7-c5ad-4c94-a7f4-739f22f1b755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_142df5c7-c5ad-4c94-a7f4-739f22f1b755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6d087a46-02e7-4fd4-ad85-e9a355d30657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6d087a46-02e7-4fd4-ad85-e9a355d30657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_196c670c-81ff-464a-a315-b2244171cb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_196c670c-81ff-464a-a315-b2244171cb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_64e5f143-c01b-432e-af3d-29cd9a25fc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_64e5f143-c01b-432e-af3d-29cd9a25fc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_cf0f4b04-256a-4e5f-beb3-6f53a5b67976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_cf0f4b04-256a-4e5f-beb3-6f53a5b67976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3eb2b734-60ec-425d-a1e1-e9f7ebe0ee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3eb2b734-60ec-425d-a1e1-e9f7ebe0ee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_816c4148-4f88-4f5a-887f-8673716b6f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_816c4148-4f88-4f5a-887f-8673716b6f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_22c23f5c-e06e-4512-bf57-902974684c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_22c23f5c-e06e-4512-bf57-902974684c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f2896b68-7764-4c12-afba-81b890f815b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f2896b68-7764-4c12-afba-81b890f815b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_dac8167e-9bf5-4637-b1be-96dacdf10956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_dac8167e-9bf5-4637-b1be-96dacdf10956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cb60408a-a45b-46e3-9f01-c25a3cea36c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cb60408a-a45b-46e3-9f01-c25a3cea36c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_376f68dc-8538-4960-9c90-d9db99cd3a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_376f68dc-8538-4960-9c90-d9db99cd3a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4046d15b-d1f9-44de-98c1-5db54a1106b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4046d15b-d1f9-44de-98c1-5db54a1106b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5331ab40-77e4-41c3-8fcd-aa999dd6e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5331ab40-77e4-41c3-8fcd-aa999dd6e5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_22017cab-b43c-42dc-b92c-0ab9251d3e37" xlink:href="cmps-20220930.xsd#cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_22017cab-b43c-42dc-b92c-0ab9251d3e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4414628b-0c4d-4915-abf4-3c335f23b789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4414628b-0c4d-4915-abf4-3c335f23b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_92524390-9788-41d0-94d0-889cab0dabe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70c7a08d-6ec3-44ef-979c-3ffd1746a599" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_92524390-9788-41d0-94d0-889cab0dabe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e1a76d6c-fd68-4bd5-bae5-3821e41bfc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3b1ad9ae-3d12-4b26-82d9-49d26f759df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e1a76d6c-fd68-4bd5-bae5-3821e41bfc8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3b1ad9ae-3d12-4b26-82d9-49d26f759df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cc4d9bcd-27db-44b2-a953-a6a0f7636970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_dbf9c9f4-915a-443f-bb83-7ae575ca8fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cc4d9bcd-27db-44b2-a953-a6a0f7636970" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_dbf9c9f4-915a-443f-bb83-7ae575ca8fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e502f240-2117-4f0c-9890-08bc452c50f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78e920af-a6df-46f2-8ee3-61d00888c3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e502f240-2117-4f0c-9890-08bc452c50f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78e920af-a6df-46f2-8ee3-61d00888c3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#AccruedExpensesandOtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a9f15911-4f46-4b31-a2f6-e8132aeba5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1dd6c699-1db4-4206-9472-7e654b55aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a9f15911-4f46-4b31-a2f6-e8132aeba5bb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1dd6c699-1db4-4206-9472-7e654b55aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3102cbfe-536a-466d-afb3-3532de2dbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ad641c37-530c-44df-99b2-6887b19b7f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3102cbfe-536a-466d-afb3-3532de2dbc74" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ad641c37-530c-44df-99b2-6887b19b7f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7b65f927-4b68-4a8c-9f67-09ff8812da34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3102cbfe-536a-466d-afb3-3532de2dbc74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7b65f927-4b68-4a8c-9f67-09ff8812da34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5f2b0527-4218-4f55-a9e8-da467790305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3102cbfe-536a-466d-afb3-3532de2dbc74" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5f2b0527-4218-4f55-a9e8-da467790305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b8a14405-322c-4d24-ad41-ed357aa5c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3102cbfe-536a-466d-afb3-3532de2dbc74" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b8a14405-322c-4d24-ad41-ed357aa5c0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cd3e7968-69c2-490f-b293-b3b19349f209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_02e3ace1-2a93-44a9-bcaa-bc2e26b6195c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cd3e7968-69c2-490f-b293-b3b19349f209" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_02e3ace1-2a93-44a9-bcaa-bc2e26b6195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dd072559-4155-4528-b729-3f13f37f89b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cd3e7968-69c2-490f-b293-b3b19349f209" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dd072559-4155-4528-b729-3f13f37f89b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsTables" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a0e56e9f-bac0-4fd5-af59-4d555daecc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_46877234-476a-4951-ad44-48e05bad347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0e56e9f-bac0-4fd5-af59-4d555daecc7d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_46877234-476a-4951-ad44-48e05bad347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7722fd05-cd82-4cd1-89bf-c5830907698c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0e56e9f-bac0-4fd5-af59-4d555daecc7d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7722fd05-cd82-4cd1-89bf-c5830907698c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d093da6-62f0-41d4-8891-b1e7420ae67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d093da6-62f0-41d4-8891-b1e7420ae67b" xlink:to="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_95317cd6-1597-4668-bf59-a439034e2d90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f02a0a2c-f2ef-427e-9409-2c92e6dbb0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_449f9ccf-1593-4875-9ebd-6882a6dd45c9" xlink:to="loc_us-gaap_IPOMember_f02a0a2c-f2ef-427e-9409-2c92e6dbb0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3aafb76a-1b16-44b5-a421-49e66dd52060" xlink:to="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_6ffbaee9-6c27-4bb3-bca0-e03b2f060d43" xlink:href="cmps-20220930.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2eb6c813-9c03-4cfc-bdf6-9288dc472099" xlink:to="loc_cmps_AmericanDepositarySharesMember_6ffbaee9-6c27-4bb3-bca0-e03b2f060d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_027289e7-6607-4c4e-b237-b8e2ef9aa290" xlink:to="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19926ea2-7dd5-4c22-9d99-c825135122b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19926ea2-7dd5-4c22-9d99-c825135122b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_cfb8553a-febc-4077-a92e-2eb6986c5f87" xlink:href="cmps-20220930.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_cfb8553a-febc-4077-a92e-2eb6986c5f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_2bb6288b-5bd9-44bc-bb22-fb83b4561bd6" xlink:href="cmps-20220930.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_2bb6288b-5bd9-44bc-bb22-fb83b4561bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80fbf802-5b7d-4971-87dc-bf44ebe158bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_NetIncomeLoss_80fbf802-5b7d-4971-87dc-bf44ebe158bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aa312df-b676-479b-9d3e-cf687295d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aa312df-b676-479b-9d3e-cf687295d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2b1d229-08e7-4cd4-969e-ae81438fa60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_c9f94ad9-022d-4b98-beac-d5a5bff62c78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2b1d229-08e7-4cd4-969e-ae81438fa60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b16db329-6012-4ea9-b80c-3669359534b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b16db329-6012-4ea9-b80c-3669359534b1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f352d3c9-bb1b-4912-92d5-a2d90d40a9c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fb18e1ee-8e19-4699-86ce-43189a315630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_EquipmentMember_fb18e1ee-8e19-4699-86ce-43189a315630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_039c1d63-d589-44bb-9fc7-be8d0bdccc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_OfficeEquipmentMember_039c1d63-d589-44bb-9fc7-be8d0bdccc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_023c355b-2e91-41c2-ac2f-835ace6389c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6f38b11-645c-421d-85e6-1f2b4292c6b6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_023c355b-2e91-41c2-ac2f-835ace6389c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:to="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e68397a9-e058-4681-9c9f-60f12a030494" xlink:to="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3793335a-bee1-47b9-885e-38d500d0ea45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:to="loc_srt_MinimumMember_3793335a-bee1-47b9-885e-38d500d0ea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cab31ba-f873-475d-8a3a-3fab9f2cb24d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e952579a-3788-4c74-b997-1b02e0078a47" xlink:to="loc_srt_MaximumMember_6cab31ba-f873-475d-8a3a-3fab9f2cb24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_095a904b-c366-4b89-90e6-50a41e6ec333" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259c13e9-4f36-458c-9cd5-b073676a1a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_26e33b27-c05b-4789-b17b-d71e587c4b37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259c13e9-4f36-458c-9cd5-b073676a1a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ecd1dc93-5faa-4802-a445-1345f2f6591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ecd1dc93-5faa-4802-a445-1345f2f6591d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_03655324-cba7-47b2-9c48-fe10c66ea6cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_c16e31de-09d6-4841-9e5e-74d1c77bfa57" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_c16e31de-09d6-4841-9e5e-74d1c77bfa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_368216e4-c079-4b20-b935-5c88a3a0785a" xlink:href="cmps-20220930.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_cbbf2099-c2d1-4338-bea2-8fe906ea5abe" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_368216e4-c079-4b20-b935-5c88a3a0785a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fbffce2d-e26c-4706-bd48-167389daaa9a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_7cea2679-4046-4159-8653-c722bb70a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ae1de40-cf85-4159-aba9-db759db8de3d" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_7cea2679-4046-4159-8653-c722bb70a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_232a4c4e-1d57-46ab-bbe8-46d4b5a496ef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions_2aedee4d-0a88-4636-a8b5-1bbc9d3690b4" xlink:href="cmps-20220930.xsd#cmps_NumberOfGeographicRegions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_NumberOfGeographicRegions_2aedee4d-0a88-4636-a8b5-1bbc9d3690b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_99c285c0-1ce4-454a-b373-fcf18f1c24b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_99c285c0-1ce4-454a-b373-fcf18f1c24b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfcc3670-e46c-490f-929a-c4dc69d2e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfcc3670-e46c-490f-929a-c4dc69d2e7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f4a75cf7-3d94-4ea5-83d2-a70469339096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f4a75cf7-3d94-4ea5-83d2-a70469339096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_30c127ad-714d-49e9-b6d5-1b053aa3f6cc" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_30c127ad-714d-49e9-b6d5-1b053aa3f6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_a098387d-4dee-4703-81a9-038d41746597" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_a098387d-4dee-4703-81a9-038d41746597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_f76b5e0e-4cf6-4b04-90df-ec6ec04118ab" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_f76b5e0e-4cf6-4b04-90df-ec6ec04118ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_8429601f-abc0-42c8-a31c-eb67bedeab63" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_427461a4-3379-4d6a-a1b7-2b6cd7e94763" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_8429601f-abc0-42c8-a31c-eb67bedeab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/InvestmentNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#InvestmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/InvestmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_72a8375e-f601-4fde-9d8e-72ee984f9e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_72a8375e-f601-4fde-9d8e-72ee984f9e29" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5fa4f9ff-e4c3-460b-9f08-841705e11fc0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DelixTherapeuticsIncMember_ddcc413a-5e5e-40b5-8893-01baf90377ec" xlink:href="cmps-20220930.xsd#cmps_DelixTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e660820c-3f90-452d-93c5-1c00d2a529a8" xlink:to="loc_cmps_DelixTherapeuticsIncMember_ddcc413a-5e5e-40b5-8893-01baf90377ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:to="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_43227dc2-1b5a-4bb3-b845-9b85b71a5f97" xlink:to="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DelixTherapeuticsIncMember_ece54014-f54f-4094-91a8-22b6eb409b8d" xlink:href="cmps-20220930.xsd#cmps_DelixTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f8f2388e-1276-4ac5-a9ab-a597b613bcaf" xlink:to="loc_cmps_DelixTherapeuticsIncMember_ece54014-f54f-4094-91a8-22b6eb409b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_16a609b5-7df5-49a0-92a2-b1f1bdab45e0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4da748f4-e65f-4ed2-8004-8612274cc14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4da748f4-e65f-4ed2-8004-8612274cc14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8cb859e1-ac52-4c60-a57b-40e3210b2d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bf735510-cbec-48bb-af3f-f6312ba65200" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8cb859e1-ac52-4c60-a57b-40e3210b2d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_d09b7c23-1705-420f-a242-d1fc2e86f46c" xlink:href="cmps-20220930.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_d09b7c23-1705-420f-a242-d1fc2e86f46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_d9f00140-7ad2-47e3-8ae8-de157d3d75bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_PrepaidInsurance_d9f00140-7ad2-47e3-8ae8-de157d3d75bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_c07a9aba-c436-4ab6-bdfd-8a25d43596b8" xlink:href="cmps-20220930.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_c07a9aba-c436-4ab6-bdfd-8a25d43596b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_2300dc66-f8a4-49f5-87e7-4aeb83fdcd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_2300dc66-f8a4-49f5-87e7-4aeb83fdcd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_ffae6fe7-67f4-437f-bb20-9061321944f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_DeferredCostsCurrent_ffae6fe7-67f4-437f-bb20-9061321944f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_fe839712-a508-4dc7-89ad-ea88ec78ac33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_DepositsAssetsCurrent_fe839712-a508-4dc7-89ad-ea88ec78ac33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_951b865c-6488-45c9-858c-f5cc4c16d835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_OtherAssetsCurrent_951b865c-6488-45c9-858c-f5cc4c16d835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36fc85da-bd19-483e-a3cc-9254a804fe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8dfd9c21-910b-4ad0-9bef-df2ad49731de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36fc85da-bd19-483e-a3cc-9254a804fe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c805c9f-9dd6-4b9e-b9c8-5470feb8e370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c805c9f-9dd6-4b9e-b9c8-5470feb8e370" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0071304d-9e4c-4000-9cf4-924717f0a601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5d8b120b-bafd-4d5c-8d3b-6dcdd0e7f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_EquipmentMember_5d8b120b-bafd-4d5c-8d3b-6dcdd0e7f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4d22a691-805d-477e-b18a-435a9658609e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_OfficeEquipmentMember_4d22a691-805d-477e-b18a-435a9658609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5ded3b57-822e-477e-b470-0321aba022b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5ded3b57-822e-477e-b470-0321aba022b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b07e5d5b-e7a2-4eb9-8c8f-98a666220b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b8152b-9a8e-4ee8-b04a-8d7acc578336" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b07e5d5b-e7a2-4eb9-8c8f-98a666220b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9cd2e9aa-9b78-4ee0-b63d-e26a3f852032" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1bd017fe-9967-4e4c-8d4d-ee47471ddc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1bd017fe-9967-4e4c-8d4d-ee47471ddc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2eb9a9e-0d58-4e55-9c54-d59c3407471b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2eb9a9e-0d58-4e55-9c54-d59c3407471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_62232070-5787-48e0-b5fb-beae1621cbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_62232070-5787-48e0-b5fb-beae1621cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4e90fc82-80b0-4bff-80f9-e0080051fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac0533ba-322f-4ef1-b5ad-15039d8db114" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4e90fc82-80b0-4bff-80f9-e0080051fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_6cd1d1c2-dd30-4bf1-bf86-91e870898674" xlink:href="cmps-20220930.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_6cd1d1c2-dd30-4bf1-bf86-91e870898674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7a704bb4-83cc-4236-9f06-7cd7778f524d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7a704bb4-83cc-4236-9f06-7cd7778f524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a1d5b7ba-87c6-4e36-8090-d262f069d4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a1d5b7ba-87c6-4e36-8090-d262f069d4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_779a7280-034c-4cc5-b047-5aef7e85c848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_779a7280-034c-4cc5-b047-5aef7e85c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9bcd3cf6-26e3-4681-b27f-ca160461f74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9bcd3cf6-26e3-4681-b27f-ca160461f74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_689e5f03-9eed-427a-bd64-0d3fd4324c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b7966b0b-e0e8-4682-8f62-c9370f02d80b" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_689e5f03-9eed-427a-bd64-0d3fd4324c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#OrdinarySharesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3283b858-2b1e-41ed-bb2b-24dd72b12453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3283b858-2b1e-41ed-bb2b-24dd72b12453" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f92041f-ba06-4ded-a027-9e2c11b164e9" xlink:to="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_331cd471-2ae7-49ca-805c-5dd1c1b23694" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66188c55-7573-4c4d-b498-6a1a9fef593b" xlink:to="loc_cmps_OrdinarySharesMember_331cd471-2ae7-49ca-805c-5dd1c1b23694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d631a98-4ab0-4f80-9309-39864e20d76b" xlink:to="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f77da4e-17ab-4be3-bb9a-00b26297c632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ecb3663-3bed-41ec-960a-21c961141887" xlink:to="loc_us-gaap_CommonStockMember_0f77da4e-17ab-4be3-bb9a-00b26297c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_30afcbb2-67b5-424b-bad3-3851308b47da" xlink:to="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020AwardMember_15bcdeb4-4852-4775-9500-fa7aadc1f698" xlink:href="cmps-20220930.xsd#cmps_A2020AwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_52e40623-6e27-4933-844a-f364ef3366b6" xlink:to="loc_cmps_A2020AwardMember_15bcdeb4-4852-4775-9500-fa7aadc1f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a4558820-a277-43bf-9164-9b4fe868e881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41192db-42ca-4927-bf4f-e4f73d8cbe05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9f1d287-f6e7-4b45-9682-402c1cd530c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41192db-42ca-4927-bf4f-e4f73d8cbe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ec7b30f-4848-4ace-97f3-c6264069291d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7a9498e7-4967-44d5-ac3c-ab572a6f991d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_edc3f6a2-848d-4b1a-a027-fd6eb7cb88b5" xlink:to="loc_us-gaap_IPOMember_7a9498e7-4967-44d5-ac3c-ab572a6f991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d4ad3a1d-6cd1-49d1-9949-27e5570a507e" xlink:to="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27b06bf5-4176-4df5-8cbf-07ff312433bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27b06bf5-4176-4df5-8cbf-07ff312433bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2de600a8-003b-4f5f-9ffa-df890614ee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2de600a8-003b-4f5f-9ffa-df890614ee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_51041402-de2c-49bd-b305-f212d483d110" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod_51041402-de2c-49bd-b305-f212d483d110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ec61483e-56db-4902-83ef-93583b3674da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ec61483e-56db-4902-83ef-93583b3674da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_b828253e-96e1-4f7f-ba6f-78f4319e1ca3" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled_b828253e-96e1-4f7f-ba6f-78f4319e1ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e14a4da-37de-4831-ab32-37be581c78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e14a4da-37de-4831-ab32-37be581c78c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c689d6f-0bce-4137-96af-48d5b4bd9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c689d6f-0bce-4137-96af-48d5b4bd9e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8115f635-4708-4c05-8f95-3c7ce5e26f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8115f635-4708-4c05-8f95-3c7ce5e26f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVotes_c5b45737-a384-454b-b8d9-298a3d74b8a2" xlink:href="cmps-20220930.xsd#cmps_NumberOfVotes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_NumberOfVotes_c5b45737-a384-454b-b8d9-298a3d74b8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod_5655d1d9-8d9f-46af-a2db-8fae60da7759" xlink:href="cmps-20220930.xsd#cmps_CashDividendDeclaredOrPaidDuringPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8b264e2-2548-463b-a9d2-b6ea54e7f674" xlink:to="loc_cmps_CashDividendDeclaredOrPaidDuringPeriod_5655d1d9-8d9f-46af-a2db-8fae60da7759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24dab3b9-0289-4ab3-b156-08f839d79cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24dab3b9-0289-4ab3-b156-08f839d79cd3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a8762323-d614-45e0-b926-f1da21930467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_6e54cd73-2686-4ce5-8d50-a038667ba634" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_cmps_OrdinarySharesMember_6e54cd73-2686-4ce5-8d50-a038667ba634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5beede4e-76fb-4051-aa67-c995e17c7552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5beede4e-76fb-4051-aa67-c995e17c7552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34abd334-86ee-4001-bb2c-7bc7b859a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd971694-5bd5-4029-ac17-e672fa60f66d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34abd334-86ee-4001-bb2c-7bc7b859a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14910590-b5b4-48d9-9526-2b02b15e1410" xlink:to="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_5b430d04-1c16-4329-954e-983499cb51f7" xlink:href="cmps-20220930.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_75ca02d2-a3b9-4a11-a809-98b1d731b254" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_5b430d04-1c16-4329-954e-983499cb51f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c11065c-6335-4d1e-ba83-e5d4b1bcef90" xlink:to="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f37cf96d-98cb-4581-a64b-a897cf5658d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:to="loc_srt_MinimumMember_f37cf96d-98cb-4581-a64b-a897cf5658d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5431513c-d634-4365-b70b-3d9d7ffb599a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0eaa11f1-3fb0-4efe-8a65-1065e8a56ddf" xlink:to="loc_srt_MaximumMember_5431513c-d634-4365-b70b-3d9d7ffb599a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_b9c13522-8204-4747-8a59-ca6504d218e9" xlink:to="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c218e148-5fb5-4c8c-a05b-449a0c07ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c218e148-5fb5-4c8c-a05b-449a0c07ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_152ecb2f-c1fd-4917-953e-1d1da9985d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f5586f74-d36d-415b-9cce-658a35e3a73d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_152ecb2f-c1fd-4917-953e-1d1da9985d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_ba6cedb8-e5f7-4bdf-8189-ac3b07371f80" xlink:to="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_65f99a16-b3c7-4813-a4ec-567707bb1e60" xlink:href="cmps-20220930.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_65f99a16-b3c7-4813-a4ec-567707bb1e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_dad842b4-1843-4725-901c-d396c70cce53" xlink:href="cmps-20220930.xsd#cmps_GrantDateJune302020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_850b305d-3a2f-439e-bdf0-0a018d64d011" xlink:to="loc_cmps_GrantDateJune302020Member_dad842b4-1843-4725-901c-d396c70cce53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdf4a83-c9cd-4fa6-81f2-0d0303bbf3f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_97b9b0ac-f821-488f-ad9d-a7b5281ad774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_97b9b0ac-f821-488f-ad9d-a7b5281ad774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_698dfd10-238d-43bc-a3be-47ea6f53e695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ed17076-706d-42fc-b120-1e154f936bc6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_698dfd10-238d-43bc-a3be-47ea6f53e695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f0f0d4-b0da-48c1-a55e-7b48af766a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_691293ee-6e26-4b70-bf41-1b59068f5213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_691293ee-6e26-4b70-bf41-1b59068f5213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eea2dd6e-4806-4452-9ca1-e69537cf6d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eea2dd6e-4806-4452-9ca1-e69537cf6d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7e67f28e-5d5d-45ec-9b19-dd1c4da023e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7e67f28e-5d5d-45ec-9b19-dd1c4da023e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_86a08004-48d4-4bb5-b3d6-a21a68feaafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_86a08004-48d4-4bb5-b3d6-a21a68feaafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_66f823da-4f40-4d12-991f-2fc14f003f1c" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_66f823da-4f40-4d12-991f-2fc14f003f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_c4ddc6ee-092d-4a94-9490-de9e9a9200db" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df4af627-a6f3-4e49-a49e-769f967c36bc" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_c4ddc6ee-092d-4a94-9490-de9e9a9200db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb8d5348-f254-478d-8991-6503476a40ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb8d5348-f254-478d-8991-6503476a40ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:to="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60bd7f84-f6d6-4009-99db-2e68ff2c23d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bed9bd41-2101-4fd6-acdd-f9b357b7411a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a7b154-4385-4791-9583-342aa9aa658e" xlink:to="loc_us-gaap_EmployeeStockMember_bed9bd41-2101-4fd6-acdd-f9b357b7411a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e256455-a0d5-499b-9d28-d30eadc9452b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24732752-dcbf-4542-ad31-e327fd889c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24732752-dcbf-4542-ad31-e327fd889c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_9b757ca4-3d3d-456d-a37b-621ceaf4ead3" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_9b757ca4-3d3d-456d-a37b-621ceaf4ead3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_9f91425f-b307-460b-9365-c4eb48755723" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_9f91425f-b307-460b-9365-c4eb48755723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_26857a57-d4a8-4d03-8b66-0148175f3190" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_26857a57-d4a8-4d03-8b66-0148175f3190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3c25741a-9ba4-49f3-b43a-f1b8b22ca358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99d11e53-90e6-4b2c-8933-0b027cf0ac45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3c25741a-9ba4-49f3-b43a-f1b8b22ca358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045c84e5-893a-4be0-a23d-a82627ecf644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045c84e5-893a-4be0-a23d-a82627ecf644" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b765c736-059e-4099-b7bf-184cd7e26c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_85a981ed-371b-4381-b70d-92a63cca08dc" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_cmps_OrdinarySharesMember_85a981ed-371b-4381-b70d-92a63cca08dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7e85723a-ff99-4bb7-b3bd-ef49f47348fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_us-gaap_EmployeeStockMember_7e85723a-ff99-4bb7-b3bd-ef49f47348fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonEmployeeMember_98c0dd78-1890-490b-88e4-cb49d26b67b0" xlink:href="cmps-20220930.xsd#cmps_NonEmployeeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cf9dd80-cd91-4df0-b827-0124a333da52" xlink:to="loc_cmps_NonEmployeeMember_98c0dd78-1890-490b-88e4-cb49d26b67b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ac03abda-e82f-4d63-b632-a1c67c913c18" xlink:to="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_ac93821a-49f5-4708-85fb-96a8940fb2f8" xlink:href="cmps-20220930.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2a866f8-4cbb-45a6-85b9-e86138433076" xlink:to="loc_cmps_A2020ShareOptionPlanMember_ac93821a-49f5-4708-85fb-96a8940fb2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9337e56e-ee18-49ec-9ebb-60fb3e94494f" xlink:to="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_161e4a37-3385-4e7a-8458-0f4a9f9a435a" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f87deb77-737d-4d17-af90-22b40b7739e0" xlink:to="loc_cmps_OrdinarySharesMember_161e4a37-3385-4e7a-8458-0f4a9f9a435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5160fbfc-cfc1-404c-b457-8c8ba64e7241" xlink:to="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_78d09f68-2842-4608-bbd5-8b14647083c8" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_78d09f68-2842-4608-bbd5-8b14647083c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_22b7b181-32c6-4a9f-b715-7e3cba73d55a" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_22b7b181-32c6-4a9f-b715-7e3cba73d55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_9bb6806e-c49d-4677-9686-a626fcf49840" xlink:href="cmps-20220930.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b87d3fda-7afd-4aa2-86af-0cf3cfb5c156" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_9bb6806e-c49d-4677-9686-a626fcf49840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc40e995-a28b-4083-babb-731a7ae274dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b688ddf-ef9c-4fc9-b717-18d25ce3a092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b688ddf-ef9c-4fc9-b717-18d25ce3a092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f6f3768-6e92-4f7f-be29-72777c2722f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f6f3768-6e92-4f7f-be29-72777c2722f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e25302a9-62c5-475a-b22d-4706fc07a485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e25302a9-62c5-475a-b22d-4706fc07a485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5efe5af9-e5fe-42b5-bffd-378f312af13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5efe5af9-e5fe-42b5-bffd-378f312af13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99825dcb-d2e0-476a-97fc-31f7c2c153d8" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99825dcb-d2e0-476a-97fc-31f7c2c153d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_714ff679-8786-4cb6-81f0-28a78fbebbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_SharesIssued_714ff679-8786-4cb6-81f0-28a78fbebbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_476c7eba-86da-490c-bec3-4ce75263c9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_476c7eba-86da-490c-bec3-4ce75263c9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f382a325-c235-41f0-a0c5-25f98fe5c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57154765-d1d6-4158-9ab3-f936968edfeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f382a325-c235-41f0-a0c5-25f98fe5c8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e00dd25-3ae3-42dc-b98c-5b76b95e0ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e00dd25-3ae3-42dc-b98c-5b76b95e0ba7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7e2d94be-01e9-4f23-9e79-7d0aa5350e96" xlink:to="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_23b7091d-ec72-45bb-8598-ce9c91be78b2" xlink:href="cmps-20220930.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_34f4d33a-f041-4eab-a106-6e7cac638f02" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_23b7091d-ec72-45bb-8598-ce9c91be78b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_cdee1816-5350-4978-9eb0-09c3aa458199" xlink:to="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a456021d-1d59-4281-b40c-0fa5eee0deeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a456021d-1d59-4281-b40c-0fa5eee0deeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_72387ad7-7dad-4a96-afcc-9aaed400aaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7e60c539-b113-4526-b0e6-7e27fb96c5a8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_72387ad7-7dad-4a96-afcc-9aaed400aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7277421a-349d-43a8-91df-632d96bed744" xlink:to="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_e47ae2f0-0457-47eb-bb8d-72a0ae567463" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1cf06e12-f128-4ab8-8849-976a2689cba9" xlink:to="loc_cmps_OrdinarySharesMember_e47ae2f0-0457-47eb-bb8d-72a0ae567463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c615bb08-8d20-4fae-84cd-dd7e464d22ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7a7ff29-c72c-4c50-99ee-399673b41887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f7a7ff29-c72c-4c50-99ee-399673b41887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_328f112b-5bf2-422a-990d-20bd5ecfebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_328f112b-5bf2-422a-990d-20bd5ecfebfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5a8a98bb-1165-45d5-a6fb-3fdd7d450775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5a8a98bb-1165-45d5-a6fb-3fdd7d450775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0887427-fcd4-4586-b593-04b7bea89cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773a1c21-b383-4030-9931-c8e881f7a43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0887427-fcd4-4586-b593-04b7bea89cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationRestrictedShareUnitDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74e4b948-d6db-4575-8a7f-ac080ef26680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74e4b948-d6db-4575-8a7f-ac080ef26680" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:to="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e58cd9a-43f2-4c6d-95ae-c467cc586559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0afa14-2078-4ff8-8ee0-5c9f1ca3037f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60ee841e-27ad-4247-a492-807f25f1ac18" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0afa14-2078-4ff8-8ee0-5c9f1ca3037f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6823fff1-e97e-4757-a999-35cf5ec7937b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_601e52be-f1df-4c46-b0ed-52925f503f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_601e52be-f1df-4c46-b0ed-52925f503f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ae6b9350-d9e6-43e8-a8bb-570bdcc9f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ae6b9350-d9e6-43e8-a8bb-570bdcc9f3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906f13b2-7c56-44ed-b777-20758469b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906f13b2-7c56-44ed-b777-20758469b1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b98a4955-4159-4792-9ecf-51fb338c9379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b98a4955-4159-4792-9ecf-51fb338c9379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_90552da7-a41b-4a9c-a504-8912ab16e5b4" xlink:href="cmps-20220930.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_90552da7-a41b-4a9c-a504-8912ab16e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_8ff58880-448c-42a5-97ab-4fdb0b6d1a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_8ff58880-448c-42a5-97ab-4fdb0b6d1a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_9dc3d8b0-4f48-4389-8180-ad81f837705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_9dc3d8b0-4f48-4389-8180-ad81f837705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1cecfe9f-062b-4ea8-8f53-9f5e8e5f9265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1cecfe9f-062b-4ea8-8f53-9f5e8e5f9265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_61a7520c-ac5c-42fa-9250-9eb8e007d136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_61a7520c-ac5c-42fa-9250-9eb8e007d136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3b37e7cd-1aa2-4a80-a095-519b91faec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3b37e7cd-1aa2-4a80-a095-519b91faec0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_bc580387-8237-4e0f-a2b2-e058db0b9239" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8854593f-0de1-421e-93e4-add346f137df" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_bc580387-8237-4e0f-a2b2-e058db0b9239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#SharebasedCompensationShareOptionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0523bdd-3025-4d45-bb22-9f828e0c9315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0523bdd-3025-4d45-bb22-9f828e0c9315" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:to="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a86f85e8-c4c4-40fd-b450-0bca0df7f4b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b912d3a-06c4-443e-9517-71ebd80bfb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71b3d07e-29ef-4a09-8151-6558fc308d18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b912d3a-06c4-443e-9517-71ebd80bfb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133ea24b-45e8-4f45-b358-7d22d77bbf75" xlink:to="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_cbeed9e9-9722-4cbc-86c8-503504670e0e" xlink:href="cmps-20220930.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_660bbbc3-2ced-465c-8bb5-7d625f99bfa0" xlink:to="loc_cmps_OrdinarySharesMember_cbeed9e9-9722-4cbc-86c8-503504670e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52917b6d-c060-4307-8998-d0d08fa42ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_205980f6-bc4c-45df-8dc5-c6b502da3aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_205980f6-bc4c-45df-8dc5-c6b502da3aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e644050-5785-4e88-8590-60d1aacb83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6e644050-5785-4e88-8590-60d1aacb83cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f131797-423a-4ffc-ad26-c984c48286b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f131797-423a-4ffc-ad26-c984c48286b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e75fb121-320f-46d6-b456-521a9b6f8d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e75fb121-320f-46d6-b456-521a9b6f8d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_169d1061-b438-44bd-a94d-6e9ac6e5e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_169d1061-b438-44bd-a94d-6e9ac6e5e670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_03e0ce45-96e0-4296-bd3f-67c2e518c838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_03e0ce45-96e0-4296-bd3f-67c2e518c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fc003072-4edd-407b-bce9-4933d8470d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40276183-ba21-4054-aa4a-d6c8a8fadb06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fc003072-4edd-407b-bce9-4933d8470d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc121d53-0e50-4b97-b0a7-b961e5c83c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc121d53-0e50-4b97-b0a7-b961e5c83c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_79b7b0df-5d16-4994-92b2-96b5c6878b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_79b7b0df-5d16-4994-92b2-96b5c6878b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24ad4faf-a42b-4afb-8968-c25958aeb23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24ad4faf-a42b-4afb-8968-c25958aeb23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fede6213-1dc5-40da-878a-1a9ee1523219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fede6213-1dc5-40da-878a-1a9ee1523219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f62d4aa1-27ed-4a40-bb4e-8aec79df8392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f62d4aa1-27ed-4a40-bb4e-8aec79df8392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b8ec4d77-25c5-4c10-8882-8bc3be5b4993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b8ec4d77-25c5-4c10-8882-8bc3be5b4993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1afc7665-d281-48e1-a7a4-c5c922ca30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e984b606-8d11-44c1-ba80-0d25f76e784b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1afc7665-d281-48e1-a7a4-c5c922ca30fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d6005a6c-25fc-4f1a-b3d5-82cc52eb1a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d6005a6c-25fc-4f1a-b3d5-82cc52eb1a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dea8285-167a-40de-b743-18c6267e5180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dea8285-167a-40de-b743-18c6267e5180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_b44a8a8b-1c38-4d49-ab42-644282b11158" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_b44a8a8b-1c38-4d49-ab42-644282b11158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0002f142-04ca-442e-8ba7-4e83006f3868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0002f142-04ca-442e-8ba7-4e83006f3868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0dd015d6-05e2-4740-8372-bba0d1f9929c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0dd015d6-05e2-4740-8372-bba0d1f9929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27a33388-67f1-43de-b690-06e4a57f7f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_67105104-e53a-42f3-ac48-c1b1a4cc75e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27a33388-67f1-43de-b690-06e4a57f7f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4dddbbe7-bd0a-4868-b7a6-5c41883bbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4dddbbe7-bd0a-4868-b7a6-5c41883bbc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3ef4529-4ef1-4fb1-b9c2-8ab24a09f893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3ef4529-4ef1-4fb1-b9c2-8ab24a09f893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_542ff40b-d1a1-453e-8a1a-dbbdd446cac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_542ff40b-d1a1-453e-8a1a-dbbdd446cac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bb145a3c-9a27-437c-841b-1b1b4576eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7b16c2b-5f10-4ea2-8857-bd03f7a54a1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bb145a3c-9a27-437c-841b-1b1b4576eee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationScheduleofValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_487c7c78-38ef-4f09-b960-805c413b8ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_487c7c78-38ef-4f09-b960-805c413b8ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc8a124c-0d79-4517-b28d-b7b1c6415036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc8a124c-0d79-4517-b28d-b7b1c6415036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96730bf7-e723-4b92-a4f9-fb036406fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96730bf7-e723-4b92-a4f9-fb036406fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8f0c5ccc-08d8-44cb-86ab-3e3a67008f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8f0c5ccc-08d8-44cb-86ab-3e3a67008f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_2bafabbf-fdf6-4f43-b99c-0ec66a9f71e6" xlink:href="cmps-20220930.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_751abef8-5319-445a-ad0d-2f2d546f87f7" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_2bafabbf-fdf6-4f43-b99c-0ec66a9f71e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_407223dc-ff36-4081-b45a-88392b81d628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_407223dc-ff36-4081-b45a-88392b81d628" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2dc41d3a-c55f-466f-8034-d491509c76db" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e13f32b8-5c16-4edc-a86c-5e147add89a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e13f32b8-5c16-4edc-a86c-5e147add89a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47d4603d-863c-40b4-ab24-42d442830aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0bf54692-d81c-42a5-92a2-c6b09d473f4f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47d4603d-863c-40b4-ab24-42d442830aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4dfc10d-2063-493a-af05-1abe088be6f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_91808cbc-199a-4bd6-b050-3d5f715ae2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b17b175d-dd2e-46ef-828e-cad480a80765" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_91808cbc-199a-4bd6-b050-3d5f715ae2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be440e9c-01dd-42a0-bb02-5709dd21081e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_NetIncomeLoss_be440e9c-01dd-42a0-bb02-5709dd21081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d04f748-944d-422e-9533-8cafb447d673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8d04f748-944d-422e-9533-8cafb447d673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c355fdc1-7f05-4264-93d7-36571e4f91be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c355fdc1-7f05-4264-93d7-36571e4f91be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_832279e5-3886-4a04-b20e-4a4b334985fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_832279e5-3886-4a04-b20e-4a4b334985fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e02da8ec-e6ba-47ef-863d-722f012c1efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e02da8ec-e6ba-47ef-863d-722f012c1efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4940f9e3-8e32-469c-b895-1377f6e8eb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_EarningsPerShareBasic_4940f9e3-8e32-469c-b895-1377f6e8eb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d403845b-8e08-43ae-a7d7-5493492dd72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_567bf5c3-fe80-4b1d-8b04-2b601c438ab9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d403845b-8e08-43ae-a7d7-5493492dd72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f85b0cf-0508-40b4-9226-2b9b3dcd597d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f85b0cf-0508-40b4-9226-2b9b3dcd597d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9903eb8a-0b31-4315-b0b7-89c9c16145ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_6fb970c0-aeca-4011-b423-81d5762e7194" xlink:href="cmps-20220930.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_6fb970c0-aeca-4011-b423-81d5762e7194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fe244373-b131-49c7-98c1-c40540391c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fe244373-b131-49c7-98c1-c40540391c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_525fa151-91cb-405d-a719-5b04bf325aff" xlink:href="cmps-20220930.xsd#cmps_ShareOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cea7819-57a6-4ec7-a200-76ee454dd463" xlink:to="loc_cmps_ShareOptionsMember_525fa151-91cb-405d-a719-5b04bf325aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fb542a7f-6451-40a8-b1a3-a5fab31320f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_da923fbc-8b86-4da5-89a6-c9d6095feef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0e1855b6-bcbb-4052-a80c-0c64406b737f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_da923fbc-8b86-4da5-89a6-c9d6095feef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a7a4f7f4-ba2b-4862-859c-440e487ae9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7a4f7f4-ba2b-4862-859c-440e487ae9c0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:to="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_56548ec5-6a86-4688-81b9-5909a9a2a705" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EastbourneTerraceLondonUKMember_ad9ecbb7-371c-4738-92b8-49217cf53c5a" xlink:href="cmps-20220930.xsd#cmps_EastbourneTerraceLondonUKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_EastbourneTerraceLondonUKMember_ad9ecbb7-371c-4738-92b8-49217cf53c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NewYorkNYMember_d60c3f1f-49d9-4947-a0b1-fe069f301af3" xlink:href="cmps-20220930.xsd#cmps_NewYorkNYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_NewYorkNYMember_d60c3f1f-49d9-4947-a0b1-fe069f301af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember_67b2bb27-b6e5-467b-908c-40abcd200e3e" xlink:href="cmps-20220930.xsd#cmps_SohoLondonUKMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_SohoLondonUKMember_67b2bb27-b6e5-467b-908c-40abcd200e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SanFranciscoCAMember_5e53bb71-68ce-4bfc-b84d-fa3be736250b" xlink:href="cmps-20220930.xsd#cmps_SanFranciscoCAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_SanFranciscoCAMember_5e53bb71-68ce-4bfc-b84d-fa3be736250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember_73d274f2-f550-474a-bf45-526dea58b442" xlink:href="cmps-20220930.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_DenmarkHillLondonUKMember_73d274f2-f550-474a-bf45-526dea58b442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember_cadd73d1-152c-48fb-8c00-e11856516619" xlink:href="cmps-20220930.xsd#cmps_WeWorkMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf36b43c-3c6a-46c1-bda1-e13532cb3cad" xlink:to="loc_cmps_WeWorkMember_cadd73d1-152c-48fb-8c00-e11856516619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1036df7b-fbdd-4da4-b68c-11cf4c1c879c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_41638c62-377b-4a78-8737-704faf6f60c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_NetRentableArea_41638c62-377b-4a78-8737-704faf6f60c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod_c035941a-3e90-4ba9-b09c-580874cabf5e" xlink:href="cmps-20220930.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_LeaseCancellationNotificationPeriod_c035941a-3e90-4ba9-b09c-580874cabf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc0bc798-3c73-4068-ae8f-537c78bc680b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc0bc798-3c73-4068-ae8f-537c78bc680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AnnualLeasePayment_b1478c9b-089c-479d-a1c0-f4469036043e" xlink:href="cmps-20220930.xsd#cmps_AnnualLeasePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_AnnualLeasePayment_b1478c9b-089c-479d-a1c0-f4469036043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_40794cd2-7db8-4596-a9dc-6f390c084f0b" xlink:href="cmps-20220930.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_RefundableLeaseDepositPayments_40794cd2-7db8-4596-a9dc-6f390c084f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseRentalRelief_6f6ebb41-b038-4904-9469-013aa64db44d" xlink:href="cmps-20220930.xsd#cmps_LeaseRentalRelief"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_LeaseRentalRelief_6f6ebb41-b038-4904-9469-013aa64db44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_7580db36-e25e-418d-bd3b-5db876167bbb" xlink:href="cmps-20220930.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_7580db36-e25e-418d-bd3b-5db876167bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_e71f0d11-55ef-4c4f-a758-7c1e915db867" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_e71f0d11-55ef-4c4f-a758-7c1e915db867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRent_fabbd3d1-61e4-49e0-bb8c-33b39dccbbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_us-gaap_AdvanceRent_fabbd3d1-61e4-49e0-bb8c-33b39dccbbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment_a06bc7f3-5bd6-4be4-a3da-5afd6edd60fc" xlink:href="cmps-20220930.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74af220c-bc51-4fba-a43a-aefa97c46073" xlink:to="loc_cmps_OperatingLeaseAnnualPayment_a06bc7f3-5bd6-4be4-a3da-5afd6edd60fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_67d0fce9-9fc6-404d-9e7d-63818adf643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d0fce9-9fc6-404d-9e7d-63818adf643b" xlink:to="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a4381620-c545-470b-b4ed-f4140780cd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:to="loc_us-gaap_OperatingLeaseCost_a4381620-c545-470b-b4ed-f4140780cd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VariableLeaseCostLeaseIncentiveReceived_9d998c03-d616-4a1a-8d3a-d5afab683965" xlink:href="cmps-20220930.xsd#cmps_VariableLeaseCostLeaseIncentiveReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:to="loc_cmps_VariableLeaseCostLeaseIncentiveReceived_9d998c03-d616-4a1a-8d3a-d5afab683965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9367ce83-9b5d-4f04-b588-48077011276d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:to="loc_us-gaap_ShortTermLeaseCost_9367ce83-9b5d-4f04-b588-48077011276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bd572d00-5831-4a4b-a0bd-010e354dfbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d8c9f6d-1826-4e4d-8609-e8e2c032b1f6" xlink:to="loc_us-gaap_LeaseCost_bd572d00-5831-4a4b-a0bd-010e354dfbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:href="cmps-20220930.xsd#cmps_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d0fce9-9fc6-404d-9e7d-63818adf643b" xlink:to="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_dbcc0b0c-dcc5-486a-af51-39001dfe6feb" xlink:href="cmps-20220930.xsd#cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:to="loc_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_dbcc0b0c-dcc5-486a-af51-39001dfe6feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2941f8ba-c677-47e5-8688-8a76e908dbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:to="loc_us-gaap_OperatingLeasePayments_2941f8ba-c677-47e5-8688-8a76e908dbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bad1aeee-a6ac-4edc-a161-d5cad71b64ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bad1aeee-a6ac-4edc-a161-d5cad71b64ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc42810e-c613-488b-a361-924e0003696e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_40afa42f-692d-4c6f-9d7a-8a57a7f5e0f0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc42810e-c613-488b-a361-924e0003696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_817e8122-d2f8-41ec-abf3-89505581bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_817e8122-d2f8-41ec-abf3-89505581bcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8f842c7-6b85-4181-8ce3-75ec7cb3f509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8f842c7-6b85-4181-8ce3-75ec7cb3f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4989520-427f-4054-9859-8d7dc2ed3ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4989520-427f-4054-9859-8d7dc2ed3ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7af6fae0-a827-476f-b014-8ee75857c5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7af6fae0-a827-476f-b014-8ee75857c5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_09f13da1-cd5c-47a8-b476-31fc50c01a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_09f13da1-cd5c-47a8-b476-31fc50c01a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bda8270-c554-416e-9b4c-af1333c19c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bda8270-c554-416e-9b4c-af1333c19c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c16fb907-2d13-4fd6-9a6d-8f38d6d9128e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c16fb907-2d13-4fd6-9a6d-8f38d6d9128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3778e62a-9539-4844-9b65-27cf90bea4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09552b37-9253-489b-9597-68fdd8a92b0c" xlink:to="loc_us-gaap_OperatingLeaseLiability_3778e62a-9539-4844-9b65-27cf90bea4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="simple" xlink:href="cmps-20220930.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://compasspathways.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cmps-20220930.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3e49849-8c79-4867-9b20-b8e4f2af9e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7fe7ba8a-6357-44df-a431-0a692d9e4787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3e49849-8c79-4867-9b20-b8e4f2af9e6f" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7fe7ba8a-6357-44df-a431-0a692d9e4787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_a8c22835-c649-4ea4-b3bb-36b5267683cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a3e49849-8c79-4867-9b20-b8e4f2af9e6f" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_a8c22835-c649-4ea4-b3bb-36b5267683cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372379552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPASS Pathways plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">33 Broadwick Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1F 0DQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">-6461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMPS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,576,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374815632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 173,076<span></span>
</td>
<td class="nump">$ 273,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income tax</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">44,755<span></span>
</td>
<td class="nump">21,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">218,451<span></span>
</td>
<td class="nump">295,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,338<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">224,520<span></span>
</td>
<td class="nump">300,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,885<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">7,817<span></span>
</td>
<td class="nump">10,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,831<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,533<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,958<span></span>
</td>
<td class="nump">16,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">454,957<span></span>
</td>
<td class="nump">444,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)/income</a></td>
<td class="num">(30,643)<span></span>
</td>
<td class="nump">8,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(230,220)<span></span>
</td>
<td class="num">(169,641)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">194,562<span></span>
</td>
<td class="nump">284,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">224,520<span></span>
</td>
<td class="nump">300,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary and deferred shares</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember', window );">DEFERRED SHARES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary and deferred shares</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374832096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">42,554,384<span></span>
</td>
<td class="nump">42,019,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">42,554,384<span></span>
</td>
<td class="nump">42,019,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">42,554,384<span></span>
</td>
<td class="nump">42,019,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember', window );">DEFERRED SHARES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372445520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 13,977<span></span>
</td>
<td class="nump">$ 12,197<span></span>
</td>
<td class="nump">$ 45,259<span></span>
</td>
<td class="nump">$ 30,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,559<span></span>
</td>
<td class="nump">9,571<span></span>
</td>
<td class="nump">32,953<span></span>
</td>
<td class="nump">24,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,536<span></span>
</td>
<td class="nump">21,768<span></span>
</td>
<td class="nump">78,212<span></span>
</td>
<td class="nump">54,898<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS:</a></td>
<td class="num">(25,536)<span></span>
</td>
<td class="num">(21,768)<span></span>
</td>
<td class="num">(78,212)<span></span>
</td>
<td class="num">(54,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,580<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">9,982<span></span>
</td>
<td class="nump">6,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">7,285<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
<td class="nump">17,949<span></span>
</td>
<td class="nump">8,906<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(18,251)<span></span>
</td>
<td class="num">(15,786)<span></span>
</td>
<td class="num">(60,263)<span></span>
</td>
<td class="num">(45,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,371)<span></span>
</td>
<td class="num">(15,849)<span></span>
</td>
<td class="num">(60,579)<span></span>
</td>
<td class="num">(46,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(15,156)<span></span>
</td>
<td class="num">(8,401)<span></span>
</td>
<td class="num">(39,483)<span></span>
</td>
<td class="num">(6,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (33,527)<span></span>
</td>
<td class="num">$ (24,250)<span></span>
</td>
<td class="num">$ (100,062)<span></span>
</td>
<td class="num">$ (52,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">42,525,855<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="nump">42,377,895<span></span>
</td>
<td class="nump">39,378,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,525,855<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="nump">42,377,895<span></span>
</td>
<td class="nump">39,378,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416365804864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders&#8217; Equity<br> $ in Thousands</strong></div></th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>2021 Award </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>2020 Award </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>2021 Award </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>2020 Award </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ACCUMULATED DEFICIT </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>Common stock </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>Common stock </div>
<div>2021 Award </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>Common stock </div>
<div>2020 Award </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>DEFERRED SHARES </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>DEFERRED SHARES </div>
<div>Common stock </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,930,331,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 196,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,585<span></span>
</td>
<td class="num">$ (97,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,743,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">188,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,573<span></span>
</td>
<td class="num">(110,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,930,331,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">196,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
<td class="num">(97,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,731,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">305,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
<td class="num">(143,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,743,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">188,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,573<span></span>
</td>
<td class="num">(110,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">154,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,695,335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">327,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,218<span></span>
</td>
<td class="num">(128,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(8,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,731,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">305,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
<td class="num">(143,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,019,874<span></span>
</td>
<td class="nump">42,019,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">284,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,840<span></span>
</td>
<td class="num">(169,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(7,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,464,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">259,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="num">(190,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,019,874<span></span>
</td>
<td class="nump">42,019,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 284,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,840<span></span>
</td>
<td class="num">(169,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="nump">461,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,554,384<span></span>
</td>
<td class="nump">42,554,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">194,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,643)<span></span>
</td>
<td class="num">(230,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,464,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">259,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="num">(190,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(17,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,522,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">224,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,487)<span></span>
</td>
<td class="num">(211,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,887,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(15,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,554,384<span></span>
</td>
<td class="nump">42,554,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 194,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,643)<span></span>
</td>
<td class="num">$ (230,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416373498352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,371)<span></span>
</td>
<td class="num">$ (15,849)<span></span>
</td>
<td class="num">$ (60,579)<span></span>
</td>
<td class="num">$ (46,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Non-cash gain on foreign currency remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,842<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,810<span></span>
</td>
<td class="nump">5,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,141)<span></span>
</td>
<td class="num">(6,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred and prepaid tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,813)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,018<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,253)<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,149)<span></span>
</td>
<td class="num">(45,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">155,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,879)<span></span>
</td>
<td class="num">(6,517)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease)/increase in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,116)<span></span>
</td>
<td class="nump">103,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,347<span></span>
</td>
<td class="nump">190,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">173,231<span></span>
</td>
<td class="nump">294,063<span></span>
</td>
<td class="nump">173,231<span></span>
</td>
<td class="nump">294,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="nump">5,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ProceedsFromStockOptionsExercisedNotReceived', window );">Proceeds from exercise of options were received and recorded in other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_DeferredOfferingCostsIncludedInAccruedExpenses', window );">Deferred issuance costs included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">173,076<span></span>
</td>
<td class="nump">293,959<span></span>
</td>
<td class="nump">173,076<span></span>
</td>
<td class="nump">293,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Short-term restricted cash</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 173,231<span></span>
</td>
<td class="nump">$ 294,063<span></span>
</td>
<td class="nump">$ 173,231<span></span>
</td>
<td class="nump">$ 294,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_DeferredOfferingCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included In Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_DeferredOfferingCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ProceedsFromStockOptionsExercisedNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised, Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ProceedsFromStockOptionsExercisedNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adioption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416377601920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and more recently through the sale of American Depository Shares, or ADSs, in connection with the Company&#8217;s initial public offering, or the IPO, in September 2020, and its $154.8&#160;million May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. The Company has not yet sold any ADSs under this at-the-market offering. The Company has incurred recurring losses since its inception, including net losses of $60.6 million and $46.1 million for the nine months ended September 30, 2022 and 2021, respectively. In addition, as of September&#160;30, 2022, the Company had an accumulated deficit of $230.2 million. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the cash and cash equivalents on hand as of September&#160;30, 2022 of $173.1 million will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, the Company continues to assess its business plans and the additional impact which resurgences or the emergence of new variants of COVID-19 may have on its ability to advance the development and manufacturing of COMP360 as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom it relies, or to raise further financing to support the development of its investigational COMP360 psilocybin therapy. While many measures have been put in place to attempt to contain the spread of COVID-19 resurgences, including existing or future variants, no assurances can be given that the Company will avoid any future impact from the ongoing COVID-19 pandemic or the emergence of new variants, including any direct or indirect impacts arising as a result of downturns in business sentiment generally or in its sector in particular, impacts on global supply chains, or other effects. The Company cannot currently predict the scope and severity of any future potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies or with whom the Company conducts business were to experience additional shutdowns or other business disruptions, the Company&#8217;s ability to conduct its business in the manner and on the timelines presently planned could be materially and adversely impacted.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416377717856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September 30, 2022, the results of its operations and comprehensive loss for the three months and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three months and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 24, 2022. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before the Company&#8217;s IPO, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of September&#160;30, 2022 and December 31, 2021 represents a collateral deposit for employee credit cards. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the inputs for the first two are considered observable and the inputs for the last are considered unobservable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for the Company&#8217;s cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimated the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 9 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the absence of an active market for the Company&#8217;s ordinary shares prior to the IPO, the Company and the board of directors of the Company, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s ordinary shares at the time of each grant of a stock-based award prior to the IPO. The grant date fair value of restricted ordinary shares and share options were calculated based on the grant date fair value of the underlying ordinary shares. The Company calculated the fair value of the ordinary shares in accordance with the guidelines in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the &#8220;Practice Aid&#8221;. The Company&#8217;s valuations of ordinary shares were prepared using a market approach, based on precedent transactions in the shares, to estimate the Company&#8217;s total equity value using an option-pricing method, or OPM. After the Company&#8217;s IPO, the fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OPM derives an equity value such that the value indicated for ordinary shares is consistent with the investment price, and it provides an allocation of this equity value to each of the Company&#8217;s securities. The OPM treats the various classes of ordinary shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the share liquidation preferences of ordinary shares with senior preferences at the time of the liquidity event. Key inputs into the OPM calculation included the risk-free rate, expected time to liquidity and volatility. A reasonable discount for lack of marketability was applied to the total equity value to arrive at an estimate of the total fair value of equity on a non-marketable basis.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 11 for right-of-use assets and liabilities recorded during the periods ended September 30, 2022 and 2021 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is Pound Sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded foreign exchange gains of approximately $1.1 million and $3.4 million for the three months ended September&#160;30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded a foreign exchange gain of $4.4 million and $2.2 million respectively. These gains arise from U.S. dollars which are held in a financial institution in one of our UK subsidiaries that has a functional currency of Pound Sterling.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, the condensed consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting currency. The financial statements of entities are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other income, net are translated at the average exchange rates for the periods presented and shareholders&#8217; equity is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standard Update, or ASU, 2019-12, &#8220;Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740),&#8221; or ASU 740, which simplifies the accounting for income taxes. The new guidance removes certain exceptions to the general principles in ASC 740 such as recognizing deferred taxes for equity investments, the incremental approach to performing intra-period tax allocation and calculating income taxes in interim periods. The standard also simplifies accounting for income taxes under U.S. GAAP by clarifying and amending existing guidance, including the recognition of deferred taxes for goodwill, the allocation of taxes to members of a consolidated group and requiring that an entity reflect the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods thereafter; however, early adoption is permitted. The Company adopted this ASU as of January 1, 2021 and it has had no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of September 30, 2022 and December 31, 2021, the Company has not identified any uncertain tax positions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022 and December 31, 2021 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months and nine months ended September 30, 2022 and 2021, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into foreign currency contracts to reduce the risk that our cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying Consolidated Statement of Operations and Comprehensive Loss as Other income, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416377679360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value MeasurementsThere are no financial instruments measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021. Management believes that the carrying amounts of the Company&#8217;s condensed consolidated financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416378470656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment</a></td>
<td class="text">InvestmentOn March 6, 2020, the Company made a strategic investment of $0.5 million to acquire an 8% (on a fully diluted basis) shareholding in Delix Therapeutics, Inc., a drug discovery and development company researching novel small molecules for use in Central Nervous System, or CNS, indications. The Company&#8217;s investment in Delix Therapeutics, Inc. does not provide it with significant influence over the investee. The investment does not have a readily determinable fair value and therefore will be measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This investment will be measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of September 30, 2022, no impairment loss was recognized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416378470656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,755&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374962048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div>Depreciation and amortization expenses were less than $0.1&#160;million and $0.2&#160;million for the three months and nine months ended September 30, 2022 respectively. For the three months and nine months ended September 30, 2021, depreciation and amortization expenses were also less than $0.1&#160;million and $0.1&#160;million, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416375011344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">Accrued Expenses and Other Liabilities<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416457488576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text">Ordinary Shares<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company issued in total 461,772 ordinary shares to settle share options exercised by employees and non-employees compared to 1,188,242 in the nine months ended September 30, 2021. Of the shares issued in the nine months ended September 30, 2021, 232,227 were related to options exercised in 2020 for which shares were delivered in 2021.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, a total of 72,738 ordinary shares were issued in settlement of restricted share units, of which 14,863 vested and were issued during the nine months ended September 30, 2022 and 57,875 vested but had not been issued at December 31, 2021. As of September 30, 2022, there were 17,112 restricted shares vested but not settled.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2021, 56,887 restricted share units vested, of which 12,607 ordinary shares were issued in settlement of the vested restricted shares units on August 13, 2021. No ordinary shares were issued for the vested restricted share units of 44,280 in the nine months ended September 30, 2021.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company sold 4,000,000 ordinary shares in connection with its follow-on offering. On May 19, 2021 the underwriters exercised their option to purchase an additional 600,000 ordinary shares. This capital raise resulted in net proceeds of approximately $154.8&#160;million after deducting underwriting fees and offering costs.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through September 30, 2022, no cash dividends had been declared or paid by the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416457488576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company was authorized to issue a total of 1,602,117 ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan, typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTAyNA_35a1f89c-3484-499d-8cd2-515ba09fe46d">three</span> or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 3,755,119 shares as of September 30, 2022, of which 761,700 shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted in 2022 under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over four year service period.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company granted options to purchase 1,400,783 and 752,702 ordinary shares to employees and non-employees, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company granted to our new chief executive officer a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant. The non-qualified share option has a 10 year term and vests as to one-fourth on August 1, 2023 and as to the remaining three-fourths in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement. <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Restricted Share Units</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the nine months ended September 30, 2022 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, there was $2.2 million and $1.6 million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of 3.0 years and 2.95 years, respectively. The exercise price of restricted share units is at a nominal value less than &#163;0.01 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Share Options</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the nine months ended September 30, 2022:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,929,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $5.5 million and $41.8 million, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $10.29 and $22.71 per share during the nine months ended September 30, 2022, and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, there was $30.7 million and $27.6 million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of 2.97 years and 3.2 years, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2022, and 2021 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.345%"><tr><td style="width:1.0%"/><td style="width:43.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416457348032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,371)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,092)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,525,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,708,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,377,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,378,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months and nine months ended September 30, 2022 and 2021 because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested restricted share units, for which shares are not in issue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279,430</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297,371</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279,430</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297,371</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416457636048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right of use assets</a></td>
<td class="text">Right of use of assets<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York, NY</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a lease with BioLabs for 200 rentable square feet of office space at 180 Varick Street, New York, New York 10014, United States. The lease is cancellable with 30 days&#8217; notice. This lease is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a twelve month membership agreement with WeWork for rentable office space.  The membership is cancellable with 90 days&#8217; notice.  This membership is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eastbourne Terrace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an operating lease located at 19 Eastbourne Terrace, London, UK. This lease commenced on January 1, 2020, and expired on December 31, 2021. Under the terms of the lease, the Company paid &#163;780,000 per year, and paid a refundable deposit of &#163;130,000 upon signing the agreement. Additionally, in February 2021, the Company entered into an Amendment for rental relief in January and February 2021 for a total of &#163;32,500, due to extended periods working from home as a result of the COVID-19 pandemic.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Soho, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#163;136,200, and the Company paid a refundable deposit of &#163;136,200 at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee will be subject to an automatic inflation linked increase of the previous years&#8217; amount.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Francisco, CA </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an operating lease commencing in August 2021 for approximately 2,526 rentable square feet located in San Francisco, California. The total monthly rent for the lease term is $10,000 per month, and the Company paid $9,000 of advanced rent upon lease execution. Additionally, the Company paid a refundable security deposit of $20,000 upon execution of the lease.  In September 2022, the Company entered into a lease extension, which is set to expire on October 31, 2022.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denmark Hill, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of five years. The rent is &#163;180,000 per year, with no deposit payable, and payment dates occurring once per quarter.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our costs included in our condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through September 30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of September 30, 2022, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:85.070%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416378461440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of September 30, 2022, or 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374989968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the UK, the Company makes contributions to private defined contribution pension schemes on behalf of its employees. The Company paid $0.2 million and less than $0.1 million in contributions for the nine months ended September 30, 2022, and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company paid $0.1 million and less than $0.1 million in contributions in the nine months ended September 30, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372535904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September 30, 2022, the results of its operations and comprehensive loss for the three months and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021.</span></div>The results for the three months and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 24, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before the Company&#8217;s IPO, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash as of September&#160;30, 2022 and December 31, 2021 represents a collateral deposit for employee credit cards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment</a></td>
<td class="text">InvestmentThe investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the inputs for the first two are considered observable and the inputs for the last are considered unobservable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for the Company&#8217;s cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div>Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the nine months ended September 30, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Research Contract Costs, Prepayments and Accruals</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimated the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 9 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the absence of an active market for the Company&#8217;s ordinary shares prior to the IPO, the Company and the board of directors of the Company, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s ordinary shares at the time of each grant of a stock-based award prior to the IPO. The grant date fair value of restricted ordinary shares and share options were calculated based on the grant date fair value of the underlying ordinary shares. The Company calculated the fair value of the ordinary shares in accordance with the guidelines in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the &#8220;Practice Aid&#8221;. The Company&#8217;s valuations of ordinary shares were prepared using a market approach, based on precedent transactions in the shares, to estimate the Company&#8217;s total equity value using an option-pricing method, or OPM. After the Company&#8217;s IPO, the fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div>The OPM derives an equity value such that the value indicated for ordinary shares is consistent with the investment price, and it provides an allocation of this equity value to each of the Company&#8217;s securities. The OPM treats the various classes of ordinary shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the share liquidation preferences of ordinary shares with senior preferences at the time of the liquidity event. Key inputs into the OPM calculation included the risk-free rate, expected time to liquidity and volatility. A reasonable discount for lack of marketability was applied to the total equity value to arrive at an estimate of the total fair value of equity on a non-marketable basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 11 for right-of-use assets and liabilities recorded during the periods ended September 30, 2022 and 2021 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is Pound Sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded foreign exchange gains of approximately $1.1 million and $3.4 million for the three months ended September&#160;30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded a foreign exchange gain of $4.4 million and $2.2 million respectively. These gains arise from U.S. dollars which are held in a financial institution in one of our UK subsidiaries that has a functional currency of Pound Sterling.</span></div>For financial reporting purposes, the condensed consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting currency. The financial statements of entities are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other income, net are translated at the average exchange rates for the periods presented and shareholders&#8217; equity is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standard Update, or ASU, 2019-12, &#8220;Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740),&#8221; or ASU 740, which simplifies the accounting for income taxes. The new guidance removes certain exceptions to the general principles in ASC 740 such as recognizing deferred taxes for equity investments, the incremental approach to performing intra-period tax allocation and calculating income taxes in interim periods. The standard also simplifies accounting for income taxes under U.S. GAAP by clarifying and amending existing guidance, including the recognition of deferred taxes for goodwill, the allocation of taxes to members of a consolidated group and requiring that an entity reflect the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods thereafter; however, early adoption is permitted. The Company adopted this ASU as of January 1, 2021 and it has had no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of September 30, 2022 and December 31, 2021, the Company has not identified any uncertain tax positions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022 and December 31, 2021 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock', window );">Benefit from Research and Development Tax Credit</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months and nine months ended September 30, 2022 and 2021, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into foreign currency contracts to reduce the risk that our cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying Consolidated Statement of Operations and Comprehensive Loss as Other income, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefit From Research And Development Tax Credit, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416461465600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416377634960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,755&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416375112816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416375001472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374907120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Share Units Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the nine months ended September 30, 2022 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the nine months ended September 30, 2022:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,929,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2022, and 2021 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.345%"><tr><td style="width:1.0%"/><td style="width:43.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416375004272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,371)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,092)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,525,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,708,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,377,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,378,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months and nine months ended September 30, 2022 and 2021 because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested restricted share units, for which shares are not in issue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279,430</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297,371</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279,430</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297,371</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416377717856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Costs Included in Operating Expenses Related To Right of Use Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our costs included in our condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through September 30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Due Under Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of September 30, 2022, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:85.070%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374766048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,371<span></span>
</td>
<td class="nump">$ 21,037<span></span>
</td>
<td class="nump">$ 21,171<span></span>
</td>
<td class="nump">$ 15,849<span></span>
</td>
<td class="nump">$ 17,528<span></span>
</td>
<td class="nump">$ 12,715<span></span>
</td>
<td class="nump">$ 15,849<span></span>
</td>
<td class="nump">$ 60,579<span></span>
</td>
<td class="nump">$ 46,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,076<span></span>
</td>
<td class="nump">$ 293,959<span></span>
</td>
<td class="nump">$ 273,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,800<span></span>
</td>
<td class="nump">$ 154,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockMaximumAmountAllowableForSale', window );">Maximum amount of stock that may be sold</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfOrdinarySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfOrdinarySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockMaximumAmountAllowableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Allowable For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockMaximumAmountAllowableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369539984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416373471664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands, &#8364; in Millions, &#163; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>region</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>region</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>GBP (&#163;) </div>
<div>region</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfGeographicRegions', window );">Number of geographic regions | region</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains</a></td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 3,364<span></span>
</td>
<td class="nump">$ 4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember', window );">United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent', window );">Cash rebate percent (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.35%<span></span>
</td>
<td class="nump">33.35%<span></span>
</td>
<td class="nump">33.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable', window );">Total aid claimable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember', window );">United Kingdom Research and Development Tax Credit Regime</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent', window );">Cash rebate percent (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.67%<span></span>
</td>
<td class="nump">21.67%<span></span>
</td>
<td class="nump">21.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount', window );">Annual offset amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent', window );">Percentage of taxable profits (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfGeographicRegions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Geographic Regions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfGeographicRegions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Cash Rebate Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Total Aid Claimable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369539824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cmps_DelixTherapeuticsIncMember', window );">Delix Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage in Delix Therapeutics, Inc (in percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cmps_DelixTherapeuticsIncMember', window );">Delix Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cmps_DelixTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cmps_DelixTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cmps_DelixTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cmps_DelixTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374847392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCurrent', window );">UK R&amp;D tax credit</a></td>
<td class="nump">$ 16,774<span></span>
</td>
<td class="nump">$ 9,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance premium</a></td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">22,203<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT recoverable</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Security deposit</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 44,755<span></span>
</td>
<td class="nump">$ 21,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_PrepaidExpenseResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416365713232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374878672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expense</a></td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional expenses</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefit costs</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">5,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll tax payable</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 7,817<span></span>
</td>
<td class="nump">$ 10,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416368447136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 13, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_CashDividendDeclaredOrPaidDuringPeriod', window );">Cash dividend declared or paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,800,000<span></span>
</td>
<td class="nump">$ 154,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">12,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfVotes', window );">Number of votes | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,887,000<span></span>
</td>
<td class="nump">55,727,000<span></span>
</td>
<td class="nump">376,158,000<span></span>
</td>
<td class="nump">12,607,000<span></span>
</td>
<td class="nump">351,449,000<span></span>
</td>
<td class="nump">461,772<span></span>
</td>
<td class="nump">1,188,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,104,000<span></span>
</td>
<td class="nump">68,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod', window );">Stock issued and vested in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,863<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted share units for which no shares were issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,875<span></span>
</td>
<td class="nump">56,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled', window );">Restricted share units vested, not settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,112<span></span>
</td>
<td class="nump">44,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares | Common stock | 2020 Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_CashDividendDeclaredOrPaidDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Dividend Declared Or Paid During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_CashDividendDeclaredOrPaidDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Issued And Vested In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Vested Not Settled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_A2020AwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_A2020AwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416368406144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2017 Equity Incentive Plan (Details) - 2017 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>day </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares) | shares</a></td>
<td class="nump">1,602,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Options Granted Before June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Share-based Payment Arrangement, Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Share-based Payment Arrangement, Tranche two | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche one | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice', window );">Percentage amount closing price is higher than listing price</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days | day</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372453968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details) - Employee stock - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum', window );">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance', window );">Maximum increase in shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod', window );">Stock plan, offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Saving period (in percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369445568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Share Option Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,755,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember', window );">Ordinary shares | 2020 Share Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease', window );">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,783<span></span>
</td>
<td class="nump">1,400,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cmps_NonEmployeeMember', window );">Non-Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,702<span></span>
</td>
<td class="nump">752,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cmps_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cmps_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374939072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - 2022 Inducement Grant Option Award (Details) - shares<br></strong></div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">2022 Inducement Grant Option Award | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">2022 Inducement Grant Option Award | Share-based Payment Arrangement, Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">2022 Inducement Grant Option Award | Share-based Payment Arrangement, Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416365725216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Share Unit (Details)<br></strong></div></th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>&#163; / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares) | shares</a></td>
<td class="nump">2,929,746<span></span>
</td>
<td class="nump">2,929,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.68<span></span>
</td>
<td class="nump">$ 16.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,000,783<span></span>
</td>
<td class="nump">2,000,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares) | shares</a></td>
<td class="nump">226,395<span></span>
</td>
<td class="nump">226,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.59<span></span>
</td>
<td class="nump">$ 11.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">143,830<span></span>
</td>
<td class="nump">143,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(31,975)<span></span>
</td>
<td class="num">(31,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | shares</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">2 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice', window );">Exercise price (in pound sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372411760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(461,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">5,035,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,035,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,106,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares)</a></td>
<td class="nump">2,929,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,929,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 14.28<span></span>
</td>
<td class="nump">$ 13.53<span></span>
</td>
<td class="nump">14.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">7.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share)</a></td>
<td class="nump">$ 16.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding balance (in years)</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm', window );">Unvested (in years)</a></td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 17,846<span></span>
</td>
<td class="nump">$ 51,162<span></span>
</td>
<td class="nump">$ 17,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">15,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value</a></td>
<td class="nump">2,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 41,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.29<span></span>
</td>
<td class="nump">$ 22.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost of options</a></td>
<td class="nump">$ 30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700<span></span>
</td>
<td class="nump">$ 27,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 19 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369481424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percent)</a></td>
<td class="nump">81.40%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">80.72%<span></span>
</td>
<td class="nump">67.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 14.41<span></span>
</td>
<td class="nump">$ 34.83<span></span>
</td>
<td class="nump">$ 14.48<span></span>
</td>
<td class="nump">$ 37.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416363431328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,504<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">$ 9,810<span></span>
</td>
<td class="nump">$ 5,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">5,558<span></span>
</td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,568<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">$ 4,252<span></span>
</td>
<td class="nump">$ 2,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374778768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,371)<span></span>
</td>
<td class="num">$ (21,037)<span></span>
</td>
<td class="num">$ (21,171)<span></span>
</td>
<td class="num">$ (15,849)<span></span>
</td>
<td class="num">$ (17,528)<span></span>
</td>
<td class="num">$ (12,715)<span></span>
</td>
<td class="num">$ (15,849)<span></span>
</td>
<td class="num">$ (60,579)<span></span>
</td>
<td class="num">$ (46,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders - basic</a></td>
<td class="num">(18,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,849)<span></span>
</td>
<td class="num">(60,579)<span></span>
</td>
<td class="num">(46,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to ordinary shareholders - diluted</a></td>
<td class="num">$ (18,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,849)<span></span>
</td>
<td class="num">$ (60,579)<span></span>
</td>
<td class="num">$ (46,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">42,525,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="nump">42,377,895<span></span>
</td>
<td class="nump">39,378,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,525,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,708,220<span></span>
</td>
<td class="nump">42,377,895<span></span>
</td>
<td class="nump">39,378,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369507712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,279,430<span></span>
</td>
<td class="nump">4,297,371<span></span>
</td>
<td class="nump">5,279,430<span></span>
</td>
<td class="nump">4,297,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember', window );">Unvested restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">226,395<span></span>
</td>
<td class="nump">160,595<span></span>
</td>
<td class="nump">226,395<span></span>
</td>
<td class="nump">160,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Vested restricted share units, for which shares are not in issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">17,112<span></span>
</td>
<td class="nump">44,280<span></span>
</td>
<td class="nump">17,112<span></span>
</td>
<td class="nump">44,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,035,923<span></span>
</td>
<td class="nump">4,092,496<span></span>
</td>
<td class="nump">5,035,923<span></span>
</td>
<td class="nump">4,092,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416368531088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_EastbourneTerraceLondonUKMember', window );">Eastbourne Terrace, London, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_AnnualLeasePayment', window );">Annual lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RefundableLeaseDepositPayments', window );">Refundable lease deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LeaseRentalRelief', window );">Lease rental relief</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_NewYorkNYMember', window );">New York, NY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LeaseCancellationNotificationPeriod', window );">Lease cancellation notification period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_SohoLondonUKMember', window );">Soho, London, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RefundableLeaseDepositPayments', window );">Refundable lease deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeasesNoncancelableTerm', window );">Operating leases, noncancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseMonthlyPayment', window );">Operating lease, monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_SanFranciscoCAMember', window );">San Francisco, CA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RefundableLeaseDepositPayments', window );">Refundable lease deposit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseMonthlyPayment', window );">Operating lease, monthly payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRent', window );">Advance rent upon lease execution | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember', window );">Denmark Hill, London, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseAnnualPayment', window );">Operating lease, annual payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_WeWorkMember', window );">WeWork</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LeaseCancellationNotificationPeriod', window );">Lease cancellation notification period (in days)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_AnnualLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Lease Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_AnnualLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LeaseCancellationNotificationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Cancellation Notification Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LeaseCancellationNotificationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LeaseRentalRelief">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Rental Relief</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LeaseRentalRelief</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeaseAnnualPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeaseAnnualPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeaseMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeaseMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeasesNoncancelableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Noncancelable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeasesNoncancelableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_RefundableLeaseDepositPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable Lease Deposit, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_RefundableLeaseDepositPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_EastbourneTerraceLondonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_EastbourneTerraceLondonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_NewYorkNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_NewYorkNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_SohoLondonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_SohoLondonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_SanFranciscoCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_SanFranciscoCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_WeWorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_WeWorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416374716384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_VariableLeaseCostLeaseIncentiveReceived', window );">Variable lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_CashFlowLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities:</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 5,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (in percent)</a></td>
<td class="nump">4.96%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_VariableLeaseCostLeaseIncentiveReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Lease Cost, Lease Incentive Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_VariableLeaseCostLeaseIncentiveReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416369263376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December 31, 2022</a></td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">December 31, 2023</a></td>
<td class="nump">1,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">December 31, 2024</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">December 31, 2025</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">December 31, 2026</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140416372379344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions on behalf of the employee</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan contributions</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>cmps-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmps="http://compasspathways.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmps-20220930.xsd" xlink:type="simple"/>
    <context id="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i596c4fa459a842c792706b9aaaa22360_I20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="i2d514775b1f24e1599e2725db606daf3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if05f01a2352340f19929b84e2fdb783c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0474e1eeb0af47839fe1968b78c85d88_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idd1d86a8348f449bb212e9dc31ca7be6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65d9f4c025464876950314f425750639_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife6820df90e3449faa37a891e77d7310_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic320fff0e53740848b78edc848132fbc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i95405ef6eec44bbaac9fdee032a0137a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78c91b535c5d4deab01c85d4d735656c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic85a709a97804361a3e0501cf690f852_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04e99a1e2762468ba33ad456ee6384e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i946e6c79976c439793df16cc9ad150f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c7d6429579e4d5489d901de0c7b760d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39e7c838434a4743bb3511c468433615_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc87b096855342a28b7610a6c449b3cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1066678671241ee8df1293eba5ee43f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2021AwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i89069162ebf84150934609fed74281ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icb7a414f30d846af97155958e7d21aa6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69ad4c5e2814404694ba16c54c9efd7a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e9e32ee38ba4810ab4493f286127787_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3c8df0b02b474d6d9d1369e7470155ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a5c404dbf07411487c062c65fb44ea2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic794b704bc624a2c8e82ca8a90a87e57_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d35501a7b994b798bb3b150095bde6a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie56a347d696345219a31e7675ac71b27_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6755946d0ae7463594da91d4a5e9a57a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie5925242606241eda223f30a9b342280_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id48210596e684e8b87d26aeeb8c60c98_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib515d46f69b343fc9a56d22004bb2629_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13bdb58279f54f18a78e5e0b660a5a40_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i98da39a461bd466bb89f458b884735f4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i185ef63d08ed431a91fd1bb8a28346cc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i69c092cad9544d7182cc6b0f1ebbbbbd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i060c433da7a748b5839bed1921540abe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d2f615c6fb3418d80683fcbc8681e63_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie12fd33674544d41aa2a56f391291315_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06c40baf5bb840f4a2732edb5af34c95_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i845c82217dbc4bbcaf62c5bea30b2432_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i47c008660987437795f6004bdf3aa8f2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2ae288fd8ae146d4bc365c5abf5bc0d8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9479266e364845e5bcca2f38d03e9949_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a02125e33964e9fa1af31b586645796_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i99d27dd8120d4b11b43f64710a22d3ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i792cfb0299e04fd8a2fdee2f25255774_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i125f25c0dca643febb4347815b8ad76f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84383e2bd7e84205988fc419ca82f7c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c315e44b8bc431fa86ce4c0715a7db0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72b982b97b964b6793d8992648332702_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iebfc5653c5b8429d8f749dc4fedac7c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i091b6e0de623464a98074345e2575290_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7dd95d805cd40f39509fb6515797148_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieb224cca99b54f1db1729d2b867bfada_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6a8bc5bae85b48c9924bda0d62dcbc4d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0fb3a6d558d7437b86d516564947533b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i666fe11914564071afc01b589931e866_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i96551c10145d4467af80d00b2f8ec49e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib906b2d3cb24439f813b95288f8ba9ec_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i040af099c030461699b8808e3daabecc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e0eac4c061d4c7fb0a29e209902295d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie748da8f76a746f280de5263b489baed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a070c3e49fc4a47b4a3837aa83925d6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic982ac60ad0243d6a23af0d1772047e6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4807ff1430444da1b1c019311c325e45_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia27028a6c13f4e2185c22066785a346c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37af0655d52644088f3ca93ae36fddc8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d0006602ef04e3ea9db6289df6795e2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieecac8bd3165451b8d042df19c203fc2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3137c453e903495eaaf7d9ad3254c18d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8c4120f8256c42b8b85596ceb05ffa7b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e65128b96b64b4d953bc090ea8f9461_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4e8120c9d53e4a378e74d67421c6687c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i728c5692d6704623aa8c0fcc42770d12_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i7191433cf01d4df1bb228323c1facbe9_I20211008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="ib94f580649ab49a0896b34592f4b080d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7276d186a62437988e54f6972e90adc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i58ad1f7848464166b04ff803b503d684_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ca94ba54c5c4d338293cf60580918bb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3abee071f8fa481083b1445474906b6a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie1704314f1ea450d9933186d70a008df_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8952b53cbd2045e785cda206c0dbefa7_D20200306-20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cmps:DelixTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-06</startDate>
            <endDate>2020-03-06</endDate>
        </period>
    </context>
    <context id="i291d3af8cf514f328ce6b2496870c764_I20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cmps:DelixTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-06</instant>
        </period>
    </context>
    <context id="id76776d937084bb6b068aef14a3affac_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71781fc181fd4d39bb070c8c01a27ba1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief874743632e4333a3f835ba18d45264_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i086cfe97e6384515ace3b2cd9e1a8caf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69b536a3e71446ef897b88f79dc31c3d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7d60c51518a44be9b0594797b5f26453_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb55899e87ce45a0a6e5f48a7d035dfb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie15077b2d3fd4730b187893fbb83cd38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68a1067ba8c745c39aa70a7c93efb438_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:A2020AwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b33a16f531f4d5e8eb681ad202ab246_D20210813-20210813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-13</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="i1e7b97b682754dbe8249580f1dc607a3_D20210504-20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="i985155b2f2d949c18fb2718219f25234_D20210519-20210519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-19</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="ifb10d785bf534ccd8a1515186b019eee_D20210504-20210519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="i67cd6c80c90e48c2b80e5fc3ba599bcd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i116fea83328e4122a910788f7882e8d5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4d2c2cd2dd514780800da78d3597eca4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie927c44e5cb04850896477090264ffbc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7fc213c5d7f4036bd82a5d59fa39b09_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8252967fea954920a4963de621717ddc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i214715ae51834a1089d9817b0bf23379_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i335fc987c66a4b2aba594c6855452579_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib1a328d9f64c4104a3a8029417180e0a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iec562706b0534cfeb692067a09d83c1b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i610168e4d50d4341abec1f5d08582cad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i943a4addcd6943e98158e8fe064d19ae_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i1626078e6ffb423ca90396bef3017393_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9d03b7f170b4a6d82400d749c8536c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41471be5a1e8469eb1c6407abc7d16dd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i168b4e16d7474cce8e24f284c7f15369_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="if753486ce3c14daba4fcbe1f311b43da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8531ca535d9d45e38737a9c50ff3c640_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf3977e8c2424d11b3e78355783d2144_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i732830fb1c7142c5a6f37a0707285a52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifdbbcb43854149dfbf0bcce7cd02755f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7964b739ce6343c381ccfca5dfb1ea6a_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i36db55c852ef4eaa89b999164b7a2a99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib34b90f4692c4d4f9bc74dd8fc80e8c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e6d7c3a8be24750a3f82abce012253e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i70760bf78092452f9552082498923167_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68d9f56a071347a7afea2e8409054eaa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i016ce66a6c4e4fc9aca63c6f704fddfc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd618f6b010d4a5f99e94d9218acf147_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i38ed6fe991c1471db93324917ceeb126_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if92840f8d4bd4abeb1cb6f957e873ca3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i487b8d6412304b83aef12793165358c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bd0dc2a39da4366b43fee2182928463_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="idba4a10786e24fbcba7e73fb1aa9d665_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87aefa457f98460d9ba72963b7697019_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5f7c123bcb2043639356b3682899ec41_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06b8dd5142c74e14af90b4df630e08e7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icefa4748348444fa952bab3678989dc2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic18cd041e9674a2fa8a04ceae64ee78a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i03df66d076904953a72557ea780c6f6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica9696938fd04b1da48bd8c16ddcb336_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i187723a49dae400c970198d5678bbf0d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16d9eda1626844e1a4d7a56935aef2e0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0192aff8fc8a44639feb49e5ff26383e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaaf53ccfc8a04ca7aca822f4ae66c4bd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3fc341a339e466c85a21126366804be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6445d031d3af49a6a06ea1db2dc1ffdd_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:NewYorkNYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="ibb6279cd6f4344d69acccb3e96e46e53_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:NewYorkNYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i8c93062327a04098856532f8d1e3bcff_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i2d32385fb8994518b1f04d199668f0e8_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:EastbourneTerraceLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i1da6eb55524b416f9a934077e9e0964b_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:EastbourneTerraceLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie5dcf53d81a142d5b2daa60f4b084c52_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia57eb47573b842caa7eb13f5560d4cce_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SanFranciscoCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SanFranciscoCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i8d6417d20a4747be9ada6c3270634e36_I20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="i397deef1a4764e6097cd7f14b27e8ec0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="region">
        <measure>cmps:region</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="vote">
        <measure>cmps:vote</measure>
    </unit>
    <unit id="day">
        <measure>cmps:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF8yLTItMS0xLTEwNDEzNg_da10d4d1-1035-418c-955e-e858f42d2409">0001816590</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF8zLTItMS0xLTEwNDEzNg_d227ce8a-23fc-4e69-8562-265cfaac683f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF80LTItMS0xLTEwNDEzNg_56875547-fd6c-4cab-8891-f70e47e07d9e">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF81LTItMS0xLTEwNDEzNg_fc2b2f17-c872-4d68-8205-614f53dcecba">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80L2ZyYWc6Njk5YTlhOTQ1Mzg2NDM0MzhkM2JlZmQ2MzAyZWI0NzEvdGFibGU6ZWI1YmE1NjUyMmZhNGRjNmJhYzNlNmYwMTdmZTA4MTAvdGFibGVyYW5nZTplYjViYTU2NTIyZmE0ZGM2YmFjM2U2ZjAxN2ZlMDgxMF82LTItMS0xLTEwNDEzNg_c5af4957-1d1e-48b2-893c-99e2f3ad2399">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4d2c2cd2dd514780800da78d3597eca4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTAyNA_35a1f89c-3484-499d-8cd2-515ba09fe46d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7bd0dc2a39da4366b43fee2182928463_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MzEvZnJhZzpmNmRjZGE4ZTQwNTQ0NzA5OTFmNzU3ZWNhMGUwNGM2My90ZXh0cmVnaW9uOmY2ZGNkYThlNDA1NDQ3MDk5MWY3NTdlY2EwZTA0YzYzXzEwOTk1MTE2Mjc3ODA_10f99276-69e6-4cdb-a1e4-e476841d8d4d"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="idba4a10786e24fbcba7e73fb1aa9d665_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MzEvZnJhZzpmNmRjZGE4ZTQwNTQ0NzA5OTFmNzU3ZWNhMGUwNGM2My90ZXh0cmVnaW9uOmY2ZGNkYThlNDA1NDQ3MDk5MWY3NTdlY2EwZTA0YzYzXzEwOTk1MTE2Mjc3ODQ_f34e585c-93b7-45fd-b8c9-cf97135e8cfb"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjMz_960c7156-acf0-49fd-8b0a-751c5309ffa1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM4_af3c226f-8d20-4a96-8172-fb0db626e690">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjY_2fc40a15-a34a-49a1-89c7-0480005a1601">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI1_7187b4e5-0d9a-4e9a-bd4a-be3a1c043ee2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM0_25eb558f-5cf6-4fee-968b-994145f0dacc">001-39522</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQw_866202cf-a69e-4d3f-9cd2-ac27fe3825e2">COMPASS Pathways plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6NzUzMGJlYzY0OWRmNDY0N2I5ZjY5ZjE1ZjJiMmU3N2UvdGFibGVyYW5nZTo3NTMwYmVjNjQ5ZGY0NjQ3YjlmNjlmMTVmMmIyZTc3ZV8wLTAtMS0xLTEwNDEzNg_14afd546-3f7f-4f92-8f4f-573f8800de88">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjM1_57ad67f8-8c09-453b-90cf-13bd40ed7603">33 Broadwick Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI3_dc2a609d-a7f4-4c4d-be0f-29ca5beb8835">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQx_5594f9e4-d492-4946-a780-778f4be9eb82">W1F 0DQ</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjIz_2abaa8ba-fca8-4caa-8706-eff555b6004e">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQy_41a3c113-c9c4-4fb9-b7c3-66246365a2cc">716</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI4_2dc36193-d819-484e-a71f-c6f68ac3c3c0">-6461</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTAtMS0xLTEwNDEzNg_af6ae789-aee9-4218-b3b2-6f5166750d5d">American Depositary Shares, each representing one ordinary share, par value of &#xa3;0.008 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTItMS0xLTEwNDEzNg_866bd6c8-0281-48e9-b2a1-2dd2faf957cd">CMPS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzEwMmZhOWZiMzc3NGJjYWE5MjRkYTNmYzc1ZGFkNTEvdGFibGVyYW5nZTpjMTAyZmE5ZmIzNzc0YmNhYTkyNGRhM2ZjNzVkYWQ1MV8xLTQtMS0xLTEwNDEzNg_9bc54161-f74f-47c1-9800-e60cffbb2c59">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjI5_9c4a335c-c8cf-4382-9a9d-79b6222afb96">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjMw_6f1ba793-cda7-4f51-acda-bfa9acad1ef5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8wLTAtMS0xLTEwNDEzNg_a51c86d6-ae2b-4761-aa2b-96dd8e40895e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8xLTMtMS0xLTEwNDEzNg_c63e5d57-632e-44b4-8cd6-131d47e599a0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGFibGU6YzgzYjYzNzFjYzlhNDAzYzhlMTRiZDc4YWM0YmFlOTgvdGFibGVyYW5nZTpjODNiNjM3MWNjOWE0MDNjOGUxNGJkNzhhYzRiYWU5OF8yLTMtMS0xLTEwNDEzNg_ea79f1d3-3e3d-4346-8352-26df8306d8b0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV8yMjQz_59a3e247-705c-41bb-bead-49ca4c81628d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i596c4fa459a842c792706b9aaaa22360_I20221102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8xL2ZyYWc6ZjAzOTMxNWU5NmQyNGNjNTljOGUzMTk0MDMyOTViZDkvdGV4dHJlZ2lvbjpmMDM5MzE1ZTk2ZDI0Y2M1OWM4ZTMxOTQwMzI5NWJkOV84MjQ2MzM3MjEwNjI4_65174503-9237-4a7d-8aff-8a04a5608d17"
      unitRef="shares">42576544</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNC0xLTEtMS0xMDQxMzY_7e2af6aa-7152-47ae-90c0-b2ebfaa75eff"
      unitRef="usd">173076000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNC0zLTEtMS0xMDQxMzY_1bcea230-d477-48d3-8acf-ed77d0dc31c6"
      unitRef="usd">273243000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNS0xLTEtMS0xMDQxMzY_d1efcab8-6a1d-4249-b9fc-70c0213d5f9f"
      unitRef="usd">155000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNS0zLTEtMS0xMDQxMzY_bd1f85ad-3407-4c0d-a4f5-9ccb6bbde1e1"
      unitRef="usd">104000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidTaxes
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNi0xLTEtMS0xMDQxMzY_617bc170-9a8c-4cb0-8ea3-4a7a435b1f32"
      unitRef="usd">465000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNi0zLTEtMS0xMDQxMzY_9bab8beb-e047-4a22-aa14-ccf9faa8ffb9"
      unitRef="usd">332000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNy0xLTEtMS0xMDQxMzY_260ab389-4092-4a81-8365-0836fcc95877"
      unitRef="usd">44755000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfNy0zLTEtMS0xMDQxMzY_0e490286-b785-4407-8e7f-f51d0a1d7045"
      unitRef="usd">21621000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfOC0xLTEtMS0xMDQxMzY_0dcd46b2-64e7-49b9-9702-e7dd166def8a"
      unitRef="usd">218451000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfOC0zLTEtMS0xMDQxMzY_25c4958a-3613-4b33-bf91-e7b5fcf9eb9c"
      unitRef="usd">295300000</us-gaap:AssetsCurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTAtMS0xLTEtMTA0MTM2_649015c5-09df-42ed-9311-1b2f3fba312b"
      unitRef="usd">432000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTAtMy0xLTEtMTA0MTM2_09520d92-b25c-44c3-9fb3-2cc650930da2"
      unitRef="usd">525000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTEtMS0xLTEtMTA0MTM2_108dd3d0-df3e-4ded-bfc4-9a3a7d554792"
      unitRef="usd">555000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTEtMy0xLTEtMTA0MTM2_f77ac4d0-6675-4f1b-8476-1957fd3cfab6"
      unitRef="usd">398000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTItMS0xLTEtMTA0MTM2_fdaaa799-c2f1-4ec4-9184-dbdb31f6061b"
      unitRef="usd">2338000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTItMy0xLTEtMTA0MTM2_ae651fbd-4faa-452b-94b1-418e0ae186be"
      unitRef="usd">3696000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTMtMS0xLTEtMTA0MTM2_27c2fa38-4c17-4c8c-94b7-43268a4900f4"
      unitRef="usd">2445000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTMtMy0xLTEtMTA0MTM2_bb1d593d-8164-4d18-9fa5-f90b07e1786a"
      unitRef="usd">766000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTQtMS0xLTEtMTA0MTM2_25b8a68a-e920-4584-9cb0-c85bf59b240e"
      unitRef="usd">299000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTQtMy0xLTEtMTA0MTM2_8e964ccc-4288-4631-bd17-cae0b667dc2e"
      unitRef="usd">213000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTUtMS0xLTEtMTA0MTM2_5500e237-b712-4bd4-8b08-5b0f039e15f4"
      unitRef="usd">224520000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTUtMy0xLTEtMTA0MTM2_33b80224-5755-469e-ab57-d0a127ed9b07"
      unitRef="usd">300898000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTgtMS0xLTEtMTA0MTM2_5c065c2c-1a45-4e3d-88f1-3ce197d62c15"
      unitRef="usd">19885000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTgtMy0xLTEtMTA0MTM2_aa80e48e-b09d-4455-8fe0-55dc064753bf"
      unitRef="usd">2564000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTktMS0xLTEtMTA0MTM2_46e56ddf-a021-4671-bf16-340dfec93621"
      unitRef="usd">7817000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMTktMy0xLTEtMTA0MTM2_35b91e2f-6ccc-4388-9037-247f7fdda653"
      unitRef="usd">10308000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjAtMS0xLTEtMTA0MTM2_ef2833f4-b667-4566-bb22-86b3fab7012b"
      unitRef="usd">1831000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjAtMy0xLTEtMTA0MTM2_1e7a00da-c55a-47ac-9485-7736e1c5822b"
      unitRef="usd">2235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjEtMS0xLTEtMTA0MTM2_2adeacb9-c99d-45dd-85b2-901ddfe252d9"
      unitRef="usd">29533000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjEtMy0xLTEtMTA0MTM2_39158612-7e1e-4b10-bf06-3468613c3da3"
      unitRef="usd">15107000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjMtMS0xLTEtMTA0MTM2_cc198d43-3467-4dfa-9993-49a6a59636d3"
      unitRef="usd">425000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjMtMy0xLTEtMTA0MTM2_27489017-50b2-419c-8d9a-50b9741dd7f9"
      unitRef="usd">1379000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjQtMS0xLTEtMTA0MTM2_3e40407b-ccb7-432e-ba6b-43469dea1df2"
      unitRef="usd">29958000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjQtMy0xLTEtMTA0MTM2_56162f9d-24a2-46c6-b0a6-a958d7b07626"
      unitRef="usd">16486000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjYtMS0xLTEtMTA0MTM2_9bf950fc-5ca4-41ff-9377-8c3fe72e0896"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjYtMy0xLTEtMTA0MTM2_f986a9f9-f7c6-455d-8b78-92d697af3652"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDUw_5614bd2c-79d7-4b10-861e-96acf62d6f5f"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDUw_84d60964-9626-4a3a-84b4-f2a4e1d6866d"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_3ad59db3-3281-4dc7-a61f-d500e6214889"
      unitRef="shares">42554384</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_92024132-5f2d-4b17-b021-7a098dabb7fa"
      unitRef="shares">42554384</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQy_9ebb4c1a-ce62-4f04-a4d2-9c68d6c7ec51"
      unitRef="shares">42554384</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_3070fbe9-7aee-4ca3-b600-d739dd38b046"
      unitRef="shares">42019874</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_87e306fb-c781-43b5-8f0c-2b4fb886dd48"
      unitRef="shares">42019874</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMC0xLTEtMTA0MTM2L3RleHRyZWdpb246NGNiNDNmYjdkNDAxNDdiYzllMGJmZTZmNWJiYzQxYmFfNTQ5NzU1ODE0MDQ2_d903db7a-36ed-461e-9015-eac286f1a7a1"
      unitRef="shares">42019874</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMS0xLTEtMTA0MTM2_5e454983-6e37-4d3e-84d0-c38750c45a32"
      unitRef="usd">440000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjgtMy0xLTEtMTA0MTM2_86f4882c-17a2-4d47-a4da-9b13684e4456"
      unitRef="usd">435000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDIw_2ca43e7e-4ac0-4018-828c-4665c19683d4"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDIw_f91c4667-0502-4178-8137-27f0d458386e"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_7584eeef-99b0-4297-9a1e-cf425eaacc98"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_7c1f8640-ffac-4d64-b2b3-99fb4af5a74b"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_89f30b60-28e4-4012-b7c5-60f52375a5e5"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_ca1d484b-9880-4260-b7cb-6592326eb636"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_cfd85e04-0082-46ff-9797-e0ed6ef04925"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMC0xLTEtMTA0MTM2L3RleHRyZWdpb246ZjFjM2JkOTNmZjg2NGNkN2JiNWMwZGEzYWNjNzA1MzZfNTQ5NzU1ODE0MDI0_ece06e4d-9651-476c-ad47-9e4c1dd70607"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMS0xLTEtMTA0MTM2_eb2c81a8-1b9f-435a-a322-85997ff510d0"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMjktMy0xLTEtMTA0MTM2_4bd3eb5a-a336-4f18-9c48-9ac607a98467"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzAtMS0xLTEtMTA0MTM2_690bd229-c4aa-4632-a377-6e2fa66291e6"
      unitRef="usd">454957000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzAtMy0xLTEtMTA0MTM2_c2d9d336-77e7-4325-aecd-6744681f1659"
      unitRef="usd">444750000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzEtMS0xLTEtMTA0MTM2_0116814d-07ee-44ad-94c8-74208b80bbd0"
      unitRef="usd">-30643000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzEtMy0xLTEtMTA0MTM2_ce08f612-f857-4dc8-bd83-0beeec7b3167"
      unitRef="usd">8840000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzItMS0xLTEtMTA0MTM2_15010639-d825-4165-bb89-cf974e4a523a"
      unitRef="usd">-230220000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzItMy0xLTEtMTA0MTM2_18cfd6ac-4683-4aea-917c-c8e77e92fdfa"
      unitRef="usd">-169641000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzMtMS0xLTEtMTA0MTM2_3abb39d5-983a-465e-a0d9-3cb97c61d8cb"
      unitRef="usd">194562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzMtMy0xLTEtMTA0MTM2_d545ae9f-289b-44f5-8b10-5bc3fffb50c9"
      unitRef="usd">284412000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzQtMS0xLTEtMTA0MTM2_0e940dbe-e0ca-44af-8322-416a7adaa204"
      unitRef="usd">224520000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yNS9mcmFnOjYxMzE2NTcwNjhkMjRjZjI5M2FjNGVmYjI5NTFjOTg0L3RhYmxlOjg4NjBjNTQzNGZjYjQyNDliZTg3NTZhZGQyNTcwZWI0L3RhYmxlcmFuZ2U6ODg2MGM1NDM0ZmNiNDI0OWJlODc1NmFkZDI1NzBlYjRfMzQtMy0xLTEtMTA0MTM2_a40077b8-181b-44c9-a518-b7abd69aef01"
      unitRef="usd">300898000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy0xLTEtMS0xMDQxMzY_bac6a4f2-9b0f-4180-90ee-ada63d1544a3"
      unitRef="usd">13977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy0zLTEtMS0xMDQxMzY_c9817bab-fab1-4a2a-932d-ce9e61eec6d5"
      unitRef="usd">12197000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy01LTEtMS0xMDQxMzY_bca15a8e-293c-4987-b057-a392af17bf66"
      unitRef="usd">45259000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMy03LTEtMS0xMDQxMzY_fe5241f0-4b4c-4281-b9fd-419f9d21e478"
      unitRef="usd">30434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC0xLTEtMS0xMDQxMzY_e19e4024-01b1-447c-baf9-f39975f04dbf"
      unitRef="usd">11559000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC0zLTEtMS0xMDQxMzY_2c1de744-56b2-486a-b85d-65911fd286a3"
      unitRef="usd">9571000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC01LTEtMS0xMDQxMzY_99bdc94b-b801-491c-adda-39a250579e8c"
      unitRef="usd">32953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNC03LTEtMS0xMDQxMzY_577d0156-9830-41d6-8a33-a2035fb5c946"
      unitRef="usd">24464000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS0xLTEtMS0xMDQxMzY_2efa4470-a4e8-49f4-a229-8c7ae0bb7f19"
      unitRef="usd">25536000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS0zLTEtMS0xMDQxMzY_04422109-2475-4b60-b503-ee6fdf49c406"
      unitRef="usd">21768000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS01LTEtMS0xMDQxMzY_2651d6f2-8620-4747-9385-267a9bf904a4"
      unitRef="usd">78212000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNS03LTEtMS0xMDQxMzY_0f62386b-ba5f-42be-b978-4d5666adcd9d"
      unitRef="usd">54898000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi0xLTEtMS0xMDQxMzY_0a074d83-9c46-4948-b737-132821f6eff0"
      unitRef="usd">-25536000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi0zLTEtMS0xMDQxMzY_87f3dff6-97ae-4b95-8f74-aaf739ee96ad"
      unitRef="usd">-21768000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi01LTEtMS0xMDQxMzY_35e18a2d-ca3f-4e9c-ab4f-f81821d5dc50"
      unitRef="usd">-78212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfNi03LTEtMS0xMDQxMzY_c6ed773e-bb5b-4110-825b-e3bff787e6b3"
      unitRef="usd">-54898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC0xLTEtMS0xMDQxMzY_2b384d67-70fc-4929-8f16-6cc2419be2e9"
      unitRef="usd">3206000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC0zLTEtMS0xMDQxMzY_0348fdf0-2d78-44d7-8dce-f9c022e7f5b4"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC01LTEtMS0xMDQxMzY_125a76bc-982f-46c8-ac4b-bbd3c111c5a5"
      unitRef="usd">3580000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOC03LTEtMS0xMDQxMzY_9bfea561-4efb-4393-ba80-78fe838fee0e"
      unitRef="usd">2000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS0xLTEtMS0xMDQxMzY_4c88c8dd-18c6-41d2-91bc-8a7d82e852d3"
      unitRef="usd">1096000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS0zLTEtMS0xMDQxMzY_d410452a-efe6-47f4-a2af-502de776b28d"
      unitRef="usd">3364000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS01LTEtMS0xMDQxMzY_959219ef-334b-4b99-81fd-6e1789968162"
      unitRef="usd">4387000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfOS03LTEtMS0xMDQxMzY_c749720a-18cd-4bf5-9545-45688036e269"
      unitRef="usd">2171000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtMS0xLTEtMTA0MTM2_4ab72ad6-d937-49e2-8cd6-ed3e701bcebd"
      unitRef="usd">-2983000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtMy0xLTEtMTA0MTM2_6e707df4-c020-4aa7-88e3-0c4c10283719"
      unitRef="usd">-2618000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtNS0xLTEtMTA0MTM2_0e303e6f-69f0-45a4-a818-3a994f293b2a"
      unitRef="usd">-9982000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTAtNy0xLTEtMTA0MTM2_dcdb6952-d626-47b7-8176-f02ea72eb1c8"
      unitRef="usd">-6733000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtMS0xLTEtMTA0MTM2_b601fe1f-8069-4c5c-a47e-0ce004b43637"
      unitRef="usd">7285000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtMy0xLTEtMTA0MTM2_f1beba89-0cc7-4d0e-a758-b0094023f835"
      unitRef="usd">5982000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtNS0xLTEtMTA0MTM2_ee49984e-710c-435d-b40b-dfa564e19fd7"
      unitRef="usd">17949000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTEtNy0xLTEtMTA0MTM2_29ff1a86-24c3-4cb6-8177-85e586ccefe9"
      unitRef="usd">8906000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItMS0xLTEtMTA0MTM2_9fab2541-46d9-47d4-8cfc-eca1dda0b180"
      unitRef="usd">-18251000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItMy0xLTEtMTA0MTM2_b4135b87-65cc-43ee-b748-85413bbb81d4"
      unitRef="usd">-15786000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItNS0xLTEtMTA0MTM2_2bd4e8fa-d881-4e2f-accf-e984f5a24e49"
      unitRef="usd">-60263000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTItNy0xLTEtMTA0MTM2_079475d7-7449-4af2-bed1-51defc554fb8"
      unitRef="usd">-45992000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtMS0xLTEtMTA0MTM2_c4e5a32b-2263-4f89-ba13-3fc88f3dd8e5"
      unitRef="usd">120000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtMy0xLTEtMTA0MTM2_a5e19509-9d87-479e-b827-2b3c23626951"
      unitRef="usd">63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtNS0xLTEtMTA0MTM2_85288f40-c566-47ec-8d8e-40f589b38bc7"
      unitRef="usd">316000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTMtNy0xLTEtMTA0MTM2_e292ae97-15eb-4afe-b345-cee27063264c"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtMS0xLTEtMTA0MTM2_fd43d91a-2a58-4f58-bde5-473aa5897cb1"
      unitRef="usd">-18371000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtMy0xLTEtMTA0MTM2_8b7e1d46-7cff-4d5e-82fc-eb6e25b9b55c"
      unitRef="usd">-15849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtNS0xLTEtMTA0MTM2_936e523f-b89d-4e06-b090-12b0e77269e5"
      unitRef="usd">-60579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTQtNy0xLTEtMTA0MTM2_257a5202-7d03-4e58-ab0d-897e507dd52a"
      unitRef="usd">-46092000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtMS0xLTEtMTA0MTM2_db22f148-7568-4deb-b26f-d7a51d5d1dca"
      unitRef="usd">-15156000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtMy0xLTEtMTA0MTM2_34ce8fbc-d6bb-4f04-8591-af0c941465de"
      unitRef="usd">-8401000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtNS0xLTEtMTA0MTM2_c819421d-f26f-41fc-824a-21eade625d20"
      unitRef="usd">-39483000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTYtNy0xLTEtMTA0MTM2_2b6a6fa5-2002-4ffa-b373-c3bc2bca4dac"
      unitRef="usd">-6768000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctMS0xLTEtMTA0MTM2_cda23808-6be7-4e0e-8bfc-c80ef4c47713"
      unitRef="usd">-33527000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctMy0xLTEtMTA0MTM2_4175607b-a686-4b25-9077-f483b34e1002"
      unitRef="usd">-24250000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctNS0xLTEtMTA0MTM2_1a655ebf-4010-4bda-b1c5-2b9fd161ffc5"
      unitRef="usd">-100062000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTctNy0xLTEtMTA0MTM2_0ea63f0d-b8c6-4993-9116-34b566deabbe"
      unitRef="usd">-52860000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMS0xLTEtMTA0MTM2_9b0a06c5-3500-4d80-ab2c-5645f8c22303"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMS0xLTEtMTA0MTM2_b2f95888-8166-42c1-a3cf-541f2bf200b5"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMy0xLTEtMTA0MTM2_47477322-f876-45b4-bbe7-d37f46637dab"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtMy0xLTEtMTA0MTM2_a20c1ad0-c162-4041-a78e-cf2062b010a9"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNS0xLTEtMTA0MTM2_59c778bd-0ec7-4408-8869-32918940b9ba"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNS0xLTEtMTA0MTM2_b2dcd02b-1b35-4899-be99-d43edc9cb2ff"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNy0xLTEtMTA0MTM2_6289e683-f587-4cd3-8623-82d6420bb078"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTgtNy0xLTEtMTA0MTM2_f3ea93e2-4df0-40bb-8f3e-e606cd6cf2c6"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMS0xLTEtMTA0MTM2_af1c51eb-ef91-4a1c-aeff-bd98dd83a166"
      unitRef="shares">42525855</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMS0xLTEtMTA0MTM2_d6ac0a4a-61b2-4ff4-9e17-bbad927b6863"
      unitRef="shares">42525855</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMy0xLTEtMTA0MTM2_54d6696b-44a7-4e39-9edd-6f1089cc7d34"
      unitRef="shares">41708220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktMy0xLTEtMTA0MTM2_aa3e67ad-4bdd-4aa0-b965-20087b895c6b"
      unitRef="shares">41708220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNS0xLTEtMTA0MTM2_472d6d6f-0ff5-4f72-bd4f-e27360f08382"
      unitRef="shares">42377895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNS0xLTEtMTA0MTM2_4c5deaa4-fee3-4b02-b0a0-a64fe4ba5a52"
      unitRef="shares">42377895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNy0xLTEtMTA0MTM2_3b524fa0-14cb-4d35-b1fc-a1b520860dad"
      unitRef="shares">39378824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8yOC9mcmFnOjMyZGE4OTcxMjkwNjQ5MTQ4YjNhM2NiZjIyMjNmZTJhL3RhYmxlOmU4ZWVlMjcxYWFhYzRhNWE5YTNiZmQ3NDM4ZDNmYTE0L3RhYmxlcmFuZ2U6ZThlZWUyNzFhYWFjNGE1YTlhM2JmZDc0MzhkM2ZhMTRfMTktNy0xLTEtMTA0MTM2_888c188d-4882-4bae-8f57-65c2e004f067"
      unitRef="shares">39378824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMC0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjoyYWM5OTk3NTVhZmM0MGFjODVjMGJlZjc4YmU1YzdlOV8xNjQ5MjY3NDQxNjg4_5614bd2c-79d7-4b10-861e-96acf62d6f5f"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMC0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjoyYWM5OTk3NTVhZmM0MGFjODVjMGJlZjc4YmU1YzdlOV8xNjQ5MjY3NDQxNjg4_84d60964-9626-4a3a-84b4-f2a4e1d6866d"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMS01LTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjowNjc0N2QyNzBmYjQ0ZmFiYmVlMmZjMDNmOTBlMzFmZV81NDk3NTU4MTM5MDY_2ca43e7e-4ac0-4018-828c-4665c19683d4"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMS01LTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjowNjc0N2QyNzBmYjQ0ZmFiYmVlMmZjMDNmOTBlMzFmZV81NDk3NTU4MTM5MDY_f91c4667-0502-4178-8137-27f0d458386e"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i95405ef6eec44bbaac9fdee032a0137a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xLTEtMS0xMDQxMzY_a33d6cec-8bc4-4bbe-8dcc-48a3a4b907c4"
      unitRef="shares">35930331000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i95405ef6eec44bbaac9fdee032a0137a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0zLTEtMS0xMDQxMzY_1ec1e1ed-f0ad-41ba-8375-3a9ad747d0f2"
      unitRef="usd">367000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i78c91b535c5d4deab01c85d4d735656c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy01LTEtMS0xMDQxMzY_94f9608f-2f5e-4ed0-827e-0040d780c641"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i78c91b535c5d4deab01c85d4d735656c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy03LTEtMS0xMDQxMzY_0532dd6c-d69b-4ef8-9f6a-82dc29a32f74"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic85a709a97804361a3e0501cf690f852_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy05LTEtMS0xMDQxMzY_f9f015f8-6342-4b94-aa70-8bd342e26c13"
      unitRef="usd">279480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04e99a1e2762468ba33ad456ee6384e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xMS0xLTEtMTA0MTM2_b0501a6a-12d4-46d3-952a-a3d36b52a851"
      unitRef="usd">14585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i946e6c79976c439793df16cc9ad150f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xMy0xLTEtMTA0MTM2_2b8bcdee-7ff1-4fec-9287-1bb455d96637"
      unitRef="usd">-97899000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c7d6429579e4d5489d901de0c7b760d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMy0xNS0xLTEtMTA0MTM2_3e62d78c-0c7a-43de-9e69-b5aac2194fc9"
      unitRef="usd">196561000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i39e7c838434a4743bb3511c468433615_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0xLTEtMS0xMDQxMzY_8c6dfb86-ad1a-47ed-bc70-afe045fcebe2"
      unitRef="shares">581328000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i39e7c838434a4743bb3511c468433615_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0zLTEtMS0xMDQxMzY_dc88c932-d4b0-43f7-b5fe-fe6873c352d9"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibc87b096855342a28b7610a6c449b3cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC05LTEtMS0xMDQxMzY_11c6a71e-85e1-43b5-90fc-3008874860d7"
      unitRef="usd">992000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic1066678671241ee8df1293eba5ee43f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNC0xNS0xLTEtMTA0MTM2_ebd4143c-83a0-4522-8a2e-e1fc1396fd70"
      unitRef="usd">998000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0xLTEtMS0xMDQxMzY_a550e5d7-4603-4973-8d8e-ea3e80e6d9cd"
      unitRef="shares">232227000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if145c94aa6b84e0893f243cd5106395f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0zLTEtMS0xMDQxMzY_a2a10398-9202-4883-8a2c-970d87e761b2"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i89069162ebf84150934609fed74281ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS05LTEtMS0xMDQxMzY_be9c9a9a-5644-4fd4-bdfa-2fd83c4fcef7"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icb7a414f30d846af97155958e7d21aa6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNS0xNS0xLTEtMTA0MTM2_c00a6a06-8054-48fc-ae0b-57ab3e408a92"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69ad4c5e2814404694ba16c54c9efd7a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNi05LTEtMS0xMDQxMzY_9d0235da-9032-4a63-8c70-44840261c640"
      unitRef="usd">1666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNi0xNS0xLTEtMTA0MTM2_fcf302a4-52fc-48a8-af4e-c076e738aba7"
      unitRef="usd">1666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i1e9e32ee38ba4810ab4493f286127787_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNy0xMS0xLTEtMTA0MTM2_1de63ce1-29f6-4ebf-8b32-1f4047122175"
      unitRef="usd">1988000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNy0xNS0xLTEtMTA0MTM2_9295a7e7-be82-4888-b506-8947e5792281"
      unitRef="usd">1988000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3c8df0b02b474d6d9d1369e7470155ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOC0xMy0xLTEtMTA0MTM2_e2d48f0c-6512-4e87-ad0d-a585f24f0f8f"
      unitRef="usd">-12715000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id529fbb5c48b4f7daec97a2f11dd5950_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOC0xNS0xLTEtMTA0MTM2_73331340-b8f9-430d-9b36-4c2b96bd80f3"
      unitRef="usd">-12715000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2a5c404dbf07411487c062c65fb44ea2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xLTEtMS0xMDQxMzY_3d955e87-7911-4d56-be51-a4bf29791fed"
      unitRef="shares">36743886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2a5c404dbf07411487c062c65fb44ea2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0zLTEtMS0xMDQxMzY_d83996f7-9801-474e-9c53-b548032716bd"
      unitRef="usd">376000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic794b704bc624a2c8e82ca8a90a87e57_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS01LTEtMS0xMDQxMzY_f0ff17db-8937-4304-bacb-9bf7b71b98ab"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic794b704bc624a2c8e82ca8a90a87e57_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS03LTEtMS0xMDQxMzY_8e089cce-111a-4c76-8162-624686ab8fa4"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d35501a7b994b798bb3b150095bde6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS05LTEtMS0xMDQxMzY_2425dc8b-2aec-4508-b900-a39717ef3df3"
      unitRef="usd">282135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie56a347d696345219a31e7675ac71b27_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xMS0xLTEtMTA0MTM2_2c23afaf-17a7-4429-a971-41337a8cd992"
      unitRef="usd">16573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6755946d0ae7463594da91d4a5e9a57a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xMy0xLTEtMTA0MTM2_e71a75b8-f74c-41a0-a9d7-8c9c01e23690"
      unitRef="usd">-110614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5925242606241eda223f30a9b342280_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfOS0xNS0xLTEtMTA0MTM2_5879bfb1-50a7-4e01-987f-05caad4bc1ec"
      unitRef="usd">188498000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMS0xLTEtMTA0MTM2_0ecefd65-9dab-44ce-b43e-4d4d44866ea5"
      unitRef="shares">4600000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMy0xLTEtMTA0MTM2_4ba81a95-2184-424c-b88f-2eeaf8f9d365"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtOS0xLTEtMTA0MTM2_728dc90d-7a5b-453b-b3dc-d84f4ba330fc"
      unitRef="usd">154743000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTEtMTUtMS0xLTEwNDEzNg_f77c7abc-0264-465f-becb-6294ed0a67c8"
      unitRef="usd">154794000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMS0xLTEtMTA0MTM2_eb6a4ad8-d4ee-418b-b481-804fbb60cd58"
      unitRef="shares">351449000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0f2ea20e411f42a6989f3fa00764c6f7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMy0xLTEtMTA0MTM2_5dec8286-f175-4ef2-bb57-d1b8ea2dea50"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItOS0xLTEtMTA0MTM2_6b85f441-892e-43de-88dc-fc4d48b1aa63"
      unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTItMTUtMS0xLTEwNDEzNg_00f91cdb-091d-4e66-a298-aa6f9348d807"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib9b51d9e9e7d4b7985f6bfee8c0f6be2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTMtOS0xLTEtMTA0MTM2_c98cc3ce-c3f6-41a3-9d7c-b409ffb062bc"
      unitRef="usd">1904000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTMtMTUtMS0xLTEwNDEzNg_5effb0c9-f597-4212-bf18-464c3f4948a3"
      unitRef="usd">1904000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id48210596e684e8b87d26aeeb8c60c98_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTQtMTEtMS0xLTEwNDEzNg_38ca5d7a-71dc-4aaa-a071-93c71d08d0ec"
      unitRef="usd">-355000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTQtMTUtMS0xLTEwNDEzNg_fd80f229-d0e9-47a5-a6f8-18e5ee223cdd"
      unitRef="usd">-355000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib515d46f69b343fc9a56d22004bb2629_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTUtMTMtMS0xLTEwNDEzNg_636d062c-af43-4c15-b294-bb0a62216413"
      unitRef="usd">-17528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i660cb57f0cc646b8af15573089e50c8f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTUtMTUtMS0xLTEwNDEzNg_afb4b9fb-55de-4f9a-9a87-42a7ce1b722d"
      unitRef="usd">-17528000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i13bdb58279f54f18a78e5e0b660a5a40_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMS0xLTEtMTA0MTM2_78f55a2a-f754-4e93-846d-fdea3f06a1d4"
      unitRef="shares">41695335000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i13bdb58279f54f18a78e5e0b660a5a40_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMy0xLTEtMTA0MTM2_91ab6b22-a4a7-46d6-bf13-ce637f07bb49"
      unitRef="usd">431000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98da39a461bd466bb89f458b884735f4_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtNS0xLTEtMTA0MTM2_0a7ff0c8-8351-4290-b321-704f11fec571"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i98da39a461bd466bb89f458b884735f4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtNy0xLTEtMTA0MTM2_b85fef89-0f8b-407d-94d6-cb24a1fa9e20"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i185ef63d08ed431a91fd1bb8a28346cc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtOS0xLTEtMTA0MTM2_bf52a8f8-9fd5-4184-969d-0bdac12089ef"
      unitRef="usd">438825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69c092cad9544d7182cc6b0f1ebbbbbd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTEtMS0xLTEwNDEzNg_fa682380-e96c-40b1-84d3-654a212f2458"
      unitRef="usd">16218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i060c433da7a748b5839bed1921540abe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTMtMS0xLTEwNDEzNg_b62f9b70-d581-4403-9644-1af58d9313f5"
      unitRef="usd">-128142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d2f615c6fb3418d80683fcbc8681e63_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTYtMTUtMS0xLTEwNDEzNg_fa88e62a-f7ec-47bc-b21e-71bfd63c5592"
      unitRef="usd">327360000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMS0xLTEtMTA0NDIz_5ffa391c-3cde-4070-814a-c246a5cb4f67"
      unitRef="shares">23238000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtOS0xLTEtMTA0NDIz_b78c0b61-cf02-4032-9462-114a64aa87fb"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTUtMS0xLTEwNDQyMw_67a7d01f-8c2e-47bc-901e-c1338b44af23"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9de9bdec68ec4d00a58ecf87a249aa9e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMS0xLTEtMTA0NDE3_c78a02f2-348a-440a-b350-de09b93117aa"
      unitRef="shares">12607000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMTUtMS0xLTEwNDQyMw_b5c87d0d-6c12-4381-877c-eca3dc2eb3af"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i21bcc2d723044501a54cee529fe0d637_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtOS0xLTEtMTA0NDIz_89a1871e-7f3e-4392-a5d4-48c8b3e01c50"
      unitRef="usd">2287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMTUtMS0xLTEwNDQyMw_d6e541be-e01d-4e32-928d-87009580fd2c"
      unitRef="usd">2287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ie12fd33674544d41aa2a56f391291315_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTEtMS0xLTEwNDQyMw_ba9aff18-9627-4e04-99ed-12206a8f1ce6"
      unitRef="usd">-8401000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTUtMS0xLTEwNDQyMw_a0b1bca2-f879-4e68-9fd0-c0401f0e9748"
      unitRef="usd">-8401000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i06c40baf5bb840f4a2732edb5af34c95_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTMtMS0xLTEwNDQyMw_dcef3e3e-f53b-4615-9782-609d45889bf0"
      unitRef="usd">-15849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTUtMS0xLTEwNDQyMw_8a50ed1a-6939-4a28-a4f0-006e654ad021"
      unitRef="usd">-15849000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMS0xLTEtMTA0NDE3_3ffb96b6-d94d-49bb-9779-9197d91d2fb4"
      unitRef="shares">41731180000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMy0xLTEtMTA0NDIz_e08dc9e2-49bb-43d6-98ac-8f4760d61814"
      unitRef="usd">431000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47c008660987437795f6004bdf3aa8f2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtNS0xLTEtMTA0NDIz_a0158ac9-1d87-4a46-90ab-c8433ff75e3a"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i47c008660987437795f6004bdf3aa8f2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtNy0xLTEtMTA0NDIz_64ffeada-3f47-4781-b221-48dd8c4bfb4b"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ae288fd8ae146d4bc365c5abf5bc0d8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtOS0xLTEtMTA0NDIz_66dedac3-d40c-4e2f-9e87-d4409bf0caf9"
      unitRef="usd">441135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9479266e364845e5bcca2f38d03e9949_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTEtMS0xLTEwNDQyMw_2b5f37bf-ea42-43b1-ae32-a4b0e4d2aaa4"
      unitRef="usd">7817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a02125e33964e9fa1af31b586645796_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTMtMS0xLTEwNDQyMw_b55f9530-8c1a-4230-8955-ca89d8cd023a"
      unitRef="usd">-143991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTUtMS0xLTEwNDQyMw_8f39e818-9d81-4c7f-ae9b-effc2e0174c8"
      unitRef="usd">305420000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA4NTg5L3RleHRyZWdpb246YWJmZWNmNDlkMDhkNDBmNzhiNzkzM2ZlM2MwODM1ZjNfMjE_5614bd2c-79d7-4b10-861e-96acf62d6f5f"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if05f01a2352340f19929b84e2fdb783c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA4NTg5L3RleHRyZWdpb246YWJmZWNmNDlkMDhkNDBmNzhiNzkzM2ZlM2MwODM1ZjNfMjE_84d60964-9626-4a3a-84b4-f2a4e1d6866d"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0474e1eeb0af47839fe1968b78c85d88_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctNS0xLTEtMTA4NTg5L3RleHRyZWdpb246YjA0ZjYwZWUzYWVjNDJiZDgxMmQ5MjA2NzRlZmUxNjhfNQ_2ca43e7e-4ac0-4018-828c-4665c19683d4"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idd1d86a8348f449bb212e9dc31ca7be6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctNS0xLTEtMTA4NTg5L3RleHRyZWdpb246YjA0ZjYwZWUzYWVjNDJiZDgxMmQ5MjA2NzRlZmUxNjhfNQ_f91c4667-0502-4178-8137-27f0d458386e"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99d27dd8120d4b11b43f64710a22d3ca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMS0xLTEtMTA0MTM2_9c625471-5baa-4460-a360-c5fee4f5b67c"
      unitRef="shares">42019874000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i99d27dd8120d4b11b43f64710a22d3ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMy0xLTEtMTA0MTM2_658c30b4-5d12-46f8-892b-a9b13be97f28"
      unitRef="usd">435000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i792cfb0299e04fd8a2fdee2f25255774_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtNS0xLTEtMTA0MTM2_b90e013e-d1b1-4059-82cc-6d70da64d123"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i792cfb0299e04fd8a2fdee2f25255774_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtNy0xLTEtMTA0MTM2_9389f9b6-ba37-4e31-aee6-5582645774b0"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i125f25c0dca643febb4347815b8ad76f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtOS0xLTEtMTA0MTM2_1b8a5a72-684e-4311-81bd-ce2931afa359"
      unitRef="usd">444750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84383e2bd7e84205988fc419ca82f7c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTEtMS0xLTEwNDEzNg_fb7a5dde-08ff-452f-94bd-25734bfee7ca"
      unitRef="usd">8840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c315e44b8bc431fa86ce4c0715a7db0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTMtMS0xLTEwNDEzNg_c3f66d18-3790-4455-92d5-d8d0b78b5794"
      unitRef="usd">-169641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTgtMTUtMS0xLTEwNDEzNg_f8495499-1b0e-4616-ad5c-53459a36cbec"
      unitRef="usd">284412000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMS0xLTEtMTA0MTM2_9f5c580c-05ed-4446-ae07-326a3cb18950"
      unitRef="shares">376158000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMy0xLTEtMTA0MTM2_51d3eec9-a63f-48e0-8162-b691a571a13b"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktOS0xLTEtMTA0MTM2_40060c5f-52a6-40d8-a48b-a835e3de3ac1"
      unitRef="usd">393000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMTktMTUtMS0xLTEwNDEzNg_adb334ef-f2fd-45e3-a576-f3f36c5c8c6b"
      unitRef="usd">397000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMS0xLTEtMTA0MTM2_8ca55c24-7748-4efc-b9da-cf3f186e55a5"
      unitRef="shares">68534000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i72b982b97b964b6793d8992648332702_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMy0xLTEtMTA0MTM2_7ad4ceb2-559c-4f62-9cee-02543bef6b83"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjAtMTUtMS0xLTEwNDEzNg_3fc9d877-6c3c-4bbc-842d-8a423b90d8f9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc91e38260264a8fa425492bda2e1b13_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtOS0xLTEtMTA0MTM2_3db08763-3461-4d5c-8862-12777c498c37"
      unitRef="usd">3128000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjEtMTUtMS0xLTEwNDEzNg_7abe19cd-ee25-4445-8bb6-dbfabb9cb118"
      unitRef="usd">3128000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="iebfc5653c5b8429d8f749dc4fedac7c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTEtMS0xLTEwNDEzNg_806cc899-a60c-4b39-b7e6-d69464952fbb"
      unitRef="usd">-7193000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjItMTUtMS0xLTEwNDEzNg_c71f3177-c5b6-4837-893f-f47458131375"
      unitRef="usd">-7193000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i091b6e0de623464a98074345e2575290_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTMtMS0xLTEwNDEzNg_ada1816e-c590-45fc-bbed-3fcf97294e4e"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2389a195d9d246ad9333e730281bee1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjMtMTUtMS0xLTEwNDEzNg_a84d114b-28ef-4c53-9710-374f06ce26b9"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMS0xLTEtMTA0MTM2_078f12e9-6094-4059-8c19-6e64c1c415d1"
      unitRef="shares">42464566000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie0a2c0b1d7e545f49f81c845e6443abe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMy0xLTEtMTA0MTM2_34ff4c55-f245-4719-a033-468ea1791a88"
      unitRef="usd">440000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7dd95d805cd40f39509fb6515797148_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtNS0xLTEtMTA0MTM2_7f9dccc9-3b38-4ca2-b877-bc15d6366924"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie7dd95d805cd40f39509fb6515797148_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtNy0xLTEtMTA0MTM2_825f9992-8a89-4271-9984-3c35c74bf0c5"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb224cca99b54f1db1729d2b867bfada_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtOS0xLTEtMTA0MTM2_2c3f0ecc-c64b-4a22-92ca-03e7aab0466c"
      unitRef="usd">448271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a8bc5bae85b48c9924bda0d62dcbc4d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTEtMS0xLTEwNDEzNg_51b49bcf-e120-4f1e-bad5-42657713c9cb"
      unitRef="usd">1647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fb3a6d558d7437b86d516564947533b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTMtMS0xLTEwNDEzNg_beece4d0-d4e3-4efb-8702-621d4ac352b3"
      unitRef="usd">-190812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i666fe11914564071afc01b589931e866_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjQtMTUtMS0xLTEwNDEzNg_1bb4b2ce-6934-49bd-86ec-749618c0997f"
      unitRef="usd">259574000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMS0xLTEtMTA0MTM2_cf3d922f-8305-4b94-be4d-5add5c8a17f3"
      unitRef="shares">55727000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtOS0xLTEtMTA0MTM2_dc4ec43a-e5ec-4fa2-b036-f1c9148cd0b7"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjYtMTUtMS0xLTEwNDEzNg_4d39dff8-15d0-4135-bab0-216c6c90bc2c"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i3603ff805fd047df8cbbd82a971d8085_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctMS0xLTEtMTA0MTM2_c9e259af-4b98-4e89-bc3c-cf6270c303b6"
      unitRef="shares">2104000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjctMTUtMS0xLTEwNDEzNg_9dd4166f-20be-42bd-b8ef-066f40e91129"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25ca2ca816464ee9a3af8d0a1b34cc6e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjgtOS0xLTEtMTA0MTM2_67af368c-bee3-4da0-8f62-30391ae63552"
      unitRef="usd">3178000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjgtMTUtMS0xLTEwNDEzNg_b0d52ce8-f6e8-4ebf-9692-af83eab47ac5"
      unitRef="usd">3178000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i96551c10145d4467af80d00b2f8ec49e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjktMTEtMS0xLTEwNDEzNg_0b6ca58a-2ca5-46bd-9cd8-a3742a2b2c12"
      unitRef="usd">-17134000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMjktMTUtMS0xLTEwNDEzNg_753d72be-e9bb-4126-a461-55c28e9065c2"
      unitRef="usd">-17134000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib906b2d3cb24439f813b95288f8ba9ec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzAtMTMtMS0xLTEwNDEzNg_f2ef9d28-fcd2-4e6a-8ac3-1ce3b65bb89e"
      unitRef="usd">-21037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4dddc1bdfa584b6b98b1043ec91c81b5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzAtMTUtMS0xLTEwNDEzNg_eec313d0-10d7-4bc4-a2ec-3c54a5633b11"
      unitRef="usd">-21037000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i040af099c030461699b8808e3daabecc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMS0xLTEtMTA0MTM2_0788bb83-f540-43df-8414-f3cb43cdd6f5"
      unitRef="shares">42522397000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i040af099c030461699b8808e3daabecc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMy0xLTEtMTA0MTM2_8065656f-e2f5-4761-a4e9-d6f083dcae83"
      unitRef="usd">440000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6e0eac4c061d4c7fb0a29e209902295d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtNS0xLTEtMTA0MTM2_74ef385e-83d1-45b3-b582-08323f22c4ef"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6e0eac4c061d4c7fb0a29e209902295d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtNy0xLTEtMTA0MTM2_eccea79e-df47-493b-b316-7d44f0fe94dc"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie748da8f76a746f280de5263b489baed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtOS0xLTEtMTA0MTM2_2fc6e7c7-6598-4440-96a5-2f61e7d38419"
      unitRef="usd">451453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a070c3e49fc4a47b4a3837aa83925d6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTEtMS0xLTEwNDEzNg_9e196db3-ee7a-4661-9ea7-31da8abf327a"
      unitRef="usd">-15487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic982ac60ad0243d6a23af0d1772047e6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTMtMS0xLTEwNDEzNg_9153411b-9d7b-47c8-bc60-2c74c9bf1970"
      unitRef="usd">-211849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4807ff1430444da1b1c019311c325e45_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfMzEtMTUtMS0xLTEwNDEzNg_796fdbf5-d366-4d45-bfec-f0375966c6b3"
      unitRef="usd">224585000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDAtMS0xLTEtMTA0NTE3_d1913e00-952e-4393-bfe4-43c2752dd91e"
      unitRef="shares">29887000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i5db3e80cb33648d38003d159fd38fe78_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDEtMS0xLTEtMTA0NTE3_db6f145e-8cbe-4ddb-8bad-c1df15584a7c"
      unitRef="shares">2100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia27028a6c13f4e2185c22066785a346c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDItOS0xLTEtMTA0NTE3_95c52932-ebd3-48bb-9c38-0ebfb770d3d3"
      unitRef="usd">3504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDItMTUtMS0xLTEwNDUxNw_b25a2fae-b8ab-4001-a9b2-6f5a6d9961ac"
      unitRef="usd">3504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i37af0655d52644088f3ca93ae36fddc8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDMtMTEtMS0xLTEwNDUxNw_98b2736b-4622-47ca-9354-cc35be75e910"
      unitRef="usd">-15156000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDMtMTUtMS0xLTEwNDUxNw_a101e53f-afc9-495c-974a-5e674f3fe82f"
      unitRef="usd">-15156000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5d0006602ef04e3ea9db6289df6795e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDQtMTMtMS0xLTEwNDUxNw_f66def56-a8d5-4410-9437-1470b8e98a1d"
      unitRef="usd">-18371000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDQtMTUtMS0xLTEwNDUxNw_6488cd75-fe19-447c-9b8c-90727d214278"
      unitRef="usd">-18371000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMS0xLTEtMTA0NTE3_504fbfeb-d45b-434d-8f58-e23d5e8acbd0"
      unitRef="shares">42554384000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMy0xLTEtMTA0NTE3_94ce34b1-1ae2-4217-bf35-44d3f54138b9"
      unitRef="usd">440000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3137c453e903495eaaf7d9ad3254c18d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtNS0xLTEtMTA0NTE3_210e9fd4-5f2a-4161-9831-eb6943f04070"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3137c453e903495eaaf7d9ad3254c18d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtNy0xLTEtMTA0NTE3_50fb3804-85d8-4931-955c-ecc1c2aed8fd"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c4120f8256c42b8b85596ceb05ffa7b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtOS0xLTEtMTA0NTE3_8a7163a1-dfea-420c-8910-b822663a5544"
      unitRef="usd">454957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e65128b96b64b4d953bc090ea8f9461_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTEtMS0xLTEwNDUxNw_d40c744d-7a3e-4d5e-8b1b-0b5d4f224181"
      unitRef="usd">-30643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e8120c9d53e4a378e74d67421c6687c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTMtMS0xLTEwNDUxNw_78e78aef-4ea0-4790-a925-2c524b5a800f"
      unitRef="usd">-230220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zMS9mcmFnOjRjZTE5N2RiM2IwODQyMDJhNTFmODI4NDY3OTEwMzY1L3RhYmxlOjAyNGJmY2RmNGI0NzRiZDU4ZDIzMGM1ZDhhYWY0MDI4L3RhYmxlcmFuZ2U6MDI0YmZjZGY0YjQ3NGJkNThkMjMwYzVkOGFhZjQwMjhfNDUtMTUtMS0xLTEwNDUxNw_83d1be6d-9637-47f7-b12b-5f79c3dfafaf"
      unitRef="usd">194562000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMy0xLTEtMS0xMDQxMzY_22cb3161-7234-424d-882d-38dd1102240c"
      unitRef="usd">-60579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMy0zLTEtMS0xMDQxMzY_3fd6568a-4da8-45f3-888b-38339ad9e26f"
      unitRef="usd">-46092000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNS0xLTEtMS0xMDQxMzY_d507603b-79dd-42bb-88b5-1a11a3ed3174"
      unitRef="usd">234000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNS0zLTEtMS0xMDQxMzY_abbb7d52-6417-4fef-80c7-264b7025e647"
      unitRef="usd">123000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNi0xLTEtMS0xMDQxMzY_1ff939c4-f6f3-413a-ad82-078797641521"
      unitRef="usd">-3842000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNi0zLTEtMS0xMDQxMzY_557d55dc-d773-4cc1-8097-380a923ae3ae"
      unitRef="usd">-31000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNy0xLTEtMS0xMDQxMzY_431f39d6-ec2c-4222-b80e-e17b34ef8f94"
      unitRef="usd">9810000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfNy0zLTEtMS0xMDQxMzY_53bd9faa-2690-485c-b241-b2f48c4ddd16"
      unitRef="usd">5857000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfOC0xLTEtMS0xMDQxMzY_be27045c-8d44-4542-9280-0fc51e91e1a4"
      unitRef="usd">1610000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfOC0zLTEtMS0xMDQxMzY_f331d818-9fba-4eaf-9a6e-9b638d1c96e1"
      unitRef="usd">1023000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTAtMS0xLTEtMTA0MTM2_112a445e-3b08-48ec-bdfc-c54cc1f3253f"
      unitRef="usd">30141000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTAtMy0xLTEtMTA0MTM2_fdd04858-c2e0-4647-9f0f-815d374600ca"
      unitRef="usd">6798000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTEtMS0xLTEtMTA0MTM2_dae0cb0c-019c-46f8-a633-305f4ceb4597"
      unitRef="usd">1813000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTEtMy0xLTEtMTA0MTM2_ad24df9a-d90a-4d25-a8a0-f988dc87a85b"
      unitRef="usd">631000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTItMS0xLTEtMTA0MTM2_7612f67d-75fb-4c5c-8839-99ce96410c36"
      unitRef="usd">306000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTItMy0xLTEtMTA0MTM2_041b7da8-9f23-4371-b5f3-d5577a3478ba"
      unitRef="usd">168000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTMtMS0xLTEtMTA0MTM2_bf911fff-1740-4cf9-b9b7-06054e398847"
      unitRef="usd">-1571000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTMtMy0xLTEtMTA0MTM2_e49324e2-3fbe-4be0-949b-dbbc26ddbcd5"
      unitRef="usd">-1023000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTQtMS0xLTEtMTA0MTM2_084cb555-f000-45a5-aca7-6ded4d9a064e"
      unitRef="usd">20018000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTQtMy0xLTEtMTA0MTM2_6b44981a-5e12-4131-971b-58937b70bd2f"
      unitRef="usd">36000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTUtMS0xLTEtMTA0MTM2_f17bbe0a-524e-4db7-b1ea-c2c85fdfdb9b"
      unitRef="usd">-1253000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTUtMy0xLTEtMTA0MTM2_2e1fa3f1-4540-4994-a619-8625e196047a"
      unitRef="usd">2266000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTYtMS0xLTEtMTA0MTM2_5cef89c7-6adf-4048-9f7e-0fec616ec6dc"
      unitRef="usd">-60149000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTYtMy0xLTEtMTA0MTM2_6439c688-bcd5-4f44-9204-81f74dbf331d"
      unitRef="usd">-45376000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTgtMS0xLTEtMTA0MTM2_0d60f094-63c1-4d25-984a-ccca89a1a71c"
      unitRef="usd">489000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTgtMy0xLTEtMTA0MTM2_6e110c59-2db5-4998-9b51-b459ca81a2dd"
      unitRef="usd">241000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTktMS0xLTEtMTA0MTM2_1b01e089-4bfc-4925-9126-7999d8010c54"
      unitRef="usd">-489000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMTktMy0xLTEtMTA0MTM2_fab51ec0-a1a2-419c-91e3-fcf61e4bdb76"
      unitRef="usd">-241000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjEtMS0xLTEtMTA0MTM2_a869377d-4138-479f-9af9-c70336c702d8"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjEtMy0xLTEtMTA0MTM2_dd712fad-a4b4-4cdf-af4c-9b38b43e9803"
      unitRef="usd">154794000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjItMS0xLTEtMTA0MTM2_8daedac5-74e5-41be-ad9a-c6151682be4d"
      unitRef="usd">401000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjItMy0xLTEtMTA0MTM2_0be55ab0-abbc-4b14-a057-e1451cba9a86"
      unitRef="usd">1047000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjQtMS0xLTEtMTA0MTM2_568d34be-930d-4258-809b-c981a138fca8"
      unitRef="usd">401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjQtMy0xLTEtMTA0MTM2_ed463eb1-7b0c-495f-acf9-2f64093c1db7"
      unitRef="usd">155841000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjUtMS0xLTEtMTA0MTM2_17dc2287-c9c7-4525-b810-105c4991c1b6"
      unitRef="usd">-39879000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjUtMy0xLTEtMTA0MTM2_5092b7f1-ccc3-4a79-968c-04441c9e6fd7"
      unitRef="usd">-6517000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjYtMS0xLTEtMTA0MTM2_2e6ffacf-e3ab-4295-bebc-fa57eb0ff75a"
      unitRef="usd">-100116000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjYtMy0xLTEtMTA0MTM2_cac32d51-1ee0-4d6a-a7bd-b5f5d6ab6a98"
      unitRef="usd">103707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjctMS0xLTEtMTA0MTM2_1011cd01-96a9-4093-8f17-b2bc735c08a5"
      unitRef="usd">273347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c7d6429579e4d5489d901de0c7b760d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjctMy0xLTEtMTA0MTM2_a481fc71-1f12-4663-b8b6-1eca4a7c7ac4"
      unitRef="usd">190356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjgtMS0xLTEtMTA0MTM2_45f68cd5-e87b-47c2-a5e6-96ea6199680f"
      unitRef="usd">173231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMjgtMy0xLTEtMTA0MTM2_95331d09-059a-4f59-a87c-f48bd08ded9d"
      unitRef="usd">294063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzEtMS0xLTEtMTA0MTM2_1690e1ce-9182-4f43-90eb-24ebe7219f0a"
      unitRef="usd">796000</cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption>
    <cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzEtMy0xLTEtMTA0MTM2_69eea733-55ea-49a6-9d1d-570aa40fa39f"
      unitRef="usd">5599000</cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption>
    <cmps:ProceedsFromStockOptionsExercisedNotReceived
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzItMS0xLTEtMTA2MjUx_e5d1bb1d-5ff4-4267-bc78-efe474efb99e"
      unitRef="usd">0</cmps:ProceedsFromStockOptionsExercisedNotReceived>
    <cmps:ProceedsFromStockOptionsExercisedNotReceived
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzItMy0xLTEtMTA2MjYw_8b12cae4-3947-4ea2-86d6-b955db22eb7f"
      unitRef="usd">21000</cmps:ProceedsFromStockOptionsExercisedNotReceived>
    <cmps:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzMtMS0xLTEtMTA2MjUx_f50685ef-3a86-403f-9f8d-69382fc0969a"
      unitRef="usd">0</cmps:DeferredOfferingCostsIncludedInAccruedExpenses>
    <cmps:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOjFmYTgxNDdjZjQwOTQ1OWY5MGM4Y2M5Nzg2MjljNDc0L3RhYmxlcmFuZ2U6MWZhODE0N2NmNDA5NDU5ZjkwYzhjYzk3ODYyOWM0NzRfMzMtMy0xLTEtMTA2MjYw_ada449a9-2325-4d12-aef2-5094600c5b7d"
      unitRef="usd">234000</cmps:DeferredOfferingCostsIncludedInAccruedExpenses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMi0xLTEtMS0xMDQxMzY_0024bad3-4131-4e23-afbc-6d7bcc3f1153"
      unitRef="usd">173076000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMi0zLTEtMS0xMDQxMzY_392839b2-b72f-4dbf-8781-c686c7e1e76b"
      unitRef="usd">293959000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMy0xLTEtMS0xMDQxMzY_271861b0-1dbb-4b14-ad9a-256f5dbe0d4c"
      unitRef="usd">155000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfMy0zLTEtMS0xMDQxMzY_0b2df24c-51c5-4b45-9d81-c5974d449574"
      unitRef="usd">104000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfNC0xLTEtMS0xMDQxMzY_f67887d2-cb18-4291-bbd3-f6645a77481d"
      unitRef="usd">173231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl8zNC9mcmFnOmJkNjEzMjI5MTYxMzQ3OWJiZmFjZGZmZThiNzY2YjY0L3RhYmxlOmZiMDRhYTJjMmYzNjQ5MDU5ODE3MGM3ZTJkNGQwN2Y3L3RhYmxlcmFuZ2U6ZmIwNGFhMmMyZjM2NDkwNTk4MTcwYzdlMmQ0ZDA3ZjdfNC0zLTEtMS0xMDQxMzY_7b6a20df-9aaf-41d9-8b7f-9e871e67b5af"
      unitRef="usd">294063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfNDg4Mw_0bc260fb-95a7-4f68-9146-330c7e7e0e8e">Nature of Business &lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and more recently through the sale of American Depository Shares, or ADSs, in connection with the Company&#x2019;s initial public offering, or the IPO, in September 2020, and its $154.8&#160;million May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#x2019;s ADSs, if any, will be made at market prices. The Company has not yet sold any ADSs under this at-the-market offering. The Company has incurred recurring losses since its inception, including net losses of $60.6 million and $46.1 million for the nine months ended September 30, 2022 and 2021, respectively. In addition, as of September&#160;30, 2022, the Company had an accumulated deficit of $230.2 million. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the cash and cash equivalents on hand as of September&#160;30, 2022 of $173.1 million will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the COVID-19 pandemic continues to evolve, the Company continues to assess its business plans and the additional impact which resurgences or the emergence of new variants of COVID-19 may have on its ability to advance the development and manufacturing of COMP360 as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom it relies, or to raise further financing to support the development of its investigational COMP360 psilocybin therapy. While many measures have been put in place to attempt to contain the spread of COVID-19 resurgences, including existing or future variants, no assurances can be given that the Company will avoid any future impact from the ongoing COVID-19 pandemic or the emergence of new variants, including any direct or indirect impacts arising as a result of downturns in business sentiment generally or in its sector in particular, impacts on global supply chains, or other effects. The Company cannot currently predict the scope and severity of any future potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies or with whom the Company conducts business were to experience additional shutdowns or other business disruptions, the Company&#x2019;s ability to conduct its business in the manner and on the timelines presently planned could be materially and adversely impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i728c5692d6704623aa8c0fcc42770d12_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjcyOQ_d225fc8b-9b1c-4ed6-a41f-cb8c4a6bec1e"
      unitRef="usd">154800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cmps:SaleOfStockMaximumAmountAllowableForSale
      contextRef="i7191433cf01d4df1bb228323c1facbe9_I20211008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjc0NQ_3fa1e5b7-522d-45f6-8673-1cc969b76537"
      unitRef="usd">150000000</cmps:SaleOfStockMaximumAmountAllowableForSale>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTA5OTUxMTYzMjc2MQ_53422fe4-87b2-44fa-93bc-88299c000cb5"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:NetIncomeLoss
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTY0OTI2NzQ0NjU4Mw_7bc31c66-f300-4e95-9ff3-a2de6d7d5562"
      unitRef="usd">-60600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMTY0OTI2NzQ0NjU4Nw_0eca619d-2848-48ff-a5d4-9758d5235179"
      unitRef="usd">-46100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib94f580649ab49a0896b34592f4b080d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfMjI5Mg_5577f8ca-63ac-4491-8dd3-5b80350722f0"
      unitRef="usd">-230200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80MC9mcmFnOjcxN2YyODZhMzdkMjRlYmJiYzUxZGQyNjcxMzdiMGM3L3RleHRyZWdpb246NzE3ZjI4NmEzN2QyNGViYmJjNTFkZDI2NzEzN2IwYzdfNTQ5NzU1ODE4ODAy_749ebfda-ee34-4bd1-9984-9aa8a46f23d8"
      unitRef="usd">173100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDc_49ddd08c-05ae-4d44-b850-44a3890df322">Summary of Significant Accounting Policies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of September 30, 2022, the results of its operations and comprehensive loss for the three months and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results for the three months and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 24, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before the Company&#x2019;s IPO, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash as of September&#160;30, 2022 and December 31, 2021 represents a collateral deposit for employee credit cards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the inputs for the first two are considered observable and the inputs for the last are considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the condensed consolidated balance sheets for the Company&#x2019;s cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#x2019;s fixed assets are primarily located in the UK. The Company&#x2019;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract Costs, Prepayments and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepayments and accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimated the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 9 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Given the absence of an active market for the Company&#x2019;s ordinary shares prior to the IPO, the Company and the board of directors of the Company, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#x2019;s ordinary shares at the time of each grant of a stock-based award prior to the IPO. The grant date fair value of restricted ordinary shares and share options were calculated based on the grant date fair value of the underlying ordinary shares. The Company calculated the fair value of the ordinary shares in accordance with the guidelines in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the &#x201c;Practice Aid&#x201d;. The Company&#x2019;s valuations of ordinary shares were prepared using a market approach, based on precedent transactions in the shares, to estimate the Company&#x2019;s total equity value using an option-pricing method, or OPM. After the Company&#x2019;s IPO, the fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The OPM derives an equity value such that the value indicated for ordinary shares is consistent with the investment price, and it provides an allocation of this equity value to each of the Company&#x2019;s securities. The OPM treats the various classes of ordinary shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the share liquidation preferences of ordinary shares with senior preferences at the time of the liquidity event. Key inputs into the OPM calculation included the risk-free rate, expected time to liquidity and volatility. A reasonable discount for lack of marketability was applied to the total equity value to arrive at an estimate of the total fair value of equity on a non-marketable basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#x2019;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#x2019;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 11 for right-of-use assets and liabilities recorded during the periods ended September 30, 2022 and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#x2019;s leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its condensed consolidated financial statements in its functional currency, which is Pound Sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded foreign exchange gains of approximately $1.1 million and $3.4 million for the three months ended September&#160;30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded a foreign exchange gain of $4.4 million and $2.2 million respectively. These gains arise from U.S. dollars which are held in a financial institution in one of our UK subsidiaries that has a functional currency of Pound Sterling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, the condensed consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting currency. The financial statements of entities are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other income, net are translated at the average exchange rates for the periods presented and shareholders&#x2019; equity is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standard Update, or ASU, 2019-12, &#x201c;Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740),&#x201d; or ASU 740, which simplifies the accounting for income taxes. The new guidance removes certain exceptions to the general principles in ASC 740 such as recognizing deferred taxes for equity investments, the incremental approach to performing intra-period tax allocation and calculating income taxes in interim periods. The standard also simplifies accounting for income taxes under U.S. GAAP by clarifying and amending existing guidance, including the recognition of deferred taxes for goodwill, the allocation of taxes to members of a consolidated group and requiring that an entity reflect the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods thereafter; however, early adoption is permitted. The Company adopted this ASU as of January 1, 2021 and it has had no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of September 30, 2022 and December 31, 2021, the Company has not identified any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022 and December 31, 2021 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefit from Research and Development Tax Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#x20ac;7.5 million which may impact the Company's ability to claim R&amp;amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#xa3;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#xa3;5.0 million plus an incremental 50% of UK taxable profits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. For the three months and nine months ended September 30, 2022 and 2021, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into foreign currency contracts to reduce the risk that our cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying Consolidated Statement of Operations and Comprehensive Loss as Other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjA_14abe1a8-eb4b-4f0c-8577-af335d4b68c0">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of September 30, 2022, the results of its operations and comprehensive loss for the three months and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;The results for the three months and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 24, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDE_e185f8d7-f459-4fd9-933a-f6282ecacef3">Principles of ConsolidationThe accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDg_a873f176-dfab-4643-80e2-5346ce2c20e4">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, discount rates for leases, the fair value of ordinary shares before the Company&#x2019;s IPO, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDk_a7b2bc28-3cff-4453-b8e0-42f0b2adf0ee">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTA_73a36144-dca5-47c1-8f86-079f7b91cd71">Restricted CashRestricted cash as of September&#160;30, 2022 and December 31, 2021 represents a collateral deposit for employee credit cards.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDU_03556681-183a-409a-8117-ba093e294de3">InvestmentThe investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjI_2c278394-aeea-4685-800e-e1462a0bfb30">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the inputs for the first two are considered observable and the inputs for the last are considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the condensed consolidated balance sheets for the Company&#x2019;s cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTE_817ab252-7b66-4f4d-8634-6d13861a4c7d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in established financial institutions. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTM_378c2af5-0e32-401c-bd23-594201533a4d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDI_85a4425a-4426-4fc5-b43d-d69d0b736ab0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMS0xLTEtMS0xMDQxMzY_e202e67e-8ef1-4cc7-b614-dc182f03b2f5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id7276d186a62437988e54f6972e90adc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMi0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjo2OGJmNWJlNDYwMDE0YmY1Yjg3MTY5ODliODk1ZjBjMl80_45735812-eb1d-44f2-a2dd-cfe2004299f7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i58ad1f7848464166b04ff803b503d684_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMi0xLTEtMS0xMDQxMzYvdGV4dHJlZ2lvbjo2OGJmNWJlNDYwMDE0YmY1Yjg3MTY5ODliODk1ZjBjMl83_5733e5d9-98d0-45c6-9edc-186181368924">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4ca94ba54c5c4d338293cf60580918bb_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RhYmxlOmUzNTBhZGE5ZmM4NDQ3NzNhYjUwZDViZWVhNTcwZjQ0L3RhYmxlcmFuZ2U6ZTM1MGFkYTlmYzg0NDc3M2FiNTBkNWJlZWE1NzBmNDRfMy0xLTEtMS0xMDQxMzY_c8258a9c-ceac-4ccc-98c7-2d61d3548b0b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjM_b86e785b-09c3-4c80-9150-2de48bdab3e1">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDM_cbaa78fc-e2fe-4cf4-bbda-251dff0cb76d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#x2019;s fixed assets are primarily located in the UK. The Company&#x2019;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cmps:NumberOfGeographicRegions
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNzA1NQ_e4f2abe6-35ac-4a66-a217-aea5e402c7d6"
      unitRef="region">2</cmps:NumberOfGeographicRegions>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTQ_a00ae512-94f9-4fe2-b0f5-b9f3e5cbaf77">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTI_669de8f2-db27-4c53-8eb9-cffa813debfc">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract Costs, Prepayments and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepayments and accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDY_3cbdedb7-dc04-4753-a845-e22413d16dfd">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimated the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 9 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Given the absence of an active market for the Company&#x2019;s ordinary shares prior to the IPO, the Company and the board of directors of the Company, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#x2019;s ordinary shares at the time of each grant of a stock-based award prior to the IPO. The grant date fair value of restricted ordinary shares and share options were calculated based on the grant date fair value of the underlying ordinary shares. The Company calculated the fair value of the ordinary shares in accordance with the guidelines in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the &#x201c;Practice Aid&#x201d;. The Company&#x2019;s valuations of ordinary shares were prepared using a market approach, based on precedent transactions in the shares, to estimate the Company&#x2019;s total equity value using an option-pricing method, or OPM. After the Company&#x2019;s IPO, the fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.&lt;/span&gt;&lt;/div&gt;The OPM derives an equity value such that the value indicated for ordinary shares is consistent with the investment price, and it provides an allocation of this equity value to each of the Company&#x2019;s securities. The OPM treats the various classes of ordinary shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the share liquidation preferences of ordinary shares with senior preferences at the time of the liquidity event. Key inputs into the OPM calculation included the risk-free rate, expected time to liquidity and volatility. A reasonable discount for lack of marketability was applied to the total equity value to arrive at an estimate of the total fair value of equity on a non-marketable basis.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTg_30fa741b-6d62-4821-b7a0-99268d59f8d7">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#x2019;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#x2019;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 11 for right-of-use assets and liabilities recorded during the periods ended September 30, 2022 and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#x2019;s leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3abee071f8fa481083b1445474906b6a_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQ5NDg1_13012f3f-9425-4b1a-afdc-6ddeea3c90a0"
      unitRef="usd">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3abee071f8fa481083b1445474906b6a_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQ5NDg1_be910471-07ed-4de4-a225-1e1d89eae346"
      unitRef="usd">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NjE_f597368a-7282-479a-87c8-303bdbd11365">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its condensed consolidated financial statements in its functional currency, which is Pound Sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other income, net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded foreign exchange gains of approximately $1.1 million and $3.4 million for the three months ended September&#160;30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded a foreign exchange gain of $4.4 million and $2.2 million respectively. These gains arise from U.S. dollars which are held in a financial institution in one of our UK subsidiaries that has a functional currency of Pound Sterling.&lt;/span&gt;&lt;/div&gt;For financial reporting purposes, the condensed consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting currency. The financial statements of entities are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other income, net are translated at the average exchange rates for the periods presented and shareholders&#x2019; equity is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#x2019; equity.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQzMDQ5_3e4595c9-26cf-4385-8de1-d9ac8dfddba1"
      unitRef="usd">1100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfNTQ5NzU1ODQzMDUz_3b850cdb-2d1f-4a9b-9452-93920786c894"
      unitRef="usd">3400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfODI0NjMzNzIzNzYzNg_8df047ff-22bb-483b-80e2-dfa1058c995b"
      unitRef="usd">4400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfODI0NjMzNzIzNzY0MA_1df4ef5d-5810-4ebe-bf34-bb9ed956bcc8"
      unitRef="usd">2200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTU_033473b7-85c4-4fe9-91db-19eccc0c7c86">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standard Update, or ASU, 2019-12, &#x201c;Income Taxes - Simplifying the Accounting for Income Taxes (Topic 740),&#x201d; or ASU 740, which simplifies the accounting for income taxes. The new guidance removes certain exceptions to the general principles in ASC 740 such as recognizing deferred taxes for equity investments, the incremental approach to performing intra-period tax allocation and calculating income taxes in interim periods. The standard also simplifies accounting for income taxes under U.S. GAAP by clarifying and amending existing guidance, including the recognition of deferred taxes for goodwill, the allocation of taxes to members of a consolidated group and requiring that an entity reflect the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods thereafter; however, early adoption is permitted. The Company adopted this ASU as of January 1, 2021 and it has had no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of September 30, 2022 and December 31, 2021, the Company has not identified any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022 and December 31, 2021 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTY_f6c2c6a6-c76f-4c61-9cf8-a68474909b5d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefit from Research and Development Tax Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#x20ac;7.5 million which may impact the Company's ability to claim R&amp;amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#xa3;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#xa3;5.0 million plus an incremental 50% of UK taxable profits.&lt;/span&gt;&lt;/div&gt;</cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock>
    <cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent
      contextRef="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjE3NTM_8235adeb-4aa2-4ef4-8b60-c0429f271ed7"
      unitRef="number">0.3335</cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent>
    <cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent
      contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjIxNzQ_e30e67df-d1f4-4446-8285-d1deb2c4d498"
      unitRef="number">0.2167</cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent>
    <cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable
      contextRef="ia954386f1133424ab03bfe1602694dd3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjM3ODg_17b1a91e-cf04-4def-a26c-e32c996d1e22"
      unitRef="eur">7500000</cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable>
    <cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount
      contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjQ4MDc_bd94a939-ab07-4cd9-87aa-b16a4d4f6a61"
      unitRef="gbp">5000000.0</cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount>
    <cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent
      contextRef="ie1704314f1ea450d9933186d70a008df_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjQ4Mzg_dcf62fc2-9d55-42b0-9059-f32ed8d17bd1"
      unitRef="number">0.50</cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NDQ_ba91260f-8928-4e8b-afd4-4be5e87f5bf2">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. For the three months and nine months ended September 30, 2022 and 2021, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80Ni9mcmFnOjYzOGRjYjgzNTAyMjQ5ZDhhYTM1ODNhMzMzODA3NzZmL3RleHRyZWdpb246NjM4ZGNiODM1MDIyNDlkOGFhMzU4M2EzMzM4MDc3NmZfMjg4NTk_f2ebf9c7-4c88-4331-a7fa-89cd56dd8678">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into foreign currency contracts to reduce the risk that our cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying Consolidated Statement of Operations and Comprehensive Loss as Other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl80OS9mcmFnOjRkZDczZjE2ZjE1YjRiNGY5M2MwMTg5MGUwOTRlNTc4L3RleHRyZWdpb246NGRkNzNmMTZmMTViNGI0ZjkzYzAxODkwZTA5NGU1NzhfNDI3_1f29ce2e-793e-4a4f-a39f-8f69422e384b">Fair Value MeasurementsThere are no financial instruments measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021. Management believes that the carrying amounts of the Company&#x2019;s condensed consolidated financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfMTA4OQ_37cb339d-a257-46b8-87a3-8365eefdd72a">InvestmentOn March 6, 2020, the Company made a strategic investment of $0.5 million to acquire an 8% (on a fully diluted basis) shareholding in Delix Therapeutics, Inc., a drug discovery and development company researching novel small molecules for use in Central Nervous System, or CNS, indications. The Company&#x2019;s investment in Delix Therapeutics, Inc. does not provide it with significant influence over the investee. The investment does not have a readily determinable fair value and therefore will be measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This investment will be measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of September 30, 2022, no impairment loss was recognized.</us-gaap:InvestmentTextBlock>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8952b53cbd2045e785cda206c0dbefa7_D20200306-20200306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfODA_e50317f5-11d3-4e30-99c8-d4f1a89d666c"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i291d3af8cf514f328ce6b2496870c764_I20200306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81Mi9mcmFnOjEzZTc2ZmZjOTdjZDQwMzFiY2JiOTBjMTNjZjY1NzdmL3RleHRyZWdpb246MTNlNzZmZmM5N2NkNDAzMWJjYmI5MGMxM2NmNjU3N2ZfMTA1_cae1169a-a677-41b4-8d1e-66120ea3e021"
      unitRef="number">0.08</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RleHRyZWdpb246OTFmYTM5NzNhMDVjNDJhNWI2MWZlOWM4OTAzZjc2YjlfMTM1_a1a73091-2f2f-4a8a-8174-51ad12d9262d">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RleHRyZWdpb246OTFmYTM5NzNhMDVjNDJhNWI2MWZlOWM4OTAzZjc2YjlfMTM2_e9bceb2d-af82-4bb5-9eb3-08c7c26f8da7">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMi0xLTEtMS0xMDQxMzY_3d6993c9-c1f1-45d4-a71e-a73b14543c6a"
      unitRef="usd">16774000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMi0zLTEtMS0xMDQxMzY_600a92c6-ff41-4177-b377-73cf63abeebd"
      unitRef="usd">9587000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMy0xLTEtMS0xMDQxMzY_96290a14-386a-4be1-b996-91d2438d92e9"
      unitRef="usd">3068000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfMy0zLTEtMS0xMDQxMzY_4360025d-69e7-4f16-b41a-ebc728ad583b"
      unitRef="usd">3359000</us-gaap:PrepaidInsurance>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNC0xLTEtMS0xMDQxMzY_3fe3f00e-00fe-46a7-bcca-9cd5c22e4c89"
      unitRef="usd">22203000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNC0zLTEtMS0xMDQxMzY_72d9b4c5-65b6-4eb5-aff0-cd13000aa52f"
      unitRef="usd">4562000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNS0xLTEtMS0xMDQxMzY_67758edf-e78f-408d-86ae-b14d05280e66"
      unitRef="usd">1348000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNS0zLTEtMS0xMDQxMzY_503b8204-d855-4669-8e26-b232bdf07440"
      unitRef="usd">1629000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNi0xLTEtMS0xMDQxMzY_dd3384c3-d5c8-443b-a4c6-4a35fb4fd302"
      unitRef="usd">0</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNi0zLTEtMS0xMDQxMzY_9d622fe7-3da8-405b-9d70-afa28da3fbe1"
      unitRef="usd">840000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNy0xLTEtMS0xMDQxMzY_b0aa2365-fff2-4a12-8a00-a32c982a8da1"
      unitRef="usd">89000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfNy0zLTEtMS0xMDQxMzY_07ee2ca5-d0db-444e-826d-04d29c5c1447"
      unitRef="usd">274000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOC0xLTEtMS0xMDQxMzY_30056477-6a63-4d99-94ff-f9f803008118"
      unitRef="usd">1273000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOC0zLTEtMS0xMDQxMzY_471c29c3-638c-40d3-8418-4c57466db1ec"
      unitRef="usd">1370000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOS0xLTEtMS0xMDQxMzY_ed1bd198-5f16-4591-889d-a74de828b5c2"
      unitRef="usd">44755000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81NS9mcmFnOjkxZmEzOTczYTA1YzQyYTViNjFmZTljODkwM2Y3NmI5L3RhYmxlOmQ2Y2FmZTA0YjQ4ZjQ0ZDViOTg3OWFhMjI2Njk4ZmJjL3RhYmxlcmFuZ2U6ZDZjYWZlMDRiNDhmNDRkNWI5ODc5YWEyMjY2OThmYmNfOS0zLTEtMS0xMDQxMzY_3153c9a7-a2fb-4916-9a8c-f372c68907bb"
      unitRef="usd">21621000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfMzgy_3627741f-5f4b-4af4-8a98-2d0b91754575">Property and Equipment, Net&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expenses were less than $0.1&#160;million and $0.2&#160;million for the three months and nine months ended September 30, 2022 respectively. For the three months and nine months ended September 30, 2021, depreciation and amortization expenses were also less than $0.1&#160;million and $0.1&#160;million, respectively</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id76776d937084bb6b068aef14a3affac_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMi0xLTEtMS0xMDQxMzY_0d7e6878-1d5d-4519-81cd-8719f2e968a8"
      unitRef="usd">342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i71781fc181fd4d39bb070c8c01a27ba1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMi0zLTEtMS0xMDQxMzY_93ca124e-56fa-425a-9bd0-cb58569f425d"
      unitRef="usd">370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ief874743632e4333a3f835ba18d45264_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMy0xLTEtMS0xMDQxMzY_6fe7895b-4b48-4475-b682-18ce6a3b3532"
      unitRef="usd">443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i086cfe97e6384515ace3b2cd9e1a8caf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfMy0zLTEtMS0xMDQxMzY_592b6f51-a45a-4b96-b2c8-aecf31d5ef41"
      unitRef="usd">315000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i69b536a3e71446ef897b88f79dc31c3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNC0xLTEtMS0xMDQxMzY_9f7a7d1d-3ff7-444b-a388-1aece5638ed8"
      unitRef="usd">80000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7d60c51518a44be9b0594797b5f26453_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNC0zLTEtMS0xMDQxMzY_e44a6011-8705-4d0a-9087-2bf1651758e2"
      unitRef="usd">65000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idb55899e87ce45a0a6e5f48a7d035dfb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNS0xLTEtMS0xMDQxMzY_57a50318-bea7-43b9-ba96-0097484bdb5f"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie15077b2d3fd4730b187893fbb83cd38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNS0zLTEtMS0xMDQxMzY_422fce3b-cf37-40aa-bc32-ce33462efa37"
      unitRef="usd">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNi0xLTEtMS0xMDQxMzY_00e82199-4887-472a-af50-e25180c7a57c"
      unitRef="usd">950000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNi0zLTEtMS0xMDQxMzY_956f2491-8a02-4f2b-8670-069e9e4ae7c5"
      unitRef="usd">756000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNy0xLTEtMS0xMDQxMzY_9bb514a6-eaf7-430c-9077-c73b50aba974"
      unitRef="usd">395000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfNy0zLTEtMS0xMDQxMzY_a4b81b85-b19e-41e1-bea2-990314ee3842"
      unitRef="usd">358000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfOC0xLTEtMS0xMDQxMzY_e78f53b4-e0ca-41d6-84c8-24f51a8b5bc6"
      unitRef="usd">555000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RhYmxlOjBhYjU0ZmEwZGQyZDRlYWQ4OTU1MWE5NTkzNzJjNDE2L3RhYmxlcmFuZ2U6MGFiNTRmYTBkZDJkNGVhZDg5NTUxYTk1OTM3MmM0MTZfOC0zLTEtMS0xMDQxMzY_ec80898a-9b7c-455a-a08e-4a4740b9f915"
      unitRef="usd">398000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDM1_4bcd7238-c9c9-428a-bd67-b18aa6a63c55"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDU5_48ed502e-9a9c-48e6-beb6-192ed7fe9143"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDQ4_34c8e843-4853-458f-8074-f1d9e002b05d"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl81OC9mcmFnOmI5ZmU0M2MwYmVjZDRjZjE4MzE1MjIxZjAxZjMwODgzL3RleHRyZWdpb246YjlmZTQzYzBiZWNkNGNmMTgzMTUyMjFmMDFmMzA4ODNfNTQ5NzU1ODE0NDUz_2e5e941c-8d70-48c3-8fea-9d1107083e33"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RleHRyZWdpb246NDk5OTJjY2VjOTdlNDJkODkzZGFmMzExMDQ4Njc1NjNfMTI5_8736fec2-f143-48cc-8238-b24840003c06">Accrued Expenses and Other Liabilities&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RleHRyZWdpb246NDk5OTJjY2VjOTdlNDJkODkzZGFmMzExMDQ4Njc1NjNfMTMw_6f70d86e-c325-4d9c-853c-f52cd36cd477">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cmps:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMi0xLTEtMS0xMDQxMzY_e529e842-af41-4ff6-9e5c-f94616146c74"
      unitRef="usd">1366000</cmps:AccruedResearchAndDevelopmentExpenseCurrent>
    <cmps:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMi0zLTEtMS0xMDQxMzY_1284d311-e398-41b0-b5c4-ee6982ede95c"
      unitRef="usd">3043000</cmps:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMy0xLTEtMS0xMDQxMzY_4946e20d-0c9c-4750-8195-d65be679affe"
      unitRef="usd">1463000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfMy0zLTEtMS0xMDQxMzY_fb67e7da-68cd-47ab-a6a8-c260e449f993"
      unitRef="usd">1386000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNC0xLTEtMS0xMDQxMzY_3997f1c2-aa79-4cfa-9d72-70c52350315c"
      unitRef="usd">3810000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNC0zLTEtMS0xMDQxMzY_15e9401b-954b-4a5a-9717-c90f7802e28b"
      unitRef="usd">5018000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNS0xLTEtMS0xMDQxMzY_7a2583ad-9fc1-49a9-9e1a-bb7b438b34fd"
      unitRef="usd">433000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNS0zLTEtMS0xMDQxMzY_3226a10c-1d44-425c-a327-8b62cab0c446"
      unitRef="usd">593000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNy0xLTEtMS0xMDQxMzY_baee9693-cf59-4cd0-9d47-5ddc3e1ed817"
      unitRef="usd">745000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfNy0zLTEtMS0xMDQxMzY_7148a861-b11e-42df-984a-fcfd08d5c99b"
      unitRef="usd">268000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfOC0xLTEtMS0xMDQxMzY_b700ab0f-e389-4920-a9ed-2ce45ad60b31"
      unitRef="usd">7817000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl82MS9mcmFnOjQ5OTkyY2NlYzk3ZTQyZDg5M2RhZjMxMTA0ODY3NTYzL3RhYmxlOmNhMTQwYzJjYjIxMzRjZTdhNjIzNzY2YmM5ZjllN2M0L3RhYmxlcmFuZ2U6Y2ExNDBjMmNiMjEzNGNlN2E2MjM3NjZiYzlmOWU3YzRfOC0zLTEtMS0xMDQxMzY_ccea8097-ec9a-489c-8d10-44fb726faae4"
      unitRef="usd">10308000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTQ0Ng_56a33d86-997c-4c70-bbf4-90b886ce2cf1">Ordinary Shares&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, the Company issued in total 461,772 ordinary shares to settle share options exercised by employees and non-employees compared to 1,188,242 in the nine months ended September 30, 2021. Of the shares issued in the nine months ended September 30, 2021, 232,227 were related to options exercised in 2020 for which shares were delivered in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, a total of 72,738 ordinary shares were issued in settlement of restricted share units, of which 14,863 vested and were issued during the nine months ended September 30, 2022 and 57,875 vested but had not been issued at December 31, 2021. As of September 30, 2022, there were 17,112 restricted shares vested but not settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the nine months ended September 30, 2021, 56,887 restricted share units vested, of which 12,607 ordinary shares were issued in settlement of the vested restricted shares units on August 13, 2021. No ordinary shares were issued for the vested restricted share units of 44,280 in the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2021, the Company sold 4,000,000 ordinary shares in connection with its follow-on offering. On May 19, 2021 the underwriters exercised their option to purchase an additional 600,000 ordinary shares. This capital raise resulted in net proceeds of approximately $154.8&#160;million after deducting underwriting fees and offering costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through September 30, 2022, no cash dividends had been declared or paid by the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NDk4_69a47d60-de3f-42db-b953-6259fc6eaf84"
      unitRef="shares">461772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTAy_61ccfcd2-bb0c-4995-85db-12e5e337ef3f"
      unitRef="shares">1188242</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i68a1067ba8c745c39aa70a7c93efb438_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg2MA_9fcd748b-3d1a-4adb-9345-93a79479e94d"
      unitRef="shares">232227</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTYx_8f3b53b8-23c2-482f-af8c-5e7399b3dfad"
      unitRef="shares">72738</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod
      contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE1NTY1_673b3c36-3860-4402-a380-b78ecab6f778"
      unitRef="shares">14863</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i8f737402f3f24d3ea5417031a82fd9c7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE2MTYx_4e754093-391c-463a-b862-1fdc9dc733c5"
      unitRef="shares">57875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled
      contextRef="ieecac8bd3165451b8d042df19c203fc2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNTQ5NzU1ODE2MjEw_fe86ffdb-4843-457e-b9db-c11809b9dc29"
      unitRef="shares">17112</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg3Nw_56b9ee19-7fa8-471d-8a1f-5b7b090fced7"
      unitRef="shares">56887</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4b33a16f531f4d5e8eb681ad202ab246_D20210813-20210813"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg4NQ_701a049d-294b-4f8b-9476-b93c4147808f"
      unitRef="shares">12607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod
      contextRef="icdd5762b4a67407bb4a677147c8e6ead_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfNzM0_0a0cf906-7c38-41a9-9bc9-26ad125a54f1"
      unitRef="shares">0</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled
      contextRef="i845c82217dbc4bbcaf62c5bea30b2432_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYzMDE1NQ_3c5a5e5e-2913-4478-b1e8-9acd2c000169"
      unitRef="shares">44280</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1e7b97b682754dbe8249580f1dc607a3_D20210504-20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTg5Mw_71e8fa2b-7af3-403b-ac4b-d3434bf6ec5f"
      unitRef="shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i985155b2f2d949c18fb2718219f25234_D20210519-20210519"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkwNA_65057555-2250-4478-8903-772f1a4a5722"
      unitRef="shares">600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ifb10d785bf534ccd8a1515186b019eee_D20210504-20210519"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkxMw_642b500e-1638-4a9a-9401-94688c70ad92"
      unitRef="usd">154800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cmps:NumberOfVotes
      contextRef="i67cd6c80c90e48c2b80e5fc3ba599bcd_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkzOA_febdcf67-6938-4640-8cd7-e45119cf8751"
      unitRef="vote">1</cmps:NumberOfVotes>
    <cmps:CashDividendDeclaredOrPaidDuringPeriod
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83MC9mcmFnOjc4OGY3ZTM2MGU2NTQ1YTZhZjljNjNmNGNhNTRlMTMyL3RleHRyZWdpb246Nzg4ZjdlMzYwZTY1NDVhNmFmOWM2M2Y0Y2E1NGUxMzJfMTA5OTUxMTYyOTkyOA_dfc028dd-c02b-4404-9802-f76575b84694"
      unitRef="usd">0</cmps:CashDividendDeclaredOrPaidDuringPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQzMw_e055bfd1-50b3-41e0-aab2-334270fdb8cc">Share-Based Compensation&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#x2019;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company was authorized to issue a total of 1,602,117 ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2017 Plan, typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTAyNA_35a1f89c-3484-499d-8cd2-515ba09fe46d"&gt;three&lt;/span&gt; or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Share Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Share Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#x2019;s officers, employees, directors and other key persons (including consultants).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 3,755,119 shares as of September 30, 2022, of which 761,700 shares remained available for future grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted in 2022 under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over four year service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and 2021, the Company granted options to purchase 1,400,783 and 752,702 ordinary shares to employees and non-employees, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Inducement Option Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the Company granted to our new chief executive officer a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant. The non-qualified share option has a 10 year term and vests as to one-fourth on August 1, 2023 and as to the remaining three-fourths in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#x2019;s 2020 Plan and the Company&#x2019;s standard form of non-qualified share option agreement. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s unvested restricted share units during the nine months ended September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and 2021, there was $2.2 million and $1.6 million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of 3.0 years and 2.95 years, respectively. The exercise price of restricted share units is at a nominal value less than &#xa3;0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Share Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share options activity for the nine months ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,929,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $5.5 million and $41.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#x2019;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of share options granted was $10.29 and $22.71 per share during the nine months ended September 30, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and 2021, there was $30.7 million and $27.6 million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of 2.97 years and 3.2 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Option Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2022, and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i116fea83328e4122a910788f7882e8d5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjI5Mw_7c394ed1-51ff-4c4b-9626-8b82b43ab323"
      unitRef="shares">1602117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie927c44e5cb04850896477090264ffbc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwOA_47804730-a4e6-46c5-8834-c108185a72b5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic7fc213c5d7f4036bd82a5d59fa39b09_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA1OA_4a4bd350-af21-484d-9ecc-61cf2e4b38b4"
      unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjMyOQ_0cf4df8e-1bbb-4135-9fd9-55890b758771"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8252967fea954920a4963de621717ddc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDk0Ng_3999fb60-03bb-477a-8285-93c4e16f9686">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i214715ae51834a1089d9817b0bf23379_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwOQ_f16e63bd-51d1-42ac-bb1a-7588348d7cca">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i214715ae51834a1089d9817b0bf23379_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTMxMg_d7c37bf8-9de9-4e61-a217-44770b2c730a"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjMyMA_573a7b3c-dced-41d6-b952-aad2a079fe29"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i922d4c474d71486cb90d994f38a92f21_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTY2OQ_814126e4-35b4-46ef-976b-f33702646ee0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDkyNA_8e905445-5255-4c02-b61a-6602733083dc">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6fe6515a2d404bcc9ec0999af57ac58b_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODI0NjMzNzIyMDkzOA_c921be18-01fc-4d4d-ada1-5a8f1233e61e"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjQ3MA_38703a1c-78f9-46fd-8710-025346ab7a92"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjUwOQ_947fb8f7-e5e0-4e75-870a-6a787f7cd4a1">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice
      contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjQyMw_5d45f934-1af7-4e56-807b-542b740665ac"
      unitRef="number">0.20</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="i335fc987c66a4b2aba594c6855452579_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMjc2NA_20d244c3-ede8-43e1-94f1-4bd733a3c7fa"
      unitRef="day">5</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzI1OQ_9db7975a-7486-4661-b42b-cc433a07bc68"
      unitRef="shares">340053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum
      contextRef="i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzUzNQ_686ed94c-dcda-4f95-a12c-6a07b6113d90"
      unitRef="number">0.01</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance
      contextRef="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzYzMg_0a2fe94f-b83e-408e-87b8-1591d33d764f"
      unitRef="shares">510080</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
      contextRef="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMzk0OA_6dc79a96-407f-4f01-b0bf-4f930e1e3b50">P6M</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ic3289a47d99341d7936ab049a3b3b5d9_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDA4MQ_244dc732-4b55-4ef8-ace3-380fe231ebb2"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDY4MQ_bc7eea4f-f797-4a07-a0b6-efedb0442614">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDczMw_cceee62f-384e-4ac7-99fa-7a35b12e3b92">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDc2MQ_926389e5-61d8-41ea-a16b-52d8dec9ab5e"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib1a328d9f64c4104a3a8029417180e0a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNDkxOA_92ab1ba6-ffaa-4063-b778-5fa34ea1169f"
      unitRef="shares">2074325</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease
      contextRef="ib1a328d9f64c4104a3a8029417180e0a_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTE3NQ_fc680cf0-1c01-4dda-b450-01247809ef09"
      unitRef="number">0.04</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease>
    <us-gaap:SharesIssued
      contextRef="iec562706b0534cfeb692067a09d83c1b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTU4Ng_7b05c652-2b37-4398-8bab-8358ce4d863d"
      unitRef="shares">3755119</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTYzNjQyOA_bd029eda-411c-4098-81cd-da39f64b858a"
      unitRef="shares">761700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i610168e4d50d4341abec1f5d08582cad_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTc2MA_6d3e6a0e-349d-4f83-a87c-70c0dbea50ad">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTg3NQ_2a03011f-b45e-411b-a68d-34ad1754dcfd"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i184c85d498ed464fbb0bd960281f1221_D20220201-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNA_da3a5c70-dd4a-4f2e-9890-1df45cd6e121">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODE5OQ_f22f5d19-907b-40ef-8625-185aa0849ceb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i93f7364155974c42be5f014b2e0d3dd5_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTk0OA_7afa47d9-c7a0-4dda-b982-0246fcddf7aa"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i943a4addcd6943e98158e8fe064d19ae_D20220201-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNQ_1dc0446a-e468-44c3-b870-80bc5fbce5c2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id82f65325d56486691f8a2c09cce3ac9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMjk5_5461617f-01b9-460f-bd24-8827641fc9cd"
      unitRef="shares">1400783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1626078e6ffb423ca90396bef3017393_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMjk5_d560fb28-b87f-4192-b6d0-bce6969f1757"
      unitRef="shares">1400783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib9d03b7f170b4a6d82400d749c8536c4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzAz_3eb77821-7b90-4f55-8fe7-08c12796900b"
      unitRef="shares">752702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i41471be5a1e8469eb1c6407abc7d16dd_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzAz_b1da32e5-f313-497e-a01e-37a9e91c5a37"
      unitRef="shares">752702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i168b4e16d7474cce8e24f284c7f15369_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQxMA_47ddbb44-b5bb-41bb-9f18-06ae79bd256e"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDQyMg_2e5123b9-7dac-4840-b2a4-f71b5a8a9512">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib9a501209c2f45288fbf8b753cccfdb7_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfMTA5OTUxMTY0MDUzMQ_6aeb6da6-b581-4e1f-aa65-c5a65dd369f3">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwMg_431e06ec-2235-4c83-ae43-92124a01c637">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s unvested restricted share units during the nine months ended September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="if753486ce3c14daba4fcbe1f311b43da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMS0xLTEtMS0xMDQxMzY_dfcb87da-6791-4717-b68d-ec27ef001f46"
      unitRef="shares">115140</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if753486ce3c14daba4fcbe1f311b43da_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMS0zLTEtMS0xMDQxMzY_c050dc58-a941-4575-a0c6-1eae145c4c66"
      unitRef="usdPerShare">10.19</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMi0xLTEtMS0xMDQxMzY_87689731-0aee-4c4b-bb5c-a4453b28d437"
      unitRef="shares">143830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMi0zLTEtMS0xMDQxMzY_aa7f6941-9817-4cc7-97b2-2f76cfd1daf2"
      unitRef="usdPerShare">14.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMy0xLTEtMS0xMDQxMzY_374057cb-9a98-4b2c-87d5-dd062e8f7e9e"
      unitRef="shares">31975</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfMy0zLTEtMS0xMDQxMzY_7c9e046b-9a8d-40de-87e1-85cffc7b9ff1"
      unitRef="usdPerShare">9.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNC0xLTEtMS0xMDQxMzY_0ce5bf36-3ca1-42f2-80ff-75efb4c8551c"
      unitRef="shares">600</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNC0zLTEtMS0xMDQxMzY_5c76656c-195e-4db9-b5fb-daf00775d14f"
      unitRef="usdPerShare">14.68</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNS0xLTEtMS0xMDQxMzY_e305355d-febe-4aef-96e0-04d70875ffb6"
      unitRef="shares">226395</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjgwYjBkODZlZjJhNDQwY2E4MmRhMjI0OTg4Y2JkODYwL3RhYmxlcmFuZ2U6ODBiMGQ4NmVmMmE0NDBjYTgyZGEyMjQ5ODhjYmQ4NjBfNS0zLTEtMS0xMDQxMzY_08ba17bf-2d23-4c4d-8213-ca03d4c147b2"
      unitRef="usdPerShare">11.59</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8531ca535d9d45e38737a9c50ff3c640_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzg1_4f862328-4c46-41ff-9f28-10917cadb96a"
      unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibf3977e8c2424d11b3e78355783d2144_I20210930"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzc5_f7db7e44-d2a9-47e8-b41e-7cae3ea9e9eb"
      unitRef="usd">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzk4_664da1d3-a101-4c3e-bd46-b62b6b18b9a2">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i732830fb1c7142c5a6f37a0707285a52_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNTQ5NzU1ODIyMzky_20be865e-b5a7-4418-bca3-017357d39fac">P2Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice
      contextRef="i902ffac128764fed9ef5f4b41a492696_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNjc5MA_09ec1ba6-c8d4-4b56-b180-59f33aa4f89c"
      unitRef="gbpPerShare">0.01</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwMw_d0be55c4-135c-48b7-b2bc-8926127a6d57">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share options activity for the nine months ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,929,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifdbbcb43854149dfbf0bcce7cd02755f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS0xLTEtMS0xMDQxMzY_ec46961f-c90b-40e7-a76f-578ae5905719"
      unitRef="shares">3915503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS0zLTEtMS0xMDQxMzY_d6ed5f18-fa33-442f-abed-4a20e782bbfa"
      unitRef="usdPerShare">13.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7964b739ce6343c381ccfca5dfb1ea6a_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS01LTEtMS0xMDQxMzY_5c828b99-4be8-4f1e-bdf1-7cf6adcc339a">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMS03LTEtMS0xMDQxMzY_c9fedd78-2417-4acb-bd26-b8f5e5087543"
      unitRef="usd">51162000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMi0xLTEtMS0xMDQxMzY_414f7956-ad80-4620-9b96-306380fadaed"
      unitRef="shares">2000783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMi0zLTEtMS0xMDQxMzY_ddb6138b-567b-4e60-9650-68356cfb2daf"
      unitRef="usdPerShare">13.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMy0xLTEtMS0xMDQxMzY_bd672159-da41-49fa-9b78-685aa42fff47"
      unitRef="shares">461772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfMy0zLTEtMS0xMDQxMzY_86abfe9a-0604-495f-b609-e08de14be450"
      unitRef="usdPerShare">0.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNC0xLTEtMS0xMDQxMzY_4181c130-c958-4450-b90e-da3cc9040525"
      unitRef="shares">418591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNC0zLTEtMS0xMDQxMzY_dab595b1-1bc9-4604-b55a-840569e9da36"
      unitRef="usdPerShare">9.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS0xLTEtMS0xMDQxMzY_bb5eb1a8-69c6-40bb-8a6e-f97a8c3798a6"
      unitRef="shares">5035923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS0zLTEtMS0xMDQxMzY_d3f4e1cf-41c5-476c-811f-f5ecaaf37e2d"
      unitRef="usdPerShare">14.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS01LTEtMS0xMDQxMzY_88467f77-d82a-44c8-a686-74673720aa77">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNS03LTEtMS0xMDQxMzY_2582fcc4-1154-405b-bf19-1148208b488d"
      unitRef="usd">17846000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi0xLTEtMS0xMDQxMzY_e734e521-9abf-40ad-8c8d-042681482bb2"
      unitRef="shares">2106737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi0zLTEtMS0xMDQxMzY_1bc24e7e-5a56-4bd4-b1a9-21a7232fb51c"
      unitRef="usdPerShare">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi01LTEtMS0xMDQxMzY_eefe89c3-e6be-4cd4-81fd-a5290419b893">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNi03LTEtMS0xMDQxMzY_536b85d6-d796-49ea-9ee2-63cad1fcf9d1"
      unitRef="usd">15544000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy0xLTEtMS0xMDQxMzY_b00e3b48-2800-4fd5-9bab-bc09d0f40d1e"
      unitRef="shares">2929746</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy0zLTEtMS0xMDQxMzY_a3a6cd79-eb83-4ac2-87de-9c1dede25f8b"
      unitRef="usdPerShare">16.68</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm
      contextRef="i2729f7716c454e46b3dd6f78a1b98cf8_D20220930-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy01LTEtMS0xMDQxMzY_9562f3fb-c108-424d-9a91-606e845809fe">P9Y1M28D</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjY0YzIyYjkxNzdkNzRmOTY5MGEzYzZkMDI4ODlkZDVhL3RhYmxlcmFuZ2U6NjRjMjJiOTE3N2Q3NGY5NjkwYTNjNmQwMjg4OWRkNWFfNy03LTEtMS0xMDQxMzY_f1646331-37bf-497e-97a0-215f5159f280"
      unitRef="usd">2302000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzAzNg_c3c5e021-e59b-490f-b7d8-99e221d1bb2b"
      unitRef="usd">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzA1MQ_d10f139c-e26f-42ac-875c-7e40629091c3"
      unitRef="usd">41800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzQzOA_1d4f8d9a-309d-4b95-b62d-b598361ef221"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzQ0NQ_251a4caf-66dd-4a5d-8cb5-5599673224e9"
      unitRef="usdPerShare">22.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzU2NQ_068ab015-8600-4cd9-84fe-5f4c2d94fed4"
      unitRef="usd">30700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzU4MA_8eb6c220-8666-4ba9-b239-23912a9030b7"
      unitRef="usd">27600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i36db55c852ef4eaa89b999164b7a2a99_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzcyOQ_c6beceae-528f-498c-a5d4-8567310c444e">P2Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib34b90f4692c4d4f9bc74dd8fc80e8c5_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfNzc0Mg_fe6a4f8f-bbf9-4369-99a6-c1d9486371e3">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNg_f3d09911-3b35-4801-be1e-c00918b859f0">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2022, and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi0xLTEtMS0xMDQxMzY_4fca3fb5-c749-44cf-a15e-89ddc855f34d">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi0zLTEtMS0xMDQxMzY_22d5cb9f-24f2-4fa8-8e55-c42596a7ec76">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi01LTEtMS0xMDQxMzY_58902d12-6f60-4273-8dce-ea9308480a45">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMi03LTEtMS0xMDQxMzY_86a1ee81-15f3-47d5-be07-0907f2486c79">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy0xLTEtMS0xMDQxMzY_55d13e37-623b-4283-9ed8-9d510fb61602"
      unitRef="number">0.8140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy0zLTEtMS0xMDQxMzY_c24d4838-1f33-4b12-bb70-fb9c6658a764"
      unitRef="number">0.6690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy01LTEtMS0xMDQxMzY_13067255-9a90-450a-b994-dac68a8c30dc"
      unitRef="number">0.8072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfMy03LTEtMS0xMDQxMzY_83692d55-4d6d-416e-8c35-85bae9e4a088"
      unitRef="number">0.6720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC0xLTEtMS0xMDQxMzY_2da2664b-c1aa-4d5f-a576-5b900a5e20aa"
      unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC0zLTEtMS0xMDQxMzY_a8cce9b8-083f-4bce-845d-8b3aadbb136e"
      unitRef="number">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC01LTEtMS0xMDQxMzY_561c20f0-73e9-4c2b-a60f-257262672bd9"
      unitRef="number">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNC03LTEtMS0xMDQxMzY_f6976557-b2c3-4007-8043-192bde21f31f"
      unitRef="number">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS0xLTEtMS0xMDQxMzY_3393ba6f-7f63-403b-8293-01ab2f3e530c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS0zLTEtMS0xMDQxMzY_214dd960-e38e-4ad7-bc50-7e54051f094f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS01LTEtMS0xMDQxMzY_ef91130b-f186-4a46-ac6d-1eb60145e007"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNS03LTEtMS0xMDQxMzY_9c323e11-1d1e-4a38-88ce-352cb5909927"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi0xLTEtMS0xMDQxMzY_f19e5393-8b2f-416e-a53c-8056d814182c"
      unitRef="usdPerShare">14.41</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi0zLTEtMS0xMDQxMzY_bb70038e-e3dd-4a9b-9d81-b0f6de5b3c93"
      unitRef="usdPerShare">34.83</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi01LTEtMS0xMDQxMzY_93ebe768-ffd8-4225-b5d1-bdad860d4a60"
      unitRef="usdPerShare">14.48</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOmQ0Njc1NTBkMjk5YzRmYzI4NTNjZGVlZTc3YzZmNDZkL3RhYmxlcmFuZ2U6ZDQ2NzU1MGQyOTljNGZjMjg1M2NkZWVlNzdjNmY0NmRfNi03LTEtMS0xMDQxMzY_aadc4436-351a-41fa-b269-44c216410418"
      unitRef="usdPerShare">37.65</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RleHRyZWdpb246MjA5NjczNDQ5ZmQ5NDU1YWIwOWJmMTBiOTk4NTA4MzlfODIwNw_bbbaf0eb-2086-4015-9c29-d3a4e0fc9ef2">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e6d7c3a8be24750a3f82abce012253e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi0xLTEtMS0xMDQxMzY_4434cd83-7d4f-4b05-9f15-94c8fb75de44"
      unitRef="usd">1936000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70760bf78092452f9552082498923167_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi0zLTEtMS0xMDQxMzY_70d47b11-3ed6-4b4f-9533-3f4af56c32a8"
      unitRef="usd">1288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68d9f56a071347a7afea2e8409054eaa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi01LTEtMS0xMDQxMzY_0481c09d-f244-4f3b-87d8-49303c110373"
      unitRef="usd">5558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i016ce66a6c4e4fc9aca63c6f704fddfc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMi03LTEtMS0xMDQxMzY_13a3d4e5-b8c1-493a-98a7-5effd00a9129"
      unitRef="usd">3023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd618f6b010d4a5f99e94d9218acf147_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy0xLTEtMS0xMDQxMzY_a19664ac-5c80-4661-a6f9-b5373e4f29a2"
      unitRef="usd">1568000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38ed6fe991c1471db93324917ceeb126_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy0zLTEtMS0xMDQxMzY_d7a10006-a1d7-4ae1-a48a-5d212daf59b1"
      unitRef="usd">999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if92840f8d4bd4abeb1cb6f957e873ca3_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy01LTEtMS0xMDQxMzY_e0ad6f76-48e3-4cfe-8717-7a520b844c9f"
      unitRef="usd">4252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i487b8d6412304b83aef12793165358c6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfMy03LTEtMS0xMDQxMzY_3aa78e74-b9d7-4b7f-88a4-5de54cf2d886"
      unitRef="usd">2834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC0xLTEtMS0xMDQxMzY_e161dcaa-c6c3-435b-a4b5-4c84962248bc"
      unitRef="usd">3504000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC0zLTEtMS0xMDQxMzY_156956c3-c287-4857-a57f-0e4c27729085"
      unitRef="usd">2287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC01LTEtMS0xMDQxMzY_6ff435f2-c972-4aa0-aad6-014ffea79a6c"
      unitRef="usd">9810000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83My9mcmFnOjIwOTY3MzQ0OWZkOTQ1NWFiMDliZjEwYjk5ODUwODM5L3RhYmxlOjNmYzhjMmYyMGQzMjQ2MmRiNmQwOTkyOGQzNDZiMTgyL3RhYmxlcmFuZ2U6M2ZjOGMyZjIwZDMyNDYyZGI2ZDA5OTI4ZDM0NmIxODJfNC03LTEtMS0xMDQxMzY_deafc390-4729-4969-b657-a8c300012ec8"
      unitRef="usd">5857000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcx_f668b583-c5cd-4552-b968-8a6e35a4afe3">Net Loss Per Share&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,525,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,708,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,377,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,378,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months and nine months ended September 30, 2022 and 2021 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested restricted share units, for which shares are not in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297,371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297,371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcy_124cb557-0d9c-454c-9428-a7c7a2ad8b70">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,525,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,708,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,377,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,378,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy0xLTEtMS0xMDQxMzY_03aabefb-c945-4651-b385-727169d5ead2"
      unitRef="usd">-18371000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy0zLTEtMS0xMDQxMzY_176c8b32-4134-4c0d-bbc7-8d873a52cee2"
      unitRef="usd">-15849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy01LTEtMS0xMDQxMzY_9171ab39-f2ea-456a-b6a1-6f406275c5ca"
      unitRef="usd">-60579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfMy03LTEtMS0xMDQxMzY_be38a69b-81be-418b-8442-cd6750255b4d"
      unitRef="usd">-46092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0xLTEtMS0xMDQxMzY_4d7e554b-f096-4bd7-920e-a13863785074"
      unitRef="usd">-18371000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0xLTEtMS0xMDQxMzY_5e42ede0-9a0a-4beb-b7d0-d9c9bf6f43eb"
      unitRef="usd">-18371000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0zLTEtMS0xMDQxMzY_a7127675-1987-48ce-9573-7db972a40af9"
      unitRef="usd">-15849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC0zLTEtMS0xMDQxMzY_c287ee3a-de37-4fd6-b6a0-6b649e4aa82f"
      unitRef="usd">-15849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC01LTEtMS0xMDQxMzY_1ffeb0f7-e4c9-4267-bb85-ed461a8556cd"
      unitRef="usd">-60579000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC01LTEtMS0xMDQxMzY_b668c95c-b549-4b03-9ed6-851212585fe8"
      unitRef="usd">-60579000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC03LTEtMS0xMDQxMzY_0642f8fa-467c-44b6-8a2e-63ce67c2e093"
      unitRef="usd">-46092000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNC03LTEtMS0xMDQxMzY_7a6d3969-65e8-4e68-b5d4-03a4672da3de"
      unitRef="usd">-46092000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0xLTEtMS0xMDQxMzY_654a50ec-2ddd-48d7-a1e2-d50104ee6478"
      unitRef="shares">42525855</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0xLTEtMS0xMDQxMzY_ca99112a-07e8-4bf7-a7ac-ea41ca37aeb2"
      unitRef="shares">42525855</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0zLTEtMS0xMDQxMzY_7e54bb76-ad73-4107-9085-d2b160af957f"
      unitRef="shares">41708220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy0zLTEtMS0xMDQxMzY_92468327-2860-40da-8a09-1be86802f571"
      unitRef="shares">41708220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy01LTEtMS0xMDQxMzY_bc5fab98-60a4-4fbd-ac54-9be687211362"
      unitRef="shares">42377895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy01LTEtMS0xMDQxMzY_bec6eda9-75ad-469b-b8cc-79e187cc7e33"
      unitRef="shares">42377895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy03LTEtMS0xMDQxMzY_8ed7b287-b8aa-4220-a96e-9f0d5a8e6dab"
      unitRef="shares">39378824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfNy03LTEtMS0xMDQxMzY_a7c19b65-8d65-4ffd-8a2d-2e156954e15d"
      unitRef="shares">39378824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0xLTEtMS0xMDQxMzY_217eea87-3d1d-4b9a-979c-84ebfb8a1d85"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0xLTEtMS0xMDQxMzY_c1a38906-c693-451c-952e-faa8845bf844"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0zLTEtMS0xMDQxMzY_44e063f1-6aa3-49e8-8a28-62e5239d71c7"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i135046e1f98f430d9fc47844351cfcc2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC0zLTEtMS0xMDQxMzY_9ef926fd-6e10-445d-864e-8e41a52d28af"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC01LTEtMS0xMDQxMzY_07765fb6-e529-4346-84e0-dbc8fbf7a75c"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC01LTEtMS0xMDQxMzY_f14f42eb-7e80-4b82-896a-1952c23cced6"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC03LTEtMS0xMDQxMzY_40bbf056-510b-4870-9027-26a22bb27c96"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOjU4NDAxZDRkOWU3OTRhM2E5NjA1OWMyMjYyYTQxNGY3L3RhYmxlcmFuZ2U6NTg0MDFkNGQ5ZTc5NGEzYTk2MDU5YzIyNjJhNDE0ZjdfOC03LTEtMS0xMDQxMzY_a167e806-6620-4e73-9109-a6e0fd5be5cf"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RleHRyZWdpb246MDMxMDc1NTQxOWMxNDZiOTljNzkyMmE4MDk5NjlmMGNfOTcz_774b786b-5430-418a-88c7-304948e13a8c">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months and nine months ended September 30, 2022 and 2021 because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested restricted share units, for which shares are not in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297,371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297,371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87aefa457f98460d9ba72963b7697019_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi0xLTEtMS0xMDQxMzY_be296e97-7f0d-4245-a024-8e8840195e23"
      unitRef="shares">226395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f7c123bcb2043639356b3682899ec41_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi0zLTEtMS0xMDQxMzY_cab6c2ec-2bc6-4b10-8f3b-493533758e94"
      unitRef="shares">160595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i06b8dd5142c74e14af90b4df630e08e7_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi01LTEtMS0xMDQxMzY_41deafea-0a8e-4297-8a55-6d17fd56c824"
      unitRef="shares">226395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icefa4748348444fa952bab3678989dc2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMi03LTEtMS0xMDQxMzY_cca01fa2-8e57-4556-8f31-963daa3a228b"
      unitRef="shares">160595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic18cd041e9674a2fa8a04ceae64ee78a_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy0xLTEtMS0xMDQxMzY_9ceb09f7-65ee-4ce4-93cf-c089d217dec0"
      unitRef="shares">17112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03df66d076904953a72557ea780c6f6a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy0zLTEtMS0xMDQxMzY_2a055d21-2bba-47cf-8cf1-52727ce97947"
      unitRef="shares">44280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica9696938fd04b1da48bd8c16ddcb336_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy01LTEtMS0xMDQxMzY_f166ec8f-ad7c-4695-8b2c-e2742f08b088"
      unitRef="shares">17112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i187723a49dae400c970198d5678bbf0d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfMy03LTEtMS0xMDQxMzY_f66b8f4a-4214-4a2f-93f3-4bb5686dc797"
      unitRef="shares">44280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i16d9eda1626844e1a4d7a56935aef2e0_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC0xLTEtMS0xMDQxMzY_fac3738b-a597-4078-9c37-314174471327"
      unitRef="shares">5035923</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0192aff8fc8a44639feb49e5ff26383e_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC0zLTEtMS0xMDQxMzY_57208019-3047-4c54-8241-5e772741ae19"
      unitRef="shares">4092496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaaf53ccfc8a04ca7aca822f4ae66c4bd_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC01LTEtMS0xMDQxMzY_897ff89e-f76a-4543-9343-d5ef1fd3ef1a"
      unitRef="shares">5035923</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie3fc341a339e466c85a21126366804be_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNC03LTEtMS0xMDQxMzY_9dc484d6-6076-4ba4-9dd1-eec3a516dbf8"
      unitRef="shares">4092496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i65d9f4c025464876950314f425750639_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS0xLTEtMS0xMDgzMjY_01f1cc24-7361-4639-8d32-0206dd1f9699"
      unitRef="shares">5279430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife6820df90e3449faa37a891e77d7310_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS0zLTEtMS0xMDgzMjY_6a37124e-d0bd-42e0-9f14-2daa3df14505"
      unitRef="shares">4297371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS01LTEtMS0xMDgzMjY_58794458-8d2f-40af-8d74-95be5b0a0d3f"
      unitRef="shares">5279430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl83OS9mcmFnOjAzMTA3NTU0MTljMTQ2Yjk5Yzc5MjJhODA5OTY5ZjBjL3RhYmxlOmFlNmYxZDBkOTQxZjRhMmQ4MTQzMGU4ZDQxYmY0Y2M3L3RhYmxlcmFuZ2U6YWU2ZjFkMGQ5NDFmNGEyZDgxNDMwZThkNDFiZjRjYzdfNS03LTEtMS0xMDgzMjY_6f9d59d3-28cd-4a7e-8986-18e12dbc7d16"
      unitRef="shares">4297371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjE3NA_43b79b1a-877f-4c69-b84d-53d30103eddc">Right of use of assets&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York, NY&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company entered into a lease with BioLabs for 200 rentable square feet of office space at 180 Varick Street, New York, New York 10014, United States. The lease is cancellable with 30 days&#x2019; notice. This lease is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#x2019;s condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into a twelve month membership agreement with WeWork for rentable office space.  The membership is cancellable with 90 days&#x2019; notice.  This membership is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#x2019;s condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Eastbourne Terrace&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; London, UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company entered into an operating lease located at 19 Eastbourne Terrace, London, UK. This lease commenced on January 1, 2020, and expired on December 31, 2021. Under the terms of the lease, the Company paid &#xa3;780,000 per year, and paid a refundable deposit of &#xa3;130,000 upon signing the agreement. Additionally, in February 2021, the Company entered into an Amendment for rental relief in January and February 2021 for a total of &#xa3;32,500, due to extended periods working from home as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Soho, London, UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#xa3;136,200, and the Company paid a refundable deposit of &#xa3;136,200 at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee will be subject to an automatic inflation linked increase of the previous years&#x2019; amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;San Francisco, CA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an operating lease commencing in August 2021 for approximately 2,526 rentable square feet located in San Francisco, California. The total monthly rent for the lease term is $10,000 per month, and the Company paid $9,000 of advanced rent upon lease execution. Additionally, the Company paid a refundable security deposit of $20,000 upon execution of the lease.  In September 2022, the Company entered into a lease extension, which is set to expire on October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denmark Hill, London, UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of five years. The rent is &#xa3;180,000 per year, with no deposit payable, and payment dates occurring once per quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our costs included in our condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through September 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the future minimum lease payments due under operating leases as of September 30, 2022, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i6445d031d3af49a6a06ea1db2dc1ffdd_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNjYy_62d962e4-01e0-42ce-b5b8-fcb76233e771"
      unitRef="sqft">200</us-gaap:NetRentableArea>
    <cmps:LeaseCancellationNotificationPeriod
      contextRef="ibb6279cd6f4344d69acccb3e96e46e53_D20190501-20190531"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNzk1_49ecbb8b-a9a3-47b3-ba5d-da71bd6eee18">P30D</cmps:LeaseCancellationNotificationPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8c93062327a04098856532f8d1e3bcff_I20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjE3NQ_6b05c604-d61b-402d-92c6-61182913f4e6">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:LeaseCancellationNotificationPeriod
      contextRef="i2d32385fb8994518b1f04d199668f0e8_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTA5OTUxMTYzMjEwNg_6f0e5bdb-261e-431a-9ba7-b379cd4f0cc4">P90D</cmps:LeaseCancellationNotificationPeriod>
    <cmps:AnnualLeasePayment
      contextRef="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NTU1_5af9f6e9-4a04-4a1d-809f-1c5a7e69b127"
      unitRef="gbp">780000</cmps:AnnualLeasePayment>
    <cmps:RefundableLeaseDepositPayments
      contextRef="i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NjAy_222fdaad-1db4-4418-8b21-060b45a92468"
      unitRef="gbp">130000</cmps:RefundableLeaseDepositPayments>
    <cmps:LeaseRentalRelief
      contextRef="i1da6eb55524b416f9a934077e9e0964b_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfNTQ5NzU1ODE4NzY2_ffa7cf20-14a1-4a0d-8d64-4ca33522ae68"
      unitRef="gbp">32500</cmps:LeaseRentalRelief>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie5dcf53d81a142d5b2daa60f4b084c52_I20210731"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2OA_84b173a2-6e3a-49a5-9666-1ff313552f1c">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:OperatingLeasesNoncancelableTerm
      contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTE5Mw_bfcf2c8d-d021-488f-9019-238cd3bee189">P24M</cmps:OperatingLeasesNoncancelableTerm>
    <cmps:OperatingLeaseMonthlyPayment
      contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTI4OA_9d589904-2c4f-4eda-9b82-1eb25e435fee"
      unitRef="gbp">136200</cmps:OperatingLeaseMonthlyPayment>
    <cmps:RefundableLeaseDepositPayments
      contextRef="i3dca6ddf547c4771b76b07d760f5f64a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTMzNw_109fac5e-fc0a-4872-871b-036e59775c83"
      unitRef="gbp">136200</cmps:RefundableLeaseDepositPayments>
    <us-gaap:NetRentableArea
      contextRef="ia57eb47573b842caa7eb13f5560d4cce_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTY2Mw_71db437b-b92f-4865-b231-c726112da226"
      unitRef="sqft">2526</us-gaap:NetRentableArea>
    <cmps:OperatingLeaseMonthlyPayment
      contextRef="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTg0MQ_917717fa-ec5d-415a-ae0d-35398458962a"
      unitRef="usd">10000</cmps:OperatingLeaseMonthlyPayment>
    <us-gaap:AdvanceRent
      contextRef="ia57eb47573b842caa7eb13f5560d4cce_I20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTg3Ng_294d36a9-2f3a-49d0-8e63-85c0dab624e7"
      unitRef="usd">9000</us-gaap:AdvanceRent>
    <cmps:RefundableLeaseDepositPayments
      contextRef="i8fcdf22c80d34a15b4b98de2f49f596e_D20210801-20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMTk4Mg_24ad0cba-00c3-404b-92ff-1cf792fac04c"
      unitRef="usd">20000</cmps:RefundableLeaseDepositPayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8d6417d20a4747be9ada6c3270634e36_I20220621"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjMxMA_fcbb4732-f211-477a-9396-fea26bf05de5">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:OperatingLeaseAnnualPayment
      contextRef="i397deef1a4764e6097cd7f14b27e8ec0_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjMyNg_2e8e24f1-5bc6-4f12-af40-065bb4ccd672"
      unitRef="gbp">180000</cmps:OperatingLeaseAnnualPayment>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2NQ_454370b6-f3f5-4017-b937-130753ee8a6f">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our costs included in our condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through September 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMy0xLTEtMS0xMDQxMzY_dfadba2e-0d09-4787-9926-3a13ba99e9aa"
      unitRef="usd">1718000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMy0zLTEtMS0xMDQxMzY_d5ec1f2b-7b89-4250-b6ad-0b76217cda4d"
      unitRef="usd">1023000</us-gaap:OperatingLeaseCost>
    <cmps:VariableLeaseCostLeaseIncentiveReceived
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNC0xLTEtMS0xMDQxMzY_268602bf-3b45-443d-866b-bb4260dca4ee"
      unitRef="usd">0</cmps:VariableLeaseCostLeaseIncentiveReceived>
    <cmps:VariableLeaseCostLeaseIncentiveReceived
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNC0zLTEtMS0xMDQxMzY_ec70b6c4-21a1-491d-9411-caf2b93426d7"
      unitRef="usd">45000</cmps:VariableLeaseCostLeaseIncentiveReceived>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNS0xLTEtMS0xMDQxMzY_8cd14827-529f-4432-9de1-a56dace5a936"
      unitRef="usd">111000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNS0zLTEtMS0xMDQxMzY_05da1f9b-e076-4597-895b-bd1411c8d3da"
      unitRef="usd">86000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNi0xLTEtMS0xMDQxMzY_91c9d49e-756e-4322-809a-5b37f7d2728c"
      unitRef="usd">1829000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfNi0zLTEtMS0xMDQxMzY_283d8a3f-70ec-4457-9c4c-c676fccc3669"
      unitRef="usd">1064000</us-gaap:LeaseCost>
    <cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOC0xLTEtMS0xMDQxMzY_f65ca081-6672-4dee-a5b0-b3ba67a1d054"
      unitRef="usd">1679000</cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOC0zLTEtMS0xMDQxMzY_4595445a-de03-40db-9814-5a9c367abff8"
      unitRef="usd">1018000</cmps:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOS0xLTEtMS0xMDQxMzY_4c4fecba-dc62-400c-8411-7178da396cd1"
      unitRef="usd">796000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfOS0zLTEtMS0xMDQxMzY_98601c76-7a6b-4acb-81c0-1d2f031d1e94"
      unitRef="usd">5599000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTAtMS0xLTEtMTA0MTM2_42fa3ccb-3949-4533-b850-bfdecd11ca37">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTAtMy0xLTEtMTA0MTM2_25b33a13-3663-4152-9b27-83a07c9d3cc1">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTEtMS0xLTEtMTA0MTM2_8f28b521-37fd-4d1f-9017-4f72bc04b711"
      unitRef="number">0.0496</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic4da9bbe049146cb87bb6e7098a16ae1_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOjYxNDg3OGIyMGVmYTRiMGI4Yzg2NjYzMTk5YjIyMThmL3RhYmxlcmFuZ2U6NjE0ODc4YjIwZWZhNGIwYjhjODY2NjMxOTliMjIxOGZfMTEtMy0xLTEtMTA0MTM2_124bf1b7-f620-4e78-84c4-3cf27f47ec88"
      unitRef="number">0.0499</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RleHRyZWdpb246MWUxYjBjOTlkNGU2NDA4Njk5ODhlMWViZmFhZTU1ODRfMjc2Ng_304ed955-2416-450a-9556-80545b7fc79c">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the future minimum lease payments due under operating leases as of September 30, 2022, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfMi0xLTEtMS0xMDQxMzY_7fa29f84-f550-43fe-9e7a-fa40a57c4dd7"
      unitRef="usd">506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfMy0xLTEtMS0xMDQxMzY_efbb915e-8f57-4875-baf2-0a5d1460317c"
      unitRef="usd">1416000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNC0xLTEtMS0xMDQxMzY_0f94713d-6de1-47b9-8016-3220292bb953"
      unitRef="usd">201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNS0xLTEtMS0xMDQxMzY_1b7e51ef-ad87-48f6-972e-8c8025748a5f"
      unitRef="usd">201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNi0xLTEtMS0xMDQxMzY_5f237e62-ff50-420c-badc-cefbe83d9d48"
      unitRef="usd">51000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfNy0xLTEtMS0xMDQxMzY_40379474-367f-4eec-84e4-f59ae92636cc"
      unitRef="usd">2375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfOC0xLTEtMS0xMDQxMzY_3b74f6ee-52a0-40aa-8453-d19e58303711"
      unitRef="usd">119000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2d514775b1f24e1599e2725db606daf3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84Mi9mcmFnOjFlMWIwYzk5ZDRlNjQwODY5OTg4ZTFlYmZhYWU1NTg0L3RhYmxlOmQ5NzNjZTYzZGU5ODQ0ZDNiYWFjODhlNWY2NjUwMTIxL3RhYmxlcmFuZ2U6ZDk3M2NlNjNkZTk4NDRkM2JhYWM4OGU1ZjY2NTAxMjFfOS0xLTEtMS0xMDQxMzY_7bddd6a5-04b9-4e18-aa8c-35494e3a4549"
      unitRef="usd">2256000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84NS9mcmFnOjNjNzA3NzZmMzIzMDRhYTM4ZTMwYjMxNTU5MjkzMWYzL3RleHRyZWdpb246M2M3MDc3NmYzMjMwNGFhMzhlMzBiMzE1NTkyOTMxZjNfMTMzNA_84ff6f37-c6f7-40da-867b-d749bd03135f">Commitments and Contingencies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of September 30, 2022, or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#x2019;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfNjg0_3e707c84-a1c4-4983-9a54-06963c9103fc">Employee Benefit Plans&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the UK, the Company makes contributions to private defined contribution pension schemes on behalf of its employees. The Company paid $0.2 million and less than $0.1 million in contributions for the nine months ended September 30, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, the Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company paid $0.1 million and less than $0.1 million in contributions in the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE2Nw_eafff74a-f275-4397-bef3-a471bcf1bd49"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE4Mw_62a4a9fc-999d-4e6e-b930-fee074c55f44"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE4OQ_77ca2358-21b2-4c30-bfe0-5313f2edf607"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic320fff0e53740848b78edc848132fbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMDM4ZjFiM2FlMzRiOTk4MGZlMTUwODc4YWJlZTJmL3NlYzoyYzAzOGYxYjNhZTM0Yjk5ODBmZTE1MDg3OGFiZWUyZl84OC9mcmFnOmI2ZWQxMmJiZGU2MTRlMDhhNGIzZjFlNzQ1Mjg4YzJiL3RleHRyZWdpb246YjZlZDEyYmJkZTYxNGUwOGE0YjNmMWU3NDUyODhjMmJfODI0NjMzNzIwOTE5OQ_0cd7605b-1a76-4202-8406-2d322c9b8df1"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( + X8U4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "P.&-5CC(:!NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VG10^CVLN))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS
M#4RG@]1CQ.<X!HQD,=W,;O!)ZK!A1Z(@ 9(^HE.IS@F?F_LQ.D7Y&0\0E/Y0
M!X2&\SMP2,HH4K  J[ 26=\9+75$16,\XXU>\>$S#@5F-." #CTE$+4 UB\3
MPVD>.K@"%AAA=.F[@&8EENJ?V-(!=D[.R:ZI:9KJJ2VYO(. MZ?'E[)N97TB
MY37F7\E*.@7<L,ODUW9[OWM@?<.;IA*BXNU.",EO9</?%]<??E=A-QJ[M__8
M^"+8=_#K+OHO4$L#!!0    ( + X8U697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK'S/5IX(OBY>53UQ(7A2'*XHD65=&<C_EUPVI[L3]?:K>MLY^0]02P,$%
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M49Y/,-$DFRCJ^($/2_9:R5ZOY*_3^1Q]FDUO45-MIG=PE?&,UL\@P1 ,4 S
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MJ-:[!>K__WFUVO[XYJ3VOZ_67^]JO/D_4$L#!!0    ( + X8U7FLWW,B@@
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MIS2*K&50J(D:954F;5=)DL!\Y%?#[9*(,>>/AOO,)V=#G_KA3@"Y1C*-7@<
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MPPZ_(HS:N36LH989QCR.!YE+Y&@W9.Q(I>YIMCNP6P[8T"?ZS#4KF!2&0_9
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MO9W6$D$1W%_6^G&K@>5&6E=!0UR\N@Z%5S\;7YE?B^_K=@E;N*:FNN(GIE>
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M;*A2.AK'K *EBN2V\&@[:6Z%G3@Z7GZ=EE:0);>NYQZ/B5O@CW2]'+]D3*\
M3%/OFZQC^M-12>!G,4D5SWTJC'J9.M+7Z5^^>YO[T1/6"+;Y]L!'F/I#D4^3
MO^\)IG=-?\648$/3\Y_Z#)\6^H=2+_CO@\;'^:^L_F2Z->ZTMBMX]63QQ?,G
M7+2MO_3MCOY:Z++M^W9+/VZL 3+@ _#]J@5)E%]P@O#G8[_]?U!+ P04
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MX%<&7)J$3DXU1;-TIH*-#%#9CEW))!%F_GMXYM[XP-@>L%8KR8Q,7"/\<N*
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M _]M?\?$ IYJJDXS&S1YKYDI>OO&4H%4 :0 A:IHB BYAS^$I!/5&C(V;VZ
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M2_J;H'8*=%\H98\;YV#\/ZU^ %!+ P04    " "P.&-5K1L/Q*8"  #T!0
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MK])\Q0MAW%*7)8H2LF,I[Z V[Q5.IQ80%'1I%NZVV; (N48,3-U%[EN5SV8
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M-+KY946S,FI'0/=+146RV3@!N^E[_A]02P,$%     @ L#AC5=B]N4V]!P
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M&6H?>N@I<TTO/G'W&EY'T1.)\/87,' TY6TTZ:0/DJF.M3*'!)6;RC\O]&%
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MX)G.02;*G;*)R7%C"@$\19>0A3D X"CQH;[;H3MQ/)V(<7<\G6(0IRK1H/>
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MPB"&&KV9G#2A*%?D>%>R'\T^Z%K9+2+,T>!2$EPH8?PD)<8.%FG1X<Q;G/P
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M6WS]\VPRCVPR_TRH#H%@QW$S]->VAU#X%PU49!_K\''F* O0%G<>W! X(!3
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M'S$-\5!VD^*G^Z:JI7J\"5:_1!!C.A<CD,P!R="9ODU6DCP"G+#M%[4IN;
MU=Q6IQY&J*@K.6;*I9P]I> K6SA;8 U^S>%.6!8%ZTU'OA CZ"Z;&Q.H&$Y1
M;0"Y^7)H_[>-7PUO2C16.!$$HWP4.OWH4*UY+F"X-))0#VI1>^ "?O<KHOSN
MR4M'QX56D3XX?>ES&@2B$OL!NX3G=KAU>14TD&FF-T!"<+[\V[* &:7CIDNL
M1: "9SA/*M$4[FH/?$LU+&'%"[2 !%1+[14)U;Y\: G3[(J=T8"IP5;=$(37
M7,TKX)R.*N@!'R[&/;%LX]=>%$-&.LF? K_@X=9[<?3T'&B\Y-@J0R&GL8]D
MM?#B[[JUN-<<+2C*3JH\14DA:PSD<5T.A>K]@%0 ,RQJ)9_6EVCQDG$# (#)
M31D,(#H#Y<YIS7%7RA)DI47[M;.SXD>P\8*C%HZ+NRCPFU5''%2BPU4#]^.3
M3&@JOLW=S$K"_WAX,$]EP.IU&/#)Q6$B]4 89G=YA8L?:Z%!/=UX[P@C2@S?
M?%QU(NI6@@GHAE+@1VT-1@MCY2U82]UJ7WQ>I;5V!XH7/D>$ =^2S0O,JQBD
M" 1D-AY2C86+7ZD&%0 PQ&%/(4*>H$)H<Z#.RKZ6BH:$5P].0051,2DRZI"$
MXMLX^#B]AHNDVAM$JH0VR-#28GI@9H0W@9VE[:FA:CX,+M&06(3'#L 5V0/?
MQX<V6LXD;>U#DL0ZLA]QDDGR 36&F1O2$]._@6!/_;XNV=^[QF8BKO)ZR_@-
M1#GU7@/<%85ZA1$-](;.C=?&XT& D!1Q8U7M='"A.XOACPHE.*C>@*\F\3PQ
MS:TKRLJE#2="2AYTLL?=PS5UEJ2#MR[%BCQULP>$R<+0[M]=_0) 9MGI<2T1
M%,'Q.O[/6PTLFO/5033$^0_7H7SP5^4J]5OQ8VT7L(5KZHDM?F%Z!4BYB\(&
M_^+OPJ2,X(]%3&(Q]NGQ8FK*R(_'=._S8G%)Y@^5V7^KID<"C7IMJK+4-'A^
M_1&P[@R>.'TQ/9E/"AGF\0>[!>GX^MG\R82R3!M*8$X2* V@DB6IU5UK0UF#
M8 >4G!QMZ+ RTAF*89T'ZJ8QE&H'YJPQ<4ZR0>+--/=&6NK"&>H.-<$6FRDP
M$HWJ@#YF=^G\^@*V<N)W1VPGG^TGAW4=,MVX&'9/M@"!,?L6ZOW1!E2&2XLH
MO^A!';>>B$G O3\^?8).$L(5S#;Z@H3;M:8@-[FE=ULR'QB4N9..Q!@K)XW,
M1=-8/^Q[6Q[/GW"Q)15B^-!&&333H8'K2(/'9T^D/H$,F_D]O.R/@XVLA'6X
M2G@W' JDMQ*'@\@#HHA5$!5:)PY\1L>$HPS2<1DSEKR'EIQ4NYQBE5I2+"L=
M$7O/#\JG_WPZ.RDV@$19KS:CZB0KRO,/Y:S)+*&R/>FXI<I4L?1=Q=X, 9X'
MYGU@$&DR>"$IS\!#*,M^(V83$_ E]AB]1X6'S$B^Z^DIMT\=(&E*NA#Y&7%/
M/]\W&BN:ZAUP L,7<#7U-C)B6BJ6ZZ&@LUT0"(*3\7G4[)'[,=_-AY]AD9[J
M-9/FJ+P81Y1&"/K%T6=>X7&O-</Z%<AJYTN#L<*:6I '<1:9.><G3"Q]AHE]
ML-7_OL?*K&]9#5(AT"5@$3HHC &S94+^@Y,.E10\B!]:-$(HQSBNXQCMQ+:Y
M@\/ TRO164G9P>"I$'G?+XLA!)_48N!3G&.5)*2O'5(^8)JHMS"^;8C/Y-VA
MF(GVI4JDI&S>#76'DX//NS,;7SR$%=+ UQC+PLS=V)&VVBO)>A=%*.-*SW8!
MM/!>0L8FU@QZ-W&LO&X6.T=B0[JGSO[2B$L6B4_"T1:]<:$ U/CX;,RH,8L,
M''$,"Y2&Q,:?@K=)OHJ* @QCW4P8FRJ4Z/]<YAD62%@'UL)Y"="@"ZQ+IPX&
MFA]#+[ZU,Z><#U)*)3:G"KC:A-Y4W8C3Q[DWGH/CHK&QC"2: Z.D(+CL3#3_
MX-0\*,:[#EB(2_ YB>V3$O)V0XU4\2/@D,9N %/IYL:TMF'M<^YR=9CU5:G"
M-T6M<!(?^9>:7OI*^@H$\=L%\@F>.:;T:E3>K6\ XZIC*LL*P5*'[HDG&H:9
MF3B!B5/?FYT'60,J6O2\U5AA*]-KF'(ZHH5$FP7EZJ68=7(3^]-\T"7H9-]N
M.::,!Q-VNZUTW*(&\<%0)C_I8RHAH.A'E#T\0M.Y(H=NW@2E5JIO:"$=1<>Q
MALV[/-P1UVD)7\C8&.(QCD"A17D!]A0A1Z=?&NAF6+ <K6LN1;<F7&=Q0!-(
M6TH6_&^3$H="X-R(.I"DHN^2B@N/W5H2J,!"TES/)872*"+'!)R:T91+PW8N
MESK0^QMTXICT+;NG?(T&0[5W TPXFH#\?!8D'GFH</,]>)U> 0/B,,B/ICE2
M[02_2]*$TS 5EA(XJEJ[T;&RY'C;R .1(G/Y$!HG>'&X"W:)\-SH(9\V2%HP
M0UW4@U8:ISSJ"<<NW-/CK;1OI-W@0G1L\0'/OCY</_#EPV6* BTP0TVZ#N5A
M%U3@*S[EBZ44P3Z$K-H5F!8LFP1P!,2>X;5/ND,__0 ZA]FMO^L#LTP\(KD\
M7>A?ZY),<S(M-Q'*/GVUUL%G_04*I(%"UZC&8EQBBVX$\(IF_Q44Z.9A&_'=
M),F&'KA:1DZR4%[Z_G+3JS:2V!:&YN7-%9TU6A*N^U:M(0U&-G2PRET>'V,0
M2(:$9:CC'CR\3F%"(O8?$/6\#(T!7M[/(SM:#A(9X!^?>O^89OCSV>Q9^&#T
M&J'/NG^3@?_WYDM*WW/#%@L1QG=&KOZS9.6TE?EL'C[(E_2!TJI,$T7%Z'2R
ME$2J$ &V+NG!66-ZAH#;:'=6TG-K>RR(SF[S*:3, I'O&--BO#@7_V,7O<4^
M]OGQCO.W?/7+!W4W'CE\P.O%VR9>QS _.?V&S^;-^?5K7X&0A,>O?4SD(]4O
M2ESMXX3>G)[.)SZLG4TQ+:XYX[CS0"$9$MDP>UHBD5\].WDR"1E&F@8_\XHU
MY# %P.<#RMTX'0[(0M3HVQ@D!'QB$?UX"(9])/Z"(-9 WJHG-[#!<QA"A#4$
MO\HC#FX)6&JJE*9)N=Z* ^/)G2(3'RP)",G'YBE=%PNL#?I=4[F\!2^6$2?:
ML[]/H_"S<;-DDM"I,YMX[\^'-)JE:F=3ZAVAW/#F 6I#PDIN/D@N/-'L,H<0
MH2?RL.13:.5C1"/D6EE;(<AE(B4;1FU.3U$??TCSJ5RWKEK;;P7'^E L9WBI
M,05/PE\,%T. 9/L:*2J-K5U(\5IQ["WV3N"J^%J[&#_$)PG;HO;NN]!GT'GO
M.AR$^ "I&T(S)S<8?,!0:N!2+',)\W HEB;WH;J%!B>)8@>*DBE!C$^?D[X]
M860[8 ?V6.B-I%\$\&V]BR%00STR&]-UP^HTGT>@J"_*) /X0>[!WV>"FA%[
MJJ@=7,*FV'@5PZ8/JG[)%I)6?N9<&_P1CH^DN&07$E$^H""WB'V&10]A'&]$
MA^UV=!<4;(BN9BD%8]T,KA626$KLAWLP20K:.U>"(R-JF!P+,7ZXQ]*YF2MF
MT-) EJ\5+G6XBH,C+H?N*(-I%O[JS /S\;%X8?-RD_J"V060Z8U5R7KVNQ-;
MY&"7WXEUGZ,;O2T+*S)=*%G:LR*!^2@\(&Q3FT^Z-FOK17QL<G+>8\-GG-'S
MBZ\VP0[4]$H[7[G@<[?]5H[H5ON[PV+WG.]\FHBNH9##!J\[HS7NV'>@Z LI
MQIJNFE!I^2A1^] &0M<J!]! O\2T-"GLVZ"XDJYW7]*I4,.V*]IL)*WWDF>
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MT.3V+HO =CV[6WC3A#ZY-9ZZ;IA6],RA90,Z+XWQAP4[&![.U3]02P,$%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(55;6_;-A#^*P=M&!+
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M%>2&- AL[N$"JHH4H1M_]CHG@TD2W.T_:G]O8\=8;H6&"UE]+PNS.IND$U;
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M>*U0W?NJ&QBYMF^:6VGPA62[*WR2@J(%.+^0TCP.R,#PR)W]#5!+ P04
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M&IV-B#2Z[X;Z@56M[T 6RE(_X\6*&DC4;@.M+Q619#-P!G8MZ?QO4$L#!!0
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MPLN\;>;XO05"!^#['>?JJ:-O].$++OD%4$L#!!0    ( + X8U46$FO3O 0
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MS89J#E1SH9J'TIK[@;J,CDKK>":O?EC6T.6[@<_52( $:;H1(_Z@>:7^T@D
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MJ^+ADOMSGN0-Q/N+.,YV3_()[+\P8O(G4$L#!!0    ( + X8U4R-",VX00
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MXKF]3 E.B# =]/,9Y^JU82:HSP2'_P%02P,$%     @ L#AC5='&R?$X P
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M>F@N%GP3FZ]R^X<H#VB8\68RUOE?M"WW#7IHMM%&)J6Q'4$2I<5__E0&8L_
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M1D<.I-FO:?:---_<YX259R '1FC<Q,,,X3IH#9@U1<[(:'D@M=.:VJG1K_+
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M#OF'CJ0'K^D#PW%RLKC"C.$PN=TBQT-$"/#W:XS9VX,PD!]_S_X#4$L#!!0
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M,%*GE5?5;=61K#3EVS.3JA@TS;WZ0P!<!ZCG6\;D6T=/T/S%2/\!4$L#!!0
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M$"SW-#E /E]1*@XW>07U\=O@7U!+ P04    " "P.&-5ZW]+0NH#  !F%@
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MHORT\/F51*RS$X#?B20107;Q@;M+'J5WD+]?"9&\7DD7L#TY__Q_4$L#!!0
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MLN+RI@;'=C/^3$.VBH-ZU144HES5C#]!>JY?'_M5+):$=$W#:3D5BUDQM-1
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MO46XWM)RK?JVY>8Q@*W$G1+^-*X<^U37NE=.))#O$,AWM)"?N3#LELL>V%_
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M2P$"% ,4    " "P.&-5CC(:!NT    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "P.&-5F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( + X8U6E=/:7R@4   8>   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "P.&-5$\F:]AL&  #Y'
M&               @($,#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ L#AC5=@.5DWR @  ]0H  !@              ("!710  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( + X8U4PKR[W% 8
M  (;   8              " @847  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "P.&-5!@GG;1L6  #02@$ &               @('/
M'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ L#AC5>:S
M?<R*"   <3,  !@              ("!(#0  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( + X8U4Z+#H^\@D  'D8   8
M  " @> \  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "P
M.&-5#/D#YM4D  !*=@  &               @($(1P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ L#AC58IM)(_2 @  2P8  !@
M         ("!$VP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( + X8U5P24X9)P0  -\(   9              " @1MO  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ L#AC57_,9?H* P  JP8
M !D              ("!>7,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "P.&-5K1L/Q*8"  #T!0  &0              @(&Z=@
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( + X8U6V'S,+
MP (  %$&   9              " @9=Y  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ L#AC5=[@><YZ!   8 L  !D
M ("!CGP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "P
M.&-56"?K%$\-  !4*0  &0              @($_@0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( + X8U52SV-?:00  (D+   9
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M970R,"YX;6Q02P$"% ,4    " "P.&-5L,VOO$@#  !$!P  &0
M    @('ZQ@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M + X8U5*8N%7#P,  (H&   9              " @7G*  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ L#AC51M2)<8\ P  /P<  !D
M             ("!O\T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "P.&-56H3K^\\"   _!@  &0              @($RT0  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( + X8U5V*XQCK@4
M / .   9              " @3C4  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ L#AC55IKMS0P!   G@H  !D              ("!
M'=H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "P.&-5
M)%[>&_8#  !\"0  &0              @(&$W@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( + X8U7++D4,+@8  "XZ   9
M      " @;'B  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ L#AC59:Q[T#4 @  2 L  !D              ("!%ND  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "P.&-5(WF0KJ &  !D-P
M&0              @($A[   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( + X8U499B?9> (  .L&   9              " @?CR  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ L#AC5=>&]-Y/
M P  S0D  !D              ("!I_4  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "P.&-5%A)KT[P$   !(@  &0
M@($M^0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( + X
M8U5B+4:<\ (  ( (   9              " @2#^  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ L#AC58 #SA]B"   /&(  !D
M         ("!1P$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "P.&-5,C0C-N$$   ?'   &0              @('@"0$ >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( + X8U71QLGQ. ,  .,)
M   9              " @?@. 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ L#AC5<TIN@\C!@  RS0  !D              ("!9Q(!
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "P.&-5H!1>
MEF8#  #I$   &0              @('!& $ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( + X8U7K/WUJ0@4   H?   9
M  " @5X< 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
ML#AC54)E^3<B!P  EC,  !D              ("!UR$! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "P.&-5:EL/!H,#  !N#   &0
M            @($P*0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( + X8U4XN< UBP,  ,P0   9              " @>HL 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ L#AC54;90]^]!
MBAL  !D              ("!K# ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "P.&-5ZW]+0NH#  !F%@  &0              @(&@
M-0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( + X8U4?
M9?:_"@@  *A?   9              " @<$Y 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ L#AC51YCR9*A P  ,PP  !D
M     ("! D(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M" "P.&-55A9>*JT"  "J!P  &0              @(':10$ >&PO=V]R:W-H
M965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( + X8U6/TW^ZB (  '0&   9
M              " @;Y( 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L!
M A0#%     @ L#AC51E?!VQO P  [!4   T              ( !?4L! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "P.&-5EXJ[',     3 @  "P
M        @ $73P$ 7W)E;',O+G)E;'-02P$"% ,4    " "P.&-5"2Y[#0P$
M  #O(   #P              @ $ 4 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ L#AC58YA./J] 0  >AT  !H              ( !.50! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ L#AC59PKTP^] 0
M=QT  !,              ( !+E8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #D .0"&#P  '%@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>258</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Investment</Role>
      <ShortName>Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Right of use of assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Rightofuseofassets</Role>
      <ShortName>Right of use of assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/AccruedExpensesandOtherLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/ShareBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Right of use of assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsTables</Role>
      <ShortName>Right of use of assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/Rightofuseofassets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NatureofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Investment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/InvestmentNarrativeDetails</Role>
      <ShortName>Investment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/OrdinarySharesDetails</Role>
      <ShortName>Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/OrdinaryShares</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2017 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Share Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails</Role>
      <ShortName>Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Share-Based Compensation - Restricted Share Unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Share Unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Share-based Compensation - Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails</Role>
      <ShortName>Share-based Compensation - Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Right of use of assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsNarrativeDetails</Role>
      <ShortName>Right of use of assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails</Role>
      <ShortName>Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails</Role>
      <ShortName>Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cmps-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 10-Q should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. cmps-20220930.htm </Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  cmps-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="cmps-20220930.htm">cmps-20220930.htm</File>
    <File>cmps-20220930.xsd</File>
    <File>cmps-20220930_cal.xml</File>
    <File>cmps-20220930_def.xml</File>
    <File>cmps-20220930_lab.xml</File>
    <File>cmps-20220930_pre.xml</File>
    <File>cmps-q3xex311ceo302certifi.htm</File>
    <File>cmps-q3xex312cfo302certifi.htm</File>
    <File>cmps-q3xex321ceoxcfosectio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="612">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cmps-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 188,
   "dts": {
    "calculationLink": {
     "local": [
      "cmps-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmps-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cmps-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmps-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmps-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmps-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 392,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 38,
   "keyStandard": 220,
   "memberCustom": 25,
   "memberStandard": 19,
   "nsprefix": "cmps",
   "nsuri": "http://compasspathways.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://compasspathways.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Investment",
     "role": "http://compasspathways.com/role/Investment",
     "shortName": "Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property and Equipment, Net",
     "role": "http://compasspathways.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Accrued Expenses and Other Liabilities",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Ordinary Shares",
     "role": "http://compasspathways.com/role/OrdinaryShares",
     "shortName": "Ordinary Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Share-Based Compensation",
     "role": "http://compasspathways.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Net Loss Per Share",
     "role": "http://compasspathways.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Right of use of assets",
     "role": "http://compasspathways.com/role/Rightofuseofassets",
     "shortName": "Right of use of assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "role": "http://compasspathways.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Employee Benefit Plans",
     "role": "http://compasspathways.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://compasspathways.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://compasspathways.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://compasspathways.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Right of use of assets (Tables)",
     "role": "http://compasspathways.com/role/RightofuseofassetsTables",
     "shortName": "Right of use of assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Nature of Business (Details)",
     "role": "http://compasspathways.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i42bc7cb116524177b8eb75138fc7cbdf_D20211008-20211008",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i88ab83623b7a4659a10d1b385d5f9eda_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "id41dc1ee45fe4c45a2ae3c7bcd3f765c_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfGeographicRegions",
      "reportCount": 1,
      "unitRef": "region",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i3abee071f8fa481083b1445474906b6a_I20210101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i291d3af8cf514f328ce6b2496870c764_I20200306",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Investment - Narrative (Details)",
     "role": "http://compasspathways.com/role/InvestmentNarrativeDetails",
     "shortName": "Investment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i291d3af8cf514f328ce6b2496870c764_I20200306",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i9a64cb06b1914fe28a2c5666b8e3ca3e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Accrued Expenses and Other Liabilities (Details)",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Ordinary Shares (Details)",
     "role": "http://compasspathways.com/role/OrdinarySharesDetails",
     "shortName": "Ordinary Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "cmps:CashDividendDeclaredOrPaidDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i116fea83328e4122a910788f7882e8d5_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
     "shortName": "Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i116fea83328e4122a910788f7882e8d5_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
     "shortName": "Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i8a7ed3681e3242ed9c187bcfbd7b4da6_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
     "shortName": "Share-Based Compensation - 2020 Share Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "ia0ecd7a1590e40b29e11deab3edfd6f7_D20200901-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
     "shortName": "Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i168b4e16d7474cce8e24f284c7f15369_I20220801",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Share-Based Compensation - Restricted Share Unit (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
     "shortName": "Share-Based Compensation - Restricted Share Unit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "if753486ce3c14daba4fcbe1f311b43da_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Share-based Compensation - Share Options (Details)",
     "role": "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails",
     "shortName": "Share-based Compensation - Share Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails",
     "shortName": "Share-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "role": "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AnnualLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbp",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Right of use of assets - Narrative (Details)",
     "role": "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
     "shortName": "Right of use of assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i9e1bd7d5cc2d4de7a7fcab6acf0483d2_D20191101-20191130",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AnnualLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbp",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)",
     "role": "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails",
     "shortName": "Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)",
     "role": "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails",
     "shortName": "Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i2d514775b1f24e1599e2725db606daf3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://compasspathways.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i95405ef6eec44bbaac9fdee032a0137a_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i39e7c838434a4743bb3511c468433615_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i65d9f4c025464876950314f425750639_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of Business",
     "role": "http://compasspathways.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "role": "http://compasspathways.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20220930.htm",
      "contextRef": "i1d0c37d2c0d642ceb6060c996dac67e6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "cmps_A2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Equity Incentive Plan",
        "label": "2017 Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017EquityIncentivePlanMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2020AwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Award",
        "label": "2020 Award [Member]",
        "terseLabel": "2020 Award"
       }
      }
     },
     "localname": "A2020AwardMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2020ShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share Option Plan",
        "label": "2020 Share Option Plan [Member]",
        "terseLabel": "2020 Share Option Plan"
       }
      }
     },
     "localname": "A2020ShareOptionPlanMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2021AwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Award",
        "label": "2021 Award [Member]",
        "terseLabel": "2021 Award"
       }
      }
     },
     "localname": "A2021AwardMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2022InducementGrantOptionAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Inducement Grant Option Award",
        "label": "2022 Inducement Grant Option Award [Member]",
        "terseLabel": "2022 Inducement Grant Option Award"
       }
      }
     },
     "localname": "A2022InducementGrantOptionAwardMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Expense, Current",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Accrued research and development expense"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "terseLabel": "American Depositary Shares"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_AnnualLeasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Lease Payment",
        "label": "Annual Lease Payment",
        "terseLabel": "Annual lease payment"
       }
      }
     },
     "localname": "AnnualLeasePayment",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit From Research And Development Tax Credit, Policy",
        "label": "Benefit From Research And Development Tax Credit, Policy [Policy Text Block]",
        "terseLabel": "Benefit from Research and Development Tax Credit"
       }
      }
     },
     "localname": "BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmps_CashDividendDeclaredOrPaidDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Dividend Declared Or Paid During Period",
        "label": "Cash Dividend Declared Or Paid During Period",
        "terseLabel": "Cash dividend declared or paid"
       }
      }
     },
     "localname": "CashDividendDeclaredOrPaidDuringPeriod",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmps_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_DeferredOfferingCostsIncludedInAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included In Accrued Expenses",
        "label": "Deferred Offering Costs Included In Accrued Expenses",
        "terseLabel": "Deferred issuance costs included in accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccruedExpenses",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_DeferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "terseLabel": "DEFERRED SHARES"
       }
      }
     },
     "localname": "DeferredSharesMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_DelixTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delix Therapeutics, Inc.",
        "label": "Delix Therapeutics, Inc. [Member]",
        "terseLabel": "Delix Therapeutics, Inc."
       }
      }
     },
     "localname": "DelixTherapeuticsIncMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_DenmarkHillLondonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denmark Hill, London, UK",
        "label": "Denmark Hill, London, UK [Member]",
        "terseLabel": "Denmark Hill, London, UK"
       }
      }
     },
     "localname": "DenmarkHillLondonUKMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_EastbourneTerraceLondonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eastbourne Terrace, London, UK",
        "label": "Eastbourne Terrace, London, UK [Member]",
        "terseLabel": "Eastbourne Terrace, London, UK"
       }
      }
     },
     "localname": "EastbourneTerraceLondonUKMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_GrantDateJune302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Date June 30, 2020",
        "label": "Grant Date June 30, 2020 [Member]",
        "terseLabel": "Grant Date June 30, 2020"
       }
      }
     },
     "localname": "GrantDateJune302020Member",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_LeaseCancellationNotificationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Cancellation Notification Period",
        "label": "Lease Cancellation Notification Period",
        "terseLabel": "Lease cancellation notification period (in days)"
       }
      }
     },
     "localname": "LeaseCancellationNotificationPeriod",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_LeaseRentalRelief": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Rental Relief",
        "label": "Lease Rental Relief",
        "terseLabel": "Lease rental relief"
       }
      }
     },
     "localname": "LeaseRentalRelief",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_NewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York, NY",
        "label": "New York, NY [Member]",
        "terseLabel": "New York, NY"
       }
      }
     },
     "localname": "NewYorkNYMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Employee",
        "label": "Non-Employee [Member]",
        "terseLabel": "Non-Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_NumberOfGeographicRegions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Geographic Regions",
        "label": "Number Of Geographic Regions",
        "terseLabel": "Number of geographic regions"
       }
      }
     },
     "localname": "NumberOfGeographicRegions",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmps_NumberOfOrdinarySharesConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ordinary Shares Conversion Ratio",
        "label": "Number Of Ordinary Shares Conversion Ratio",
        "terseLabel": "Ordinary share conversion ratio"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesConversionRatio",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cmps_NumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes",
        "label": "Number of Votes",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberOfVotes",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmps_OperatingLeaseAnnualPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Payment",
        "label": "Operating Lease, Annual Payment",
        "terseLabel": "Operating lease, annual payment"
       }
      }
     },
     "localname": "OperatingLeaseAnnualPayment",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_OperatingLeaseMonthlyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Payment",
        "label": "Operating Lease, Monthly Payment",
        "terseLabel": "Operating lease, monthly payment"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyPayment",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_OperatingLeasesNoncancelableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Noncancelable Term",
        "label": "Operating Leases, Noncancelable Term",
        "terseLabel": "Operating leases, noncancelable term"
       }
      }
     },
     "localname": "OperatingLeasesNoncancelableTerm",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_OptionsGrantedBeforeJune302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted Before June 30, 2020",
        "label": "Options Granted Before June 30, 2020 [Member]",
        "terseLabel": "Options Granted Before June 30, 2020"
       }
      }
     },
     "localname": "OptionsGrantedBeforeJune302020Member",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares",
        "label": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_PrepaidExpenseResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Research And Development, Current",
        "label": "Prepaid Expense, Research And Development, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidExpenseResearchAndDevelopmentCurrent",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ProceedsFromStockOptionsExercisedNotReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised, Not Received",
        "label": "Proceeds From Stock Options Exercised, Not Received",
        "terseLabel": "Proceeds from exercise of options were received and recorded in other current assets"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedNotReceived",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_RefundableLeaseDepositPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refundable Lease Deposit, Payments",
        "label": "Refundable Lease Deposit, Payments",
        "terseLabel": "Refundable lease deposit"
       }
      }
     },
     "localname": "RefundableLeaseDepositPayments",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount",
        "label": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount",
        "terseLabel": "Annual offset amount"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent",
        "label": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent",
        "terseLabel": "Percentage of taxable profits (in percent)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Cash Rebate Percent",
        "label": "Research And Development Tax Credit, Cash Rebate Percent",
        "terseLabel": "Cash rebate percent (in percent)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCashRebatePercent",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Current",
        "label": "Research And Development Tax Credit, Current",
        "terseLabel": "UK R&amp;D tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCurrent",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Income Tax Expense (Benefit)",
        "label": "Research And Development Tax Credit, Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit from R&amp;D tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Total Aid Claimable",
        "label": "Research And Development Tax Credit, Total Aid Claimable",
        "terseLabel": "Total aid claimable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditTotalAidClaimable",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use\u00a0Assets\u00a0Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adioption",
        "label": "Right-Of-Use\u00a0Assets\u00a0Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adioption",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdioption",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_SaleOfStockMaximumAmountAllowableForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Allowable For Sale",
        "label": "Sale Of Stock, Maximum Amount Allowable For Sale",
        "terseLabel": "Maximum amount of stock that may be sold"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountAllowableForSale",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_SanFranciscoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Francisco, CA",
        "label": "San Francisco, CA [Member]",
        "terseLabel": "San Francisco, CA"
       }
      }
     },
     "localname": "SanFranciscoCAMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price",
        "terseLabel": "Exercise price (in pound sterling per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance",
        "terseLabel": "Maximum increase in shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase",
        "terseLabel": "Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Unvested (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price",
        "terseLabel": "Percentage amount closing price is higher than listing price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Stock plan, offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition One",
        "label": "Share-Based Payment Arrangement, Vesting Condition One [Member]",
        "terseLabel": "Vesting condition one"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionOneMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Three",
        "label": "Share-Based Payment Arrangement, Vesting Condition Three [Member]",
        "terseLabel": "Vesting condition three"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionThreeMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Two",
        "label": "Share-Based Payment Arrangement, Vesting Condition Two [Member]",
        "terseLabel": "Vesting condition two"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionTwoMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Options",
        "label": "Share Options [Member]",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "ShareOptionsMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_SohoLondonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Soho, London, UK",
        "label": "Soho, London, UK [Member]",
        "terseLabel": "Soho, London, UK"
       }
      }
     },
     "localname": "SohoLondonUKMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Issued And Vested In Period",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Issued And Vested In Period",
        "terseLabel": "Stock issued and vested in period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardIssuedAndVestedInPeriod",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period",
        "negatedTerseLabel": "Vested (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Vested Not Settled",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested Not Settled",
        "terseLabel": "Restricted share units vested, not settled (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVestedNotSettled",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Kingdom Research And Development Tax Credit Regime",
        "label": "United Kingdom Research And Development Tax Credit Regime [Member]",
        "terseLabel": "United Kingdom Research and Development Tax Credit Regime"
       }
      }
     },
     "localname": "UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME)",
        "label": "United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME) [Member]",
        "terseLabel": "United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)"
       }
      }
     },
     "localname": "UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_UnvestedRestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Share Units",
        "label": "Unvested Restricted Share Units [Member]",
        "terseLabel": "Unvested restricted share units"
       }
      }
     },
     "localname": "UnvestedRestrictedShareUnitsMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_VariableLeaseCostLeaseIncentiveReceived": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Lease Cost, Lease Incentive Received",
        "label": "Variable Lease Cost, Lease Incentive Received",
        "negatedTerseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCostLeaseIncentiveReceived",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_WeWorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WeWork",
        "label": "WeWork [Member]",
        "terseLabel": "WeWork"
       }
      }
     },
     "localname": "WeWorkMember",
     "nsuri": "http://compasspathways.com/20220930",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r83",
      "r84",
      "r204",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r210",
      "r246",
      "r247",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r436",
      "r437",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r210",
      "r246",
      "r247",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r436",
      "r437",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r182",
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r210",
      "r233",
      "r246",
      "r247",
      "r282",
      "r283",
      "r284",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r436",
      "r437",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r182",
      "r187",
      "r188",
      "r189",
      "r190",
      "r203",
      "r210",
      "r233",
      "r246",
      "r247",
      "r282",
      "r283",
      "r284",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r436",
      "r437",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r38",
      "r39",
      "r83",
      "r84",
      "r204",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Total accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Payroll tax payable"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r177"
     ],
     "calculation": {
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r43",
      "r44",
      "r45",
      "r425",
      "r445",
      "r449"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss)/income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r52",
      "r53",
      "r54",
      "r86",
      "r87",
      "r88",
      "r325",
      "r396",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r294",
      "r295",
      "r296",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r90",
      "r91",
      "r92",
      "r93",
      "r103",
      "r155",
      "r156",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r294",
      "r295",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r409",
      "r410",
      "r411",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r250",
      "r298",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.",
        "label": "Advance Rent",
        "terseLabel": "Advance rent upon lease execution"
       }
      }
     },
     "localname": "AdvanceRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r81",
      "r139",
      "r147",
      "r151",
      "r163",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r322",
      "r326",
      "r345",
      "r397",
      "r399",
      "r414",
      "r424"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r29",
      "r81",
      "r163",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r322",
      "r326",
      "r345",
      "r397",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r12",
      "r71"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r72",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r71",
      "r76"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r360"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease)/increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r79",
      "r81",
      "r107",
      "r108",
      "r113",
      "r116",
      "r118",
      "r126",
      "r127",
      "r128",
      "r163",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r208",
      "r209",
      "r213",
      "r217",
      "r224",
      "r345",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r416",
      "r429"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r191",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in GBP per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary and deferred shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r57",
      "r419",
      "r431"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r131",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Conversion of Stock [Line Items]",
        "terseLabel": "Conversion of Stock [Line Items]"
       }
      }
     },
     "localname": "ConversionOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock [Table]",
        "terseLabel": "Conversion of Stock [Table]"
       }
      }
     },
     "localname": "ConversionOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company contributions on behalf of the employee"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r137"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r252",
      "r253",
      "r288",
      "r289",
      "r291",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r58",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r104",
      "r107",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r339",
      "r340",
      "r420",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r58",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r107",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r339",
      "r340",
      "r420",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefit costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost of options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Vested restricted share units, for which shares are not in issue"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r52",
      "r53",
      "r54",
      "r86",
      "r87",
      "r88",
      "r91",
      "r100",
      "r102",
      "r125",
      "r169",
      "r224",
      "r231",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r338",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r396",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r354",
      "r356",
      "r358",
      "r359"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r70",
      "r358",
      "r359"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Non-cash gain on foreign currency remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Research Contract Costs, Prepayments and Accruals"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r412",
      "r417",
      "r421",
      "r434"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r101",
      "r102",
      "r138",
      "r307",
      "r317",
      "r318",
      "r435"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r303",
      "r304",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred and prepaid tax assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r68",
      "r384"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r157",
      "r159",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/Investment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Costs Included in Operating Expenses Related To Right of Use Assets"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Due Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/Rightofuseofassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r81",
      "r148",
      "r163",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r323",
      "r326",
      "r327",
      "r345",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r81",
      "r163",
      "r345",
      "r399",
      "r415",
      "r427"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r33",
      "r81",
      "r163",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r323",
      "r326",
      "r327",
      "r345",
      "r397",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage in Delix Therapeutics, Inc (in percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r46",
      "r48",
      "r54",
      "r56",
      "r70",
      "r81",
      "r90",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r114",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r163",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r340",
      "r345",
      "r418",
      "r430"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r104",
      "r105",
      "r115",
      "r118",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to ordinary shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r106",
      "r109",
      "r110",
      "r111",
      "r112",
      "r115",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to ordinary shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r97",
      "r103",
      "r122",
      "r155",
      "r156",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r294",
      "r295",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r409",
      "r410",
      "r411",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS:"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r382",
      "r389"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r378",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r386",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r28",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r355",
      "r357",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized gain on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "OTHER INCOME, NET:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r27",
      "r174"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r8",
      "r172",
      "r174"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance premium"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r9",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid income tax"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r293"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r13",
      "r176"
     ],
     "calculation": {
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r178",
      "r399",
      "r422",
      "r428"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetTables",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r301",
      "r407",
      "r456"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r12",
      "r71",
      "r76"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r231",
      "r399",
      "r426",
      "r444",
      "r449"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r86",
      "r87",
      "r88",
      "r91",
      "r100",
      "r102",
      "r169",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r338",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "ACCUMULATED DEFICIT"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r81",
      "r162",
      "r163",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/InvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Share Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PropertyandEquipmentNetDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r249",
      "r251",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r257",
      "r273",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r79",
      "r126",
      "r127",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r217",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Saving period (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r256",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r297",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting percentage (in percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Unvested, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Unvested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding balance (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r383",
      "r389"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r79",
      "r81",
      "r107",
      "r108",
      "r113",
      "r116",
      "r118",
      "r126",
      "r127",
      "r128",
      "r163",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r208",
      "r209",
      "r213",
      "r217",
      "r224",
      "r345",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r36",
      "r52",
      "r53",
      "r54",
      "r86",
      "r87",
      "r88",
      "r91",
      "r100",
      "r102",
      "r125",
      "r169",
      "r224",
      "r231",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r338",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r396",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r125",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r224",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r18",
      "r19",
      "r224",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted share units for which no shares were issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r224",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r224",
      "r231",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r224",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r224",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r224",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r81",
      "r154",
      "r163",
      "r345",
      "r399"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r231",
      "r232",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinaryShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r90",
      "r91",
      "r92",
      "r93",
      "r103",
      "r155",
      "r156",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r294",
      "r295",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r409",
      "r410",
      "r411",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT recoverable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average ordinary shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average ordinary shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r457": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r458": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r459": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r461": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r463": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001816590-22-000115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001816590-22-000115-xbrl.zip
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MK>'#6F2=R=J@MO]8VVWN3"6]_C;I]7VD/_!AA (8P,!1=0JZPRL3> J:-S>
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M+,HW#,<R@CLT,W,%($YB'=/8Q)99IS3"'M4QT+DQC[E9(H:8!8J8'QLN"D,
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MB+L4\R9Y'&.#$5@7RQA/0"2014B3U)?PR)<H%(L0.'M^0FN)N/8Y.)HP1GV
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M9@'[3&S+X8NV-;4VW0JK_.R/4U657Q25_W1%Y556;!T3D(SPE(!SFAB#@M
M@5%NA&[J.+45N_-Q\ZKRBZORLS\X555^052^<]7*9U2G E4BRI;F&-(!<889
M(IRUD+@5GKM25]J:5=N%K2H_UR-25>471>6O6OD8HL^>&R=1\;)-X;.59UJ1
M1#DZS=&S8-;655N+52/VM3SMU_*T,SFQ\:,3-BN.FC//U1A/,:L5NV<.B=OC
ML8[,<%E"EHBARA((,A '&K/C@Y2"!Z&$7EO7;6[DC.*^-U.9)=KR>:P8,/-T
MCHH!]X,!5VE18AY]EEQ6^J )1(K$:6F(I]0"Y2(9(=?6Y2P\H8H!JX4!,\_X
MJ!AP+Q@P%@U!!&L-(-&,!@)"1N*!>A*3DPJ0V10S#V"Z;6%6C8PK"*P(",P\
M*Z2"P/V P%4BP&U*S!E%. 21G0&O2GQ$$R-1&A4"IG*VV[3MW<]V+PT&/(IR
MO">#0<LWB5;G@9&2$W++OCT_JB"TC&"X&.5XOY;:^K5_<KR9?[3;.\LS>5Z+
MZZ1WGBSW);B,@^V/P[[+DNCV7/_3SA"/!QE;RW#[)T='#;H.L8^#&GB>(;#N
MC$=9LG/L\WI@!%2T!'0$8D(*!(-C,3KJF:&979DVE^/I=;,KWK4PX>B*)0]=
MT;=BR;)@R562YH$)Z8TF2H;BJ2$2K\%DDI8O>.\-BY"Q1+:UF6>-\(HE2X8E
M\RL*7+%D2;!D+.K#?00TR9%H3"E%P!-Q(22"UD"2C@-"=O@4;7,UOB->L>31
M8LG\Z@I7+%D6++G*2ZBVH&741&>F2L E3CQ&1B2+F(*4D+Q96P?9MG:>E<H7
M!DL>5:V3G2]1HXNFSX^LSLD]1X@F@>:$;,**:5-@VNYXW"8 2B>X)SP3( +)
M6.(=$T2D8$P2,1J4V=?BXS75;@YH"W8<LJKJ7'-<JJK.2%6OT@\GD64@M<1&
MHPEHB\0;K@GW(G"A>$99EEV9N[@Q55,76%-GGHE2-74VFCH6=#"29^,)E 2I
M2A8^!F*R(25 DS36"^.#7EL7["[1RZJJ"ZRJ,\\7J:HZ(U6]:E216^[0:L(D
M^N+39Z,J0)+L]G*=716N(&3^2U>(_SZ&?(\.#EM')X.:W[%8^1U9++6;VCR0
M[8]QSSY%$-$R1[B3)GOV)=T]HLQT1+C\CM7!LR8C0TPH>+2"T<JJ_0^=D5&U
M?W[:?Y779,:)+((B.J1$($HDAI=\+*^02V^]E*')H3 3LMVK]C]:[9]?#D75
M_KEI_U@ P@J%DHM$O+&1 %)%/+64,.YIQG&N;(GJ*]J6NFI_U?Y[R'JHVC\_
M[1\[Y"*UDUD^1$<JLO9GYN\\C21S?I14QRA+W1]0;5KS%*8(V"QT>L*H2VM6
ML-,^'F)OT/T;FP#(G9HI+TJ7WWJ/>[K'HZH4/-:]:%AJ<Q\U.7@M%]^=#8:E
MHM4CJQB\&('"!LXV+Z/9I;3):RNJ;_3BP5<9;GP1828?>ZD66)\I[W@U'G&,
MGO/$P! ME2$0T1//52(QTQ$6960QN";FP.0,SFTL"KNHD' _T<,*"4L "5==
M$0$!378<253>$T@4B)&6$9=HL, @6Q LY^V!SF /HB+"(B+"_"**%1$6'Q'&
M0I/!, N<19(*-0"6 C$<'.$,743%9>1T;5W8-DSH/5 A824@87YAQ@H)2P )
M8_%*KYQ*3F9A4YY)0G+$"RU($#YP'QQD2]$4+5;CK0F6%A$>0U!R<RP<62L1
M+U2890)25LR;/>:%">>NHN/"4$.41UUV:)$8G[E0,!2SK$%K)C(-$FW)Q_M-
M3IUZNAA[-+40X2+'5RH6W!<67.4_P+145'OBE%$$/)?$4JU)RBZ0%X!YE?"U
M=0YM+F>0AEZQ8%6P8'Z1E8H%]X0%8^$1YI24Z!.!++>,!3'[0BQDU\C;%)EB
M*079G$=I4W67Y(T*!BL&!O.+J50PN"\P&"LX@TZ)1"/Q)F1B8*T@EC%%!'BI
M5$3G/:ZM2]XVZE$0@^4^N78SG;\XN=8ZQ7YK<.CZV'+#8;_KSX;.'V%K>-*Z
MJ 0UNGQX<I3%-OB??QC.^,_>#;JAY7JQ%;M'9T.,=XF/383)A9NQ_W.G1UQB
M"_ <^_ME!<PV7,2O-03;KM_+\S:X^-U?REK[@O*THOP-4/[MA-+)GCJJ,L<3
MDF;*%PTESO- I *93.!<4/'];@4/O1"V1E!3E\)=EX+GR4IC##&L%([@@1$G
M0B(26.(^<4I]9O_T"8QOC:[.SD@U4H_ 2-TQCEF-U)R1:2Q&J4%KP3E)V9 0
MD!Z(+SL74>@$2@D=G;^5D;JWA5"-U(R6@N,T,!<I"4QQ A2RD=(&2<CV27%/
M&76V&"DQOEM?C50U4DMDI.X88*_8-&]L&@N?2QNT-CX2BJ71)]!,I8VR1'#+
MC 7JK7>W,E/WMA0J7YG)0O \ADBY)\P+2<!82SSF/Q$$QF!#]K32VCJKGE0U
M4@OT;+<Q4G?<^*G(-&=DNDJ?%3<V^SR")%G*^(8HB%$\_^'%LE#OJ3:W,E'W
MMA J6YG14D@"G168G:B8:/:DO"<FOT<PDXL057:H@BI&BHVG *Z.D7H,B=!_
M-?_ V')Y5.XM7MG"&[1.SH:#H>N5![KI1MXT<W7CK=W%-H_7@N)H%F>[_4&O
MPN"%$#=&,NR<'7OL[Z5S-&R0<;#W58XWRXVHV'D3['P_OE7B$@N2H2>8+"/@
M6" N8PSQT9H8C7!,J05=,6-+Y9Q9U?4RQ_42E0O4@2.*^>:0$1"+3!/O7;1<
M>V646%L'WI9<MHV4/[:X#UU9YU&"^AVW"RJH+Y227B7$$J)25GD"X,JI&&&S
MDL9(5&+4V!!T%+"@*Z:"^@.LERQ+5-K%DBB=_SA'B;>J.4AJM#=6!N4SJ+.V
MIJ;-)S2QJJ"^"*!^Q^!Z!?5%4M*Q4#QH'E54B="49&9>FF>2#HD@UT+11(TP
M?$%73 7UAU@O049T#DA"%!G9:5XO-".[4Y 0O)-.\H:I"ZW;&>,KJ"\DJ-\Q
M'%U!?:&4=*RPEY<<4M9*!B'3]2@D\:66CV/Y C6*1A<7=,544'^ ]6*,"<R8
M3-*-X1G4'1*3I"9*!HZ40J)*-V6?A#9MP^$!0/U\(^+BRQ?0)YM/3/Z!:8S#
M5QL@L@V()V?E-,\W1N &=ZD_>#\_V*R%GYH35_G_8_?O]7_G/Q=?N62E V8
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M+6,=,[J<JTP",YNWG#@9@8 )Q@ND+,A26Z[-S9TW9RHL5/2N8JIB6E(Q/60
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M+I5PIS#;,5B&PG!%LZEV)CG@V3GG/CJ.S#-1S?;"F>VQ+("\"!0-,A')G2)
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MZLC4D>F..^#*G'-L<(89MXP%.Y?(;)9IXH4S3%[%TGE!H<S#R8D;!R5K[$Y
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MLX(Y3P5W"+ $(\8U19H+@@!;"/6$&/C^Q2;NP*43RSJQ[%=WL_XI".W$LKO
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M79DG!/G?L?#V>(,4'H:(=B,@?0TS']G5.DQF, W4:$-V@O$.>6\/>=>4%B&
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MB%#*C)),*\X,-\Q24/8D-3[/>*AX(;3NP./>P>-\52@U@@#J2X.,"\V&C#&
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M:?K5B2VTZIS5*[ZT&O ][+\+Q<3U.W*W"8;[,@JNAQ">=W^%[UYL+@)DV&_
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M:USQZ*X;S4T[BRO7A#/7S6"3>3'5\HEW+MCV9F[;F#*7WI'L-;'[U"1$0T<
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M#JZ:4:LH;<TBYSL)IY^D\8?#CTM-JT:Y$X7=*G5PTNKWQD^PE>^][%>0YDV
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M#OU8,*8!N'L#N/-%.J<+JK$A'#%5F%1"3I#5ND@=3BEGRFL:]-HF6\?%8@+
M#0%N.0P\*(S-G7)E ./53]Z[$I9F\C["Y%U@)YP!/P&(184.$O%("F0Y,2A8
M)^$1>J&839.7"?W")N]K"++5'&25:MBMJ,B2<7AY:'8OP:9J^*ML@>7.6..#
MW3/*M7]=$G&*@46, \(X!L0+ SZ8<P8E10E':>!. 46A=)UB=D].V%-QM9I9
M?=]!E696_YA9O<!=)/7:<B=0(6R!>+ "F1@Q<IXP,#EC!(UKFWQ=%/2%3>K7
M$#_Y<VMO6GF^B9H\=-0DEY%O>1_\GOG^*;C0R?G<#93=-Y3]L4A0"GA^*OB(
M@E01<:P\4H4)R!+NL: *AZ)8VR3KC#<QE!<\E>\KAM),Y4>;R@NL1&!F%<4<
M>9645(M"(Q5H@2QEU/J()><X3>6"-A&5YQ=1J9/DDXQVZ)?*:X/AH FD/#0[
MF:U.6 9DL?,]>'01^KT&PVZ"84LR=+QG3'''D!=.(<Z9188[\+$,$]'RZ!FF
M:YNYT)'^_,)\JV;V/@ A63Y[FUEZDUFZP#2T+RB-02+F#<Q2+"S27F)DHJ'*
M&Q9M2%77?%&T_7G/T-<0_?BC5(A-1=M95ZH)?SP\P<@#/2CK&QN,N@5&+4D.
ML=@8R@J!P! I\ ="D3(8,"IUSE+4 $XEC'IIKM#R&?JR)^+]<85F(MYY(BZ0
M!2Q#H,X(Y+&WJ;][0(H6'F'NJ7;"$<[EVB:]:<;]PTVX5QMBV%U29]W$%QYZ
M^9_2-FC"I/>,1[O+4C(P%@4\.%28@B'NM4::QXBBC@K#AXH0E<*D5#89&2]X
M^MX7:6BF[X-.W\6\44D<\ :&"J8<XM@SI#A1B#LA>5%X2X++&Y:RB3Y<[B=<
M];NJFJ<2,&%G2=]ME.10<D7/ZZP)O,^A>3%0>L_5,U5^VZSL4X.M]XVM2Y)!
M@B?6$ZV02.GX7&B"E$HJQ)+[H*BRPM&U3<[7I5@44+U=W.0^9M(/CK<T.-K@
MZ).BI V./BZ.+G!41@1SVDAD:+2(:P!3;8"M1B:I*Y3&TMJU39I2<4B#HQ-R
M^U-6SGN(GEE"/2<)U^+!)5P_]).L[_#\0]><#@$AWO[OJ)/K!YZ>O.;NKQ4(
MP.3^<O(9IY99^R=_'G_9_G3\Y?@MW[F WQR___[E> O^VX'S'5[,RVON'W?A
MV!\O]B]^@>.VO[9_2^VT#B_@^F ROSO9V8;_+K;X[G8[[EP<GA^P@DK)200F
MQ&$&F\B1,D",J,=6$RFXD&)>TY58IS!501$;N=-4<^=CX8S3$?XJ_**F:_D,
M<FW<^ &L@Q%=T9%AJ8JK%=I[ZX-PD7%ME5:J8(9'[9V"BXZKVB1<?=6S=\FY
M#=3HP#W\9TVTPC#O"-<22RXL>R8RHU-#'R9#GUJ&WI^P:(4K9 Y7&JG11FJT
MD1IMI$8;J=%G,JB-U&@C-7HKW_\_QD[812,QVHCNK0S]>%E(67C-)%;<VL+B
M0ID0"3?,Q&C<]4/H*_RZW_J]P>#)!'9NZ=.5@9WC7X[VCS_C+R=OOWWY[>,Y
M_*:[_]='OKOWF>S\]5:T][Y>M"]^/VYOOZ7S@9T=N(;VWJ>3_;U?OG[9_AW\
MP#^/OFP?PF\^?]_?^TIV]W;8SLD.WMG[LE1 %'MPKY54B'CA$1=$(T6<1TH2
M'6G0\-#4VB;C]U7V_33B-HUZ: -DUP4R2:0BT1'XQW//M+588J<<)H9*:\CU
M8]@-D-T?D"U6<#!G".4!B2(:Q*DP2%N/D;-"B4)'>,<#D-U;#L73![+74-NQ
M&V/JD+>2DC:U'36,A:@DEYP5C ;.&#,L*B8 OY3G@E:-/!L^]J@PMJ3(HXA!
M*BTLXI:G<E$ID"T4120U7C7,,L%RPL*=,SF?197'*YVK6!4N!@W,G"F@Y,*X
MP"QU7@=BE#.QH1P_8JXNRE-H:HLH"#)<)+5>G90IG$(FN,C GPJ1$Z <Y+XR
MBY[*7'T-@:YWHS[,SU&_;.D;.]_3ZZ9V9"5D%=H*!@M4D(3S LB&EE:I*+5W
MC#CF&WKQZ)"U3+U31VFD)QZQ&&4J7;/(,*40 <P* I:;X-7:IGIIB>;-5)T.
M:/@".V 51)F4^J M%II+F*\B@A\@6,,N?L1476 7@7-38$*0DE@@[K%!&BN)
MJ(VD$"2)W($G4-R97#RQJ?H:HA;_"680CGI=GSJ^]WM_EZWIF]C%RKTD*X32
M.BCI E!M;(H@(E>PDF$F?+0-N7A\Q%I2;"&D$9@1A6PP0"Z8U<@:<(HPUI(K
M;N$Q1B 7+\T=:J;J=)B1""REI9Y%SR7#EBBI-(O6*N8\4PVY^!%3=;'FE-*8
M@DK(1093%1N#K&,4P7N,%S1$PR20BQ<V4^\:N+B+3W&'/>-G#0CW5TK9 ,)]
M <*R/! <%"5:(Z[ Q^"2&F2BP"A0\!.Q@Y5=NK5-+5[/]FDSOQ^YQ*^9W_<W
MOQ?3(T0!^)O*GPVFB$=JD2HD1KC000=N@G1B;5.*.R_YSV9^OXY PV#PIF6<
M&YV,NB95 /EPUH=9F,NE7EG X5\_@+5L389^>VKDX74WI!< =%LG/1BCB_S^
M2A!L\.\F^+>LLZJU\$1-@8))&Q\,.Z3!445.,BNPL49+OK;)]&)PXM_/U=MI
M9O1#\)1F1O^8&;W : RWBE@E$#S1@#A)O9*#H4AKS @/@2E.84:+Q2X_SW9&
MWW?\XIHDKM%Y>:"A>=KH^I2"/.W0 .9- '.93&CJAR:8Y2A@9P P?8$4=PI1
M'@4QR@KKBK5-<7<AK'N<(L^C$*@!R 8@?W"4K '(&P/D8L:-4UAIE0J'I$-<
M"(,,5L M#9<<6QTU$<E'O'/?R!<"D"L4KF85K99K7#UM,9WEND)7ZP1-.X0Y
M;]A,>8*M4*K7#5K?0C^TNF$P: V/X.;^ZR9IML+KR!VF@A=<R4*GA N>BMND
MP 73E5"6G!'*F@(4L:1#Q)4^[!A8BN<)++<6SFKO?13MB\]D=_LM;F_OD -N
MG9>4*>2TTX@#C"/K"PDNJ#(FJ:\[ 0B!-U9IX(&M=FO;N,ECOY4^6O/8[^6Q
M?Q8'7 4O, U(&PT+@PH%LO ,$-$T>!D#K.DL/?951?+U8X^]?M;?&A[U0VB=
MP!,^&F1;. 4(JO\. '^^-2/_TTH/M=4/@[, A_T[=,\W6N_N<"RR/K,/<!54
M@0WU;HE7,12*8A\U#HQS'8UATBA-@I1>,H*SX9(:KTACN/=HN!_Y 0/_+BC.
MP&8%_"-41 H6*Q0)K&$84XM34?3]XY5C%,<8<1 ,F)/BRDJ80@Y>$$:C==5C
M)\UC?P"\NCB@003-B4,J]3#DRC&D8@!>ZTF::XH%QJ[QV-=G(&>1R6VLE NL
MV!1/PGVY Q5\_4T_=$TZ5*775_E04[^JB#">_,18H+VCX>J?S!/(BJ>BY#^_
MT=/O9$Y<OK6H0/5$>"?1LR,Z_>_UE6$+,E:&/>I/%*L. [+]8+XB$^&6WYCN
M-W,^6/MI=CAA+*LK$FHC/;U5 S\ST(3E[\X.=?GFZI&,\6%&DNE_EL\3\*37
MSY;Z!AR:T$_?@LLQ3^9:6K!T UK^X^I'*M<V][*89B^V_N]/YMG>Q*]ID<BE
M#F9SF:D_ R5C^>!*QEO.@0<^''PPY^F9PY_]4?#_Z1C;Z0(LAD&M?S[UUD3D
MN))#?R):QW1G+'C^4<!QS_=I.L97!FO;>8K-[-!/1[ &?M_9V\*[V_NLO;>_
ML!:VM^'X>[\?[],_CW?W?+>]_?O7W>VO%U]^2VO@VQ2_X>UC1]K'[;BS]UX<
M*,F*&!P%GI.YCX.5,'EM<# %YHV9P\6\"K MN&91.P?.-&=*V&A98B[12$<5
MD_-:Q]5C:;VMJ7+B2&6_N:GG<AO9XZLN9/.![>\/=Q3\J!MVXZ+I911ZO;:U
M\^V@B!)[500$'#>5Y8%#"-S:H2BH\ZQPGLL%6WD&(:_:G,.T.?>R.7<GC_\>
MI:0;X>A&./H%"$=?NE$W9?4+/L=34I4N&5BC+=UH2S?:THVV](_:3J\I2#\,
M@NF[HTQ!?/@[='MYB[OF)HWL=*/6^F"9:.[D;/"FLL1/E2&"O[T],</*X7M.
M;<=NZRE5;<?:1SM['[_M7X"7=/S^.US;\9<]?]0^?G_1OMBG^R<[XLMQM]NF
M.W@^(V.?OOW>WO[E>.>DW=DY?GO1_JT-WWM+=XYW6/OX2V?_HGNR^]=GMG_Q
M::DZ=1!4!\4I,I$3Q&,LD X"G"W-"U(07KB4M4_66?%ZZI8:Q&L0[SY3RQK$
M^X&(MY"#1JCBGA&" M,*<6(QLL)Q%$*A%0T^:.'6-MDZOKL"[+-!O-=0J5F3
MW[-^+X;! !ZGZ8Z#<:^L4//'U&FFX?\P-?KO0GA6O66?!^0M*<WD0.8"Q1YA
ME[*KI,!($2V0+X0-A=0FQI!('B\:T>L7/)7OL4"SF<J/,Y47V$NTA0S2&U0H
MYV$J&XM,811RM, AY?]IS;*_IAIIJ><;H'.]D\1+)KFC-IR&V$F-9@>WE+%\
M%<*[]T56WIZ<=7OG(7P*N0Q]:GN^ ;E[!KEE&MI,:QF)H\@8J1%W,2562HHD
M=H*R5)!1NFB*-#+:+W@VWQ=?:6;S8\[FQ8!+2I7&Q"(MN$7<I+YADDCD-(Y2
M80H/UJYMBG5,[JOL[ZG,YM<05OE@SON];K<U--];9V4^91-,>:Q@2CGV>^;[
M%)0U:'5]M%HBL2T-%8H9CW1T!'%M-$I-H9"UTG*F+./1KVURUD1*7O \O>](
M23-/[SI/%U@%H[0P!#M$/.>I&ZE#AE&)E"VH,Q8[SI/6BGYI\_0UA$%VY[.B
MFXC'0S.*^7*7!J9N 5-+MEZL"4$7FB$710IE>(RTYQ()[QT+)'A%Y-JFY"^M
MR5 S21^ 3C23]%XFZ0*7D(0KHPJ"+"$!N(2/2"MN4'318^6%T]JN;=*BB4]<
M[D!<];M&S.UAA^;% .8]QDEF"GVKLM[%JLLF$'S/,+M,'M-*C,$SBR@P!5Q(
M4XR,#A[1W'/.%]C" K@IUX$2W9/3]ASTWQI,;3#U.9'0!E-_(*8N4%>@=T9A
M+5%PVB"N4K&\)QAQ'JVD130FI/H-O,[PG=GK"P'5%:*:,QH22R4UKR<.)/%8
M'.@9B*VH!Q=;^6/8<U]3*][0'R0QW>%YNS<,$SF5)Z)UP79J3;%CQ^$W,/-W
MZ,YOGVE[[R/9W_L"L[][W#YNG\ ,/6KO?8)S[IPO:%U<',+U>;BV_6]?]O9)
M>_O/H_;).YC!<"RZCV&VD_9OGV'F_AX!,7#[\$ 4AC&O"J1UDL1U$B-K(T<:
M6Z4*%ZB+9%Y)13NA)0O:<2UX4%$KKRB)47-/@Z9B7AUCMP^SP/3/6W\<F?ZM
M)%.N/.-S4.#8'O63C$82U;B.'.1Z_N:OO1.XU/-69S!(F7E)@J,W--W6RI5W
MD,=X;O%542:=/AH9.#2>!2,XD9@1HVCTVLDKY$7?M]\MG5;O\T65]_4!!J7G
MRR></]P]2Q<V>/L]]%UG$/SU%F+\RJ;AE+0??.\K/RBTX1*<$1@9%E,PR"*K
M!4,%%3JZ(IBH8$7E!5F7<E&.M-6KYUII!V MK4$8#I/:2GJCU2N?2BO4CZ5E
MSUNARE"J]$5[IVCR3LH%A1_Z=*2;&9WS7LB"6FX*L#UI\PL)CK53 >[#7Z$1
MV1C=XQC=WM;Y04&<B\Y3P'X,JX#6 BD!ED>2T"1C,@!PI+1NHM0ZY4O,+DL#
M70O7R$9KMU06JBQT"MFN>83U&QIBH0S!A;1&.<F%8]H8B8UTFH68DBH:0_QQ
M)&0+W!UXO;=_OKMW2'>V#@#DO.3*(N8)>!0&K% S+N ?(S67.L":O[9)&5VG
M=#%.4^H9]\M,RP19BW@'A@9/&6>MYF]''7=4&V+^J0_=#K@ X^^1U1JH+X5F
MF(I2).G)I\PJ/H7!$/@B/-C\M:UOIN_;8;@;W_7Z,72&HWR%S32["N_WOQ^H
MR*Q@5B'*' 6WG48$O,(A$233VC(?#4PR2=<E6W3;%SA&GC@3&"_Y1A9T 9/J
MCY]:Q4"230W6TT?E[/M1-I?+XF]L<.5WMT[]GR&IY+T_+7_0V-TU[(X<%))9
MYEB!F"I2D A39)@"EU.JX(PMHI0*> 9?5TM*05M_YR'/''7:Y/S- "___MD!
M785Q#9&XTM+H3D(X'J3@\" 0TP08;<$,LJJ@B$3OM'>2L=0.6\AU)1=S7VI+
MLZ-AZ\@DCVC8LB&<UA9GAJUI9;F*UFX-$JBM<.3!7+/-WLSP LP*IZQGI!!<
M$*L\3ND!1#N*671T^4;DG4&NQ+9V;_A'AO+&YJZVN>.WWPYB4$6,0%AY[L@@
M9 #7'?YTA"BLX:6C&M!-KA.RQ(6:7R@'TU:8++!<5_VS(Z3O'\ZS>^000P/,
M=_7P6/O;@2BL#H%H)*-1B$OB$3CH$0DK+=8XNN E0'.QKM02!V\YGZSFRJUI
M);>,&5)$P4CD7@05;*&(\6 U)MUR94B*,%2_N,J0TFE^,>!Q_CI53;W5[YO3
MPTR.?SF??.6#.4]O98,J-RG>G\)MCM*;@[R_N7=D3JN80L,\;VQVO/WQ0&)B
M,-<>49WJ *.R2'-9 $0SQP$R%%8IQD77"[S$[&[D\R2XJ\![$=5+>P6+W!H=
MC@;#%F$U@?A1V/> GE#L? \>781^[]6:8OMB!Q]@@UW4N$#2L:3ZE<JZK-.(
M%L83*L"AB&1ML]V[F>'5[<96V%IM:C>.ZW#A%*5$>NNXM<[$@CIA@V$8;IZ5
MK//^#:IAG3=$MHN=Y%=_/ !7QH@@ B ;K$\<H Q9$A32QJ6M<XQ) ;R3\W6J
M%@4+;A2Z?V[4<_>TM6/.6[QFE],[JH->]Z9Q !*DU1*8 07GTMN@*-="X4B\
M@T7#L IR!>:H?G$52S"I#4>> ^U1&FOX(Y^YG#CO3_> +PS*BVOFPS56>K'S
M[4""\4=#+9(FPGS S"(#0(8\XXS;6 0G8*7GZV![Z;^K,1>F"-C!:2AMY%MG
M>-1*P%JVQD#P5B_&D"!NHU59'-&ER66+R[V4OO7!2>A/;T3 1YU^M4&1MBK.
M1GUW!&RP!?,D)0X-2XW FYFH5H((86FD7G/MB(J62J(HT9$*RGAMHD"_ZQ>-
MB3ZJB7[]UMXZ* 064@B!*!6XA&RE,4-2TD@,-T)2NK997-- -UI[1YU!RYFS
M3MK(Z1NPK\0&1MUA24]/PS )3[H0?.8#Y@S^^@X/91BZYS?K]VD)]C(U+1*,
M.^?!<P.#(ZJPF(!7%Q8@<-:^%AL_3IG7KZGW#$R5["E]"BYT_@Y^]^;V]8/;
M0_YH^_J>FAAQ:@7& 9$B\4VC#4HB*/!/H923V'@-]D4$WUB5ECGN#)J:"<(3
M]"/X]/1P F;ICUCGC-0 6"J$W1M/6)E9^5@$XJUQ1W.S#=C1L /\=)"QO<PL
MO#0YYN_>,,QG)$CG"Z>PTSAPY:A5.(CHF#5"@U_@;[B+5>/RGW"FV2U0N&^7
MYLDWN(=!.&T@N)PB%[M;!S%8[V(A4:'3%"DX1LIYB0(7A&@7E13@DO5.PY+M
M 1CGY,&;;K<%(YW7]<'(GG2&5=:!J;X2IQGG?_\#EF'Y\Z THRHE%1C#C'55
M;[>F#"T?L5_"80OF$D#DJ1^LMSJ XZ?GZRTS@(LX;]F4O."Z.5?+GN<3VQZX
M5>DJ? =^/^SU\TH!\^GP:.D^Q>,U+)^WX%_-X&B[NK7MZBYV^Q],9\9W;&(+
MEYOU.9BUCPY3Y0$P,3!@SF$AU@I3%&4!C,,J7FB^MGFZ)-+@X!E,["MO?.5-
MK[%5]?JM,W@BM7559CT']G?*76?/*7==/WCN^B1+?3=.1Y$K);E?TUJ[$$0>
M/)F,]O-Z,KS_MKL'9[[XB'?_^O)U%R9#^R\XYW:W\^7X[;?R&.E\.V)^,NP<
M;XGVL;MH;W\47TX^BO;V9[+_%QSOK]]/=O9^R=?;WMOB.Q?=Z<F =[8_7@ -
M"AA\H>@)$MB")T@"1L98BACC5.+HK7)N/KL=O'D%#F+A(X[ RZ4.\-""#9H'
MP:WP\]GM^0&@_ 1:TP_I%FGN5Y]Z]E)Q(3AQ0G(K"ZZP-E0R890L+"&Q,'%I
M6GPUC^CL/.(/.8WR$=\DWZ3CKC&Q8%+(5KD-TGI_FOI\I97O0]><OAA>^?DT
ML\8EY  <.5BH4P72-"'()!LHQL#U.V7 P!SV0]YP&,R&M;X!'3"CX1$<XZ*D
M#CE8O+@1L;XR-<ND*#-0&_C_*GTRO]>I'T7.*D\!D'&6^/I<TGBZVI/,+K*[
MF;Z[E(OT\J7#LTH;)X,1<.VIDY21[M.J"VG_)/UX)HF]O/$ZPS-__1!\Q70_
M9Z/^8 0OTY6F+P%%.QG4?&RU?:VWJHAZ_DIZ9P.^T?I]!%XRO*77ESZRQ5MK
M&0^75<9XIH^U-_UG\LC38CN)X^>K3P=ZFUK;G?63&[]C3DVY83BYUGR9;W?>
MKT^-1/E$/O_/]$-9.&X]5O6W-_[8N#3Y?Y; SE]_-C5_TCE-#6,OIYW/+7!\
M:2[/E7/MUAFUA!0Q&,4858$32HTF6"H5X3\:E!=7YOO<>?=Y-L2W-;ZY9Q+9
M^W&4XZ)]_#X'GQV#Y3I1#A(CXBGNK M:(&45M9P9RVA6R"\P72=+E 86@L\Y
MX-(]3\&5WF@X&,(LS:^KJ5PCWFB\HDP#3*?7KR'P_8?=EQ.7V;WZ[F&JGI^E
M=12P.VV0MGI_IW6T-7,C*3Z".M_14<?#O;YY389[WMXZ +9(8BK:9ESQ5/?C
M4PR$@NT*:[".@1=^;7-X!%2C,IVT\ESF]01-I>/ 5YW%7(%SIPLN)=:8%CQ&
MZZY3L7M;[!KO(H\#!F0Q&.9'_7$P[%5AU>XVO+]UD!)=N&3@"/%0(%XX@91B
M'+F4U*2$D=2*M<W8&_71>3#]>2^F!1/V[XX+K;,\P.5FV,I%[C2O)O.)*S(Z
M2I@37D:.66&]HD9XH:-AVF)]1>AH01$B&X.]VE[L9?;R*8'+ *PF42P@7.,E
M#=%79B< #239B>'6,P%V$BE)&:T>@3OJ4$%<I(%;IBQ?VV1L8S%1_Y^7I]@O
M-0I-J8?%4G*?U- *9S7V6O/(E-$4KN *HZ"-43PBT=DYW_UX@%WD/JJ B+46
M<<($TM%K)(32V$JAI"3@RR]FU_\S.9YG:3/][] ]7Z^=#),&/J_4F=Y4?E^G
M#RNW.3U-17F#Q(JJ;[O>"3PR5SI&W@Q#MKGL?1A8_%T8'RGGM  'R,M_^D(_
MG!CP6>"C!' I G\-*G483D,_<XGP_:PS2>1?N@@J*J@N)%!Y+9+.E.&Z8#X4
MX"X2Z?VU%\';V._;='GYRTMBYO4*F&[\E5DP+'\8+/>B??'^?&?[:]*^8%KK
M: N,,$L6+*5!BJI4:NIX $],%ZI(XC4+:V"VFU;L]TZRE63S [O,]K/1:GU:
MGH=WF7FMH*J7V!@E7!)A@B"P>AM8O+77BDB+;:2,R>6K:$.T'HMH?3R(I @%
MLQ[(-'B#G!J'K"4& 3+"$U->.F<>EFC=RD2:-?7QUM2=[SN'!V (3-JHD/9!
M(R#E!!E8*%)2D,26.N#J9L4Z>H\KY_^.3'^8X@QEL5K.^MAH76=KK_*D*_><
M"_#?SWJ#G+WV)A?BPP7\_*WCAT>U:-S4KZK-"#SYB;&#7G<T7/V3^5!%);*%
MDF#@&SW]3A;T*M^:DOE*=A?Z3R702/'<&$_]>]2OK^8,)@JR\%B^HOQDWICN
M-W,^6/MI=F1@6*J#"[61'L2J,9P9,\+R=V='K7QS]:#$^#"#PO0_RT<#.-0K
M><R;,@(&WX++,4_F6EI'_82R_[C&MO;:YEZ2>\OQX)_,L[V)7]/B<IH:0)K-
M95:[=$_SRCW*N3U-QF@T#M9.' *X?T0%JPB\2'(@L) MW]-\-G'+O:D-JYH/
M]M(&TVFH]QAPN9,U&-EC\)$NS2QK/.GGN.K/>M([6P=",B,M<\B[X,&3]JDH
M3:3VDYX:+'4,J6YX*0.H%_W16;7L Y/L=L!YZ#F7]4]=1IU_=?Z=/[W,H;B5
MW30.Q:.8S#X%AP)@D- B<,2$Y8@7(2(-,(H &V4*KQ<AX)RPV%KJ3RRA@C..
M:]Y4_E>GLI3ZH_2ZVZF8Y<QN\/\9+&Q5Y6[!\%=*YFZ%[^XH/??UJDZBW!\&
MS]@D+&@E;!R;;[QB5Z&(H1#@RH"%8FZ=T\%A<-Y-%-(XH6QCFT\DK)(VE530
M6' ND*!"(.XP1;8 Q[<H,*S]#"OF7;6I5$92%DRUSEN81.INM@3>RERNWD]O
M%L$'LIJ4CNTT)380A3")#G'//3+>$ 1<,1+*&/C%P/^7B+5,W&! &6<J\QAV
MNG59;.>T%4?=[I6;WY4OFIG<<^25*\I_5]),<Q>6R9B(3BOIBL)P2TVJ7."N
M4$)PF/97QI::*?;@I.'X(P-NR93$S!"'I(H:2$/T2$F"$::"\<)8:5(AT VY
MY?4(Y:U,Y#%W05[GBKUS_#F%IS67T:HH41 !HR27!8:!894V4LDHG>>&W!N;
M+(.1WIQ77+#6:QMTOJ.\/[?L>'>CG>G=4@DF!SV[O4$ZUEF_X\:\=BQ ^[C8
M1V=E$F[+2R<@MW62.F+\6M[BAW2'[P?_#X"P5(WY3SF,^?U7#(<S;O?'\YUO
M!\)S$37CB!B8!CR( BDL+1*<6LEQ40CCR@#M C0>Y=$%(S*G,Z9:FE>BKP8\
MG&# Z%>:%LR&!UM3[V99>T#-!RGO/!7D!C=*$?R]ODG1X>T4=7X6!8:/CJJ.
M@N]#L:><.X:"#PIQ%E+);22(6P^NCV%.QK3I!P.ZI/YJ,MJM83G<"3('\]LP
MS[.D PCGVRJOO.P#T?I0ZQU<I[+C#N3\,3GX?&G E?<]KCAX^\>'#^M52GU9
M.U!ET_^2L^G!B9EDHY?T_=27=?Q_5Y&5Z?+1Y5^WP0$\M$*,9?;-%+6KWSH-
M@_FT__'-? J'G12_R3CVQQ"6^U+PZK3U+I5GO$-DF5)&G7N<BP?27<*7.L-.
M3G8 G G]ORM-U^E,^J-2X\A4\<O165E5>UNA:B.#9X4B@5%.@T^Z&-*Z")/2
M<F^*)JW^B8'IQ7N2**JW4DMAD.0JI:JF#JFP-B/G.& I+-6P-JYM,H[7L5@B
M%[RD%<:92<V=.F<FK];C.I<IVZQJ<E)Q/RSA61@I/[IQ\=%@SFC_-IUNWMQ+
MJ_[89K]U4OW4""#+#*O$GLZIZX<T[4/2%/C=G([2M9%UF)6 9J?5UOW4^V.Q
MXMD?3&W0P\NRF#N5-\&]YJDP+G*"25\B3 4D79C:$^_M9I3WSC/H;HQD*SD-
M:93?5X/X_G1^)@$$O:]&?\*,=^/NI&0B:XSLF.^=D]')*R;"%Y\OVA\/"E7
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MKI,LET161MVP&]N]TU)%?7)1N0 G7])6B@=TAN?9_]B#"_BE"Q^]LDF7MNT
M]CDC 1?!(4I9:GJ0\N "9TA30KG!Q!5,KK4"T*XS&.AA?Q0N\S6>LDK/5FLP
M.CF9WMG.F?J#.O%_?G:.*@M:I4_O;[J+EQ(#!]52-7AS%_]FF!WG<;2H#Q"4
MMC*[YFP0WM0O?O:=P5G7G+_IG.;!R#_Z>?9YI1 'K*&YN*B*!.73E1]7D1(M
M-[#(LWS8A_]\?>(JCK*1/_IIZ!<_DV2#\M4?XPVR\K/+#DOH!J&K?WK982__
MC&/YC"Z67.^7/^6G5CXYL(UD=;D9^6S4ZPUND6Q;]?$N^2H]^YZ^O"1^.&=+
MI1G=]WQ7<]-]84G*D;WVN+ZF=#3'\^WJ^WMI0_%7_@-0:0LNRAR&5G:T6TG,
MJ/7.=/JM/TUW%&X[0%?8UV*V12JIC_'G2X8P16 ?9P"O7COR"'ZNUX)$Y:;*
M#ZO*G)FBMK1EN7(LZ=7C4N%YQO^S82O7G+72+<Z,&&XM&;<<I7Y2 W>SX%0$
M7RRU< O,$>Z--3PZ"]R?$6(Y\V6Y*0$W]5K!J=L$#*K]OC%]G U6O>C8U-'^
MR??N[O$AO/_+U]WM+]TOQ[\? 9/\MD_?\IV33T<[Q^_Q[MXAWZ>_P^?[W^K?
MP+E&7^CG JZGL_/;1]X^^?-DY^0M;F__<KR_=WC^Y;>WYSO''^%<1\?[)_#Y
M\2]QYP_\_3][;X?I_W,\ZV+_P,/#5M(;5$@-/I\D$MF4%1\<E2%B3")/;<V)
M6"=\,:#UW_\@!?YY?N+=SV1+'^5)=_W)=@F*7HF(\^O/ R+&DT/:_WJ8)WB#
M)_>D8'(T2/U2,OK<"U;>7Y?4>:2L24;%,3+%2 PC$8S,+QI\O!D^7LSCHP,O
MS#NAD-$<\%%(@0QV!2+!!,*%XZY(^ C<?[&2^*6BXXW)9Y7JN^SZY1.'QM_*
MD..MN.62VWZ1#%)C&M/..E5)=#MX':*(W')BN*:%7AY$;%+'GBU,=A9I)#QY
MI24C")L0$'?<(FN%0X9SP2Q5GJ>,,\+9NF)WII&7P,E#P>'<*:]-%J\+ 4\.
M]ZY/"9?=XC-%M]7$[XX0MYP!WAO -33PGO%M@08:(V.1&*!6X"%SEQ0II:6(
M1EFXZ(DW,6W4\PUU9QKXQ-#MGB*-SX+L_9F=JKO$$9\AU_O7CR)[I5!=VB N
M5:W*"KT2T<;2<M/[R.-TCN#?+\LM:EC=75#O?)'5,<FQD,XB;;1"W%*'E/0"
M>8\+&E2408>U34;6]9)6Z_^^J>/[5-S;&U[J2^-SRV[Q:2/84^%S=XCH_=F$
M\QX"T19XG'0Z8%XD1%,><>Q3U[! D!(N1B>MCI&L;>H-O2C(>;MHWE,!M=<4
MLWO7Z\?0>7U1NQ_&Y.Y]7Z/Z>_P@YW>$&Q2\-@JV?UWD==@%82,K$'.&($XC
M10K'B*0(T28!,T%<KF*X ZE[8FYL$Z1K@G2/3>I6PEG#\^X9X19XGG"R*$3A
M$-%)[-%;C:R(%GD3,992>)*ZPQ*^4:@F7G>GS,"<2?T$TP/'R>#EXZPSPN>J
MA6^?*E@E<S-XU+XW2JGA>8_^%2<2*L&(,X()KST7@2F9]":< &;!DI;(S?3-
MFT3")XRX2Q() \/PZ(5',=C4LRM$I(N $>9>8B5%C+98VZ2T6&=Z,5AXIU29
M.TW%)M+81!H?DI3>#A6;E,%G@X0+W!,K:XBT$5%/6<J%\4A1PI SF'GN")>Y
M53/9$/>5,OA4\"QSSY]RS=NTWM-4J?!S;F&QM:(AS*Q4:#^TO@$#_:_+H.)>
M( *)>8QX6REP_5&JNB[/,1D#04:'P5[JBS3]^:^]P;#=&^X'N#C7.SR% ?)C
M2"B>)R3<D[+:(3G@4164496F=8$XB<!R(OQ)L";2&? SBR0!O;&HJM8"B^S6
MW;-N8ATV,BUE4(YRRCTAE@6I@&G!/YX2SLN<\WGK6!!1:(SC88W#B8,HO96!
M<^2IT8C#,T.6DX# , (+27HO*<F3C6*U<0# C$[[X[&=[;OF8/1;6<BNU#2Z
MHEAZ5H>O;L[>&:0F.L%5Q[!)!F1\NJIS\K>*(R!3U2Y6VO9)->PRN?#;Q-\>
MR4K+=)%WO7[U5OI>TW9YJ25_Y0=%P;TAGB&3'A9W+"#K ?!L06UAB;+: (5A
M&ZLZ]4S)TRZU% D0RG"TQ$G":=(7B;#D88DE5<((NE2,MK&4)V<IYP<4VZ *
M ?8AC$2<$\ \9QA*(M5">J8!$-*"./'Y9TUE3BPT2\B$[Z'O.@. G7ZG[ F[
M0@T"L,P,LW3;2><TM7M*_DMN;)FT94Y;B4VSGU>NM8?V[(%W$N[6B_7M_XXZ
MP_/WIW#OHZR]M)OXY1[<6>74O:T&ZD,:I^?NM]W>)H^=V-DZP#JXW*/8*<\1
MMP+@BBB,A(Z,&0/,38,EX@U,%I??U. I&]9U6R \87W'+ M4:@%59O)CU("6
MFWU.Y*RNJY$$JB6!OAUXP%$A'$>$B:0$9R6RU#JD &\(39JCXCJ20,_&F=Z;
M$9"KM'6R5! <9+!<N6M&"\Q4QC-NZ'<=/:#G)0!$M+R- !!G&\#?'D13!S^,
M %#17&QSL9Q<SV8;::5&6FE.6JGFP:U,A)N1F8S,I['$:Y),3WPWZ;KN)>'8
M?^TG_VLAH>\5C=;6X6$_'"9!KO<P-IW3 ?#AO 76^E>6)^R-X.#^]D/T:E)Q
M5HMS5<DW\PI==TV^>8WI-=%;ZRQG2L!*J7VT$5L8%>D\IE*(>#.=KCO4'D\]
M[7;5SO3E)];LX_V+]^?PV??VA?_:OOAT L<0.[^]O=B_^/)U9_L]W]WN?OVR
M_>?1_'9R^_C3\<[Q[W O;UF;?F3MW_;!.?SZ;7^O?=P^^?AMY_B0[_[UZ2M<
MPU*%KN!XH0L2D=,X]Z>5R,@B(B&5"4)C(8E>VV3KFHAU@1>;A[U4%9I&HZO1
MZ%H:NS4%=Q87EFC"8Z"IJZ8HBL*JP)QAX28:7?>#DG,I-R\J:OO8\+B0;>.+
MX$5JP1$-8XAS&I&QP2-N*$"EHM9&L[:9FDB]*FB\R3&N?4// BN6;SCJ@EO)
MM L%X\PQ19R+S@B@4228PI0;C@D4T 0=[C<#;S4@C)VT*1\MN6CTA>TZ/C96
MD,6J$$65U1IQ&Q3BD:1M[4B0=+$PWCG&-&"%VBCX0M[:U2Y@PUX:]G(#]G(O
MK 6Q^^O:=-5F\SA:,@Z6Y%C)%*Q=SP]D#7A=![S8@A*ICL%[J1#E28+*.)N:
MC!?(JBA"ZH\H.%O;%&2=%(O9AR^5Z;PF68-&BO0:G19OD\'02)$^6YQ<(D7*
M8?V46A3(>(41+RA&VNH",5PPA:/Q)OBU39H:-*Y+=6>G\(F5_S8Z!R]?Y^".
M('?S4-?@+FJD3;CK#NBV&.[RMB!,620*:1$/!:!;(3 J%!.%BY9Z$W.X2RU6
M&3Q[9&N.\4J%66L,:;19'YO]7B;/.IW+.WY"#;F]-_A?HLAJ?2$I$1IYD]J1
MZ&B W$H%\"^,X13 @LNU35Z0=2D7HP"-).M3FMR-4,+39K4UI#7$]@&0;8'8
MJL+8&+1!\-0Y()N(""Q HX"5#X3;P 5.Y3M2OC#1A.88KS>DVRC5/M.H;O7@
M1G"M6Z?^[?>S3C\?8?":&A,\SF*Q3,"6$T4<81@Y+13BL#0@JW$ 5LR<TYAC
M00708*+6A5XL]VQ$;)\2%C3!W:=-@Z>@KB'"]X]MBQ%>8X46EB!BG48\L6$K
MA$$*4*W000/&%:E% 7MIRK7-,9KRH4<2[WV-]4/4"\*E!&2)E <BM Y44N'3
M N--9#>3YVWJAY[D>K*D?LA:$2PQ"A7:%8AC:Y$R14!12Z. :FCX:VU3K&,F
MUC5]54GR30;N:\[ 74' ;X>33?W0\X#'1;K-(CQE%Q$G3B N"X<4(1%%$9R!
MQRT#];E3!+TSWWY.T-C4#\V"@J0Z2DD*QP4/O+#,^R)*98C5RD55>>4 "JN5
ML9KZH6>&%0OU0TKQ0H(9(*^H09P[A4RA"B3A;28I-D;*7#^TH(O9U \U[.5!
MZX=NQUJ:^J$7"UX+]4-4*!I=4A@D@H,?*"RRD6CXDRN*E>5*):(CUP'D7@W3
MN:?-YJ<?8ZN<ABQA^% QMN>['_U,(VE3#[6)I-TS@BZI+ J2\2 H0=I8\!>Q
M\4@YY1'FM% )16UJ[$+7"2[6@0^^O.V99O/YI;#'IQW[FL*U)O9U?X"V$/LB
MUL%CE@$)(PK$K>?($J,1)4921J/-?:#E!GZ!6'9/;._)3ONG&L9:/;=7A;%>
M6O.-QY[V"V$L<(>"THZA4*16G0ZFO2+1(R.HQIQHJS1+TU[1>PEC-:3BE9"*
MIQ:26D2<V= 3:0).]P@S"P$GP0JKA"^0EQK8A0X&Z1 H*I@SGD07M2=KFTFU
ME/,7QB]>3>K6I G[P^9M-3&EIGGZ2X'*966]& =FN4)488QX] )I:RRR#FN/
M(\>>A!19TE2ORWL+SS^5('Q3W?ORJWOO,[+4M$%_@IBV$%PRS!0.J!\*5K&D
M5TB1DCX@[8@//E 15>J&6VP4]Y58]83P[)Y(WY.=^O<=7;I;H\Q5LWI51*D)
M*-UIJB\$E+0H:&31(D>P0JE-.=)&$P38'A07"NL84LD2*9Y"7E3#)9[2O3VG
M@-)M<YS&^-0$G.X1AA8"3I$4O&",(";3_KR60#:D@<6&B"C 7")X5\F+8OB^
M!)*?"N/(\::?<J_1<91E#FAOWROV$9!@W!+6C%NR=<8MV<JNWKTX;OU:]P?W
M+9\UR:[=_C7WI4\ZZJUO9M#ZKQM SQVKLI%XH"WR24UV[FT_"SMC0"F>)Z#<
MOB,X7%O[\, Q)P(\;12$MH '."(KO4)IW:#$$VLI>"!B0RPV! ?S[B:32 9S
M$SMQC.(8(PZ"28Y5ZN.L@G?P@J3]=%?V&:GMA#1V\J/MA.Q\// $1\*T0X$6
ML&Y0X\!3%0[)P'%!-=;$L:0FLK'HJ-:&LM[JA\%92#VI0_?\RB[RSZI-]Z68
M/-N4NS-H@26Y4==4>P()F7TGQM /IRZT;!A^"^$TOUVC>.LLY?*D8Z5WYYI\
MP_1+[T;3Z4_.N:PY>*\/JZ+IGY<'&%1=P7N#^2,.C\RP=63\W.D'K6[O6T@_
M,:>W.^/+>N;?ZD:RIFHD>Y@"9,@G*Y@=FMGA/2Q[%%R]OCX5]9.[*%N_O*#A
M'9#TX\7NU@'Q/"JO#6)8>\2M%L@6U",KM&(%"1'6W;5-@C>H7H32*]?:%39S
MQS6WL9D?9S.X_?& "F*X,Q$5A4]M^T3*JK8""?#O"\DHN/H:O#:Z(1>5O%IG
M@-DE MW0%5@?^P(O=>G>FMV17W2"UM-@P<C=U!>Z91AF@=J^/3GK]LY#^"/T
M_X8E>/FT&X=.\@P;9/8Z_?FOO<&PW1ON![@XUSL\A0'RT[K4KYC;?J8PNW"A
MC,5$(%6DG67G-5(\!B0B=]1K>.GYVB;#&XLIOK=W@K@WVMJ N2:\<%9):XL@
ML5:&%":0LI=98R _W$#XSM:! H[E8+J"@10I!]QH9"G3"/XCU&C,L)4 OW)C
M,>M@;"" ,Z/3_GAXP1HFXP]_#(8 L:5+,.S!-ZN4H1GFN-[Z=M1Q1\F#"-\3
M&I=?MJ$U==P>K*$M,R:GJ":G9WFE39=QV?84*[P5PBE!0^3!&*6MUIJDQJ &
M[E0OY9:/9)$E5WC7ZU=OI>^]M+SG.UBJ.]_]>. *&UPP@%U4I?"N<@C( D=*
M $T@V''.4Y+,AI;SP<]6&K32F[S,0"P#QHHC+S0%".-16R>Y]RHZA8-R8BF1
M; SD21@(WCD\B*$PX']$9&W4B+-"(ZU-@1R!A4X53)+ 8*W;6$AK+^WC4B*8
M?I&,I7,ZRL]HAAI6O(L+(&9GO4%^.&\RY,&A?O[6\<.C>K=KZE?E-L ;//F)
ML8->=S1<_9-Y#EIM!J"T8_E&3[^3-Q[*MZ:V(QR0U=!_*@'_A<30J7^/^O75
MG '"(]L/YBLR$:[^C>E^,^>#M9]F1P:&I3JX4!OI0:P:PYDQ2WW!%T:M?'/U
MH,3X,(/"]#_+1P.DJ%?J2;\!_R'TT[?@<LR3N9;643\AYC\ZU&&F(K',A 2>
M6N$('@%6$EAG"#0> '?8RT7G:7'^R3S;FT@9)&G'-]_#$JN=@X<2?R,XKT[
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M%8\S2DF@5012 41#&@8!"7(N\C"2 1,)2@66W%?^M)8*STHJ1(E*@5"$'].
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MU"*F+ ;WBM#4("%(3=(PQAE#61HSP7V1I^NU<F\ W=2FV"-0#D)G:!T(V-
M*"=7$481?1)E$4\U%R)A^<KL1JU2:Y7Z\E3JXR1/:M'XR*)Q(<%"\UQG?AX3
MS65*.(MBDF5)2+3B$15)&$92K:=4-X!R:F/LP>DFBZ)$IJ$D6<A3G/ 8D!2G
MNB4A992%29CK9&5BKE:IM4I]<2KUD?)^M6!\5,&XD!GT0>OE22X(CV)).,]
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M@3,^\PTEF-JX>'QR21F/DH#%A"613[BO!$F$GQ*:Z21*?):',05=01NQGS3
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M5 E+'0WM(0#-N3*=94W9HC1?  VEY= [+T8=!3?%L0X#K492FT\7O[?CP8X
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M9LIC^$%(GTNL>KPB<;!@/3L/W=N?CN5<6RY5D2,X^F4;(YQV1 >HJ5(/;0P
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M)V[^^NMMP_6\C4LS,"7?+LM1U9(&(C"?QR1SJ7)X#7",QJ_AR,>LW\"]#,Z
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M<E[D?ZE151[>) R[YF_\2:H9AMZMU=F$@*F J8)9\?<X*/DA['+X(DIAKMF
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MK2P"4-9X'%WEA89<U;"6KST!9FVNY2"D*\6<"*:P,<WJ".DJVBEF^OAA#&M
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M@S<W'K0;:T29BZ@"<_D]W B2S F'$SCE0R#AAH3[LR(I#@D8L,CI?>"N81C
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M-^>;156Q#X#+]:\ZTB!M2FC:W?RGLX%I[5$^XYQ/2N+/L[AFO7ZVED=:JTM
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M:0GDU<)#Q)0MV3>S90C1C2MG8K]&0]$2:#M8#GX6.0&[<TV_G%@ZSKIZ+]D
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MS=IP<\8)6W+HTBR8=IP$*J/M.T-F&&_TY,][(+^)-^M.?-S=$7# Z#QCJR)
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MUKDT4=&FO2AJI>$,6RDG)]I%QDPORAA5 D=ZA1N3^G13%5O@S7L9Z$7<)*Y
MQ<U*ZY21U8^]EG_L.=G7N&(,?MW7">0=]F2[%.LDC%RLY,(FB<T*[D1W66T?
MY[)X=3(#0C5(IOAY*M:R0DC5#]"U43>:[ \VEV.%[8P6;8_/M=C*^:']W8;.
MC 1/]>P?P7A>SIZ%+X:C6-L N.!>OA?^NG*-9H:+LKD(SWU9&:4D7EX<+T1]
MU9(X_S7QA9H+LC9X@E102VP!\G_+5?1]OF[:V?.WW\\'BV+_=8JV!4N]T&+1
MLJ3N=3VQUB42&+<,A373LTV6!1:E8^3+CX[VV.+WER0/(KJ$^%\\"]]$*<F:
MD4?/]P,V0=DBCM:]$Q;B5;7 LSHFV,3A>?OS:#1FW OK(FS&H<IJ[+80IRKQ
MBQ[^6%?!*'V2^=HS'KD!B^"E85N7QG<&7:7BB;>T8=069$80TN+*/(Q!;]R0
MAV_8>2TCQ'LSW%.&/B6#8/%4!S'QHI&&TXA$*:<;K2NB.3P]M*U3P]NV+8/K
MW+<ZXGUMYW E,2!.E*4N@?U%G%B9<Q%8:7NUYH0U.O9DP:ADLT;%)+8T!)<
M\T>F)3H!P?7UD9MXSI?5N1+O.L?KCOZ MOE."E/WGKE+<0.KPY*Z2RV-*6'E
M(@GL_E);S$/L@T6!M;Q_=DU9_'LOP*2@SVTFG21W3E1A0S?8P3R#NYTXHTE.
M.UI*M184&<)C=#'3[JF#/X6 =$*:3DC3"6GZJR--_S0A32>DZ80TG5R,S^(A
M:H0UCZYB+*3%T.]HOB'%#)-O>-^^8582&)L"7ZZ7R=J1 @0TW>0SR:, 8?U,
M)03-WGBX*3A3%FT(_!3(D=7(H"0Z!72?=;LFR9YQ%$*" XL3HR7LJET^0;[I
M)B8AI>2V'_AU@\AC0K#>_[YF949QCZ+8BDRMPTNQ$M8H_R8*E7T[NO_GKM*Y
M[:G-A1R6 2IIS$.D$Z%>,XO)#+3B$JIDD@MSIVFU+%V&,'+:^?>Z+GH@J\JN
M+,>DV?:T-P @T2PI '3DU8 1.'IR^\RM  :G&;U/C":G,6SSNY1OBO/F*A)1
MUE;5Y^;O'VV=#&6,5.0YH2YR=!E;N>10<;,R_263(M3T%UOO=\ZCDM2[?HKW
M[QWOS[JY)KBEL(K,-:E"QY3N!DA7J,]8517"4NLKU#G>]A0ALJHX2Q=^1&C#
MP>*6D%'9"D%M;?1EO2B<'!1L$A?2,;X-@76@1?.$K\F'L+I88@))DH&FWJ7X
M.[LVTXD;" QQ=*N-%GD<C@ 7D<?QKZSE7PQ0HP[)H(;0CGVU:2/MS+"5+D.[
M"0J3ONSY6G.:KH3B?JG4"@3,#:?A(# J4A2&6P47V12:VXPC6_2U$W75V$O$
M"S$;6U[<4"G)#;BC&4=H=FJ!\6B5IMV'N@H9,N*!LMWHY!6.6;:4W7$V>R;*
MI +^]C?U!4B9W 'V)"T-TH/MB%\46/FQIW4%29)F=,$N]-M?PQF>:QWT<$1\
M:Q$ER:_G3SVH:BJ&))SFP?22I4^QII$5%RR%/7GU+BKR'Y>+RQI\PS=*FM?*
M\>#875+=53%6T5WS],2#QWJ^9U8,CY$@0ZCZUAAQ,<DJ.(X+C3R=JFW)["_*
MG,P2:E/FX5J%?>\:D8_^8,RBW/:J)^H6W2,^%U6>+%7YW0&703D\&&MN=.HY
M\ HXT&1DP]_V;<)\8,]S\^+WG\V3.TMS6>#K3Z!TG6,9=5OPF9S(P_=0I_A$
M/-^[A$$=06G=DZ@*,>>)SU%B_HNV+,>=TEQT.I>R3O98D+\"#5Z0LCBX5>!-
MQR,3!6S(5?^9XH8\?XHH]O:#K)PBO=E$70\\JI"+K3E>?4T2JYU0FC[4-7$<
M3>CUDW7WV&SRN*TZMS36-VZ+$N0G9%$&QJF;A- 7!=6?%5P6P1UGL^]/6U-*
M_=?MBYED%YGGZH5@R9]G_L_^RDJ $\_,Z:3*/;8E5V 5.OE283;:?I"INP3G
MW'SBN;-<25[8X)$>%4&"6[K4:=$'_^Z$=3J_PQZXPUJ>^Q-4C/."3,(:K*R5
MOG_L@<.W7">$O:8YL,YMC>T[RA7A^P))#QQ<F*;E$^))D3\"(>X%#<&VNUE<
MEL 2>-R6;_A+:^EL]I\ENS[$50I+6BZ-DRM!B"P[?6!D.&;)&9 Y41KC?%HJ
MR8P,#,A(5OM$ZRJM30*&S;7MO0N;MG-VH.;BY2;_VJOR@O;2L,<RNW(,5;D
M5#4G+H'7:4_E)GJ8G\=T?Y)Q'AW@,?L\.%5\(!GY7#?:!R<C4;#SXJ;1($QC
MR*R?Q/BR#62(7B'V;02_IH$*QP0DN]=<56X&[VC9]M=0F/*2/"5V-G74_9J[
MVJ*).C^)OYH2R_>;ADSI"*)S075?A,@ ]0>&^,8!2LF*<IDU9%N*;=3#G";N
M_MF:=VU97P#CMQ( []PY4VSB IZO"N83493"\(_,RP34FX!Z$U#O$X%Z?YZ
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ML_6TDF2@[E$60)'"RT.3D2A">/[5HPZXL_+O356NE],\?5[R5T( %-*W2A5
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M(O>OT!8$[K1=U0DXZV:NCPT8)_'<>K&$P'0\=*1V=BLM0@R/OT;\!'N:V+H
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MD)=CD#X.QZ$E,"R('U<0_3[_GJ5U,M%A7[8:2U$>W^<\N:ZKCJJ/!F*1#,Y
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M@&[:;<-P7'L81(,$54JTC5J@Q?(:5Z0RT:?U) Y]I]=/49O=24N*GWAQY+F
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M4&;"X$P8G/O X'P]87 F#,Z$P7G(A#)W#D=]3^](0*KQYGPL%D5RI-#,OSC
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M#$Y.R3WF.51FK/,)?80DX_Z*#U'R+[& *,FN<H=.)FYTM V5ZW)A]64!H!U
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M^$NNVG5D>TC9$""U9%4.)?),IM4:%?)<=XA9RY;8G;$^'W0)0X+$+[@,##)
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MQUMP]EK\AT#6_R%=_;<V #L,LR&7/[FU7ZA\8W-_,$(894+8C/))7['S2 @
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MC8$," #0Z0HT3QSZP5V9+38NO;!?=UU$*>DX=67&T&!=T5(@NNB+$'_NRA0
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M^'W]U=,_"02)AQ$6]7/T&#=M715QC1&#F7[]W(Z$'W1[)8S_GSAESZGF,V0
M20TN_U74/2!'0F<FLF208MW$TA:G55L-W)V?A6%MP1+_5V5W;!1IK5<2C_ZY
M*,-RSW7$A6>X$N9"E9M-WP0\ +I[V%L>UH'2<"!PP2KZD@^):\5P8H@%D MJ
M\<S#>S/U,N?8IW:.Y,-$9@[W*M$ V?)-)3I51D!YUXQ1LJX:>M@K!M>H1^35
MR7 ,SFRQD2K'%PM@JE.1[F+]UWY6DAR(I$"*&^FZVNZ>X([>4%H:@$?1BAF4
MU>%3?]!Z(Z-QP7::T=M+\ 7" 9EB')",0;5-'U)J6A$=N^<<CSP;//+8!VV<
M['R0/H%EB8P3^R#2)V70+YOK(_=E$;J3GO;AZN6BRI7+!F)=6=]&$:.&U@K.
M&L#C2\Y/M!8.U' E*) &#N-R*VAP,\\RQ2$Y/2H(32(*-".-6371;8R)H^S%
MS>BZXX,&5HZ;W/_*/.#"W_.ZA7FNW1IQM  VCX/8W\$E..RBS,R&BDXS<Q$7
ML+LA15<CP'VEMG!QG31=2!';)T74#I8?P;FDS"+X]56_AO5*##S9@QG3F16,
M'6#+IR7,><;>M#7%V7+N]NB@/]2 _H33JZ A=B;@'&0P.]=O-Q^>''94O1'+
MP*ZVL#J5E>/Y#V^>S8V0X[J G'C7R8;X1["Y1#;(^?(R\K\$/T@=P>&!]HW>
M/5Q4';'.)]B;$+;'''?MC+F9=SWW?,,K)I79NKR);=,LT;23UEH*="!U0W.H
MO-5R"&B>S SDT M-#FT-! "]LS';_,Y>C]&#,#9U.BT2-A87E*R5,$;[.P +
M,59M@V/<:&?1.NTEW5MI-UL&#G>4>XLKT?E]EGUJ7\;+.:62NHL!FN8>=2@I
M,)H?CU%*1L!:"1PB)S=R,$9L&E.8PURJY08EC2EV5EJK7$:*AL3["LDM@,IP
MI_FKS"!D9NAW$/)*5GJ"ATSPD D>\BO#0_[]JPD>,L%#)GC(8_(>8UAE9>7V
M UV%\^!AU2;744!PA8<X>\,'J3/Q:F+"/", '<OI>PG< V=Z(N%T59V\<),J
ME<\MC&&>W!4'---G:4![0N=D2I1Z+4K@VHDDB<*FC1TR DQ'P.3?S:YJ?;@N
MKQ,CU)1@H&/'-OP\T^+]FNY(7M;[Q:N4G+P,GUI[J9;1&-HHC./CN&@:06YX
MW@U9"CQ467K)T%^%4!6/OE< >4)JCK&95]Q][$?+N/>JE67/YMKBG368B[#[
M1^HA )<?EU(NLI[!* :)(M%DK[H/\^C)CG/7A?<$O*9O%V4W@)LD?)!&R\S*
MEA?1H46F75@;8["*)A3T0X:5VG?EJG=AYU#9.,'0Q[)>OXM$[WRL$?2U=[ ?
M8\[U^0#8PP(DRVPCO<@GU)_SR(72E$AYLX)?2RG1;R9K.U3R<[>NI$_0, .-
M!3WS8:FFU.H7VW%G'4!?E+V9>_)%=QW)D0JX23=MAG8XFQVHQSN<WJ%7M\5U
MO,H^^V)@@0GU/P6>]^7!"OSOB*7ZE8OPL]=A^AIRD0X;D20Y!G"-<G?[MO94
M%;$,KT'0C+;D0'U<JYSCB5"74A1[;8 W-)]2/D,(8;T%Y@3VG=@[40VY\_+"
M3;(,PW,A!K R*$M>DO-D6B:^LR4T\B,'] *5MJ;XY36VQ[BJ-2FZS#9*GR=K
M,G"3*4@)G&]=B7!QHLYEJ&\L5> :?2('DQ8G#0XU8C3W5Y8CKB+&\1&T89Y*
M]Y8UU;K42UABLL\E+1;/PZL#/H0W&/)%2[JRG.C2.!QZ4-T_D:1#+$D<K$@\
MS)$^>@!][[O-Q9J8HKRU3&I"3KW8UY+K5($X3:^]?/E,"' O5.5($Y1_??'#
M&_&R]O ?VM>: T%LA.<)5.LFQ \[EX%KNM8LMFU??"7Q36&[AN%FT297@_@R
M7.-+/'=!,IO,5NJ77[Z/)OV+*GS8U"Q8*MN[/OVAU&>IJ?NHB"Y4P35A22_?
M9X,Y'Y0Y;/S4F[;J9\PN-R!LNYE]_8>YEE7WR+EJ*T+N&;4\.(G""U%@(Y_D
M3/6IG+W U1PGG @Z//U34J[Z\E%6$-[9@%<=VV&? %:K&)G4,&KI^@C).M3X
MG27N!9\MZS)?Q#XCSVL3M"6-H4,LIY<BT$/7[0V'5-08,.;HY49R-9E&GA=U
M5PZ;B>DOTC_879:#[28%)6+4Q360'6;^VP#\D>[FB=7RTK._;]J$?A/S^TZ0
M:/ .7;$JH7VXE#Z/6":P;G@N4N%YL - R3Y6@@^)Q(B#2:%W(JZ8P87#)ZIF
M*8'@_A0BC-F#WVYE:/1(]S:*@4M7]LNFOMD01_)%=5:>S6<?RIO@""R!)Y!K
MFPZ&HIN0U#^(YANNEP-3DS!+:3'H)R.3F=OTWMOQ=_A2BBAB![=K],]?@\X]
M@LLR*A29S\;";NXT%H=L1VG T?;K1 PT>N3R]>FW]>'!5-D*%7X[B_R>&LF\
M<.P)V>F.<71HW:EAN('F^T/U==N.>"5_Z^17LWLG:2H%E_2;/_[^VZ^3<EJX
MWN__3;J1:@SSQ;HYYVA3?D$S*M AH+_#:EKKQC&F6OR&HC]KU$2::-FS(=78
M6C8DI'R'"($%.5!"?"('-2!NZK9C3R[2&LQ2$F*,>*3%JF":>.Q"PDX.0A(:
M]?<LP(E,/007&<Y1 +;-;-TL+P3&OD9-OC/6K2W4<KL!G\E<6%1_"J^JIG93
M+A,#C@(\05Y8=X7#1[ ?2YUQ#!*!H>-KX7&?@G%-T3[ P\N] L1P&R069!5!
MMF0EC!SCT?E B'#__ )MY*Y:S$&SNBFQA$BIEHQFGC--\9#U1" A9'0%V;/.
MQX--CVD:GG5$:J7N$PGZNITUH3!I)4ME+^ :<$9%J8I'N1R&R.H!KCEB4"0;
M>HH!5Q25A0^FG.)-M1B,E^^?Q+08<8C758C)^"O#;+R]K$J0Z1F':2?:/^%"
M_-C #^O*]>H)#CPB(YI$$_6BQ%EE*='G0ODM:T1B;>'TH]IIGC:@P[:JRF5^
M!.L)TNX&[QX[CY3M.KS2[N>R78=_$]8FRJU,J$/#&4_S7WV'E&<<LO<<Y^7,
M])[C, W&!'R;\/*O@J>S3-.Q*9%8K;J-;2I@6MCH8ZZE<+[%SPD #8'=<$CW
MWW$/;"_1^U@GH]G*V)Z51=QRTMLSY_+7M"]%A8?Z5P\Z$6; -;]5*EE<F=BX
M,)T5V=+BO=XJ+!QXU>CA/%]CQTO2Y^WSY_C'_K $FP1%=B'NUB64#_R<RK7!
M$DIWVWDIXY<YCQG0+>(=_8B-[0KIQ>IVZN5'+^AL]E:*,4;)RHT2R6&&81O&
M[Y5[@#0^:&7%:MC2PX\+[/"^8YJO6$)R;J=:4!Z]F9:\6^=NX\WCUG[_W<%'
MBI/V/7C\2SXARR_N"0^9@Z,/Z/5,O3%0>BGDS.>"(@[+X/?&UWQ@:1EO,PM%
MX3TZWWV0.=(+668)=3EX(GX621/I(4[N<\Q+!*/YA:5)KJ'^.9(\H$#9A/*9
M4#X3RN?71OD\G5 ^$\IG0OD\8!*8PT=HS,=+'M_GCB3FN/OYK;1Z3']%1MG#
M']=R99LT,3Q:(LH!#YVU%R+Z<%52(M3@TB8XR!,?[D/EH^N[OP,+K91%[)H,
M^.Q!T0I&E@Q,MTOC=/32L8'4P0!<HZJ+(T28.C@WZOIJ=W9P1_H%D-*,V'<5
M]9?L]>*H-JQI[*H-_WI;ZY",4,5'MA0BFH;$L3KO@_-1$\*0)_17*131MRE(
MT)GH;SC]#MGM,1;12[UUS#3IV&_1@/D1H17!2HE[/O$G6O/BK9S#-SG/J20D
M?5MU9)T'I8?VFCJ6QIE <5HDO\(=[\)QG*M9&>1AH&)5?JPZYM&R[(G^T>5J
M(-I;+(S[DLDY60"5S$V[QVP;(OF:X_:C:V-&U3U,=TW5I+!=0B#*!*:LL87T
MDP:SV'?A$OX]$7,AX_<D%M5NO_50W-T229'#9MG'""_EB@'82FA^=FQIJLN4
MN)5=$L+$[-/T37#"E_/EWKQD:)^-P-$D1;/!>\;6P"/32;A66(I;C+\AZNQA
M0J [S+I+"I0(N#N,59RBJRK,*^JC+L86JO#8..V2"!2;E_I*0[LDHA.-V\7R
M,]%PM+'ZKJG&S. I9JEY6NMF)E,K^O86."&4DLG3-2FB17:-S@^^(B*S>QQ%
M>[E"X3[="GAG)&=HM9I1Z;%'F$Z,V>6]KE=5=*D<X#7!7P>YXT$E2!% 5EZ]
M9J]>I\A+2S"/%]>M3]$ 1"(PDY3F<^"95GBR=CX2>>?U=,>O-*CQ=X/^*Y0@
MM#@871)9Z]NV4@ O\)/GA:4*V!VH-9W1$BF;[B'.S 0KS4?R@[#D?PI+<^=^
M!_.'/<<L/#J3')=#<&E8#)3M@$-) 0WAK%Q&41@/&IMK@Q:6/$OGV###>J[Q
MNL7V,H4='+DJWZK&#CQ/C<R1"\MI4 4C4951^P]-_H.T8]3FB[ .(_MU(GUS
M57!)#%6/<KM%BG271/PN3,&RV<1\VE4C,,Q5<=4P30_0L=EP@%^:$'5B_P6_
M1WW-L*K^L\7'M%BFFMI.Y3QFJ?*;RN!+-^ R:Y_=K_[;$>1T'4:O"1U#)/L'
MQ=[A:SI:.9]]=ZV9WRA%  4SNEY=SEC$, A#K@&"I:S,DE)X&GEIC!$&,B)Z
M;*WQB\+5(4Y152L7],AEYE;\3%\-)U$X,(,'6ZUG+\J%&)IO(F<"^3)&GD>V
M!8'NWCBYTD*4CP\CP>*\'^2].Z7\;7!;JE8/0H(V#PV<#,8Q)\754;.]&=DV
M\Y>*5$''\&( \F0RDGU-RGNFY3<N_.J:)PL032ZM_??]=[%*@09@Q6K$!\10
M[_+V<%X1WHVRZ1_8$.$0N*K:7<_1[W0<OHE38>YG^%;X_1<_QD7\981=9?PZ
M7V3'BS\L!A'E/";+N3H3!1!RV7VMQ?QN]L4S7%GGK-PMOIQ]$=;'R[#WOYR]
M<=7=\"1__O++L]G?FNN2$&4Q"6$4T"MCNJ@6N#J\C""KF 4';=\%??-TB&JO
M1.YWNAY@*]:-+2>,>M'=NC,MYM<Y]L6(@U"WKA0:"/E<-#(CMJO:&'Q#JA!+
MLN>0+1-FZ!R'-+*99:R(O'Q_R_7.9O\89SV-KY#+$&Z:.HQ<V)<)P.*@*$__
M^,VW3__][ _[6)3KIETO*0PQCD.Y#"<-8"A1]$L?H3(P%TP,'! ?:_LLAWM3
M\:P.5550[*F;ZZB*28^\DQ%9-!=U]7.T_M_-I)7GJEH*]DR+/FX4_0/$*9\G
M?W]^((.@P( J'/:"R(H(T5@X^LY\CKZV:B58._Y>?2C]#>?9;"4.K(%CFY["
MY:BD3)42%_")XG#KIK_#*,0U[[HD+IF0J5=5N[&RVJ$G&JF:H2"E;[\*I^)L
M)>?%0W6<3@2@O[OT?*4SKP>>48?^VK+@-)EB-"S6-VR%$<$U:E\.JED0IF(T
M'R)X[.,-6QQM66U"V-R)457!:2$+J18":--.*]^<HU I)$B,[31>,8KPBC?N
M+_\)\J1W&2]1 U)=,VNW&$7_"*6P.2I1LDQX@%Q@ZKY"85L9*=K#A[JT;PW!
MLXX]:7'"C"WHNAV9M&!>LD4VPO1\&X^X0?V&ZS'E(L>T1\-E@.A7-*4!()2D
MS^AX3)!3='#=G-HCW?=Z"T=A-WN++J$^/,DK<S:!2TMGSO.WS^;^;H($QH_X
M@=FF<N-"@UHHJE@KV' 8UQ&YEEZ1QAJ_=E=&MLU?&,(X:');BO7.IW:L2?EL
M]KU/5VY 80PJ/WU#/=W3"[_"+8&[:E-^89E&P=QF]X57\]FK?^);__PR7)G)
MMO 4-\3.G)?.RH+*1CG Y:E\;MA"?@Z3L**+\3J^FC6?HB,X7-L95O3V5=NT
M%T6M9X%:;=4['62\W8-G_-?^1%%H84QZ^[9@2XL0DNXRS;*P;1Y=+'Y/)Y.1
M8E6=V-?2\7&)IR1/ MG$)^3,*X'<42/CERG 3XIQ?_?F1>IDC]N;&DLEP75;
M21WP"Q*"3^B6"=TRH5M^;73+UQ.Z94*W3.B6!XQN@:^BO1?K:E6B@YS.T%53
MB2YU.%%P1E==7FR+1Z<T-* 9GS6H2NE>T$V!:K+X1T(@P9K0($!,@HN.$-V<
M+7RU2)@*.A7,3>QK8\-'2.TTN8<6/B-4EK'C1"M ,<)DV)D *Z:NVO2[)\WJ
MR;99(,;3S@WF,[Q/L0J'-&1RS6^\84J+B(%4;$JJ*T=<R7&*'T6R0)!GW977
M60I40["UCE742C=&1 $MJ!NG[F!],[AM9/-6G:5T447/6"2[E(<@J<4N-4:+
M@_<HP]@?13Y*@.1LY3(Y<1?<G^[V'D_&@(0F"HMGF'QA,$)KB;"J&G_+@-3D
ME=\M\8'I!">-E='O<IG8LVONY);(]#JM-J]9R_:<D>XLR80,'O@1KHQ7RC]C
MPQA3I7.'E%DGS$M*I4;PV=R:/19:1Q(YM1Q#D$6+&N^Z@%"78*:FY-K7T#:[
MA1H(10[J[(:X2-_!TGQ2Z';KTC"9D:[,!D?O7I<7S:Z*@>SN2&(183K)A="3
M"?H72<'@**(WIRM=NI<Q'*IO*\M>*-7&GG"@Z*%#J7:ZUI8LI0K_E!&Z>\HU
M9]/5>1H27MTIWQE%1_+4UJ?E08^_@/'7GCLV=K+]*M:.#8IRA3U9ZM@!_AC9
M3-Z-IPY3N1';_A*576%VP)+',B:P<>D20C*D+G\G'#+M5:*\W\B9O7=#<4=6
MR,5Y[OWC::ADF-34L)$>N:/@UX2]@L\Q^QR>"A]@AF:V!MPI$0G9^D#+GSD"
M82>-Z%X7^P_.Y[9M?"^5C**3 86F3@39-36V%?IWA;A8!R;Y:09Z&G_7S GM
M0*(/34SD8EVVJ4V_A+9X60L E!LW,7L9/]6])(G=41)WH4QTHL*B9=G 'ON3
MVY+:LD:9=./PQ+46]MR-H%:O&JTRYNN+VN/2QJ\>.5>0IG7I&,9:D&X(XSIL
M'$ W2C"Z6DFL$LFJ8D$(??C7(EC(9Y<((NP_(K>+.L.WM648MMI2HXZ2$.D_
M?4"7RJ0#-?"\59 E>KY-FVT 66%X4DU2RA-'.+0%%#K,AU.R][,PS%0/'L,\
MQ!FX!SH([("^( %$T[@=V&PC0<2C=.;^FJK3PXKFH6I14F([EK77W[%F6=8J
MH^A2^'-#_8K3)IN5-9>4>F:I0M&#B,8C(:;LXF8UC)B?'RVM';+*ZHJP'\!S
MD\JRZ(:XZ[V+)#A)B3Q\53MIC5XPG47<;57W?TY9)EF^[9L_#A;.D]]PY1"K
M]<=O[64^_R/D8_/T]Y)V+)*(0SC/5\'N2VD09#2Z)K?KHOYVFH1[G 301LT=
MEQJML-16UR@UX0@HVIMI$NYU)S@_P+P\Y=%8F/\WS<!]S@#RHD_B+O@6VV :
M[WL<[[JLZ+-(%YKF4^IFSZU\G*&W@@%\SVB.\(]R5-CI=,:4[ON@4Q0\DQ"&
MP']7A$T*/@Y)Y8[Y@XZ233U"W"K+:@U=1UQY%,'D&-%1JR>Y#NEO\+YMLQ91
M-'6THAC8 *E'Q4&)\S7,4Z= 4)G';YRG,XI6F67"0V^:9:E,]0B%[64M$Q)]
MYI$WMR!!*TI'YB3J&1&SC9<XF[U%OO5@+D1+,VWYQ*?^LEJ1!IM578<_"V5E
MR5S+3&_B@3H.)\3A2UD#=: R255AI.X[;0GS"XC18ZIW,5V#T=[-V*H;_LA4
MYK5T[NZ]G>8))4H8Z&1AUC\_^O%1AGC?QQRQ!,,"(MTO!FH>0V?%L65;2_KZ
M!LCX8'0J:;[ 0KU1T<VC,S%88$QYH*>B&7)8RKR/0^7>)?CX:;=#$ETH[ ;9
M9J:,)0S$TL0_B#"TAN!YOLKRZ,ZZ(4'6R@:NXO"PQ0\G,;9<0,"RF-T"3AD=
M-'[;\%Y=OR4#F+EQ?>H4=!#%9D;&4GFC#EQK8>30KRNR(.@KLS-AO]YZ *4<
MTV1H%Y$$7Q=FKY1T?3NAPR9TV(0.^]718=],Z+ )'3:APQXR.LP1M!/I4[4$
MATL]<\!N. X)22W9^9$KBDSH\?I7SW-VGDO^P'GN+N$.@)M\449UL?-R39R^
M'.Y)UTF0".,/ 4]^77THX=L]0M]6HN)+=J&6M8O<$F>$IA]]/RO;71V8/X<:
M#4,-%0L(_JG6];19RT2R0GBF63711M[I,RD-0O#$KD@0"I7R<'.27X8E?P%P
M2J742>2*-[TMDS/;4T++B#"696=MK7/UI6/%IKX(X?,Y&2*(>&)?8? '11&X
MR5X$_!3+7M5^%^0]I<18MV@K$1&72%K2Z!8Z&ZN%UD-U.5U6V]@.[,$V89Y[
M5%-0'HH8PA3HRZ)D4.&Z)?7O@]VQ*7>7S3(LKXL\1GZ$B_=[67TVM5?E>CX+
M42GHZ>,H=&XAA=_=S(H+63A7I;0K=OEJU^[MC#[%[W>W:B*F:D@9I)6JN#ZR
M] [K>'$.!Y8KW"$LM8K-[)"B0)EN**+7)-D$NY/0W^M*,1@3EV+2L]#:H%O'
M!J29SXRHR<NB^1<-'P^A$B(=324EYN0!QR_O<MZO/X"9(9C0C@VV?U=N(U&(
M*)<Z#CI^?"5#TDIILAL'XR;5G6Q$#@A+S<=YB49YC,QP"-71 -Z%KG;:&0=&
M&A9[D[#![#)<!6V[(]B>GHOMO%KJ:H@$-A34DO!8\SGCBTIN)DDZ!+7AP&H[
M3UL@_7-BEZ&=,+1#+LLVTARI>&PCL(]F#>!GT$2%A]P0G*7IH10\8TT/$(/I
M Y(&BOO!PPS'E>9^C2E\C ;-M]'G:6,>N9';+0T%UYCT_0H?4**^1TZ7=BY/
MI^9;[Q@>=,0QRJ@QRLT6.UREA+H=<C>P2^HC5 1I7N6XU72_9#/@?O!.0YZC
M>\2@WB%5&6P ,70.@FH/(+A.ZW9U@*-<?>"J:&^2V;?CPE'6 P.B%"QQ;C5'
MW-UTNQ([\ONAA07/3<YOOZH^ZGZ'RH7#2.T]X9R$'L'9J79-&PE[\%1R0:;:
M5A7VS[/4U.G$/C.S;=;8^<HV/8X5*<IAB/R" Z 8"(@&-<.1W5\"^MDBA%M+
MFF.>>;+L!Q06PY+-,*NW;_\B&RALIJC%%JTJTQV X^M74&A"AK_2"DQLXL^:
MB['GE/M/F_O-WLEL/4)K]XYMP.N*;EG4!UO(H<DQ RE5CAW*A>IH3,P4.HDQ
M \)&P),W&GL5/&X2'#=4N"O6;-TO/X;;=GHP@2(1:'%6@G0ESM'T(^%"&+J7
M[Y^ B&8NG#[_C[TW;7+D.+8%_PIL/HR)9MDMDM+5E2['GEF+B\2G2Y'&)B]M
MYEL6$"BD&I4)Y5(EZ->_\.-+>$0F4%5D%UG%P1>)70!RB<7#E^/GM"+Z>^1R
MF=U =P5AY9@J9T$TC20W<+";< ,8@/ZN.\#[M@XH)N_LRDIP?%5[!NZH=UAR
MQLKQ]%P\: S31E#:.]$<A!F5\ZFBJA^S+]$%W3VNILTU4P Y%YAWYUR(T#B-
MR3-@9Z=TD!\^YZS)*?Q^IX:2XLWIL-?M[(Y T4<QX^TF6 @^^7&H<^4N+MM&
MQ5.YF)D\=F^BQ^2#';#9 8*-TU,?3[0I/ GT,TDL]_I>Q ,;SWF[M:-UQ)I*
M'ERFF>M1JJF33.-/T7>QMJ/Y*[Y(\Q:7!ASN]#KN3&1Q*N-=71XX;2O! EX'
M<N6RHG1^ B6RIVRSO%Y]167EO3(\:5+D372S7OVM6;^C@@"^.S'_TJZY:A;8
M#/UAB(TQB,T5F"#<@7I#^P@*9.2^[8X#B9>UJJ4X<?";PDF^6 I1H-5&RX7B
M1/R;&3>Q;RN-*4F=E6*?(U'D;I@U5"IZLJ\SIPQ&?>CLW=ADP,HGK\HIR'[^
M/9OM![YE>J\^$)<<@_D/(*WN0>E-!</DHE-]^'@0*)^7!J9[FR$A"L!75WUS
M1089>F7Q(>9LK=+65QPAW_]-Q<.!/@?%!<%_X_ H-I=?] .>SS_+?80^[D,R
MVEO*?GG[KJKFI;J9YQ-/M-TT"$WT6*03]_O$$!_O\.%'O_WC[W[[^:>.>$Z6
M;OI6TCY.<VI!,! D4QQ9UNI57;=,$JX2HMV%G^/("1*"WW2JQ@DJL6'USQC$
MLU86 RYH=5YA@GG5T;/>5#2NU\V6TC-QZ*>V@>Q26ADDR:UK)H[2NR9Y?!*X
M;RIN+.'F5WH2B$4QR']GCS.U>RY]AZ,D%')I;CN]3+2.\ZK^F'/$UD>)\=/J
MMNPO9X<ZIKF7J_T5H_R5'9<%I^+'G%SMA%AM\-S")K=+N:1#0RRNQ"D.#3,Z
M=QS-Z4O,/G[#&2MR_3>A,'>GDBQ;35EGZJ<S_T:)C$S4357F-]&:QUBL@P]5
MTA2[^S.B0B\S[E)4BMQT0WZLUV4UA_"6:>6QCO1R!L^/\?Z^.]*M:0%!^[!G
M"<I1\LWV?EFO@O(8<QQE#I)/H8E%<EFT^3G&G469Y('#45DER4PH6:L*YGD8
MX5EN@NILI.>4OVY7(B9>%2OXS!,ESS@UQV5/A^Y3(VFG9 !TF^F\IW+#,)XX
ML!UY74'P7;Y_:8O[<)A&\T6;X5TE:X@^(6FX=D.'ANLJNW6RL97JP/:Y^;Y@
M5"X8E0M&Y7UC5'Y_P:A<,"H7C,I+<OFRJJ#&D LT'BEGN9B_LB":?6U-5#$G
M$><,Q'.SM@+!E#?*II.$6Q/KY'>[PCM((50&O)@GQ+QK(N*>3(5M1,Y'(MBG
MQI":"N.5=XMRGRAE(5BOA)+]*:.1%0' MI\'[5F Q[$AUS7*ZDCJSI ZB4&
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M>%::(KRGD:Z7R0MKL9]*A(%:P7/1A01X%3P3X * OBZ#7?FX$JSK"UQ[7[I
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MRZA<H6UBZTMB\\+;E^AG^*9\=@O,6AH&E368JZ#1*=G7S8VT\"K"N*RD\QN
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MG1?OE'+794T]=1R9L>V'GN879W]6R 9<DB%%7/Z6"GC.KU* *J7(E];.DH=
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M"R!0A8<EDL(+"QLC3X^81KQR2B^]$IL5#!P.^N^R 06LGN;? $ID&UX1AXQ
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MM%SUS09Z<\,8MS8W23_!LLJSGFB-REVF^Q.AY>PMI[.?BI_F!1JRM_FA9][
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MTM_B'X[U?711Y[L(G57;:4B=<H4$(O'3-&MQ ?:II=C$Z.)@\B.3Q&>,&D8
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M6GZ*U"^9F^I^FU"M/OWJZV%)2J8J3 *.'B):;%3NZ/033T/2QSPI0!N/1@1
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M1AC\4,YAA3#3W[K>Q&#7C&(S<%8>LFCMF"(]43!5P:QD8?:"R)N&908ESFR
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M0UV=!UUC:WV63RZT.!>PUP7L]=[!7A]=P%X7L-<%['5Q3)Y$LMSR79J>H:;
M36-9'&FAY;S7.FPH\\ )F$.W;UBI>H2#6T:[%X_R:</+O,TA3U.YU!-3KMQ<
M@8+%=S?F*<N31<X$&-HN37-2*:)BF][0,UQKI7A.42W\-*$-Z*&B^@^KIAY%
M3O44CTO>9*C$D:*1G"CHT^T<W KM5I9=I4:@N $NX<_36AF7KCB1&Q,&$303
M&1<2X[8T?/&,3'DOMC&<<Y(8>"Z[FRS@BB+M^+3!\!@+3.VK[<3]QI?U\)3K
M@0 M-X?LB%$6H*N]\2HP;+=CC3'DZ7/F$S8<:ZF?3.@&YZH8ZUS'XPD54T+
MU,P(L8214M(!% F<? Q(%:AFK<POS26/]K3+PG%C9,7.+<N!>(Q8LA_NX(+W
MXC$?PO\V4\JX3.-33F.FO12HW#:UN'E#U!#1;=DW=0**"+TSB,!D2E,M^S)1
M3SE1/F5-F;T6=  MI"D8XNZ!K4!0:L:9\#?=7 6/^7/4:2MQXT"J)N"=J1]>
M9OEI9]E[X^(N%S5':W+QZ6!@W%(5_3)+/]/9%Z.3#'VG<K9*D9/U<"B'W2F_
M^C)K/TL4SOTRIHYI<?"2EZ)5EO"O&,&@)R9'%8NLKEY#28$3G3"\4E1>LI:E
M%LP(K6NB$PXEA2E=UL)3K@6J]](<"')7FP!=]'#"R9ES50OZ4^(<*@+O5=AC
MPJX7\DZL(FJ(JR&DD= @%=9 -XU\8$LGAW^4.H8W##A09M*F]^1T)NZ<"/6$
MJUJ9)20[!.IJ2Q,J<MB([6H28ETC,^UH[2XK\6G3+9G*F$RDAD0]Y O5EE0/
MR/!>9NMG.OD-ZC_N5,RPU-(#^M,DX3N#)*:N@R*'FCAE+]/X<R;DV0B2B64[
M&'WPL2=IQY3%3*2B%]OX"R%QBJI)/6T:[=#S"IJDHB!!T7:I H(#&T$N%.(A
M&JPL:GTXU'VVC=WET/-"#<B)!!/\GG]Y\^:;RT)XRH608.VIXH".7>%!8Q,\
M,EYOI/;;*RH74.];O^$^V37U1+$O)'O<V^+$[7;==1MJY+E,Z%-.*&G_!4HM
MD4^SE_8SUPC/R:F%"D"U8C&5$2GF$?2+?+A>@2.XQF9'ST&,P^**6&V(2#HN
M .JK")_01Y>9_7D\))6?V2/ "NN:.T.M(VM;.D2N4^4E]C@ED7?I=^GIU7>A
MOFVH&5N9;;W^"L=@=R!@@#,B3*0:/K+^(:AORL1[1@Z:NGV27*PCKH%FR%%<
M4;3>"&- O"*'#W&3Q!_%K<<  9395@WH;Q9W(?(A09D9#W&?N;IO215MTCN^
M>NA9K7/I7E QGA\F[MLW?:,X @2&(VZD2J&R_.'ZF#Z<01.$<8"B[.N$SR>:
M\V%0*J D)4%) LZ6<\^_[VA2%0HZ<:"8HYW0>!B9O@I\]7%^%*KKAP, X)0
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M&/VX7::-HG?(GE%:D5 ' ;!2S'7% *>;9DRS3G,P+-JWUZNWVDP4'P";8G!
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M:SPX77\Q[$KQ>/1;TZR>\ER]+W;2@4U$ ?ZQ+<]PLMXK*/>]A!&>_$$&/GK
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MM5%B="IBWTZ4>YAZ;G18.V+5.?A(JN#I1]BE"SA0CN8D; YR1+6EU\,K)\P
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M<KMO]'&;YCTLD_=>6Y%HOW7]&.P.4'+TZ,5Q<SLG=PT3SAW5?.&\*9H@./L
M.881D .H\4D83]U%2"4: #P77%^YK;J0S$LR,>HL;?WY74.MWLY5O-"'OMR:
M]3D./?]!M&0.[&@]X-^ \JMF!=&YSY8%99[D\@:V"YTRC0HF%-52RA!(/W7
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MXJ#-[.]%-;=K] :+2_)9@\??/_'10SSQ$(C*7?N %<PJ*WJHB_E,?&U*O+9
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M>:!^]7T$IJ4/? BU$U#66L+SCKF0]&DBR)E]=2FLJ?;2M8)*H1U'(D^3(B/
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M\,*[G\Y*5%<4ACI8'=I]G@?;@"D)7)G\)]6G_MGDDL8\U0J!X#)'^LF]C"S
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M$BC>\6+_%G)FTD4KH\8;/;OQA8T9;VD4_ER9"OV_G9O& 5*K@2Y.)$&;D>8
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MYL;SJX?SPY*!186#9H,R<DV'#.-A;,7\[7_-ZP=_NP71C*OG%!F<*FB;G:9
M"/ACE4!%FED8Y8G2!"'A8K73PLA-$#X%+CN@/,%QXN@EVDA4_ASL#DON6.E;
MLS_GVJ8_6MU3,E,\PPNL;O^G*Z)][Q2FQHO^Z6TC'],-4:T[M],A/M<F+=WU
M'9R5J&*7#PD*<>=;MOV61 ("Y$8N6P5DV?]X\O3A_L.979M"5*!]1,_\U'2Q
MBX,Q:63\'$1<W'.D\!/CL^8::E#!7Z]ZCBS09F&?QA"@7\TP=8#ZZ=VF+AK]
M55:YLK5"U=$T2.VV5#*P4WX45.&E5N3P23@3N]YT6%S50$$@U7G7Y-#46>II
M8 PQ1NBTI)3:55W?Z/JY'?KCD__NX9>;O+16W"W32@)"UBW=!-;23AD%NA;>
M-T:)KBD?8]8;J>TE^.A.-88;W?Y0@_']I*[.X#(H7T' V3K0AR$ R,?7[9L7
M'10:/<5>*BX; ,_-*H[*.A;1%6U-WL_;R,X*X4_DA[1L;ZF5P*"G7';Q')VJ
MO<UDX8!@X[UIPC5"?7;#1?/ZCLL\OI\!J8UCLY//BFJ7WL:B>Y9!ZP!WX43&
M2=C"$9FOTXJBT(7YTA?#7<('_5?584V6Z2)(!>:,?MX(C,*N\M99G\R+0"N,
MWZF)SQW5Z./\>VG/ZCR^/D^9L*XHEXJV:@V$BVP,PC)+TCX;Z?@R()I)9MJ/
M%"I+=C[@UU&_>DA&PZ$%>^1[^<W&6,.\[H, %$1Y83*41)E>N//%=S%;^NO(
M[CC_G'&]OF,NLM/VLRPT:&;)-1/4V^>SH'(&>YL,-[>'%0IWV-6<*'5$[?AY
MDFON;)_Q4S8R<3LI5T.\F7$G7^$<U^Z[UE?.U;@ECF<7E]A%F!62(_B!<)J^
MBEH"!>1'0 @P[DOPMSAIRK8FO=[CA[E(('.5>\\](#+3J[!','C]9>!HC-X-
M-!EFQZ*U$;U]X0*A;SJFQ("<ZZ^+??::5R.\HOWW^=)D1:3-VB]>K?.X&>_B
MR?\PJC<QTY\4C^^/-WO87& DJX-599+21752<L$J(K.\8UH2YA?^7L!VG=;S
MO)6R$2*WRYC GO=!8AAKZNR-6!60"/N !0(%C(J6E)N<N1<PH4ZZY<Z(B.*A
M*T#4_*L/GE3&O'KF[2F(1E,59 ]!0KB@J]^ER&/RT\[N;HID9"%A)BS)O[@X
MK,=;QVO<TX$A' .ZM.EQ^IU'RL8C08*3-9Z]L[$T6G05,!".4+I%;:!B55F-
M*=>Q [1+F=#*2?TYMV+3!: _')5;V4,A<54&7 ?ZC_8VY8J>'/#AM=<#P01Z
M*L&5.VAEG(2?SF6X:T9(=:E2LVU,L93J<YTZ/IR9.1(M$E2R\R=?$CYU2>QV
MKMTEBM$IB!F,S)47)![?P]%T1R05>B1D1)L[R7/^JR]@;/I^%L]JAMER20#Z
M)[K=YUOMJMIZ<&+];1!64T+]P$]4J<O2=4J,1FS+X%*"4)^YNH8V;SM 1+DJ
MA9S!)HQZQH5'H=11M,M13V9F$1-DGB>8)W"JXB.!HV?/@E5[07V)U.OH)QD-
MI"AS]WU-[45M-+?"R1!6+Z>G:5XX2EG$I:0>$8P%C1GYCK2KOFA.Y##; R*\
MVRY_(K&H4OIA!#?*;LF?\$D3/FG")UT7GW0PX9,F?-*$3[I+!E7DF>/"CS/%
M/<""ZSD<F?L[@R1DL5_L<U_@LHT[X#Y$="FG^G;$5V]I>>$59W%!P:%$;WV*
M0\5#:2X<5Y4S727?H,"YL)(;V*%3*C+TS02X\0$ "87U<WW,F?U+3L[W7W87
MW1U=8_(&Q;&3<LIT++A,:X-&AE28WVJ6[5Y%E,Q4@:!1^ I%:6PD(U-2"QB)
MK UVL_D8;9E\C!]TWU>L;VKRY@5G\2_'9Q"2[23"BQ]]!L =94 _.:&45DM,
M-&OVWUUUG(R<J0/()S[5(I*YH>\#0R;N_#K]G*_)>T'>BQLWG0I@2$HGK(,M
MM36^ '9'0S=FBR\,9?Y&._L0!33' "*^?&R)>"[6DS$,&3L.EH#(<RE/.-:@
M@_<K (O( O ,QV;&SSHVFY:!D@<,E'PX.TL;I:%P<SU_'H,!V;\.'ZSG+]Y0
M!K5)R2-B5J4Y4R_;?-[D$IV[E^^;_<1S*A%H=AM,Y_YLWCFRA(;C3,C*+6N-
MU?%B^"6B+^\QPLZZB2SFW"2N0IZ;5^W^73_V8.@+7&+5 G&W!CJ8&^H<N4$V
M5 [ZV<J4*  3<4*6AO%OM)C$ZQ= F+FM>!2//^>@)$(1,I!E$BS*L=.!$TBK
MB-S8&4GD1*?CLND$!C3S0J134:#9#KY-I$B,FX$-YJ_G3S\2,*\,UTID;Y=.
MZ3:HH^J=/]##I$S' RQN[GNS[5PWH2_K#8IIA+R!=.XCZ+"09490$PV&XYE=
MG49C<*K'*1E5K96<9T1B>F-A9BTF@>E/LUW%]_-PG\^98:PU1[Z+@+:02E&E
M9#(Z/@F:#]7.F#:#*B+ZD*NHH\NK[MWB=Y[V'M/2(R?FNDJZOUY?3$NC9Q%!
M[CT@-9E4]Z55]\K:JBUX+V)N#DA7;8+V=LIW(\>5%#PU@@R,+[&+^W;7CHZ$
M%^G960,@O=W'WUC@[6-#1>NI#D!P5.1,HL2G1(=R11UZ2_?WBMY02!>T<4PC
MVH8JC[I_!4[K3[/GM,Q$V$1G^4/ZR7@K]XVI3TS0/U/_JOU<M)2 -8] T#=%
MRFERB@+BBNU!&00DS@>X&2 7?L(Y!(O4*@67Q>N&(NVN>;3]$9]^DY;W[R13
MSJ\F9H>[RJH)2YO/9KLD[%66S7>AZ?5L"?N%$1[*GD%J+Z)_C@1@?W:DK>4+
MABSV.>_(T(M'&Z25!L\;X1H87#?#)X:4A/1(UUUO&7#*R5M %AV=#I>F]$>B
M)^0Q_0M3,'@,I-VEC-'^[B7S/+NM*N5\]I37+$D$PG7=UL@<! ,I*P&QJ&)6
M"490Q8;M<',E;_@N)=$\5].X[^&SB0[ F@6^.YK\2O;\#/WRG"5I>H^0FC/#
MO6DO'*E]J%Z?'MM_MJ):E<"!$1ZK@?:ZGXP\$NWAM%4PI_9;1Z-^)W78A\$<
MG4N8SE LA@I @4C)SK@M1VV67UHX]+6Y0#L T8SJ&@'V":K22*N_944\D%)S
MEE*3.T/LI.LUF2"5P'YEGP#3(YJLND5$*B0OC%[[UZOL393 >?2TMUM[WW"[
M4"3Q](=O1Y 4K\W!8\YC_4J1@:#%LE!/!V F-@J-8YX.Z9>Q2:%G [(9AC^1
MJ3@+.S"K!<L=X[ALM*U.I#<$!2[T<!>U2;.MJPK@5FXR/B3\QYZ+3X?DV?.M
M _^EC%9FSAJZE/A]*^Y>;M]_WUJWM1721R-TO5RI(*X<D"1JK2NCZ7FG)HF&
MGX>HAI"8!55+:7";\4W)WCJ>ZOP];@$/(EO &>Q#6G&G7;#;5<.YCV'?["/[
M_'68-T*IT3SS4JMP9:J5+BS?\6FA=&O,1N0PX*I9E<AO.KU?\?3:.S+IG:E+
M'P& CG0;.1@A)\OZH_8_ALM6$6UR13ET7LCKSRK#9C%)Z9 =_(N<(]<AE:>4
M*!+0::X+)ZC*C:L[711BIY)2AC@V6S9,"YM&9/"[CP\_ D%W^V$3KRY,E BA
M3'^?T$@3&FE"(WUQ--+AA$::T$@3&NEZ)M@W,KCNAI4,TV:RDF^YE7PT%!B[
M?R<H0]1]B/H#9HYX1_[<GE$ZNTY/ZG2S:J2O]KIK (D#H*E9(?H[!W>*!%8D
MH8(_I@486LA>N\].;-LSI2&]Q(S:*+O()LVS'B'0PB#Z=G!(Y07MJ@DEC@1P
MQ)2-)4VC@&)T#@X74")8HRM:UY,(WZ0(OY9<O)0VI%2DWI5MZB1:,[;:D#%N
M*3-0F?<3QH1$"FG,W1OI7Q0T>Q?%B7H^>P&5/OBBL!(<@9)?6OEA4HP^H["+
M=D([7\QR5W$G"00../EZ?G-*//O^7"3!A_OG%.6ES+8U/)R<LRR*7HY=]3RF
M>]FCJRW21PYE_$ YD[I(@+=MK[ L'%^R*[(_>]75[4I(LX)U=YZOVY<= PO8
M/<*E3L:62A<6??=\6<\?69Y8OOP23=KE1K7+TNXO>2Q:3J:2(QE\!^ -I?12
M]P.JI\.PR_@%I>\S_IYRFL(JN1/3WF?0&(N/$(@[X8H:P>%!X^=?VP&TU>4E
MU&7;XD$W[M[-)MF\4>-M*!K8T'2SJ7)*S3/W#;D\$?<>>D/A'J2T(?VT,,H5
MY-GK&'842DZLU3Z5Z#7E_8L8V1R'6O$,(>R31XY@L\.7F<D#^"I"="R(.L(Q
MIJ<5NW>920N^$!M3<-_K4:0#%Y\B:&L^+\R&>Q]H*4/D.)PQ"6@@AF,5#,@"
M@5% #1CK75(ZW=<O,[Z!&=B6:5Y+SXG4JMJP\+\G;5ZN5?HEDB["-@G9C6JJ
MOM6HFH3WNE6^L* UX+0A-[DA:"7H*(Z!M&Q6[-0OJ$?30C"Q[<H;/ !-TCTQ
M-ZNT6$;:FHT>5=S876:A<(2'XUI>"FO\.03&"DXYM1]BL"1ZIY%R(<X"HL>6
M8B9O@_B&DAX?3I>/R2<YNE$Y>E=7A&>C5F6$@;7W_N_4QX6KB+S.%=Q;$[#K
ML7M+W%,S)ACG)D^AA4%55:XDB>Z1C.AKF)Q*/L?\?4S$- =\>$DM<Y"[%$4_
M.4@W*@%O\J8PX!4D."*S(W-#ZJ[T;=U:WD'=>VPO,72)!E(.*J"?3):G;H,9
M! X*S;IF2R1?XR.M*2;3\&9O;8$R!8$/JD86OI[@6A@QVETI*KUCMJSM=M9\
M'Z@S0;;<$/@/M"N\S]C@W#!U?@L6%*+N;_9GK^2I<,NUZSW*7B2(E>"*<-WE
MJ.< 80MT,M:"A3_+$3/ZJ+^D'.0VKQV[&F#.X+NVHS^QD\6#B)FNH!(#XC\%
M(+F@@'CK+CKVTHG4M-M<#4XY2>Q5G9F6))7YY7NT1P5%+3)R6=5L"#EDEW!Y
MJ*,7<R-)<6N0YI)#H&+?QUY;\5Q;"R5^IH)+I*,$OV'7"S3[0 5MC!YV1ZP7
M";9^>P^0=(\%M]AR!%=_ M/;012ECC)_(\.8-.J-FMU6$55;PR%<M$7I![='
M5*G[?4OZSIA=<1*:\\%W/S0S],"D2O+%RAZ (,A'9C(YSG,JDU+I&NDGO.O!
M1H;O\R!!U^C>6]U@D0%!>0*N BO7PG'8&,H;MH&K+AA_5,WU0D]4A(>W<]')
M!D&$K.?$C\249.P<C"A2N!O>W:'H[.S,S.TQO;5(]RN66GU8F2 %/ZA1(8^*
M2(M-4+:JE ?;C1 K\G)B=?NYGE1929C%]JJ.^BTI$!ACX[T$5S)#^?WJ!NOB
MR@D5J%UFPL5-OE$2TK^TNYY!=-L)VT7HXNEI%,]A;QY<0SV"ON>NE,&:<[/#
MAP^?)II% \6WE$\KP9P,3$0DB.8)7V S$)M^;27%WUB2!J)"Q9#&#'QVO_(K
M]B2TK\(+@ U<Q3BJ"&?/!:%"DS@*BK^/?/$W#OWA#R\P"8/PHQW5<]?,^N?T
M3!LS*"%\76%Z73/CODM!W?!W6C>\Y.91&L^FUBJ;H''I^ZXPL\>'C^_-[_LF
MPGZ6$XAU K%.(-:; +$^FD"L$XAU K%>Q@#[1O969&AQ7)Y[J\O]G#C:Z>C"
M9XO&?CG?V L_"Z[SN6G/C"DO;?/T&F5U8J!%X2'ZY@M[YYZ1E?%WH>!Y[JT7
M,AL$:B9QG\#L43]#C"+I)Z.EW'?11OZP<_$5(M:&=:U3+>I-!@X^PD2.B%.D
M+Y":P$+CUD1,&_#1&1XD7%+6^6Z8_ZXJF29*XZV96:-7HT3G^4#B _"2-W:C
M$U^\A?0<WB@O.Z$F(NZ9&R-^)Q&T4 TT3P .@1W]R&"]]TE-.0/>A)%GTH0*
M1X\UQ:R^KN@I"YI(D<B&S_26'?PF7PBH'.U2+.C_SN0YJ8H0Q28HB[@_HQY+
MS4J9^Z&1$_LI(6%S;QI4'' K*Y(0T KUO.CXHJ#;!HX3Q_*%J=WZ=J!GY3^1
M0S]/RT]3V/YKBUA0[ZH1"$88^7!ZQ-\UIO]\=HF4WI![+.+X9$&N*W2[JTH*
M$\S3)I= _!:<@%JQT@_V5/4NVM"DQQL:Q/N)-309/,IS#O8U9A1D\5.3#C*(
MJ0ZGJ+DT3J.S?@7/:5#?0:[>DIML5\L@)B9,GR@#.LN;"2+US6]XUT*-29\=
M%[ PQSBNLX (,J; 7%5\E=XCRBU.)E6U "<^;^]K!-[EA0(>M'N,_1%EWP_Z
M1841P>O[XBT:>\?[[X?AS-1JY(SS=Q+E#V.5>=#1-A<R/=>,#Z>(6PQKYTT7
MAC0Q34=&FC]CK(@VYAAO2S<\D?X0XBITM'"[@(UA11%F=ZGS1Q^6[#=7Y#7Y
M28DO4-@QF,MT/F^XS(@YE)* *D@9'94_&Z#4F-$+MP.1*R,MQI:'A[2J4$5W
MGY8 V=O"?!)?4RO9NH9;QZ1JQ/3XPV+:3RX*C2H6^/"BQV/7 E1%;^B=TP=D
M2*%7#B/O&,*KJ%^JM;-W#$,FG@VKH,8>%@3Y)7_>#2<.6#A/7?JNNN/K>RW_
MWAGS+W2'U!@^.0F@S9]1C,TW>E_:U>KQP(73L7]_QAP<%ZQ&2.[5 C/OU!T;
MES3!^\PX6.2?3"&]5XD"*M>N5JB!C?<JVM8$2TND("FZ^V)!I=$5W=0&RR4B
M!2LAR*O8$9^DW :-E]7%,>Q_]F<_;@6[ I9*S=#&DLBKWW0+ZI*U[ I=>@G%
ML-?'TL4$>)B4;A>O/U?%];<@4<77#"ZJ-.+2C&X4;8HL[;+%>V6L]^7NFLOM
MVOA[E@%[Z*17O[7=$T/!',NJ\O=8LV9-C(Y4D8*26[*%@XH [C$'6E^F@(0[
MJ1^DXLRDQ^[CTN9.Q8=WMX!\XB2FIUT<J6</G@<^86[X:C69TL8BE);F!0&'
MN"_PJ;:^=6^.8<[Q0422N&K8%;%/K9DE$R ?B4BVK?6/Y#;QM82AQ:48/-8H
M/O6KE?]-9%02#YIUEVE;H#/)5*)!EP+1Y>$L8R=]GV.S7&42^.,#?P:M&469
MJ<4U'<2;/(@4[_V]J^IN'8+G) XX%NI679ESW$^-@-^[M,B78(30 SH:B.1.
M%2Z,OYZI)#%90(!H^ Q8FS?@8_21"J4'4MSW[-SM*J_;[5Z[(G00- <EJ^TO
M,^6LFMU[](ALBR>/#G[X-P#F?'P*0 7N!:!WBOGL_)/2W33@UR/+CY1.YVZ@
M^U$<DWPV@6YH5!7V3M=09*P1VG$UZ,=BIO%M&=0#6[5VHFV2\6Q OOR9FANW
M!;L\/VS-N;M,7\B,1C-\8T:6&8;&K*T-0'S6@Q"@4V(L3B)GULACW9IU"_3&
M\6"*U&L'-C3Z6+2+W*;YEEM1$@6;CRUSJZ:"[@DG"+VU#+8,:QE;!K<TDW-%
MD-A;\G!5\-BFHIN$D4R^];O<?26UH+$GC6+S=A,607_7CS^Y#:'+(*NMU5EX
MB-#+C[=TO<Y5T&_+V7]T5J,=/B+DS\'31*8JYUS3EIF58)</B<\F"8Y'K8.6
MTUYH;;@P,$!^K.G7W@2P[V#J>+O4I)SELZ0K_B,M.S)N'TD; QRXVJ!+0LIJ
M@WT-@;,+7IE'9Q^QL>*]3A>F ZZ#$65DIN=E)_I)*8#5S>6OHO4!0R5?6+\/
MY]J/X1\^)H^!!A.!<<6MAE&M26-D'FW[6R=D/OC.],K/C_3%9VGC=0"W1_4Y
M7"NZ"^/6A(=S@&=3J!=\&VXA!U][D[JOL-JR;]6DIH^5AN8)%^[#OXG7L?%(
M+Y\377=MAQX5OEVWE8F_OWE'QA9@9IJ#L*+:+5,*'<#I2!<Y-PV FJ0JEP6:
M/MF1$)<P'U7[G*!NAJ^G)&::),AA8R\\:QA;^SDM=@W)[A(]<2@=0F7,D+VC
M5F^/9/9W:N]LQ3:'84AKC98(:W:J[(,*<Y(WPL8B-YP]Z)^DCPVAY"M'RXV1
MT2H,)VHO;.J2@>__H[/+-'O#'[(S?.\'1\?S<'8OG:!U$[1N@M;= +3N\02M
MFZ!U$[3N%D/KD$@RV?W9/1]A_Z4"TU4Y>TT7G;UIW]556]D1.3M-+G@B/0O[
M(12%LPF]26@O^OX#[TLEA'^*_6<. H>>B>!*((*N*-!LCGT/W0ZHZHW1%WYP
MG-47U$>_\YYB0!#6/<&"8OAVBZA;1]S$8D:!07PC&IQS78)Y--NF-6LNK_-4
M)8'=[DQ<,AJ=Q:4!.]AM5[.U HMI?_:J#TBDSH3/[:[CHQ^HN#0T@,3XG)L%
ML6>X=F,Z^U'/X5#!B=P00^([%+I8%R!.6.CK6M2RABU)M&:_:9@WHJZLW]XA
M46&7G6S8M74C<VJ29=_]AKV%XQ:-\LA89/>;R/4"JQ'M4^WR<(R#WN!+P\[K
MT-9T<R:?X71(;]11"T[7AZA7[&:'))V J/+D=[M,;4A]25[0F-RQVP;WF!UB
M:=\1I==$W@-_NK>]\A1,2QY#WTM]J]ZE=8THL4RY7^-*!UV;O6#,C1\RTF&(
MCQ>58&,">0#$+WXIDC+R4JHQ^HA#FV[RAE/O>+T,Q;F'O7B09.EPC!VEJW7X
M."=445[2*AB)?,=;U;".</Q\:]1+4;\N3&(@1X@2F2#<8)V?M*YS:TLO$>5#
M!HL:Y4H$\>7+(W3C2*'=!%.6Y12KXB+ F@)HU%ZWO2)CV2V)5WQ \-]:-@2S
M"\LG0PEC989>:]BDDC0KEY6&1%^DU<(K@%*6\DCNTT9@@X7Q-:GZ9;3HXQWT
M/GVCTD*)Z,:73KW\Z/J.CH>-Z,QU);.Z0DLD*KGXPZ*@QH@Z@2#AT:C3&02F
M1"!$=%]VM3V1M$F4$E;O%"KDI*HR0MEP@5FB=?^2SDCG N>*ONAC-]84I;RU
M:\U.? ,G4J<67#"F/,WKJN2(1__LRW45A."")*8/V)&2%_)E[3+$ 3G$M:6
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M1 8SD6"L)?2N;X+J=@C!')D>*U-E:/#EM7]BF&=G  &O@3M$QK22Q]=EJZS
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M=D(!: W@T2J;SX0L@=YKJ[].!9$WB<5D#RB^91G/$N[4IBIR/LS>@_)A'V<
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M@X6SX[\YLOMQ_\MS,9>]D*3C8RQ2,F\D\PM!37PE?/!*LN::5=<"+N.^(.>
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M6V^'FC-%S:V]$HF!.A'?EU@5=+[AEX2A4; WL*4=M=*&-%$Q;@;N+OV&G:,
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M:4V7%/L:RV\$1.1(P]C;N!+0H8=C,+S#4^HZUCFN!1;,">OH:!21=J\=&3X
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MF!LSKIA%?=K!=F3\\.D4I"=]VZJ?TYR(19!0Q($H=Q=W]6B69!/V9V_=OL!
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MEZ4,V^68'6"*51*\^NNEE_HP4()0C(^>]A9_[QNN/B+^3W_X=M&A>&T.I/6
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MCUJZ0L&0YY*V6,Q/M,A>>$DKY[U!SR$W8(CEHDV%^=W^IC B"])EU8Z%*X[
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M&PN&2M*,09$I;A4%16JO8-E8$<EO9'@LG%M(NNTIE1[WQK-OP+NXS6*?<">
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MVVRXO:%9SR6WF)LXM\SA^#L,2PS-:;G&A+-5HP8Y1UZ*@[.(H@Y!&FW+ZL&
MV4=L)&3I$:0<;1VL/&$CF)P@21W!7YAR,=GQSZ-2S[FW<%YX::1695/7,,8+
MLT_X [<9CBV60]$F>4/Y7":\U UER>MJ?OK$@V%JR6E9AWB^CA?W>NP<>%Y
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M,7D^<\3C!?-]Q@:1!Y;Y8EGK;<6$PLDV;86^!\&W)LREG]_\#U!+ P04
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MPH*,TJWVB]/O@K.S)<;%)6'+XJPOE'Z6H.HN)XK+HO(1@LB&%)%2;KY_^PJ
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MVYGA'3*15C!=E>,, -7)&[L7T($=LMT%=^^<^Q9<[[!!W ^.C$U44=,*$#R
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M/:/^2%:IWF$O7H79[#-!OBAC3"+R+ 3QP-4RQI05>.,1 CJNI"O!L-8I0(.
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MYV]_^^.JP;WBW-=\"R52(*M"7D0LJDY(*%9FER*RU@.Y'@1T@!%<!Y?YM)?
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M5<I6@C#.@$JHP67-(##IC+$Q&/F46C@<7FB/-H'8A.,=[J9^./MP.OV,>&.
MPM4@H(B8455_MD0B4Y-3$8R%Y+U&;I/5NOD4MG5@7K#FM!74WG.LI0HQ2ZG
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M0H 3-?G/*DL$:0^)J&(J"^Z:][^_\?J7Z0?M*H<.'7XNH5P/77\<3*>3BEM
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M,"Y#,"I'I?)P(W[ST<](HKNQK6%+PHLRREL6H0Y23$MOHFK<<NR()3<A1VD
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MAE=YS2!V5O>O7Y^FV+N^5..WUC:OY H?_9?RAAQL( (:(W"S?B4W,(%;!;:
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MGWL/?Y==>GV(YXFKFK99HXN"26[5RK)VK7A>]X@1O9%K,<TIWGH7F/>S];.
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M;4+B0#(9$XA$9)II>P3B)-3_#!07S!-AC&.7_8O5J&/;HJS+#ZVF !0]Z2Y
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M()!6]>G[%')L/%A("HRHX/=20L?T_EYFTM*&?>?YZ9E57:9FP)2"\]B]>^)
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M-1C>R_8^4W34"?=.HKA]4(5,)]>S1;IXNY=/J8E5G"V,XV\BB K#Q ]AA'
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MY.//'3@*N5:YPTCD^LN;>DM?7N:SPAE[1[/;K."=TE>[ZG$TB<.$^2+2)KY
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M2&3Q3280(QI#JJ2*3:60V'<RS8\/,[8%OI%RZZBBR5?Z!*IV7^OV6/5]F-,
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M>Y#[=I[<7MV RT59?ZWPGBSFX(Z6E7\[K_WMC%!W+A++<8?VC;C!<<0IXOB
MAMW_7EYIFIG3F-OL0YJ_SG,ZO56?YIHE]4"BK/NQ'T:,D)+*%-/PE>=!%)#0
MY&!+&!,6^4&0>%Y$G#H#-A!B;'2VT<%TW3"RPT+X\HOOVDBPR:S845G?6/?,
M:MLP9V"EP%'(!^I0V +/KKH7-A%AV,Z&+4 ZZ'K8YEG-(\@?,ZJYUYR.5CW!
M A,YBGT/8A0(B C1.\0X\F"D]X<1\T(?"ZM:A76#C(WDUC'2&T$;]U@[ +2>
MO[J"J6_7D#M"C:+(3T'0*HS\X*&#QY&?4NM8(/G):]T7^2>-^?3N>3Z3GY?%
MMH"HD$?,+&X5F<@JYD/L1P$D(:(Q$6'BV\6('WOXV!9U(1\H! 2EA/:+^0"X
M\XNX#1P]+UX'))P6[2F5&RW6@X<-MDA/J;&].$]>TS"8>=T8_7A.?M%CK0I:
M.MX=?4(]AF7,* P$3R 2B8 $$0&QIU <AU[(?">'2WN1QD8 *XV*=H%%>0ZV
M6YYC4_A@5:3C8I6A\.884]U^/NVV.</.4L^\=+1F2MVD5/T>>\I[[0S:KB+"
MVPLT; 1Y9P >1)QW]^26AVJEB\K4V)A$$4H27T401TQJ6\I#VI92"(H 1YP*
MR3WA%$%X9(RQ!=08U_5.*MWM9]<$NF-(.AZ4-<-GL..Q5?R,$;##X)D:];L^
M"-L:X7V.OPY5/'GH=>329DN\+-WW(/DR*Z+R_I8NGN?+Q;VD(IV^?9#:8GE)
M9X94/M(T^XU.E_+RQ03X31@3V(\]TYL%F\1;LY]*_ @RYN, *\]GDKE88HTE
M&9L!=C/[*O/%BW,KNN938<<D@P#<,]]4!4 W2H!OI1:@4@-LZP&,(J#01%M3
MA2[=,5-K.#OBK^9R#,IRK>':Y\+V#VQ<J.VELKT*LRR_72[R!9V9PO@3%06(
MA2R"26SR*U3$(9,D@;'RF2<HBW'@3;[*C,T=RK.=',YE86X/VM_Z+*4%N1'W
M LPWHA9508M*H#76@3O>@:]"Z44*)CA*( H##[(B*]H/O"CA>A(XF^B/9CH7
M#PN:+8;%?'_@_G#_63ZE,U/ &S"J?\%E3W@3(A*) @(9"37*0E%(E2<@%C[V
M)9&8*5'A?3T3[X'V:M@>OT'E"]TOT':?]*Z@Z_FK7;'"0\D*I:078$O63BL+
MGD6DNVJ"IX<:NH+@6:6/5 T\?T^3?G)2+6?"?':+P+P/\G6>IXO*SY5/9"A$
MQ/0',HKTU@%1+X0L-NX#CA*JR3H)D54DKL588]L7;*2M G%%*:]+BZYZ<.M)
MHV/(>N:,+;3*!E>5J!<KGZE3;[MZW%S:DW6&WU MQIKCZ-@1S J9^JY>]8\8
ML#.7E2Z[W;7L;FFVY[C+Y"M-Q2/]+O7;2C%5,F0P\B,,$6<*,DX4E#21DGE<
M_\0I7F_[X6/CS$JV*H\1+.AW-QMK!S@[FZHI'#WSX0J)0J[N[*5CVG9D'^T\
M>E![Z)A2^_;/T6N:KDZ3O[AX,SVQ%Y<S83P3KV5A^4?]Q*(/#\4!)T))&"=Z
MSX3BD$."PP1BAGU.]"_CP*EJN\688UO+6R&=C_KGJ?DD%?%]C=H>V8!NN^ [
MA;)G'FB,8@-JL,:E,\8X/^+ 1&(-P2&_V-_:,$M)_.]E><Z0/\[OI5$IG<K/
M<K$Y''J<NY;MC&5,HXA3&!)BW&@^A1A3T[T[C!+%/<XY=DIHZD'(L1';EHXF
M*R=;:6FJ+H"IUM#\U/R=FV*AR[(^Z%;7;KK6T#$OJH\7P(XSWWM:>R;9O1E=
M*PA,R=>=DV[SZS'4@.US0KI*[NI#Q&'SP'H$^2!EK,^Q&F:7S7A6[FW+_]_,
M*B-Z51HF8@H+*A4,4*(_&2HAD.@M*12,(AJQ ,5!D_[!Y\:U(H[ANP>O=FQ'
MJHKQLN9!H^S[L[-@Q^"=@#I0EE@E*OAQ)>R?S =TA6\E<(=)8);0=)7P=6ZX
M89.[+)4_2.2RO:\Q]VC6T[OUZG$_RYE4IF5Y2&7B:;:AYB@!4:4@B9) \TX8
M\4#%.$9>,\HY-MQ(F>9F[1U;D8TSI1P%UYI)&F,U&($8?+2(*[( /U92=ABJ
M> :'[MCBZ"A#DT2=JD>XH?;R!L>,93[*K?I%SI\R^OJ<\GOY9 *A)YS'@1 ,
M:ZM#^1!)PPA2((@$$L*+%5+4JJ-O_3!CVX.6@IJ<CZ>UJ'HG^O1_NWNWYD9R
M)$WT?7\%GG:JS82S<4%<T&NV9JJ\U,@F6\J3J:JVL7J@X9KB&8K4D%16JG_]
M G$A@[<@  +!R&-M7:62(@+NGT<X'(#[YY;DVJ=A-3A;] )68%?0X/0@P59*
M\,4C3A9GB5[P&N@8T0DWNP/$LW#TGAV>OGNX8\.S&NR<&)Z_VO-QQ#[%1"[B
MLLQ*!'6L!%&:1Y"R-((("5;F/(X+:=7[W'3@L?G.5NYJ@;81VM-QA!NO1P@H
M@Q]0UB+?@$KH73"'8>^P12WTL<5563ILP3 ^P/##QK'M4N#2FGN;TKU:O3XW
M)7!'FG)/4D*+&.<49HCI9DE<)TN4!2QD3B3.1)9E1O7"PX@[-L_XF]),K6&K
M'%>^F,W(<@742U'GNQJFNPYD:(/X=%3F"^R-NT7&76V[E<;ZJ.)H,;+6^:93
M/ ,Z>M^ 1G/0J@XJW4?U,M@VOQG+2S%D+YU1O!P._7J&L-7Y]C]!I1BXF] 0
MB!XV)QID5$>>$CTX/2\?W9>OKDF[FZ_6R^H[7E5LCX]/9-Z6Z7_[MJSVA>_F
MZ^5TOIJR2IW[154S*O@DR:@DN8QA05BIXA6,(!8HAE+(#,6YB*A=<N?U5!E;
M+/-[(]<-(*WD8-J*#KYKV2W93Z[WEI@M(G\.VX\_$&J*CCMX-&V+U@J1MB6=
MFOHVK]4&E;;V> .,1]Z6JQO7%]_+]109EB?FZ@8[X)>YOD1N\_,GL5H)L<L
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M5J'ZH2.N)9GO938RFU6&0S[P?'$2]!O0U0;T7#=$/8D?O'W1#5\FS+"$Q%Z
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MYX"9IW#99N1!@V8'2/9#9Y='N#FPO2;JG[3!-6/OXED--$G*,L]13J"@L28
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M <NL%% 6O"0B*D5NR;Q_;)31N81*2->XX3B0AA_]I?"$_N9K9#8"!CCD[(7
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M!V>N=OON[^9LJ8L.WHOZWW?S*A-O4Y%0\^!/$$WS-(ICF*>9^OI3F4/"L%J
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M; [S!A@&Z:.TZX"1^465F]5I:JW_T&6;@]K,9^7F,((/7[PYJ$&.UF\.*\'
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MCLUU:(DKFB@M,_BS%M)RMC< VLQ1^(4OL,^P1,Z^*,T8#%]59><''+8LS!B
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M?9!QR<_WZTO%K'E-#RTU[[?6#8!S(8)PA8EHA-78NB;G<8K&==@' EE#)70
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M"1^D9-R4[.[ V$!='5C+*^G\7F?3O*]-I]\6$MR+Y1)7-[>!RSF;4AO/F7:
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MGYXW@)J)(A0#P7FM0F )O*-H@KF8E!9)$RB?RRUZ1F_0.O2"A4+++M?$^2+
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M_L,?E[,&%>=>Y%@GB0=:_K1)Q*+JH,MB978I(FO=-?%1@D8.T4?'RWPHY76
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M'ET4(@6I72^QRA[TS+Y:9I*PI3509EDFL/W-U:"(T8H#GOB.\4L"]B&NCT(
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M^@'2]=8=-!1$2P^1<W(,M3 0ZQ!4NI1MB=XD'5K/>NBT+V60&)_M2QG"TPX
M\80>;16%=(GT[5M?!/'!,$&7)L^:;+6H@Y<42\!*T(C(B(<GRLT]=KPNP'0(
M"/9+GQTMD5F [5NGA!72V9 M>8)ANR390"@I@0\!LV+D'4X MBY;6,8%VV$2
MZ0%L3S:XU^) 54=FR&V/A QTV?-<P$B*14S$;)L//'[UDR:.\:?:2*H#R#W2
M3L]380:Y@,*%(Z6)Q"&G/'AK@C#.IQA:>^OSF30Q2+PO3YH8PNNI$P"/3DM
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M^8YQ:VCW):Z3PEF%*GKE()M<9U];#8Y<<PB).89%&.-:C]Q]+86SQ@E92N&
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MHR8[GF1O2><]27LU3S>C('P:A1P$M_D\]CQ9J['/A+N[#+(^VLAR 9VY(9_
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MS'3GK8 Y:-9;'8S#D!LXB,!"NNSX,-ZJF+@C6IC'=\$,&G) 3#F3S\FJT#
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M     &-M<',M,C R,C Y,S N:'1M4$L! A0#%     @ L#AC53Q_P])P#P
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M,#(R,#DS,%]L86(N>&UL4$L! A0#%     @ L#AC515!>YDH=@  ''$% !4
M             ( !";0$ &-M<',M,C R,C Y,S!?<')E+GAM;%!+ 0(4 Q0
M   ( + X8U69",*CE@@  -(I   >              "  60J!0!C;7!S+7$S
M>&5X,S$Q8V5O,S R8V5R=&EF:2YH=&U02P$"% ,4    " "P.&-5_)DN888(
M  #P*   '@              @ $V,P4 8VUP<RUQ,WAE>#,Q,F-F;S,P,F-E
M<G1I9FDN:'1M4$L! A0#%     @ L#AC54]2QFF7!0  6R$  !X
M     ( !^#L% &-M<',M<3-X97@S,C%C96]X8V9O<V5C=&EO+FAT;5!+!08
1    "0 ) &X"  #+004    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
